, powerful

There’s more to life with Fludara ®
New 1st line confidence in CLL
Name of the medicinal product: Fludara®. Qualitative and quantitative composition: Fludarabine phosphate 50 mg per vial. Fludarabine phosphate
10 mg per film-coated tablet. Therapeutic indications: Intravenous. Fludara® is indicated for the initial treatment of patients with B-cell chronic
lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves. First line treatment with Fludara® should only be
initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms
(weight loss, extreme fatigue, night sweats or fever), increasing bone marrow failure, massive or progressive hepatosplenomegaly or lymphadenopathy,
more than 50% increase in peripheral blood lymphocytes in a 2-month period or an anticipated doubling of these cells in less than 12
months. Oral. Fludara® tablets are indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or
whose disease has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Contraindications: Hypersensitivity
to fludarabine phosphate or to any of the excipients. Renal impairment with creatine clearance

Contents
Corporate Members supporting EBMT . . . . . . . . . . . . . . . . . . . . . . . . . 2
Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Organising Committee / Secretariats . . . . . . . . . . . . . . . . . . . . . . . . 4/5
Programme Overview
Sunday, March 28, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6/7
Monday, March 29, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8/9
Tuesday, March 30, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . 10/11
Wednesday, March 31, 2004 . . . . . . . . . . . . . . . . . . . . . . . . 12/13
CME Accreditation at EBMT 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Scientific Programme (Satellite Symposia)
Sunday, March 28, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . 15–21
Scientific Programme (Physicians)
Sunday, March 28, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Monday, March 29, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . 23–40
Tuesday, March 30, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . 41–57
Wednesday, March 31, 2004 . . . . . . . . . . . . . . . . . . . . . . . 58–68
Posters Physicians
Monday, March 29, 2004 (P407 – P668) . . . . . . . . . . . . . . . . . . . . . 69–89
Tuesday, March 30, 2004 (P669 – P927) . . . . . . . . . . . . . . . . . . . 90–109
Scientific Programme (Data Management Group)) . . . . . . . . . . 110–113
Scientific Programme (Nurses Group)
Monday, March 29, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114–117
Tuesday, March 30, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118–120
Wednesday, March 31, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Poster Nurses Group (P991 – P1086) . . . . . . . . . . . . . . . . . . . . 122–127
Instructions for Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
List of Chairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
List of Speakers and Authors . . . . . . . . . . . . . . . . . . . . . . . . . . 131–152
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153/154
Social Events and Daily Tours . . . . . . . . . . . . . . . . . . . . . . . . . 155/156
Sponsors supporting the EBMT congress . . . . . . . . . . . . . . . . . . . . 157
Useful Information about Barcelona . . . . . . . . . . . . . . . . . . . . . 158/159
Travel to and within Barcelona . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Barcelona City Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162/163
Metro Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164/165
Exhibition Floor Plan / List of Exhibitors . . . . . . . . . . . . . . . . . . 166/168
Floor Plan Level -1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
1

Corporate Members supporting EBMT
The EBMT would like to thank its corporate members for their generous support:
2

Dear EBMT members, colleagues and friends
It is our privilege and pleasure to welcome you to Barcelona for the 30 th Annual
Meeting of the European Group for Blood and Marrow Transplantation, the
20 th Meeting of the EBMT Nurses Group and the 3 rd Meeting of the EBMT
Data Management Group.
The scientific content of this meeting strongly reflects that haematopoietic
transplantation is a rapidly evolving field, with the discovery in recent years of new
indications for the procedure and development of improved transplant techniques.
Thousands of patients have already received treatment for classical indications such
as malignancy, marrow insufficiency and congenital diseases and an update on the
positive results obtained in the treatment of these disorders will be given. What is
more, recent observations demonstrating the plasticity of haematopoietic stem cells
have led to their use in repairing extrahaematological tissues, and emerging clinical
applications of this therapy will be presented at EBMT 2004.
Transplantation techniques have further evolved and alternative haematopoietic
stem cell sources are now widely used in place of marrow from related and
unrelated donors. In the latter case, increasingly refined HLA-matching methods
and more accurate criteria for donor selection promise improved results. Cord blood
has proven to be a valuable source of stem cells for transplantation in children, and
recently also in adults. Methods to exploit graft versus malignancy effect while
avoiding the risks of high-dose therapy are now feasible through the use of reduced
intensity conditioning regimens. All these topics will be extensively reviewed during
the meeting as educational sessions, workshops, meet the expert debates and
plenary lectures. Critical care of the transplanted patient, another burning issue in
clinical practice will likewise be covered, presenting the views from a haematologist,
an intensivist, a nurse and a patient’s family.
EBMT 2004 not only offers you a full scientific programme led by top scientists in
the field, but also takes place in one of Europe’s most popular cities. An impressive
list of tourist attractions are bound to keep delegates busy outside of congress hours
and Barcelona’s pleasant spring climate will make visiting the city all the more
enjoyable. Modernist architecture, Roman ruins, Olympic grounds and the seafront
promenades of Barcelona’s city centre never fail to capture the visitor’s imagination
and we have tailored the social programme to incorporate a taste of the arts and
culture that thrive in this cosmopolitan city.
Welcome to Barcelona 2004!
Welcome Address
Jorge Sierra Charo Laborda
Congress President Nurses Group
Hospital de la Santa Creu i Sant Pau Local Organising Committee
Universitat Antònoma de Barcelona
3

Organising Committee
President
J. Sierra, Barcelona
Vice President
A. Urbano-Ispizua, Barcelona
Scientific Secretary
S. Brunet, Barcelona
Honorary Committee
H.R.H. Princess Cristina de Borbòn
Joan Clos Mayor of Barcelona
Ana Pastor Minister of Health of Spain
Marina Geli Minister of Health,
Catalan Government
Carles Solà Minister of Universities and
Research, Catalan Government
Lluis Ferrer Rector, Universitat Autònoma
de Barcelona
Josep Carreras President of the José Carreras
International Leukaemia
Foundation
Ciril Rozman President of the Catalan
Commission on Haematopoietic
Transplantation
Vice-president, José Carreras
International Leukaemia
Foundation
Emili Montserrat President of the European
Haematology Association
Alvar Net Dean, Faculty of Medicine,
Universitat Autònoma de
Barcelona
Josep Antón Grau General Director,
Hospital de la Santa Creu i
Sant Pau, Barcelona
Local Organising Committee
R. Martino, Barcelona Physicians
M. Rovira, Barcelona Physicians
A. Sureda, Barcelona Physicians
R. Laborda, Barcelona Nurses
E. Gris, Barcelona Nurses
C. Canals, Barcelona Data Management
F. Mc Donald, Barcelona Secretarial Support
E. Mc Grath, Barcelona Secretarial Support
4
Members of the
National Scientific Committee
I. Badell,Barcelona A. Iriondo, Santander
J. Bueren, Madrid P. Marín, Barcelona
D. Caballero, Salamanca J. Mª. Moraleda, Murcia
E. Carreras, Barcelona J. Odriozola, Madrid
E. Conde, Santander J. J. Ortega, Barcelona
J. L. Díez, Madrid J. A. Perez Simón,
Salamanca
I. Espigado, Sevilla F. Pròsper, Pamplona
M. N. Fernández, Madrid J. Román, Córdoba
A. Figuera, Madrid M. D. Ruíz, Malaga
J. García, Barcelona M. A. Sanz, Valencia
J. García-Conde, Valencia G. Sanz, Valencia
A. Grañena, Barcelona J. F. Tomás, Madrid
F. Hernández, Madrid A. Torres, Córdoba
EBMT Board
J. Apperley, London President
A. Urbano-Ispizua, Barcelona Secretary
H. Schouten, Maastricht Treasurer
M. Stephens, London Nurses President
Working Party Chairpersons
F. Frassoni, Genoa Acute Leukaemia
H. Schrezenmeier, Ulm Aplastic Anaemia
A. Tyndall, Basel Autoimmune Diseases
D. Niederwieser, Leipzig Chronic Leukaemia
A. Madrigal, London Immunobiology
M. Cavazzana-Calvo, Paris Inborn Errors
C. Cordonnier, Créteil Infectious Diseases
G. Socié, Paris Late Effects
N. Schmitz, Hamburg Lymphoma
G. Dini, Genoa Paediatric Diseases
T. Demirer, Ankara Solid Tumours
EBMT Society and National
Scientific Committee (Nurses Group)
M. Stephens, London President
B. Quinn, London President Elect
M. Ni Chonghaile, Dublin Secretary
M. Jansen, Maastricht Treasurer
R. Laborda, Barcelona Local Nurses
E. Gris, Barcelona Local Nurses
Data Management Group
C. Ruiz de Elvira, London
R. Brand, Leiden
P. Ljungman, Huddinge
C. Canals, Barcelona

Physicians Scientific Secretariat
Salut Brunet, MD
Clinical Hematology Division
Hospital de la Santa Creu i Sant Pau
St. Antoni M a Claret 167
08025 Barcelona / Spain
Tel. +349 3 291 93 96
Fax +349 3 291 94 66
Email: sbrunet@hsp.santpau.es
Nurses Group
Mairead Ni Chonghaile
HOPE Directorate
St. James's Hospital
Dublin 8 / Ireland
Tel. +353 1 686 0722
Fax +353 1 410 3428
Email: bmtco-ord@stjames.ie
Data Management Group
EBMT Central Office
Carmen Ruiz de Elvira PhD
Department of Hematology
Macdonald Buchanan
Middlesex Hospital
London W1N 8AA / UK
Tel. +44 (0) 20 7380 9772
Fax +44 (0) 20 7380 9597
Email: c.ruiz@ucl.ac.uk
Entrance Parc Guell
Organising Secretariat
ISAM-EBMT
c/o AKM Congress Service
P.O. Box
CH-4005 Basel / Switzerland
Tel. +41 61 686 77 11
Fax +41 61 686 77 88
Email: ebmt@akm.ch
www.akm.ch/ebmt2004
Local Agency
McCann Meetings
C/Josep Irla i Bosch, 5–7 entr.
08034 Barcelona / Spain
Tel. +34 93 206 46 46
Fax +34 93 204 97 32
Email: ebmt2004@mccann.es
www.mccann-meetings.com
Secretariats
5

Sunday, March 28, 2004
08
09
10
11
12
13
14
15
16
17
18
19
20
6
Auditorium
Level 0
16.00–18.00
Taking
transplantation
to a new level
F. Hoffmann-
La Roche
18.30–20.45
Physicians
p. 19
Opening Session
EBMT Lecture
Van Bekkum
Award
p. 22
Room J
Level -1
11.00–13.00
Overcoming
the burden of
fungal infections
Merck, Sharp
and Dohme
13.30–15.00
Valganciclovir
for anti-viral
prophylaxis
Hoffmann-
La Roche AG
16.00–18.00
From oral to
I.V. busulfan
Pierre Fabre
Médicament
Nurses
Room H
Level -1
11.00–13.00
Novel strategies
in graft
engineering
and cellular
therapy
Miltenyi Biotec
GmbH
p. 15 p. 15
13.30–15.00
Peripheral blood
stem cell
transplants
Genzyme-
SangStat
p. 18 p. 18
p. 20
Data Managers
Room F
Level -1
13.30–15.30
Serious fungal
infections in the
BMT patient
Pfizer Inc.
16.00–18.00
p. 17
Antifungal
therapy
principles and
practice
Gilead Sciences
p. 21
Business Meetings
Room A
Level -1
16.00–17.00
Thalassemia
Fresenius BioTech
GmbH
p. 21
20.45 Welcome Reception at the Palau de Congressos de Catalunya
Satellite Symposia
p. 155

ProMISe
Level +1
13.30–15.00
Practical
session
(continued)
Sunday, March 28, 2004
08.00–10.30 08.00–11.00
ProMISe 2
Training Session Business Meeting Business Meeting
Working Party Working Party
09.00–10.00
Paediatric
diseases
Chronic
Leukaemia
09.00–11.00 09.00–11.00
Database
Business Meeting Business Meeting
presentation
p. 110
Working Party
Solid
Working Party
Aplastic
Tumours Anaemia
10.30–12.30
Practical
session
p. 110
p. 110
Room D1
Level -1
Room D5
Level -1
Room E1
Level -1
20.45 Welcome Reception at the Palau de Congressos de Catalunya
Room E3
Level -1
11.00–13.00
Business Meeting
Working Party
Late
Effects
15.00–18.00
Registry
Subcommittee
Meeting
(RSC)
p. 155
08
09
10
11
12
13
14
15
16
17
18
19
20
7

Monday, March 29, 2004
08
09
10
11
12
13
14
15
16
17
18
19
20
8
Auditorium Room J Mare Nostrum Room F Room A Room B
Level 0 Level -1 Hotel Rey
Juan Carlos
Level -1 Level -1 Level -1
08.00–08.45 08.00–08.45 08.00–08.45 08.00–08.45 08.00–08.45
Educational 1 Educational 2
Workshop 1 Workshop 2 Workshop 3
Anti-fungal Relapsed
SCT in Auto- Chimerism & Transplantation
therapy
p. 23
lymphoma
p. 23
immune diseases
p. 24
MRD
p. 24
in ALL
p. 24
09.00–10.30
Presidential
Symposium
11.00–13.00
13.30–15.30
Oral Session 1
Lymphoma 1
16.00–18.00
Working Party
Chronic
leukaemia
Physicians
p. 25
Working Party
Acute
leukaemia
12.30–13.30
p. 26 Cellular support IX
p. 28
Amgen (Europe) AG
p. 29
13.30–15.30
Oral Session 2
Multiple
myeloma
16.00–18.00
Working Party
Paediatric
diseases
13.30–15.30
Oral Session 3
Reduced
intensity
transplant
16.00–18.00
Working Party
Aplastic
anaemia
13.30–15.30
Oral Session 4
Stem cell
research/
Nonhaemapoietic
tissue repair
p. 27 12.30–13.20 12.30–13.20
Meet the Expert 1 Meet the Expert 2
Stem cell
plasticity
Unrelated donor
p. 29 p. 29
13.30–15.30
Oral Session 5
Graft versus
malignancy
16.00–17.40
Paediatric
issues
18.00–19.00 Poster Presentation:
Physicians: P407 – P668 Nurses: P991 – P1086
(Level -1) p. 69–89 (Level +1) p. 122–127
Nurses
11.00–13.00
Working Party
Solid tumours
Data Managers
11.00–12.30
Working Party
Autoimmune
disease
Business Meetings
13.30–15.30
Oral Session 6
Cytokines /
Gene therapy
p. 30 p. 31 p. 32 p. 33 p. 34 p. 35
p. 38 p. 39 p. 40
16.00–17.40
Nutritional
support
p. 116 p. 116
Satellite Symposia

Room H
Level -1
08.00–09.00 08.00–08.45
08.00–09.00
Educational 1 Educational 3
Educational 2
Central venous
care
Acute GVHD
p. 23
Complimentary
therapies
p. 114
p. 114
09.00–10.30
09.00–10.30
Supportive
care 1
11.00–12.20
Donor issues
16.00–17.40
p. 114
Addressing
clinical
issues
Room D1
Level -1
16.00–17.30
Room D4
Level -1
Educational
Good Clinical
Practice
11.00–12.30
MED-B sessions
Autograft
16.00–17.30
Business Meeting MED-B sessions
Working Party Infectious
Autoimmune
diseases
diseases
Monday, March 29, 2004
Room E1
Level -1
Room E3
Level -1
ProMISe
Level +1
ProMISe 2
Training
Sessions
09.00-10.00
Database
presentation
10.30-12.30
Practical
session
p. 115
12.30–13.20
p. 111 12.30–13.20 12.30–13.20
12.30–13.30
Meet the Expert 3
12.30–13.30
Meet the Expert 4 Meet the Expert 5
Natl. Nurses
Groups 1–5
Transplants in
paediatrics
Natl. Nurses
Groups 6
Acute
leukaemias
Acute Promyelocytic
leukaemia
p. 115
p. 29
p. 115
p. 29 p. 29
13.30–15.30 13.30–14.30
13.30–15.00
Oral Session 7
Infectious
diseases 1
(viral)
Oral Session 8a
Autoimmune
disease
p. 37
14.30–15.30
Oral Session 8b
Aplastic
14.00–15.30
MED-B sessions
Acute
leukaemia
14.30–15.30 14.30–15.30
Workshop 1 Workshop 5
Breaking bad Stress reduction
Practical
session
(continued)
p. 111
15.00–16.00
p. 36
anaemia
p. 37 p. 111
news
p. 115 p. 115 Workshop 2
Internet skills
p. 117
p. 111
p. 111
18.00–19.00 Poster Presentation:
Physicians: P407 – P668 Nurses: P991 – P1086
(Level -1) p. 69–89 (Level +1) p. 122–127
Room E5
Level -1
12.30–13.30
Spanish Natl.
Nurses Group 7
14.30–15.30
p. 115
Room E6
Level -1
12.30–13.30
Natl. Nurses
Group 8
p. 115
14.30–15.30
p. 111
p. 111
p. 115
Workshop 4 Workshop 3
Presenting skills Research skills
p. 115 p. 115
08
09
10
11
12
13
14
15
16
9

Tuesday, March 30, 2004
08
09
10
11
12
13
14
15
16
17
18
19
20
10
Auditorium Room J Mare Nostrum Room F Room A Room B
Level 0 Level -1 Hotel Rey
Juan Carlos
Level -1 Level -1 Level -1
08.00–08.45 08.00–08.45 08.00–08.45 08.00–08.45 08.00–08.45 08.00–08.45
Educational 4 Educational 5 Educational 6 Workshop 4 Workshop 5 Workshop 6
HLA
p. 41
Reduced
intensity
p. 41
Regenerative
therapy
p. 41
Infectious
diseases
p. 42
Innoculum for
Allo-SCT
p. 42
Immunotherapy
p. 42
09.00–10.30
Joint Session
Nurses/
Physicians
Critical care
11.00–13.00
Working Party
Infectious
diseases
13.30–15.30
16.00–17.30
09.00–10.30
Plenary Session
Stem cell
sources for
allotransplants
11.00–12.30
Working Party
Lymphoma
13.30–15.30
16.00–17.30
11.00–13.00
Working Party
Late effects
Oral Session 9 Oral Session 10
Oral Session 11a
Reduced
Oral Session 12 Oral Session 13 Oral Session 14
Acute
leukaemia/
Myelodysplastic
Lymphoma 2 intensity 2
p. 49
14.30–15.30
Infectious
diseases 2
Graft versus
host disease 1
Paediatric
diseases 1
syndromes
Oral Session 11b
Solid tumours
p. 47 p. 48 p. 49 p. 50 p. 51 p. 52
16.00–18.00
Joint Session Working Party Working Party
EBMT/WMDA Immunobiology
Stem cell donor
Inborn Errors
Physicians
p. 43
p. 44
Nurses
p. 43
p. 45
p. 55 p. 56
12.00–13.30 12.00–13.00
Nature Publishing
Group
12.30–13.20
p. 46
European
LeukaemiaNET
European HSCT
How to get
published
p. 45
Meet the Expert 6
Myelodysplasia
platform
p. 45
p. 46
13.30–14.30 13.30–15.30 13.30–15.30 13.30–15.30
p. 57
18.00–19.00 Poster Presentation:
Physicians: P669 – P927 Nurses: P991 – P1086
(Level -1) p. 90-109 (Level +1) p. 122–127
p. 000 p. 000
20.00 Gala Dinner at Reials Drassanes de Barcelona
Data Managers
Business Meetings

Room H
Level -1
08.00–09.00 08.00–09.00
Educational 3
Educational 4
Nutrition
Acute
in transplant
leukaemias
11.00–12.40
Standards
of care
p. 119
12.30–13.20
Meet the Expert 7
13.00–14.00
Solid tumours
Nurses General
Meeting
p. 119
14.00–15.30
Debate Session
Protective
isolation
16.00–17.40
p. 118
Psychosocial
issues
Room D1
Level -1
p. 46
13.30–15.30
Room D4
Level -1
09.00–10.30
MED-B sessions
Myeloma
11.00–12.30
MED-B sessions
Allograft/HLA
13.30–15.30
Oral Session 15 MED-B sessions
Graft MDS &
engineering/ relapsed CML
Cellular
therapies
16.00–17.30
Statistical
Symposium
Tuesday, March 30, 2004
p. 112
p. 119 p. 53 p. 112
p. 120
p. 112 12.30–13.20 12.30–13.20
Meet the Expert 8 Meet the Expert 10
Reduced intensity Umbilical cord
p. 113
Room E1
Level -1
14.00–15.40
Managing
care
18.00–19.00 Poster Presentation:
Physicians: P669 – P927 Nurses: P991 – P1086
(Level -1) p. 90–109 (Level +1) p. 122–127
p. 118
p. 46
p. 120
Room E3
Level -1
14.00–15.30
Oral Session 16
Late effects /
Quality of life
20.00 Gala Dinner at Reials Drassanes de Barcelona
p. 46
ProMISe
Level +1
ProMISe 2
Training
Sessions
09.00–10.00
Database
presentation
10.30–12.30
Practical
session
p. 112
p. 112
p. 54 p. 112 000
Room E5
Level -1
12.30–13.20
13.30–15.30
Practical
session
(continued)
Meet the Expert 9
Haploidentical
p. p. 000 46
18.00–19.30
Business
Meeting
Working Party
Solid tumors
Allo-Subgroup
08
09
10
11
12
13
14
15
16
11

Wednesday, March 31, 2004
08
09
10
11
12
13
14
15
12
Physicians
Auditorium
Level 0
08.00–08.45
General
Assembly
09.00–10.30
09.00–10.00
Plenary Session Joint Session
Biological IBMTR-EBMT
aspects of GVHD Umbilical
cord transplants
p. 58 p. 58
11.00–11.45 11.00–11.45 11.00–11.45 11.00–11.45
Educational 7 Educational 8 Educational 9 Workshop 8
Algorithms in
AML
p. 59
Aplastic
anaemia
p. 59
Complications
in children
p. 59
Solid
tumours
p. 60
12.00–14.00
Oral Session 17
Chronic
leukaemias
Nurses
p. 58
Room J
Level -1
12.00–14.00
Oral Session 18
Paediatric
diseases 2
14.15–14.45
Awards &
Closing
p. 68
Room F
Level -1
12.00–14.00
Oral Session 19
Stem cell
source and
biology
Room A
Level -1
12.00–14.00
Oral Session 20
Donor issues
p. 61 p. 62 p. 63 p. 64

Room B
Level -1
Room H
Level -1
09.00–10.20
Critical care
issues
p. 121
11.00–11.45 11.00–11.45
Workshop 9
11.00–12.30
Supportive
Workshop 7
SCT in STI era
care 2
Gene therapy
p. 60 Medical
update
p. 60
12.00–13.00 Awards & 12.00–14.00 12.00–13.30
Oral Session 21a
Closing
p. 121 Oral Session 22 Oral Session 23
Supportive Care
GvHD 2 / Minimal
p. 65
13.00–14.00
Oral Session 21b
Regulatory
Tolerance &
rejection
residual disease/
Graft versus
malignancy 2
p. 68
issues
p. 66
p. 67
Advance Notice
Wednesday, March 31, 2004
Room D1
Level -1
Room D4
Level -1
08
09
10
11
12
13
14
15
31 st Annual Meeting of the European Group for Blood and Marrow Transplantation
21 st Meeting of the EBMT Nurses Group
4 th Meeting of the EBMT Data Management Group
Prague, Czech Republic, March 20–23, 2005
13

CME Accreditation at EBMT 2004
We are pleased to inform you that the participants of EBMT 2004 are eligible to
receive Continuing Medical Education (CME) credit points from the European
Hematology Association – European Council for Accreditation in Hematology
(EHA-ECAH).
CME accreditation for haematologists is one of the pilot accreditation activities initiated by EHA in
association with the European School of Hematology and eighteen other haematology organisations
throughout Europe. EHA-ECAH is partly funded by the European Commission-Leonardo da Vinci
Programme. European haematologists are increasingly required to provide proof that they are
continuing to update their knowledge and skills through participation in CME activities. They are also
highly motivated to do so; over 5000 European haematologists have already opened an on-line CME
account. EHA-ECAH facilitates identification and registration of CME activities which have been
submitted to a peer-review accreditation process and responds to pre-established quality standards.
CME accreditation is now a permanent feature of EBMT annual meetings and physicians attending
EBMT 2004 are eligible to receive one CME credit point for every hour of accredited scientific
programme. CME points will be awarded for the following sessions at EBMT 2004:
• Presidential symposium: 1.5 points
• Plenary sessions: 1.5 points per session
• Educational sessions: 0.75 points per session
• Workshop sessions: 0.75 points per session
• Working Party sessions: 2 points per session
• Meet the expert sessions: 0.75 points
• Joint sessions: 1.5 points
• Oral sessions: 1 or 2 points per session
In 2004 EHA-ECAH has initiated a new pilot activity for the accreditation of corporate symposia.
EBMT is the first society to participate in the pilot scheme, which is designed to measure the interest
and feasibility of extending accreditation to corporate symposia. Symposia organised at the 9 th EHA
congress (Geneva, June 10–13, 2004) will also be eligible for accreditation. The results of this initial
pilot phase will be evaluated with all partners after the 9 th EHA congress.
F. Hoffmann-La Roche Ltd, Miltenyi Biotec GmbH, Pfizer Inc. and Pierre Fabre Médicament have
participated in the pilot project and have successfully been awarded CME accreditation (under certain
conditions) for the symposium they will host at EBMT 2004. Information on the CME points awarded
for these sessions and any relevant commercial disclosure information is included together with the
symposium programmes.
How to claim your CME points
EHA will be present at EBMT 2004 and will be happy to open CME credit point accounts for delegates
at the meeting. You will subsequently receive an ECAH username and password by email in order to
have your own personal CME overview.
In the congress bag you will find a CME attendance card and EBMT 2004 evaluation form for the
main scientific sessions. Separate evaluation forms will be distributed at corporate symposia
accredited for CME. Once you have participated in all the sessions you plan to attend, you should
take the attendance card and completed evaluation form(s) to the EHA booth (located near the
secretariat) in order to claim your CME points and certificate of attendance.
Further information on EHA-ECAH is available at info@ecah.org and www.ehaweb.org.
14

Scientific Programme Sunday, March 28, 2004
Satellite symposium
11:00 – 13:00 Important new evidence to overcome the burden
of fungal infections in BMT patients with caspofungin
Chairs: G. Maschmeyer (Berlin, D), R. Martino (Barcelona, E)
Welcome/Opening remarks
S1 Changing epidemiology and challenges of fungal infections in BMT patients
N. Milpied (Nantes, F)
S2 Experience with caspofungin: results from a case-documentation study of
118 patients
A. Glasmacher (Bonn, D)
S3 Clinical experience and treatment study results with caspofungin
R. Martino (Barcelona, E)
S4 New advances in the empirical treatment of febrile neutropenic patients
G. Maschmeyer (Berlin, D)
Panel discussion – Q&A
Faculty
Closing
Satellite symposium organised by Merck, Sharp and Dohme
Satellite symposium
11:00 – 13:00 Novel strategies in graft engineering and cellular therapy
Chair: A. Urbano-Ispizua (Barcelona, E)
S5 Haematopoietic stem cell transplantation for autoimmune diseases
R.K. Burt (Chicago, USA)
S6 Adoptive immunotherapy with antigen specific T-cells
M. Topp (Tuebingen, D)
S7 Natural killer cells for the treatment of haematological malignancies
J. Passweg (Basel, CH)
S8 Allogeneic transplantation of engineered selected peripheral blood stem cells
from haploidentical donors
J. Greil (Tuebingen, D)
S9 Bone marrow stem cells for cardiac repair
M. Vanderheyden (Aalst, B)
Satellite symposium organised by Miltenyi Biotec GmbH
Room J
Room H
This symposium has been accredited under the EHA-ECAH pilot project and attending physicians are
entitled to receive 2 CME credit points on completion of the evaluation form. See page 14 for details.
Commercial affiliations
There is no affiliation or significant relation between any member of the faculty and the organising company.
15

Scientific Programme Sunday, March 28, 2004
Satellite symposium
13:30 – 15:30 First things first: managing serious fungal infections in the
BMT patient
Chairs: E.J. Bow (Winnipeg, CAN), C. Cordonnier (Creteil, F)
13:30 S20 Welcome and opening remarks
E.J. Bow (Winnipeg, CAN)
13:35 S21 The importance of epidemiology in the diagnosis of invasive fungal infections
J.P. Donnelly (Nijmegen, NL)
14:00 S22 Strategies for early antifungal therapy in the BMT setting
E.J. Bow (Winnipeg, CAN)
14:25 S23 The threat from invasive aspergillosis in allogeneic stem cell transplant
recipients
P. Ribaud (Paris, F)
14:50 S24 Combination antifungal therapy
F. Menichetti (Pisa, I)
15:15 Panel discussion
15:25 S25 Concluding remarks
C. Cordonnier (Creteil, F)
Satellite symposium organised by Pfizer Inc.
Room F
This symposium has been accredited under the EHA-ECAH pilot project and attending physicians are
entitled to receive 2 CME credit points on completion of the evaluation form. See page 14 for details.
Commercial affiliations
Name of speaker Affiliation
E.J. Bow Research support, consultant, speaker, scientific advisory board
J.P. Donnelly Research support, consultant, sc advisory board
P. Ribaud Speakers’ bureau
F. Menichetti Speakers’ bureau, scientific advisory board
C. Cordonnier Other
17

Sunday, March 28, 2004 Scientific Programme
18
Satellite symposium
13:30 – 15:00 Valganciclovir for CMV prevention after stem cell
transplantation
Chairs: P. Reusser (Porrentruy, CH), G. Ehninger (Dresden, D)
13:30 S10 Valganciclovir for CMV preemptive therapy early after SCT
H. Einsele (Tuebingen, D)
13:50 S11 Strategies for the prevention of late CMV infections after SCT
M. Boeckh (Seattle, USA)
14:10 S12 Proteomics for early prediction of GVHD and CMV infection
E.M. Mischak-Weissinger (Hannover, D)
14:30 S13 Use of antiviral agents against other herpesvirus infections after SCT
P. Ljungman (Stockholm, S)
14:50 Discussion
Satellite symposium organised by Hoffmann-La Roche AG
Satellite symposium
13:30 – 15:00 Peripheral blood stem cell transplants
Chair: J. Sierra (Barcelona, E)
13:30 S14 Introduction
J. Sierra (Barcelona, E)
13:35 S15 Update of the EBMT/IBMTR PB versus BM transplant study
C. Bredeson (Milwaukee, USA)
13:55 S16 Does thymoglobuline prevent GvHD in allogeneic RIC PBSCT?
D. Blaise (Marseille, F)
14:15 S17 Low dose thymoglobuline in matched related PBSCT after myeloablative
conditioning
J. Russell (Calgary, CAN)
14:35 S18 Peripheral blood stem cell transplant with thymoglobuline
A. Bacigalupo (Genoa, I)
14:55 S19 Discussion / conclusion
J. Sierra (Barcelona, E)
Satellite symposium organised by Genzyme – SangStat
Room J
Room H

Scientific Programme Sunday, March 28, 2004
Satellite symposium
16:00 – 18:00 Taking transplantation to a new level
Chair: N. Schmitz (Hamburg, D)
S27 Introduction: What is required to enhance the utility of transplantation
and improve outcomes?
N. Schmitz (Hamburg, D)
S28 Eradication of minimal residual disease: purging and maintenance in
follicular NHL
R. Pettengell (London, UK)
S29 Achieving long-term remission in mantle cell lymphoma
R. Buckstein (Toronto, CAN)
S30 Stem cell transplantation for chronic lymphocytic leukaemia
E. Montserrat (Barcelona, E)
S31 Expanding the curative potential of transplantation in aggressive NHL
C. Haioun (Creteil, F)
S32 Summary: Taking transplantation to a new level:
how far have we come?
N. Schmitz (Hamburg, D)
Satellite symposium organised by F. Hoffmann-La Roche Ltd.
This symposium has been accredited under the EHA-ECAH pilot project and attending physicians are
entitled to receive 2 CME credit points on completion of the evaluation form. See page 14 for details.
Commercial affiliations
Name of speaker Affiliation
N. Schmitz None
R. Pettengell Research support, speakers’ bureau
R. Buckstein Research support
E. Montserrat Research support, consultant, scientific advisory board
C. Haioun None
Auditorium
19

Sunday, March 28, 2004 Scientific Programme
20
Satellite symposium
16:00 – 18:00 From oral to I.V. busulfan: new perspectives in
conditioning treatment
Chair: A. Gratwohl (Basel, CH)
S34 Introduction
A. Gratwohl (Basel, CH)
S35 Conditioning regimen for HSCT: What did we learn?
D. Blaise (Marseille, F)
S36 Pharmacokinetics/pharmacodynamics of oral busulfan-based conditioning
regimen
G. Vassal (Villejuif, F)
S37 Busulfan pharmacokinetics: improvement of the therapeutic window by
I.V. busulfan formulation
C. Puozzo (Castres, F)
S38 I.V. busulfan based conditioning regimen for HSCT:
current experience in adults
J.A. Russel (Calgary, CAN)
S39 Does I.V. busulfan reduce the risk of VOD?
E. Carreras (Barcelona, E)
S40 Discussion
A. Gratwohl (Basel, CH)
Open discussion
Satellite symposium organised by Pierre Fabre Médicament
This symposium has been accredited under the EHA-ECAH pilot project and attending physicians are
entitled to receive 2 CME credit points on completion of the evaluation form. See page 14 for details.
Commercial affiliations
Name of speaker Affiliation
A. Gratwohl Travel support
D. Blaise None
G. Vassal Research support
C. Puozzo Employee
J.A. Russel Research support, speakers’ bureau
E. Carreras None
Room J

Scientific Programme Sunday, March 28, 2004
Satellite symposium
16:00 – 18:00 Antifungal therapy: from principles to daily clinical practice
Chair: J.F. Tomas Martinez (Madrid, E)
16:00 S41 Introduction
J.F. Tomas Martinez (Madrid, E)
16:10 S42 High-risk BMT prophylaxis
F. Aversa (Perugia, I)
16:35 S43 Empiric antifungal therapy for haematologic and BMT patients
C. Cordonnier (Paris, F)
17:00 S44 Current and future therapeutic strategies with liposomal amphotericin-B
J. Gavalda (Barcelona, E)
17:25 S45 Combination antifungal therapy: What for amphotericin-B
G. Jackson (Newcastle, UK)
17:50 S46 Closing remarks
J.F. Tomas Martinez (Madrid, E)
Satellite symposium organised by Gilead Sciences
Satellite symposium
16:00 – 17:00 Current trends for the treatment of hemoglobinopathies
with focus on Thalassemia
Chair: E. Gluckman (Paris, F)
16:00 S47 Current results and perspectives of treatment of hemoglobinopathies
E. Gluckman (Paris, F)
16:20 S48 Long term follow-up for thalassemia and first report from the
hemoglobinopathy registry
E. Angelucci (Cagliari, I)
16:40 S49 Allogeneic peripheral stem cell transplantation in beta – thalassemia
K. Hossam (Cairo, EGY)
Satellite symposium organised by Fresenius BioTech GmbH
Room F
Room A
21

Sunday, March 28, 2004 Scientific Programme
18:30 – 20:45 Opening session
Chairs: J. Apperley (London, UK), J. Sierra (Barcelona, E)
18:30 50 Welcome
19:00 51 EBMT lecture
22
Congress President: J. Sierra (Barcelona, E)
National and local committees
President of the EBMT: J. Apperley (London, UK)
President of the Nurses Group: M. Stephens (London, UK)
Data Management Group: P. Ljungman (Huddinge, S)
SCT for CML in the imatinib era
J. Goldman (London, UK)
19:30 52 Van Bekkum Award
NOD2/CARD15 mutations of recipients and donors associate with GvHD and
TRM following allogeneic stem cell transplantation – results in 2 independent
cohorts of patients
E. Holler, G. Rogler, J. Brenmoehl, A. Dickinson, G. Jackson, H. Greinix, G. Fischer,
H. Herfarth, J. Hahn, G. Eissner, J. Schölmerich, R. Andreesen
(Regensburg, D; Newcastle, UK; Vienna, A)
19:50 Catalonia Philharmonic Orchestra and Puig-Reig Poliphonic chorus
The Catalonia Philharmonic Orchestra is renowned for its innovative style and
vanguard streak, whilst Puig-Reig Poliphonic started-out in the Catalonian
folk circuit and now performs widely in the international arena.
20:45 Welcome reception
in the foyers of the Palau de Congressos de Catalunya
Auditorium

Scientific Programme Monday, March 29, 2004
Educational session 1
08:00 – 08:45 Rational use of anti-fungal therapy
Chair: H. Einsele (Tuebingen, D)
53 Invasive aspergilosis
D. Denning (Manchester, UK)
54 Emerging fungal infections
C. Cordonnier (Creteil, F)
Educational session 2
08:00 – 08:45 Transplant in relapsed lymphoma
Chair: C. Gisselbrecht (Paris, F)
55 Non-Hodgkin lymphoma
C. Gisselbrecht (Paris, F)
56 Hodgkin's disease – autologous
A. Josting (Cologne, D)
57 Hodgkin's disease – allogeneic
A. Sureda (Barcelona, E)
Educational session 3
08:00 – 08:45 Prevention and treatment of acute GvHD
Chair: A. Bacigalupo (Genoa, I)
58 New pharmacological agents
A. Bacigalupo (Genoa, I)
Auditorium
Room J
Room D1
59 Monoclonal and policlonal antibodies and blocking coestimulatory molecules
A. Zander (Hamburg, D)
23

Monday, March 29, 2004 Scientific Programme
24
Workshop 1
08:00 – 08:45 Stem cell transplantation in autoimmune diseases
Chair: A. Tyndall (Basel, CH)
60 Current results and ongoing randomised trials
A. Tyndall (Basel, CH)
61 Advances in non-transplant treatment for autoimmune diseases
D. Jayne (Cambridge, UK)
Workshop 2
08:00 – 08:45 Making decisions based on chimerism and MRD
Chair: T. Lion (Vienna, A)
62 MRD: Quantitative PCR
J. Roman (Cordoba, E)
63 Chimerism: New insights
T. Lion (Vienna, A)
Workshop 3
08:00 – 08:45 Transplantation in ALL
Chair: J.M. Ribera (Barcelona, E)
S64 Transplants versus chemotherapy
B. Labar (Zagreb, HR)
S65 Post-transplant therapies: Maintenance, STI, McAb
D. Hoelzer (Frankfurt, D)
Room F
Room A
Room B

Scientific Programme Monday, March 29, 2004
09:00 – 10:30 Presidential symposium
Auditorium
Chairs: J. Apperley (London, UK), J. Sierra (Barcelona, E)
09:00 66 The VAV regulatory elements are functionally active in adult haematopoietic
stem cells of the mouse
E. Almarza, J. Segovia, G. Guenechea, S. G.Gomez, A. Ramirez, J. Bueren (Madrid, E)
09:15 67 Prognostic value of pre-transplant host thymic function in allogeneic
haematopoietic stem cell transplantation outcomes
E. Clave, V. Rocha, K. Talvensaari, M. Busson, C. Douay, M. Appert, C. Rabian,
M. Carmagnat, F. Garnier, A. Fillion, E. Gluckman, D. Charron, A. Toubert
(Paris, F; Helsinki, FIN)
09:30 68 Randomised controlled clinical trial of intracoronary autologous bone marrow
cell transfer post-myocardial infarction
B. Hertenstein, K.C. Wollert, G.P. Meyer, J. Lotz, S. Ringes-Lichtenberg,
C. Breidenbach, P. Lippolt, L. Arseniev, T. Korte, B. Hornig, M. Galanski, A. Ganser,
H. Drexler (Hannover, D)
09:45 69 The impact of post-remission therapy on outcome of patients with poor risk
MDS and secondary AML (sAML) treated with intensive chemotherapy with or
without stem cell transplantation in a joint study
T. de Witte, A. Hagemeijer, S. Suciu, A. Belhabri, M. Delforge, C. Aul, M. Aivado,
D. Selleslag, H. Schouten, V. Runde, A. Ferrant, T. Kovacsovics, P. Muus, J. Jansen,
F. Beeldens, A. Gratwohl, U. Hess, E. Helström-Lindberg, P. Wijermans,
G. Ossenkoppele, J.P. Marie, R. Willemze, S. Amadori
on behalf of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups
10:00 70 Transferring donor immunity to pathogens across HLA barriers
K. Perruccio, A. Tosti, E. Burchielli, I. Volpi, F. Topini, M.F. Martelli, A. Velardi (Perugia, I)
10:15 71 Adverse impact of FLT3 internal tandem duplication in patients with poor-risk
acute myeloid leukaemia allocated to autologous transplantation
S. Brunet, G. Perea, J. Esteve, J. Berlanga, P. Torres, M.P. Queipo de Llano, J. Bueno,
J.M. Ribera, M. Tormo, A. Llorente, J. Bargay, R. Guardia, C. Pedro, J. Sanchez,
P. Vivancos, J.M. Martí, L. Font, J.F. Nomdedéu, E. Montserrat, J. Sierra
for the CETLAM Group, Spain
25

Monday, March 29, 2004 Scientific Programme
26
Working party
11:00 – 13:00 Acute leukaemia
Chairs: M. Labopin (Paris, F), F. Frassoni (Genoa, I)
Report of ALWP activity:
72 Hematopoietic transplants in acute leukaemia in Europe
M. Labopin (Paris, F), F. Frassoni (Genoa, I)
73 Results of matched unrelated donor transplants in acute leukaemia
N. Basara (Idar-Oberstein, D)
74 Role of genetic factors in patients with leukaemia
V. Rocha (Paris, F)
75 Report of the Registration Study
V. Rocha (Paris, F)
Auditorium
76 Prospective study of imatinib after stem cell transplantation in Ph + ALL
O. Ottmann (Frankfurt, D)
77 Results of haematopoietic transplants show similar results in Eastern versus
Western Europe
B. Labar (Zagreb, HR)
78 Presentation of mesenchymal stem cell trial
K. le Blanc, O. Ringden, W. Fibbe, F. Frassoni (Stockholm, S; Leiden, NL; Genoa, I)
79 Prospective evaluation of early allogeneic transplantation in patients with
high risk acute myeloid leukaemia defined by karyotype and response to first
induction therapy treated in the multicenter aml HD98a treatment trial
R.F. Schlenk, D. Bunjes, F. Hartmann, J.T. Fischer, F. del Valle, A. Glasmacher,
H. Pralle, K. Götze, W. Grimminger, E. Koller, H.G. Mergenthaler, H. Salwender,
H. Kirchen, J. Preiss, S. Kremers, F. Griesinger, C. Waterhouse, U. Germing,
M. Hensel, K. Döhner, H. Döhner on behalf of the AMLSG ULM
80 Syngeneic haematopoietic stem cell transplantation in acute leukaemia.
A report of the acute leukaemia working party of the EBMT
L. Fouillard, M. Labopin, E. Gluckman, A. Gratwohl, V. Rocha, E. Polge, F. Frassoni
on behalf of the acute leukemia working party EBMT
Abstract

Scientific Programme Monday, March 29, 2004
Working party
11:00 – 12:30 Autoimmune diseases
Chairs: A. Tyndall (Basel, CH), A. Fassas (Thessalonika, GR)
11:00 81 Summary of activities and current autoimmune disease therapy environment
A. Tyndall (Basel, CH)
11:15 82 Scleroderma and ASTIS
D. Farge (Paris, F)
11:30 83 Multiple sclerosis and ASTIMS
R. Saccardi (Florence, I)
11:45 84 Cytopenias
J. Passweg (Basel, CH)
12:00 85 Crohns disease
C. Hawkey (Nottingham, UK)
12:15 86 Allogeneic HSCT – indications and limitations
A. Gratwohl (Basel, CH)
Room F
27

Monday, March 29, 2004 Scientific Programme
28
Working party
11:00 – 13:00 Solid tumours
Chairs: T. Demirer (Ankara, TR), J.P. Lotz (Paris, F)
11:00 87 Introduction
T. Demirer (Ankara, TR)
11:05 88 Random-ICE trial – an update
S. Leyvraz (Lausanne, CH)
11:15 89 Phase-I allo-mini transplant study – an update
D. Niederwieser (Leipzig, D)
11:25 90 New trial: phase-II randomised study in renal cell cancer
D. Blaise (Marseille, F)
11:35 91 HIDOC intergroup trial – an update
J. Ledermann (London, UK)
11:45 92 STWP-01 (relapsed ovarian cancer trial) – an update
T. Demirer (Ankara, TR)
11:55 93 Pegase-III trial – an update
P. Biron (Lyon, F)
12:05 94 New trial: phase-III metastatic breast cancer in PR setting
M. Aglietta (Turin, I)
12:15 95 New trial: phase-III metastatic breast cancer in CR setting
N. Ueno, M. Aglietta (Houston, USA; Turin, I)
Mare Nostrum
(Hotel Rey Juan Carlos)
12:25 96 Non-myeloablative stem cell transplantation in metastatic renal cell cancer:
delayed graft-versus-tumour effect is associated with conversion from mixed
to full donor haematopoietic chimerism
G. Massenkeil, J. Roigas, M. Nagy, C. Stroszczynski, A. Wille, M. Mapara, S. Loening,
B. Dörken, R. Arnold (Berlin, D)
12:40 97 Graft-versus-tumour effect following reduced-intensity allogeneic stem cell
transplantation in renal cell cancer
L. Barkholt, M. Bregni, J. Peccatori, P. Pedrazzoli, M. Remberger, O. Carminati,
F. Ciceri, J. Siena, R. Martino, J. Sierra, M. Brunes, S. Lenhoff, P. Corradini,
G. Rosti, T. Demirer, D. Niederwieser, O. Ringdén
on behalf of the Solid Organ Tumour Working Party
Abstract

Scientific Programme Monday, March 29, 2004
Senior patron symposium
12:30 – 13:30 The evolving world of cellular support IX
Chair: J. Apperley (London, UK)
12:30 S98 Introduction
J. Apperley (London, UK)
12:35 S99 Full dose vs reduced-intensity conditioning for haematopoietic stem cell
transplants: comparison of early outcomes
J. Sierra (Barcelona, E)
12:50 S100 Pegfilgrastim: the potential of the long acting G-CSF for stem cell mobilisation
N. Russell (Nottingham, UK)
13:05 S101 Mucosal damage: the burden on patients and the potential options for
management
N. Blijlevens (Nijmegen, NL)
13:20 Questions and interactive discussion
Senior patron symposium organised by Amgen (Europe) Ltd.
12:30 – 13:20 Meet the experts
Session 1: Stem cell plasticity
Chair: W. Fibbe (Leiden, NL)
Session 2: How to select the best unrelated donor for a patient
Chair: E. Carreras (Barcelona, E)
Session 3: Current indications of transplantation
in paediatric patients
Chair: D. Niethammer (Tuebingen, D)
Session 4: Best conditions for transplantation in
acute leukaemias
Chair: C. Gorin (Paris, F)
Session 5: The role of transplantation in acute
promyelocytic leukaemia
Chair: M.A. Sanz (Valencia, E)
Room J
Room A
Room B
Room D1
Room E1
Room E3
For the “Meet the Experts“ Sessions the participants have to register the day before at the
Secretariat. The number of participants are limited. “Tapas” and drinks will be served.
Availability will be on a first come – first serve basis. Fee: € 10.–
29

Monday, March 29, 2004 Scientific Programme
30
Oral session 1
13:30 – 15:30 Lymphoma 1
Auditorium
Chairs: A. Sureda (Barcelona, E), N. Schmitz (Hamburg, D)
13:30 O102 Rituximab versus nothing after high-dose consolidative first-line
chemotherapy with autologous stem cell transplantation in poor risk
diffuse large B-cell lymphoma. Results of the first interim analysis of
the randomised LNH98-B3 GELA study
C. Haioun, N. Mounier, J-F. Emile, P. Feugier, B. Coiffier, H. Tilly, C. Recher, C. Fermé,
J. Gabarre, R. Herbrecht, F. Morschhauser, C. Gisselbrecht (Créteil, Paris, Villejuif,
Vandoeuvre les Nancy, Pierre Bénite, Rouen, Toulouse, Strasbourg, Lille, F)
13:45 O103 Dose-escalated CHOP+ etoposide and repetitive autologous stem cell
transplantation (Mega-CHOEP) in primary treatment of aggressive lymphoma:
dose intensity counts
B. Glass, M. Kloess, A. Engert, W. Berdel, B. Metzner, L. Trümper, M. Löffler,
M. Pfreundschuh, N. Schmitz on behalf of DSHNHL
14:00 O104 High-dose therapy improves survival in relapsed follicular NHL;
data from the randomised CUP trial
H. Schouten, W. Qian, S. Kvaloy, A. Porcellinin, H. Hagberg, H. Johnsen, J. Doorduijn,
M. Sydes, G. Kvalheim (Maastricht, Rotterdam, NL; London, UK; Oslo, N; Noale, I;
Uppsala, S; Copenhagen, DK)
14:15 O105 Addition of rituximab to TBI/CY improves the outcome of first-line autologous
stem cell transplantation for mantle cell lymphoma
B. Seyfarth, V. Boehme, R. Stuhlmann, R. Sonnen, M. Kneba, N. Schmitz, P. Dreger
(Hamburg, Kiel, D)
14:30 O106 ASCT is not superior to conventional-dose, anthracyclin-based chemotherapy
in peripheral T-cell lymphoma
A. Gallamini, D. Mattei, C. Stelitano, M. Martelli, S. Cortellazzo, G. Todeschini,
F. Zaja, L Rigacci, L. Devizzi, E. Brusamolino, M. Brugiatelli, M. Federico
on behalf of the Intergruppo Italiano Linfomi (IIL)
14:45 O107 Prognostic factors affecting long-term outcome in patients with Hodgkin
lymphoma who relapse after autologous stem cell transplantation
M. Constans, A. Sureda, R. Arranz, M.D. Caballero, J.J. Lahuerta, J. Hernández-Boluda,
M. Vidal, J. García-Laraña, J. Rifón, J. Ribera, P. Fernández-Abellán, J. Moraleda,
M. Bernal, M. Mateos, M. Martín-Mateos, R. Córdoba, J. García-Conde, J. Sierra,
E. Conde on behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula
Osea (GEL/TAMO) Cooperative Group
15:00 O108 High dose therapy and autologous peripheral blood stem cell transplantation
as salvage treatment for HIV-associated lymphoma in patients on highly active
antiretroviral therapy. A multicentre study
A. Re, C. Cattaneo, M. Michieli, S. Casari, M. Spina, M. Rupolo, B. Allione, A. Nosari,
C. Schiantarelli, M. Viganò, I. Izzi, P. Ferremi, A. Lanfranchi, M. Mazzuccato, G. Carosi,
U. Tirelli, G. Rossi (Brescia, Aviano, Alessandria, Milan, Rome, I)
15:15 O109 Phase II study on sequential therapy with rituximab and PBSCT in
B lymphoproliferative disorders
P. Mazza, A. Maggi, M. Specchia, G. Pricolo, L. Stani, A. Prudenzano, B. Amurri,
G. Palazzo (Taranto, I)

Scientific Programme Monday, March 29, 2004
Oral session 2
13:30 – 15:30 Multiple myeloma
Room J
Chairs: A. Alegre (Madrid, E), B. Björkstrand (Stockholm, S)
13:30 O110 Preliminary results of the IFM9903 and IFM9904 protocols comparing
autologous followed by mini-allogeneic transplantation and double transplant
in high-risk de novo multiple myeloma
P. Moreau, F. Garban, T. Facon, C. Hulin, M. Attal, L. Benboubker, G. Marit,
J.G. Fuzibet, C. Doyen, L. Voillat, C. Berthou, P. Casassus, M. Monconduit,
M. Michallet, A. Najman, J.J. Sotto, J.L. Harousseau on behalf the IFM group
13:45 O111 Long-term follow-up shows no clinical improvment for CD34+ selection of
autologous transplant in patients with newly diagnosed myeloma despite
purging efficacy: an EBMT phase III randomised study
J.H. Bourhis on behalf of the CLWP Multiple Myeloma Subcomittee
14:00 O112 Outcome after autologous transplantation in primary plasma cell leukaemia
M. Drake, C. Morris, A. Hagman, T. Lopponen, B. Bjorkstrand, G. Gahrton, J. Apperley
on behalf of the the Myeloma Subcommittee of the Chronic Leukaemias Working
Party of the EBMT
14:15 O113 Outcome of autologous transplantation in rare and common-type multiple
myeloma
C. Morris, M. Drake, A. Hagman, T. Lopponen, B. Bjorkstrand, G. Gahrton, J. Apperley
on behalf of the the Myeloma Subcommittee of the Chronic Leukaemias Working
Party of the EBMT
14:30 O114 The combination of sRANKL/osteoprotegerin ratio, beta2-microglobulin and
CRP predicts survival in patients with multiple myeloma post autologous stem
cell transplantation
E. Terpos, M. Politou, R. Szydlo, E. Nadal, S. Avery, E. Olavarria, E. Kanfer,
J.M. Goldman, J.F. Apperley, A. Rahemtulla (London, UK)
14:45 O115 Low-dose TBI-based non-myeloablative allografting in newly diagnosed
multiple myeloma
B. Bruno, F. Patriarca, M. Rotta, D. Maloney, N. Mordini, M. Casini, A. Rambaldi,
F. Carnevale-Schianca, B. Allione, D. Soligo, P. Bavaro, P. De Fabritiis, L. Giaccone,
G. Aitoro, P. Corradini, A. Busca, R. Fanin, A. Gallamini, P. Coser, A. Levis, M. Aglietta,
E. Pogliani, M. Falda, M. Massaia, A. Palumbo, B. Sandmaier, R. Storb, M. Boccadoro
on behalf of Gruppo Italiano Trapianto di Midollo Osseo
15:00 O116 Changes in serum free light chain concentrations after high-dose melphalan
and autologous stem cell transplant in myeloma patients
G. Mead, A.R. Bradwell, R. Lovell, G. Pratt (Birmingham, UK)
15:15 O117 Risk factors influencing outcome after melphalan/fludarabine dose-reduced
allogeneic stem cell transplantation in patients with multiple myeloma
N. Kröger, J. Perez-Simon, H. Myint, H. Klingemann, A. Shimoni, A. Nagler, R. Martino,
A. Alegre, J. Tomas, R. Schwerdtfeger, M. Kiehl, A. Fauser, H. Sayer, A. Leon, J. Beyer,
T. Zabelina, F. Ayuk, R. Brand, J. San Miguel, A. Zander (Hamburg, Wiesbaden,
Idar-Oberstein, Jena, Marburg, D; Salamanca, Barcelona, Madrid, Jerez, E; Chicago, USA;
Tel Hashomer, IL, Leiden, NL)
31

Monday, March 29, 2004 Scientific Programme
32
Oral session 3
13:30 – 15:30 Reduced intensity transplant 1
Mare Nostrum
(Hotel Rey Juan Carlos)
Chairs: J.F. Tomas Martinez (Madrid, E), S. Slavin (Jerusalem, IL)
13:30 O118 Comparison between anti-thymocyte globulin and alemtuzumab as part of the
melphalan/fludarabine dose-reduced conditioning followed by HLA-matched
and mismatched unrelated stem cell transplantation in patients with lymphoid
malignancies
N. Kröger, K. Thomson, T. Zabelina, K. Peggs, R. Chopra, A. Shimoni, A. Nagler,
D. Milligan, C. Craddock, A. Parker, R. Schwerdtfeger, M. Kiehl, A. Fauser, H. Sayer,
R. Chakraverty, J. Beyer, F. Ayuk, A. Zander, S. Mackinnon
on behalf of the United Kingdom Collaborative Group for Non-Myeloablative
Transplantation and German Cooperative Transplant Group
13:45 O119 Effect of age and previous autologous transplantation on treatment-related
mortality and graft-versus-host disease in 110 patients treated with reducedintensity
conditioning and allografting for advanced haematological malignancies
P. Corradini, F. Zallio, J. Mariotti, M. Bregni, F. Ciceri, A. Bacigalupo, A. Dodero,
M. Lucesole, F. Patriarca, A. Rambaldi, R. Scimè, I. Majolino, G. Bandini, A.M. Gianni,
C. Tarella, A. Olivieri (Milan, Genoa, Ancona, Udine, Bergamo, Palermo, Rome,
Bologna, Turin, I)
14:00 O120 Reduced-intensity conditioning allogeneic peripheral blood stem cell
transplantation with or without alemtuzumab in acute myelogenous
leukaemia and myelodysplastic syndromes: comparison between two
prospective studies using fludarabine and oral busulphan
R. Martino, A. Ho, J. Sierra, M.D. Caballero, J.A. Pérez-Simón, A. Pagliuca,
S. Devereux, M. Kenyon, J. Besalduch, A. Urbano-Ispizua, G. Sanz, C. Solano,
J.M. Moraleda, G. Mufti for the Spanish and King's College (UK) Miniallo Study Groups
14:15 O121 Allogeneic haematopoietic stem cell transplantation after reduced-intensity
conditioning regimen from Societé Française de Greffe de Moelle et de
Therapie Cellulaire (SFGM-TC): study of pre-transplant and post-transplant
factors on outcome
M. Michallet, Q. Le, Z. Chir, K. Bilger, M. Attal, A. Huyn, D. Blaise, N. Milpied,
P. Moreau, P. Bordigoni, M. Kuentz, A. Sadoun, J.Y. Cahn, G. Socie, S. Fürst,
X. Thomas, A.S. Michallet, J.P. Jouet, J.M. Boiron (Lyon, Paris, Marseille,
Toulouse, Nantes, Nancy, Créteil, Poitiers, Besançon, Lille, Bordeaux, F)
14:30 O122 Intravenous busulfan versus melphalan-based reduced-intensity conditioning
prior to allogeneic stem cell transplantation: lower TRM and a more favourable
toxicity profile
A. Shimoni, I. Hardan, M. Yeshurun, A. Avigdor, A. Papatryphonos, F. Tsolakis,
A. Nagler (Tel-Hashomer, IL; Nicosia, Limassol, CY)
14:45 O123 Role of ATG in fludarabine phosphate-based nonmyeloablative stem cell
transplantation: a national dose-finding study
D. Bron, P. Zachee, J. Maertens, K. Theunissen, A. Ferrant, P. Martiat, C. Doyen,
L. Noens, W. Schroyens, D. Selleslag, H. Demuynck, R. Schots, A. De Meuter,
M. Boogaerts on behalf of the Belgian Hematological Society
continued on page 33

Scientific Programme Monday, March 29, 2004
13:30 – 15:30 Reduced intensity transplant 1 (continued)
15:00 O124 Comparison of reduced-intensity conditioning regimen to conventional
conditioning regimen in allogeneic haematopoietic stem cell transplantation
for acute myeloid leukaemia
L. Fouillard, M. Labopin, V. Rocha, J.M. Boiron, N. Gorin, E. Polge, F. Frassoni
on behalf of the acute leukemia working party of the EBMT
15:15 O125 Allogeneic peripheral blood stem cell transplantation after reduced-intensity
conditioning in refractory or relapsed Hodgkin lymphoma
I. Alvarez, A. Sureda, D. Caballero, A. Urbano, J. Ribera, M. Canales,
J. Hernández-Boluda, R. Arranz, T. Bernal, J. de la Serna, J.L. Diez, J. Moraleda,
D. Rubio-Félix, J. Sierra (Barcelona, Salamanca, Badalona, Madrid, Valencia, Oviedo,
Murcia, Zaragoza, E)
Oral session 4
13:30 – 15:30 Stem cell research / Non-haematopoietic tissue repair
Chairs: F. Pròsper (Pamplona, E), W. Fibbe (Leiden, NL)
13:30 O126 Increased engraftment after transplantation of CD34+ cells derived from two
unrelated umbilical cord blood units
A.J. Nauta, A.B. Kruisselbrink, W.A. Noort, R. Willemze, W.E. Fibbe (Leiden, NL)
13:45 O127 Repopulating haematopoietic stem cells show broad organ distribution after
bone marrow transplantation in a competitive mouse BMT model
R. Bistrian, Z. Fehervizyova, B. Rüster, R. Henschler (Frankfurt, D)
14:00 O128 Relevance of haematopoietic progenitors' mobilisation in the generation of
hepatocytes expressing bone marrow-derived markers
O. Quintana-Bustamante, A. Alvarez-Barrientos, I. Fabregat, J.A. Bueren, J.C. Segovia
(Madrid, E)
14:15 O129 Haematopoietic stem cell properties of Fanconi’s anaemia (subtype A)
knock-out mice
J.C. Segovia, P. Rio, S. Navarro, A. Jacome, J.A. Casado, J.A. Bueren (Madrid, E)
14:30 O130 Mesenchymal stem cells inhibit immune responses by arresting T-cell
proliferation in the G1 phase of the cell cycle
S. Glennie, I. Soeiro, E. Lam, F. Dazzi (London, UK)
Room F
14:45 O131 Mesenchymal stem cells are present in peripheral blood and can engraft after
allogeneic haematopoietic stem cell transplantation
E.M. Villarón, J. Almeida, N. López, M. Alcoceba, M.D. Caballero, J.A. Perez-Simon,
L.I. Sanchez-Abarca, F.M. Sanchez-Guijo, J.F. San Miguel, M.C. Del Cañizo
(Salamanca, E)
15:00 O132 Human umbilical cord blood-derived stem/progenitor cells for cardiac tissue
repair
A. Nagler, F. Grynspan, T. Peled, J. Mandel, E. Guetta, R. Holbova, M. Feinberg, I. Bar,
H. Galski, J. Leor (Tel-Hashomer, Jerusalem, IL)
15:15 O133 Chimeric status of buccal epithelium after human haematopoietic stem cell
transplantation
A. Spyidonidis, M. Waterhouse, R. Zeiser, P. Faber, M. Follo, K. Grüllich, H. Bertz,
J. Finke (Freiburg, D)
33

Monday, March 29, 2004 Scientific Programme
34
Oral session 5
13:30 – 15:30 Graft versus malignancy 1
Room A
Chairs: A. Figuera (Madrid, E), A. Torres (Cordoba, E)
13:30 O134 KIR-ligand disparities are associated with a decreased risk of relapse after
allogeneic stem cell transplantation for myeloid leukaemia
D.W. Beelen, H. Ottinger, S. Ferencik, A.H. Elmaagacli, R. Peceny, H. Grosse-Wilde
(Essen, D)
13:45 O135 KIR ligand incompatibility has no signifcant influence on outcome after
allogeneic haematopoietic cell transplantation from unrelated donors
M. Bornhäuser, H. Martin, R. Schwerdtfeger, C. Theuser, K.H. Frank, G. Ehninger
(Dresden, Wiesbaden, D)
14:00 O136 In vitro generation of tumour-specific T-cell lines depleted of alloantigenreactive
T-cells for transfer to renal-cell carcinoma patients undergoing
allogeneic blood stem cell transplantation
T.C. Wehler, B. Brandt, M. Nonn, R.G. Meyer, E. Schnürer, C. Wölfel, U. Hartwig,
C. Huber, W. Herr (Mainz, D)
14:15 O137 Indentification of a novel lymphoid-restricted minor histocompatibility antigen
encoded by a gene on a 3.6 Mb region on chromosome 17p13.2
H. Dolstra, B. de Rijke, A. Zoetbrood, F. Maas, P. Martin, B. Otterud, M. Leppert,
T. de Witte, E. van de Wiel-van Kemenade (Nijmegen, NL; Seattle, Salt Lake City, USA)
14:30 O138 Donor antigen-presenting cells regulate graft-versus-leukaemia effects after
allogeneic transplantation
E. Waller, J. Li, S. Lonial (Atlanta, USA)
14:45 O139 NK cell conditioning to T-cell replete mismatched BMT monfers immediate
responsiveness to infectious challenge
L. Ruggeri, K. Perruccio, C. Montagnoli, L. Romani, A. Velardi (Perugia, I)
15:00 O140 Graft rejection and leukaemia relapse after haploidentical stem cell
transplantation in adult patients with high-risk haematological diseases
L. Uharek, U. Hilbers, G. Hartung, T. Lange, M. Uhrberg, J. Hasenkamp, B. Glass,
D. Niederwieser (Leipzig, Duesseldorf, Goettingen, D)
15:15 O141 Mass spectrometry identification of renal-cell carcinoma antigens recognised
by allogeneic CD8+ cytotoxic T-lymphocyte clones from HLA-class I-matched
healthy donors
A. Dörrschuck, A. Schmidt, E. Schnürer, C. Wölfel, V. Lennerz, M. Glückmann,
C. Albrecht, C. Huber, M. Karas, T. Wölfel, W. Herr (Mainz, Frankfurt, Darmstadt, D)

Scientific Programme Monday, March 29, 2004
Oral session 6
13:30 – 15:30 Cytokines / Gene therapy
Chairs: M. Cavazzana-Calvo (Paris, F), J. Bueren (Madrid, E)
13:30 O142 Haematopoietic stem cell transplantation in RAG immunodeficient mice:
effect of Interleukin-7 treatment on increasing MHC incompatibility
I. André-Schmutz, D. Bonhomme, F. Yates, M. Malassis, F. Seltz, A. Fischer,
M. Cavazzana-Calvo (Paris, F)
13:45 O143 Influence of IL-18 on T- and NK-cells during allogeneic activation.
Relevance in aGVHD modulation
A. Paiva, R. Silva, A. Freitas, C. Teodósio, A. Orfão, F. Regateiro (Coimbra, Salamanca, P)
14:00 O144 Small interfering RNAs (siRNA) directed against wt1 gene induce apoptosis
and inhibit in vitro growth of leukaemia cells and acts additive with Bcr-Abl
siRNA
A.H. Elmaagacli, M. Koldehoff, R. Peceny, H. Ottinger, D.W. Beelen, B. Opalka (Essen, D)
14:15 O145 Lentiviral and retroviral gene therapy in a murine model of RAG-1 deficient
severe combined immunodeficiency
F. Yates, C. Lagresle, M. Malassis-Séris, E. Morillon, C. Hue, D. Stockholm, O. Danos,
F. Rieux-Laucat, J.P. de Villartay, A. Fischer, M. Cavazzana-Calvo (Paris, Evry, F)
14:30 O146 Kinetics of lentiviral vector integration sites in human NOD/SCID
repopulating cells
G. Guenechea, S. Laufs, A. Gonzalez-Murillo, K. Z. Nagy, M. L. Lozano, J. A. Bueren,
S. Fruehauf (Madrid, E; Heidelberg, D)
14:45 O147 Redirection of CMV-specific T-cells towards anti-leukaemic reactivity using
T-cell receptor gene transfer
M.H.M. Heemskerk, M. Hoogeboom, R. Hagedoorn, R. Willemze, J.H.F. Falkenburg
(Leiden, NL)
15:00 O148 Similar functional and phenotypic variations in human T-cells subjected to
retroviral-mediated gene transfer and ex vivo expansion
M. Lamana, A. Balas, J. Vicario, J. Bueren (Madrid, E)
15:15 O149 Lentiviral vector and suicide gene systems for T-cell therapies
W. Qasim, I. Chatziandreou, A. Thrasher, H. Gaspar (London, UK)
Room B
35

Monday, March 29, 2004 Scientific Programme
36
Oral session 7
13:30 – 15:30 Infectious diseases 1 – viral
Room H
Chairs: M. Rovira (Barcelona, E), H. Einsele (Tuebingen, D)
13:30 O150 Which children die from overwhelming adenoviral infection following
haematopoietic stem cell transplantation?
B. Kampmann, D. Cubitt, P. Naik, M. Depala, A. Hassan, K. Rao, H. Gaspar, G. Davies,
A. Jones, C. Cale, K. Gilmour, P. Amrolia, M. Real, M. Foo, N. Bennet-Rees, N. Hewitt,
P. Veys (London, UK)
13:45 O151 Identification of HLA-class II-restricted T-cell epitopes of adenovirus serotype 5
L.M. Haveman, M. Bierings, E. Legger, M.R. Klein, W. de Jager, A. Sette, S. Albani,
B.J. Prakken (Utrecht, NL; San Diego, USA)
14:00 O152 PCR-guided modulation of immunesuppression allows to manage EBV
reactivation in allogeneic SCT without immunotherapy
S. Cesaro, A. Murrone, C. Mengoli, M. Pillon, E. Calore, G. Tridello, S. Varotto, G. Palù,
C. Messina (Padua, I)
14:15 O153 Decrease of the EBV viral load under antiviral treatment after allogeneic
haematopoietic stem cell transplantation
S. Maury, K. Gourlain, C. Besson, C. Pautas, B. Pellegrin, M. Kuentz, D. Challine,
J.M. Pawlotsky, C. Cordonnier (Creteil, Paris, F)
14:30 O154 CMV-seropositive recipients of CMV-seronegative allografts do not mount a
pp65-antigen specific T-cell response during the first year post-transplant and
are at very high risk for CMV-viraemia and disease
S. Ganepola, U. Hilbers, G. Hartung, T. Lange, U.G. Liebert, J. Hofmann,
D. Niederwieser, L. Uharek (Leipzig, D)
14:45 O155 Viral load as risk factor for development of CMV disease after allogeneic stem
cell transplantation
P. Ljungman, J. Jonsson, E. Sparrelid, J. Aschan, L. Barkholt, K. Larsson,
I. Lewensohn-Fuchs, J. Winiarski, Z. Yun, O. Ringdén (Huddinge, S)
15:00 O156 Prospective comparison of PCR-based versus late mRNA-based preemptive
antiviral therapy for HCMV infection in patients after allogeneic stem cell
transplantation
H. Hebart, P. Ljungman, C. Paya, T. Klingebiel, J. Loeffler, I. Lewensohn-Fuchs,
L. Lunenberg, B. Top, R. Razonable, R. Patel, M. Litzow, G. Jahn, H. Einsele
(Tuebingen, D; Huddinge, S; Rochester, USA; Boxtel, NL)
15:15 O157 PCR-screening for viral infections during allogeneic SCT: clinical benefit and
economic considerations
S. Matthes-Martin, T. Lion, A. Lawitschka, B. Keck, S. Karlhuber, C. Peters, H. Gadner
(Vienna, A)

Scientific Programme Monday, March 29, 2004
Oral session 8a
13:30 – 14:30 Autoimmune diseases
Chairs: R. Saccardi (Florence, I), I. Espigado (Sevilla, E)
13:30 O158 Haematopoietic stem cell transplantation for severe systemic sclerosis:
the European experience
D. Farge, J. van Laar, A. Tyndall on behalf of the Scleroderma Study Group/Working
Party Autoimmune Diseases
13:45 O159 Immunoablation followed by stem cell rescue in refractory multiple sclerosis:
long-term follow-up of MRI and quality of life
R. Saccardi, G.L. Mancardi, P. Di Bartolomeo, A. Donelli, M. Filippi, F. Gualandi,
G. La Nasa, A. Murialdo, F. Pagliai, F. Papineschi, G. Saglio, A. Solari, A. Marmont
(Florence, Genoa, Pescara, Modena, Milan, Cagliari, Pisa, Orbassano, I)
14:00 O160 Impact of cellular therapies on autoreactive, long-lived plasma cells in
autoimmune diseases
F. Hiepe, R. A. Manz, B. F. Hoyer, A. Thiel, T. Alexander, G. Massenkeil,
G. R. Burmester, R. Arnold, A. Radbruch (Berlin, D)
14:15 O161 Autologous stem cell transplantation for severe juvenile idiopathic arthritis:
a multicentre survey
N. Wulffraat, I. de Kleer, D. Brinkman, A. Ferster, L. Wedderburn, G. Horneff, P. Veys,
R. Bredius, A. Prieur, M. Abinun, F. Zintl, R. Ten Cate, W. Kuis (Utrecht, Leiden, NL;
Brussels, B; London, Newcastle, UK; Halle, Jena, D; Paris, F)
Oral session 8b
14:30 – 15:30 Aplastic anaemia
Room D1
Room D1
Chairs: P. Marin (Barcelona, E), J. Marsh (London, UK)
14:30 O162 Evidence for the polymorphism VNDR 1349 (CA) 12 of IFN-gamma as a factor
associated with susceptibility to acquired aplastic anaemia
C. Dufour, L. Giordani, J. Svahn, M. Capasso, A. Marrone, P. Di Michele, R. Haupt,
A. Bacigalupo, C. Pongiglione, D. Longoni, M. Calvillo, A. Locasciulli, U. Ramenghi,
M. Pillon, G. Menna, A. Iori, M. Lanciotti, A. Iolascon on behalf of the AIEOP AA Study Group
14:45 O163 Horse ATG (ATGAM) versus rabbit ATG (Fresenius) for treatment of aplastic
anaemia in children: results of prospective double-blind randomised
single-centre trial
M.A. Maschan, G. Novichkova, D.D. Baidildina, E.V. Suntzova, E.G. Kravchenko,
O.V. Goronkova, L.I. Zharikova, M.M. Schneider, N.Y. Bogatcheva, A.A. Maschan
(Moscow, RUS)
15:00 O164 How can we quantify the risk of squamous cell cancer (SCC) and death in
transplanted versus non-transplanted patients with Fanconi's Anaemia
G. Socie, P. Rosenberg, E. Gluckman, B. Alter (Paris, F; Rockville, USA)
15:15 O165 Integral management of Fanconi's anaemia patients in Spain
J.A. Bueren, J. Surrallés, J.A. Casado, E. Callen, A.A. Jacome, J.C. Segovia,
J.C. Segovia, S. Navarro, J. Sevilla, A. Cantalejo, E. Cela, G. Garrido, A. Villegas,
C. Benavente, J. Cervera, A. Muñóz, M.P. Martinez-Badas, M. Tapias, J. Sánchez-
Calero, A. Rodriguez Villa, T. Ferro, M. Talavera, I. Badell, J. Estella, A. Dasí,
J.J. Ortega, L. Madero on behalf of the Spanish Network on Fanconi Anemia
37

Monday, March 29, 2004 Scientific Programme
38
Working party
16:00 – 18:00 Chronic leukaemia
Chairs: D. Niederwieser (Leipzig, D), P. Corradini (Milan, I)
16:00 166 Activities of the CLWP
D. Niederwieser (Leipzig, D)
16:10 167 DMSO toxicity
C. Morris (Belfast, UK)
16:20 168 Phase III trial of DLI versus imatinib followed by DLI for CML relapse patients
C. Guglielmi (Rome, I)
16:30 169 Plasma cell leukaemia
M. Drake (Belfast, UK)
16:40 170 A phase II-III, randomised, multicentre, clinical trial comparing thalidomide
+ dexamethasone versus thalidomide + dexamethasone + bortezomib for
myeloma patients relapsing after autologous transplant
L. Garderet (Paris, F)
16:50 171 A phase II study comparing non-myeloablative allogeneic haematopoietic
stem cell transplantation following autologous transplantation to autologous
transplantation alone in multiple myeloma (NMAM2000)
B. Björkstrand (Huddinge, S)
16:55 172 Stem cell transplantation in MDS: improvement over time
T. de Witte (Nijmegen, NL)
173 A prospective 2 x 2 randomised study evaluating the role of remission
induction and consolidation chemotherapy prior to allogeneic stem cell
transplantation and mobilised peripheral blood stem cells versus bone
marrow stem cells using HLA-identical sibling donors in patients with
myelodysplastic syndromes and

Scientific Programme Monday, March 29, 2004
17:40 – 18:00 Chronic leukaemia (continued)
178 Registry overview and EBMT CLL Autotransplant Protocol
M. Michallet (Lyon, F)
179 Prolymphocytic leukaemia
W. Wiktor-Jedrzejczak (Warsaw, PL)
180 Purging for autotransplant
L. Fouillard (Paris, F)
181 The impact of non-myeloablative conditioning on the outcome of allogeneic
stem cell transplantation for chronic lymphocytic leukaemia: a retrospective
study by the EBMT CLWP
P. Dreger, A. van Biezen, R. Brand, J. Esteve, R. Martino, G. Lambertenghi Deliliers,
J. Hansz, J. Finke, E. Kimby, D. Milligan, M. Michallet, D. Niederwieser
on behalf of the Chronic Leukemia Working Party
181a Prospective EBMT study of RICT
P. Dreger (Hamburg, D)
Working party
16:00 – 18:00 Paediatric diseases
Chairs: G. Dini (Genoa, I), D. Niethammer (Tuebingen, D)
182 How to improve data transfer from National Registries to EBMT Registry
J. Cornish, J. Ortega, T. Klingebiel, A. Pession, C. Ruiz (Bristol, London, UK;
Barcelona, E; Frankfurt, D; Bologna, I)
183 The Haemoglobinopathies Registry
E. Angelucci (Cagliari, I)
184 Haematopoietic stem cell transplantation in children with juvenile
myelomonocytic leukaemia: results of the EWOG-MDS trial
F. Locatelli, P. Noellke, M. Zecca, L. Korthhof, L. Korthhof, E. Lanino, C. Peters,
A. Pession, H. Kabish, C. Uderzo, C.S. Bonfim, P. Bader, D. Dilloo, J. Stary, A. Fischer,
T. Revesz, B. Strahm, U. Duffner, C. Niemeyer on behalf of EWOG-MDS
185 Quality of life in children undergoing mini-transplants:
proposal for a cooperative study
A. Lawitshka, A.M. Faraci (Vienna, A; Genoa, I)
186 The Registration Study
G. Dini, J. Cornish, T. Klingebiel, J. Ortega, F. Locatelli, E. Gluckman, M. Labopin
(Genoa, Pavia, I; Bristol, UK; Frankfurt, D; Barcelona, E; Paris, F)
18:00 – 19:00 Physicians poster presentation (P407–P668)
(please refer to pages 69–89 for details)
Abstract
Room J
Level -1
39

Monday, March 29, 2004 Scientific Programme
40
Working party
16:00 – 18:00 Aplastic anaemia
Chairs: H. Schrezenmeier (Ulm, D), J. Passweg (Basel, CH)
187 Working Party report: state of the registry, ongoing studies
H. Schrezenmeier (Ulm, D)
Clinical trials and prospective studies
188 EBMT-G-CSF trial: ATG plus cyclosporin A with or without G-CSF: update
A. Tichelli, J. Marsh, G. Socié, H. Schrezenmeier (Basel, CH; London, UK; Paris, F;
Ulm, D)
189 Fludarabine, cyclophosphamide and ATG for alternative donor transplants in
aplastic anaemia: a report of the SAA Working Party
A. Bacigalupo, F. Locatelli, G. Socié, G. Dini, A. Pession, A. Locasciulli, A. Prete,
H. Schrezenmeier on behalf of Severe Aplastic Anemia Working Party of the
European Group for Blood and Marrow Transplantation, (SAA WP-EBMT)
190 HLA-identical sibling transplantation with reduced intensity conditioning in
elderly patients
A. Bacigalupo, J. Marsh (Genoa, I; London, UK)
Discussion of new proposals for refractory aplastic anemia, relapsed aplastic
anemia, non-severe aplastic anemia
Working Party Registry and retrospective studies
191 Late clonal complications after stem cell transplantation or
immunosuppression for aplastic anaemia
G. Socié, A. Tichelli (Paris, F; Basel, CH)
192 Comparison of outcome after alternative donor transplantation or
immunosuppression in patients failing to respond to ATG
J. Passweg, E. Korthof, H. Schrezenmeier (Basel, CH; Leiden, NL; Ulm, D)
193 Influence of previous immunosuppressive treatment on the outcome of
matched unrelated donor stem cell transplantation for severe aplastic anaemia
E. Korthof, M. Knoester, J. Passweg, H. Schrezenmeier (Leiden, NL; Basel, CH; Ulm, D)
194 Autologous recovery after SCT for SAA: What is the outcome?
S. McCann (Dublin, IRL)
195 Allogeneic transplantation for PNH
H. Schrezenmeier, G. Socié, A. Tichelli (Ulm, D; Paris, F; Basel, CH)
Discussion of new proposals for retrospective studies
18:00 – 19:00 Physicians poster presentation (P407–P668)
(please refer to pages 69–89 for details)
Abstract
Mare Nostrum
(Hotel Rey Juan Carlos)
Level -1

Scientific Programme Tuesday, March 30, 2004
Educational session 4
08:00 – 08:45 HLA and clinical outcome
Chair: A. Madrigal (London, UK)
196 Clinical impact of molecular matching: the NMDP perspective
C. Anasetti (Seattle, USA)
197 Clinical impact of molecular matching: the European view
A. Madrigal (London, UK)
198 Minor histocompatibility antigens: current and future impact in stem cell
transplantation
E. Goulmy (Leiden, NL)
Educational session 5
08:00 – 08:45 Reduced intensity transplantation
Chair: E. Montserrat (Barcelona, E)
199 CLL and low grade lymphomas
E. Montserrat (Barcelona, E)
200 AML
R. Martino (Barcelona, E)
201 Multiple myeloma
B. Bjorkstrand (Huddinge, S)
Educational session 6
08:00 – 08:45 Regenerative therapy with stem cells
Chair: F. Pròsper (Pamplona, E)
202 Stem cell plasticity
F. Prosper (Pamplona, E)
203 Cardiac repair
C. Stamm (Rostock, D)
204 Vascular regeneration
T. Asahara (Kobe, J)
Auditorium
Room J
Mare Nostrum
(Hotel Rey Juan Carlos)
41

Tuesday, March 30, 2004 Scientific Programme
42
Workshop 4
08:00 – 08:45 Early diagnosis and pre-emptive therapy
in infectious diseases
Chair: P. Ljungman (Huddinge, S)
205 Viral
P. Ljungman (Huddinge, S)
206 Fungal
H. Einsele (Tuebingen, D)
Workshop 5
08:00 – 08:45 Tailoring the innoculum for allo-SCT
Chair: J.M. Moraleda (Murcia, E)
207 Stem cell dose: patient and donor issues
V. Rocha (Paris, F)
208 Mesenchymal cells: effects on engraftment and GvHD
F. Frassoni (Genoa, I)
Workshop 6
08:00 – 08:45 Different strategies in antitumoral immunotherapy
Chair: J. Apperley (London, UK)
209 Donor lymphocyte infusions
J. Apperley (London, UK)
210 Gene modified cellular vaccines for haematological malignancies:
current status
M. Theobald (Mainz, D)
Room F
Room A
Room B

Scientific Programme Tuesday, March 30, 2004
Joint session Nurses / Physicians
09:00 – 10:30 Critical care in transplantation ◆
Chairs: J. Apperley (London, UK), M. Stephens (London, UK)
The different points of view from a haematologist, an intensivist, a nurse and
a family member
09:00 211 Haematologist’s perspective
H. Schouten (Maastricht, NL)
09:20 212 Intensivist’s perspective
E. Azoulay (Paris, F)
09:40 213 Nurse’s perspective
O. Power (Dublin, IRL)
10:00 214 Family’s perspective
B. Kay (Grantham, UK)
Plenary session
09:00 – 10:30 Stem cell sources for allotransplants
Chairs: C. Gorin (Paris, F), A. Urbano-Ispizua (Barcelona, E)
09:00 215 Marrow versus peripheral blood
N. Schmitz (Hamburg, D)
09:30 216 Cord blood versus marrow in children and adults
E. Gluckman (Paris, F)
10:00 217 T-cell depleted versus non T-cell depleted transplants
J. Cornelissen (Rotterdam, NL)
◆ Simultaneous translation into Spanish
Auditorium
Room J
43

Tuesday, March 30, 2004 Scientific Programme
44
Working party
11:00 – 13:00 Infectious diseases
Chairs: C. Cordonnier (Creteil, F), P. Reusser (Porrentruy, CH)
218 Reactivation of toxoplasmosis infection after allogeneic haematopoietic stem
cell transplantation. A prospective study by the European Group for Blood and
Marrow Transplantation Infectious Diseases Working Party
R. Martino, S. Bretagne, H. Einsele, A.J. Ullmann, J. Maertens, R. Parody,
C. Cordonnier for the Infectious Diseases Working Party of the EBMT
219 CMV-retinitis after haematopoietic stem cell transplantation; the final report
on a survey from the EMBT Working Party for Infectious Diseases
K. Larsson, J. Maertens, J. Arvidson, G. Juliusson, H. Einsele, A.N. Békássy,
A. Lindmark, G. Gentile, R. De la Camara, A. Dekker, A. Zander, G. Socié, M. Boeckh,
P. Ljungman, C. Cordonnier on behalf of the Infectious Diseases Working Party
220 Long-term follow-up of hepatitis C virus-infected patients after stem cell
transplantation
P. Ljungman, V. Gomez-Garcia de Soria, A. Ferrant, A. Locasciulli, I. Franklin,
J. O'Riordan, M. Rovira, J. Rodrigues Fernandez, L. Perez-Bercoff, A. Gruber,
A. Fassas, P. Shaw, M. Potter, A. Békássy, L. Brinch, H. Greinix
on behalf of the Infectious Diseases and Late Effects Working Parties
221 Management of febrile neutropenia in regards to fungal infection in stem cell
transplant patients: a survey in the EBMT centres
D. Engelhard, C. Cordonnier on behalf of the Infectious Diseases Working Party
222 Results of a prospective study on central nervous system complications
following BMT/SCT by the EBMT-IDWP
A.J. Ullmann, J. Maertens, P. Ljungman, R. Martino, M. Faraci, P.J. Shaw,
S. Cesaro, P. Mundhenk, E. Faber, K. Schäfer-Eckert, H. Einsele, A. Bosi,
A. Locasciulli, M. Sanz, M. Rovira, A. Wahlin, C. Cordonnier, D. Engelhard
on behalf of the Infectious Diseases Working Party
223 Comparison between early and late immunisation with three doses of an
heptavalent pneumococcal conjugate vaccine in allogeneic stem cell
transplant recipients (EBMT IDPW01 trial)
C. Cordonnier, V. Chesnel, M. Labopin, P. Ribaud, A. Ullmann, K. Pauksen,
T. Ruutu, H. Einsele, A. Locasciulli, A. Karadimitris, K. Yakouben,
R. de la Camara, R. Martino, M. Rovira, P. Reusser, D. Engelhard, P. Ljungman
on behalf of the Infectious Diseases Working Party
224 Immunisation guidelines in stem cell transplant patients: an update
P. Ljungman (Huddinge, S)
Auditorium
225 A survey on the use of caspofungin in combination with voriconazole,
amphotericin B or ambisome in the treatment of invasive mycosis
(aspergillosis) in paediatric patients who underwent high-dose chemotherapy
or haematopoietic stem cell transplantation
S. Cesaro (Padua, I)
226 Validation of severity grades of infectious complications in allogeneic stem
cell transplant with reduced-intensity conditioning regimens
C. Cordonnier (Creteil, F)
continued on page 45
Abstract

Scientific Programme Tuesday, March 30, 2004
11:00 – 13:00 Infectious diseases (continued)
227 Survey on the impact of prior invasive aspergillosis in allogeneic recipients
conditioned with a reduced-intensity regimen
R. Martino (Barcelona, E)
228 Prospective study on candidemia in onco-haematology patients
O. Cornely (Cologne, D), A. Ullmann (Mainz, D)
Working party
11:00 – 12:30 Lymphoma
Chairs: C. Gisselbrecht (Paris, F), N. Schmitz (Hamburg, D)
229 Facts and trends in transplantation for lymphoma
N. Schmitz (Hamburg, D)
230 Lymphoma transplants in children
A. Claviez (Kiel, D)
231 Transplantation in Hodgkin's disease: autotransplants (HD-R^2)
A. Josting (Cologne, D)
232 Transplantation in Hodgkin's disease: allotransplants (HD-R Allo)
A. Sureda (Barcelona, E)
233 Transplantation in mantle cell lymphoma and follicular lymphoma
(The European MCL network)
M. Dreyling (Munich, D)
234 The CUP trial
H. Schouten (Maastricht, NL)
235 The EBMT LYM1 trial – an update
R. Pettengell (London, UK)
New projects – proposals and discussion
12:00 – 13:00 How to get published
Room A
How do I prepare my article? How do I submit it? What the editors are looking
for? What happens in peer review? What happens at the publishers?
John Goldman, Editor of Bone Marrow Transplantation (BMT), together with Jason Wilde
and Victoria Giblin from Nature Publishing Group will present the editorial and
publishing perspectives, and answer delegates’ questions.
12:00 – 13:30 European LeukemiaNet
Open forum for presentation of the European haematopoetic stem cell
transplantation platform
D. Niederwieser (Leipzig, D)
Room J
Room F
45

Tuesday, March 30, 2004 Scientific Programme
46
Working party
11:00 – 13:00 Late effects
Chairs: G. Socié (Paris, F), A. Tichelli (Basel, CH)
11:00 236 Report from the chairman of the LE WP
G. Socié (Paris, F)
11:15 237 Cardio-pulmonary complications
C. Uderzo (Monza, I)
11:30 238 Late vascular complications: overview on the subject and study presentation
D. Wojcik, A. Tichelli (Wroclaw, PL; Basel, CH)
11:50 239 Quality of life in RIC versus myeloablative transplantation:
overview on the subject and study
J. Halter, J. Weis (Zurich, CH; Freiburg, D)
12:10 240 Late effects in the IMUST study
J. Hows (Bristol, UK)
12:25 241 Bronchiolitis obliterans, BOS
M. Arat (Ankara, TR)
12:40 242 Rules on the LE-WP
E. Kansu (Ankara, TR)
12:55 243 Closing
G. Socié (Paris, F)
12:30 – 13:20 Meet the experts
Session 6: Transplantation in myelodysplastic syndromes
Chair: T. de Witte (Nijmegen, NL)
Session 7: Transplantation in solid tumours
Chair: G. Rosti (Ravenna, I)
Session 8: Reduced-intensity conditioning transplants
Chair: S. Slavin (Jerusalem, IL)
Session 9: Haploidentical transplantation
Chair: M. Martelli (Perugia, I)
Session 10: New perspectives in umbilical cord transplantation
Chair: M.N. Fernández (Madrid, E)
Mare Nostrum
(Hotel Rey Juan Carlos)
Room B
Room D1
Room E1
Room E5
Room E3
For the “Meet the Experts“ Sessions the participants have to register the day before at the
Secretariat. The number of participants are limited. “Tapas” and drinks will be served.
Availability will be on a first come – first serve basis. Fee: € 10.–

Scientific Programme Tuesday, March 30, 2004
Oral session 9
13:30 – 15:30 Acute leukaemia / Myelodysplastic syndromes
Auditorium
Chairs: S. Brunet (Barcelona, E), J. Cornelissen (Rotterdam, NL)
13:30 O244 Unrelated donor haematopoietic stem cell transplantation with myeloablative
preparative regimens for the treatment of de novo acute myelogenous
leukaemia in patients older than 44 years
M. de Lima, M. Labopin, V. Rocha, J. Finke, G. Ehninger, T. Ruutu, D. Bunjes, L. Kanz,
A. Fauser, N. Gorin, F. Frassoni on behalf of the Acute Leukemia Working Party
(ALWP) of the European Blood and Marrow Transplant (EBMT) Group
13:45 O245 Intensification of the conditioning regimen for high-risk AML patients with
188 Re-labeled anti-CD 66 monoclonal antibody: final results of a phase I-II study
D. Bunjes, M. Wiesneth, I. Buchmann, S. Von Harsdorf, R. Schlenk, U. Seitz,
J. Kotzerke, C. Duncker, M. Stefanic, W. Grimminger, D. Dohr, A. Buck, G. Glatting,
M. Ringhoffer, T. Zenz, L. Bergmann, H. Döhner, S. Reske (Ulm, Mainz, Dresden,
Frankfurt, D)
14:00 O246 Allogeneic stem cell transplantation for patients with acute myeloid leukaemia
or myelodysplastic syndrome having chromosome 5 and/or 7 abnormalities
H.M. van der Straaten, A. van Biezen, R. Brand, A.V.M.B. Schattenberg, R.M. Egeler,
R.M. Barge, J.J. Cornelissen, H.C. Schouten, G.J. Ossenkoppele, L.F. Verdonck
on behalf of The Netherlands Stem Cell Transplant Registry
14:15 O247 Prognosis of patients with core binding factor acute myeloid leukemia after
relapse: Results of the original data based meta-analysis of the German
AML-Intergroup
R.F. Schlenk, J. Krauter, T. Büchner, C. Sauerland, R. Krahl, D. Niederwieser,
G. Ehninger, M. Schaich, H. Döhner, A. Ganser on behalf of the German AML Intergroup
14:30 O248 Immediate allogeneic haematopoietic cell transplantation during induction
chemotherapy in high-risk acute myeloid leukaemia
U. Platzbecker, C. Thiede, T. Illmer, M. Schaich, U. Schäkel, U. Schuler, A. Neubauer,
G. Ehninger, M. Bornhäuser (Dresden, Marburg, D)
14:45 O249 Feasibility and results of autologous stem cell transplant in de novo acute
myeloid leukaemia in patients over 60 years old. Final results of the
CETLAM99 protocol
A. Oriol, J. Ribera, J. Esteve, R. Guardia, J. Bueno, S. Brunet, M. Tormo, A. Llorente,
C. Pedro, J. Sanchez, L. Font, A. Novo, R. Vilà, A. Julià, E. Carreras, J. Sierra, E. Feliu,
E. Montserrat on behalf of the CETLAM Cooperative Group
15:00 O250 Myeloablative treosulfan as preparative regimen for allogeneic haematopoietic
stem cell transplantation: a single-centre experience
R. Trenschel, M. Ditschkowski, A. Elmaagacli, N. Steckel, M. Hlinka, R. Peceny,
H. Ottinger, M. Koldehoff, H. Biersack, D.W. Beelen (Essen, D)
15:15 O251 Low transplant related mortality following allogeneic peripheral stem cell
transplantation with reduced-intensity conditioning regimen in myelodysplastic
syndrome and acute myeloid leukaemia from MDS:
a prospective study from GITMO
E.P. Alessandrino, G. La Nasa, L. Malcovati, P. De Fabritiis, M. Bregni, P. Mazza, P. Di
Bartolomeo, A. Locasciulli, R. Scimè, N. Mordini, A. Olivieri, G. Lambertenghi Deliliers,
A. Bacigalupo on behalf of the GITMO (Gruppo Italiano Trapianti di Midollo Osseo)
47

Tuesday, March 30, 2004 Scientific Programme
48
Oral session 10
13:30 – 15:30 Lymphoma 2
Chairs: J. García-Conde (Valencia, E), C. Gisselbrecht (Paris, F)
13:30 O252 Graft-versus-lymphoma effect in peripheral T-cell non-Hodgkin lymphomas
after reduced-intensity conditioning followed by allogeneic transplantation
P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni,
F. Patriarca, M. Boccadoro, A. Rambaldi, A.M. Gianni, C. Tarella
(Milan, Turin, Bolzano, Modena, Udine, Bergamo, I)
13:45 O253 Efficacy of autologous stem cell transplant in aids-related lymphoma patients
J.L. Diez-Martin, P. Balsalobre, P. Miralles, A. Gomez-Pineda, R. Carrion, I. Buño,
S. Resino, E. Conde, J.M. Ribera, D. Serrano, J. Berenguer
on behalf of the Spanish cooperative groups GELTAMO and GESIDA
14:00 O254 Single or tandem autologous stem cell transplantation for relapsed Hodgkin
lymphoma according to prognostic factors at relapse
P. Brice, F. Morschhauser, P. Feugier, P. Quittet, M. Divine, C. Sebban, C. Ferme,
O. Casanovas, P. Colombat on behalf of the SFGM
14:15 O255 Predictive value of gallium-67 scintigraphy in Hodgkin lymphoma patients
undergoing haematopoietic stem cell transplantation
I. García Escobar, J. Pérez Simón, P. Tamayo, J. Mateos, E. Pérez, D. Caballero,
J. García-Talavera, J. San Miguel (Salamanca, E)
14:30 O256 Allogeneic or autologous haematopoietic stem cell transplantation for
non-Hodgkin lymphoma: status at transplantation and outcome
A. Ferrant, E. Van Den Neste, L. Michaux, J. Durbecq, D. Latinne (Brussels, B)
Room J
14:45 O257 Comparison of outcome of diffuse large B-cell lymphoma versus peripheral
T-cell lymphoma with high-dose chemotherapy and autologous stem cell
transplantation
M.K. Angelopoulou, A. Nademanee, A. Dagis, A. Molina, H. Fung, P.M. Parker,
M.R. O'Donnell, A. Stein, P. Falk, A. Krishnan, N. Kogut, R. Rodriguez, F. Sahebi,
E.P. Smith, D. Snyder, R. Spielberger, J. Zain, L. Popplewell, D. Smith, S.J. Forman
(Duarte, USA)
15:00 O258 Poor mobilisation status: an independent prognostic factor to predict outcome
in patients with malignant lymphomas
V. Pavone, F. Gaudio, U. Vitolo, G. Console, A. Guarini, T. Perrone, A. Giordano,
R. De Francesco, G. Loseto, P. Iacopino, E. Gallo, V. Liso (Bari, Turin, Reggio Calabria, I)
15:15 O259 ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell
mobilisation regimen in patients with relapsed or refractory diffuse large cell
and Hodgkin lymphoma: a single result of 100 patients
S. Akhtar, A. El Weshi, M. Rahal, H. Humaidan, A. Tbakhi, I. Maghfoor (Riyadh, SA)

Scientific Programme Tuesday, March 30, 2004
Oral session 11a
13:30 – 14:30 Reduced intensity transplants 2
Chairs: E. Conde (Santander, E), D. Caballero (Salamanca, E)
13:30 O260 Reduced-intensity conditioning with thiotepa, fludarabine and melphalan for
allogeneic transplantation in multiple myeloma
I. Majolino, M. Gabriel Arana, M. Riccardi, A. Locasciulli, A. Bacigalupo,
P. Di Bartolomeo, R. Scimè, A. Olivieri, F. Narni, P. De Fabritiis, P. Corradini
on behalf of GITMO (Gruppo Italiano Trapianti di Midollo Osseo)
13:45 O261 A comparison of non-myeloablative versus reduced conditioning for
allogeneic stem cell transplantation
O. Ringdén, K. Le Blanc, M. Uzunel, J. Mattsson, L. Barkholt, M. Remberger
(Stockholm, S)
14:00 O262 Radioimmunotherapy with Bismuth-213 as conditioning for non-myeloablative
marrow transplantation: a dose de-escalation study
W. A. Bethge, D.S. Wilbur, D. Hamlin, E.B. Santos, R. Storb, B.M. Sandmaier
(Tuebingen, D; Seattle, USA)
14:15 O263 High response rate to DLI based strategies for the treatment of refractory
disease/relapse following allogeneic HSCT for lymphoproliferative disease
N. Russell, J. Byrne, E. Das-Gupta, M. Gilyead, A. Haynes (Nottingham, UK)
Oral session 11b
14:30 – 15:30 Solid tumours
Mare Nostrum
(Hotel Rey Juan Carlos)
Mare Nostrum
(Hotel Rey Juan Carlos)
Chairs: J. Perez Calvo (Pamplona, E), G. Rosti (Ravenna, I)
14:30 O264 Bone marrow mammaglobin expression as a tool for assessing micrometastatic
disease after reduced-intensity allografting for advanced breast cancer
M. Bregni, J. Peccatori, F. Ciceri, M. Bernardi, A. Pescarollo, E. Guggiari, F. Lunghi,
S. Deola, F. Re, M. Monari, B. Mazzi, K. Fleischhauer (Milan, I)
14:42 O265 Early high-dose chemotherapy for adult patients with extragonadal nonseminomatous
germ cell tumours of the mediastinum and retroperitoneum
G. Rosti, G. Papiani, H. Wandt, S. Leyvraz, T. Demirer, U. De Giorgi
on behalf of the EBMT Solid Tumours Working Party
14:54 O266 High-dose chemotherapy with stem cell support in high-risk primary breast
cancer. Effect on overall survival
T. Palshof on behalf of the DBCG Transplant Group
15:06 O267 Feasibility of high-dose paclitaxel in the conditioning regimen for autologous
haematopoietic transplantation
J. Perez-Calvo, O. Fernandez-Hidalgo, J.M. Aramendia, E. Salgado, J.M. Lopez-Picazo,
J. Rebollo, J. Rifon, F. Prosper, E. Rocha, S. Martin-Algarra (Pamplona, E)
15:18 O268 Long-term follow-up after high-dose chemotherapy for paediatric patients
with extragonadal germ cell tumour
U. De Giorgi, G. Rosti, S. Slavin, I. Yaniv, J.L. Harousseau, A. Tobler, R. Ladenstein,
T. Demirer, G. Dini
on behalf of the Solid Tumours & Paediatric Diseases Working Parties
49

Tuesday, March 30, 2004 Scientific Programme
50
Oral session 12
13:30 – 15:30 Infectious diseases 2
Chairs: M.A. Sanz (Valencia, E), R. Martino (Barcelona, E)
13:30 O269 Outcome of pneumonia and clinical impact of bronchoalveolar lavage in
allogeneic stem cell transplanted patients
J. Mattsson, A. Nordlander, P. Ljungman, O. Ringden (Stockholm, S)
13:45 O270 Prospective evaluation of mucosal barrier injury following various
myeloablative regimens
N.M.A. Blijlevens, B. van'tLand, A.V.M.B. Schattenberg, J.P. Donnelly
(Nijmegen, Wageningen, NL)
14:00 O271 Advances in the treatment of patients with central nervous system
aspergillosis
E. Thiel, S. Schwartz, M. Ruhnke, P. Ribaud, L. Corey, T. Driscoll, O. Cornely,
U. Schuler, B. Dodell, I. Lutsar, P. Troke (Berlin, Cologne, Dresden, D; Paris, F;
Seattle, Durham, USA; Sandwich, UK)
14:15 O272 Pharmacokinetics of oral valganciclovir versus IV ganciclovir for CMV
pre-emptive therapy in SCT
H. Einsele, P. Reusser, B. Hertenstein, M. Bornhäuser, N. Kröger, P. Kahls,
Y. Chalandon, F. Rohde (Tuebingen, D; Basel, CH; Hannover, Dresden, Hamburg, D;
Vienna, A; Geneva, CH; Grenzach-Wyhlen, D)
14:30 O273 Cytomegalovirus-specific immune recovery following allogeneic HLA-identical
sibling transplantation with anti-thymocyte globulin-based reduced-intensity
preparative regimen
M. Mohty, A.M Mohty, D. Blaise, C. Faucher, K. Bilger, J. Gastaut, D. Olive, B. Gaugler
(Marseille, F)
14:45 O274 Prophylactic use of ribavirin in combination with preemptive cidofovir
treatment protects paediatric stem cell transplant recipients from lifethreatening
adenovirus infection
J. Greil, P. Bader, P. Lang, R. Beck, T. Bock, T. Feuchtinger, D. Niethammer
(Tuebingen, D)
Room F
15:00 O275 Comparison of infectious morbidity after allogeneic T-cell depleted peripheral
blood progenitor cell transplantation versus T-cell depleted bone marrow
transplantation
A.E.C. Broers, B. van der Holt, S. Haze, J.W. Gratama, E. Braakman, B. Lowenberg,
J.J. Cornelissen (Rotterdam, NL)
15:15 O276 Infections leading to death occurring later than 6 months after allogeneic
stem cell transplantation
A. Björklund, J. Aschan, P.-A. Broliden, C. Löfgren, O. Ringdén, J. Winiarski,
P. Ljungman (Stockholm, S)

Scientific Programme Tuesday, March 30, 2004
Oral session 13
13:30 – 15:30 Graft versus host disease 1
Chairs: R. Willemze (Leiden, NL), J.A. Perez Simon (Salamanca, E)
13:30 O277 Tacrolimus instead of cyclosporin used for prophylaxis against graft-versushost
disease improves outcome after haematopoietic stem cell transplantation
from unrelated donors, but not from HLA-identical sibling donors
M. Yanada, N. Emi, T. Naoe, Y. Atsuta, N. Hamajima, M. Tanimoto, S. Kato
(Nagoya, Okayama, Isehara, J)
13:45 O278 Thymoglobulin as part of conditioning in unrelated donor allogeneic stem cell
transplantation. A dose-finding study
M. Remberger, B.-M. Svahn, J. Mattsson, O. Ringdén (Stockholm, S)
14:00 O279 Association of pharmacogenes polymorphisms with toxicities and GvHD after
HLA identical sibling bone marrow transplantation
V. Rocha, R. Porcher, A. Filion, H. Bittencourt, D. Zanette, G. Vilela, W. Silva-Jr,
A. Devergie, H. Esperou, P. Ribaud, G. Socie, E. Gluckman, M.A. Zago
(Paris, F; Ribeirao Preto, BR)
14:15 O280 Proteomics in the clinical follow-up of patients after allogeneic stem cell
transplantation
E. Weissinger, T. Kaiser, A. Rank, H. Kamal, H. Mischak, H. Kolb, E. Holler, A. Ganser,
B. Hertenstein (Hannover, Munich, Regensburg, D)
14:30 O281 A GITMO randomised trial in steroid refractory acute graft-versus-host
disease: 6 methylprednisolone with or without anti-thymocyte globulin
M.T. van Lint, C. Uderzo, G. Milone, R. Scimè, S. Dallorso, A. Locasciulli, S. Guidi,
S. Sica, L. Cudillo, F. Fagioli, C. Selleri, A.M. Raiola, A. Dominietto, A. Bacigalupo
fot the GITMO, I
14:45 O282 Keratinocyte growth factor ameliorates acute graft-versus-host disease in
a novel non-myeloablative haploidentical transplantation model
A. VanClee, E. Oving, H. Schouten, G. Bos (Maastricht, NL)
15:00 O283 Leukotac ® (Anti-IL-2) as salvage treatment of steroid-refractory acute graftversus-host
disease
J.L. Piñana, D. Valcárcel, R. Martino, M.E. Moreno, P. García, I. Alvarez, A. Sureda,
J. Briones, S. Brunet, J. Sierra (Barcelona, E)
15:15 O284 Cyclosporine-A and mycophenolate mofetil versus cyclosporine-A and
methotrexate for graft-versus-host disease prophylaxis after stem cell
transplantation from HLA-identical siblings
F. Neumann, T. Graef, C. Tapprich, M. Vaupel, U. Steidl, U. Germing, R. Fenk,
R. Haas, G. Kobbe (Duesseldorf, D)
Room A
51

Tuesday, March 30, 2004 Scientific Programme
52
Oral session 14
13:30 – 15:30 Paediatric diseases 1
Chairs: G. Dini (Genoa, I), J.J. Ortega (Barcelona, E)
13:30 O285 Megatherapy/SCT activity in paediatric solid tumours in Europe
R. Ladenstein, U. Poetschger, O. Hartmann, H. Juergens, E. Koscielniak,
S. Dallorso, F. Doz, T. Philip, G. Dini
on behalf of the Paediatric Diseases Working Party Solid Tumours
13:45 O286 Cummulative incidence of adenovirus infection in children following
allogeneic stem cell transplantation according to donor type, graft
manipulation and adenovirus specific T-cell reconstitution
T. Feuchtinger, K. Hamprecht, H. Einsele, T. Bock, J. Luecke, F. Neuhäuser,
M. Schumm, J. Greil, D. Niethammer, P. Lang (Tuebingen, D)
Room B
14:00 O287 HSCT activity in childhood: report from the EBMT Working Party on Paediatric
Diseases
G. Dini, C. Ruiz de Elvira on behalf of the PDs WP
14:15 O288 Haploidentical transplantation – a single-centre experience
J. Motwani, D. Chandra, S. Kirk, P.J Darbyshire, S.E Lawson (Birmingham, UK)
14:30 O289 Unrelated transplants in Fanconi's anaemia using a fludarabine, low-dose
busulfan, non-irradiation protocol (GEFA-protocol)
W. Ebell, J. Kühl, S. Lehmann, J. Savina, J. Vormoor, H. Tönnies, D. Schindler,
H. Neitzel (Berlin, Muenster, Wuerzburg, D)
14:45 O290 Reduced-intensity conditioned bone marrow transplant in children with
haemophagocytic lymphohistiocytosis
N. Cooper, K. Rao, A. Hussan, G. Davies, D. Webb, P. Veys, P. Amrolia (London, UK)
15:00 O291 Reduced-intensity conditioning in first and second allograft in children
without immunodeficiency: experience of three British transplant centres
C.P. Raghuram, R.F. Wynn, A. Will, T. Carr, P. Veys, D. Webb, P. Amrolia, K. Rao,
S. Barber, J. Cornish, C. Steward, N. Goulden (Manchester, London, Bristol, UK)
15:15 O292 Analysis of risk factors for the development of GvHD after allogeneic stem cell
transplantation in children and adolescents
C. Peters, S. Matthes-Martin, A. Lawitschka, G. Fritsch, T. Lion, A. Rosenmayr,
P. Höcker, G. Fischer, H. Gadner (Vienna, A)

Scientific Programme Tuesday, March 30, 2004
Oral session 15
13:30 – 15:30 Graft engineering / Cellular therapy
Chairs: E. Olavarria (London, UK), A. Iriondo (Santander, E)
13:30 O293 Human bone marrow-derived CD3+CD8+TCR-/low T-lymphocytes facilitate
engraftment of CD34+ cord blood progenitors in NOD/SCID mice
S. Bridenbaugh, C.P. Kalberer, E. Bouliong, E. Chklovskaia, A. Gratwohl,
A. Wodnar-Filipowicz (Basel, CH)
13:45 O294 Intravenous infusion of apoptotic cells simultaneously with allogeneic
haematopoietic graft alters anti-donor humoral immune response
S. Perruche, F. Kleinclauss, M. de Carvalho Bittencourt, D. Paris, P. Tiberghien,
P. Saas (Besançon, F)
14:00 O295 Early chimerism status predicts engraftment after unrelated-donor umbilical
cord blood transplantation
F. Moscardó, L. Senent, D. Planelles, J. Cervera, S. Oltra, A. Valencia, C. Martín,
M. Reig, C. Jiménez, I. Lorenzo, S. Cantero, M. Remigia, M. Marty, M. A. Sanz,
G. Sanz (Valencia, E)
14:15 O296 Stem cell factor for haematopoietic stem cell mobilisation:
results of the randomised IFM 99-01 trial
A. Huynh, P. Bourin, M. Attal
on behalf of the Intergroupe Francophone du Myélome (IFM)
Room D1
14:30 O297 Human stromal cells engineered with interleukin-7 enhance the survival of
naive T-lymphocytes
M. Di Ianni, P. Sportoletti, B. Del Papa, M. De Ioanni, L. Moretti, T. Zei, F. Battelli,
M. F. Martelli, A. Tabilio (Perugia, I)
14:45 O298 G-CSF stimulated peripheral blood transplantation contains higher doses of
lymphoid and CD16+ dendritic cells than bone marrow transplantation
C. Talarn, A. Urbano-Ispizua, R. Martino, M. Aymerich, J. Petriz, F. Fernández-Avilés,
C. Herrera, J.A. Pérez-Simón, M. Batlle, I. Sánchez-Abarca, A. Alegre, E. Carreras,
A. Torres, J. Sierra, P. Marín, E. Montserrat (Barcelona, Córdoba, Salamanca,
Badalona, Madrid, E)
15:00 O299 Antithymocyte globulin Fresenius or SangStat (Genzyme) as part of the
conditioning for unrelated donor HSCT: emerging differences in posttransplant
immune reconstitution
H. Baurmann, D. Judith, C. Zey, M. Schleuning, R. Schwerdtfeger (Wiesbaden, D)
15:15 O300 In vitro separation of GVL effect and GVHR from anti-leukaemia CTL lines:
a perspective for adoptive immunotherapy after allogeneic HSCT
D. Montagna, F. Locatelli, L. Daudt, I. Turin, E. Montini, D. Lisini, M. Zecca, P. Cerutti,
A. Moretta, P. Comoli, R. Maccario (Pavia, I)
53

Tuesday, March 30, 2004 Scientific Programme
54
Oral session 16
13:30 – 15:30 Late effects / Quality of life
Room E3
Chairs: J. Odriozola (Madrid, E), A. Tichelli (Basel, CH)
13:30 O301 Late adverse effects of AML treatment in children – comparison of
chemotherapy only and allogenic stem cell transplantation in first complete
remission
D. Reinhardt, A. Llort, A. Hunold, J.J. Ortega, U. Creutzig for the AML-BFM Study
13:45 O302 Secondary malignancies in recipients of allogeneic stem cell transplantation
for CML in chronic phase using HLA-identical sibling or HLA-compatible
unrelated donors
S. Avery, R. Szydlo, N. Salooja, E. Nadal, E. Olavarria, E. Kanfer, A. Rahemtulla,
J. Goldman, J. Apperley (London, UK)
14:00 O303 Underlying disease as a major risk factor for occurrence of avascular necrosis
after allogeneic stem cell transplantation
C. Schulte, D.W. Beelen (Essen, D)
14:15 O304 BMT nephropathy after allogeneic SCT with an intensified conditioning
regimen: diagnosis, clinical syndrome and management
T. Zenz, I. Buchmann, D. Dohr, S. von Harsdorf, M. Ringhoffer, H. Döhner, S. Reske,
D. Bunjes (Ulm, Mainz, Zurich, D)
14:30 O305 Quality of life assessment in patients undergoing reduced-intensity
conditioning allogeneic transplantation
J.R. Gonzalez-Porras, J.M. Garcia-Cecilia, M. Salinero, M. Salinero, M.D. Caballero,
M.C. Canizo, J.F. San Miguel (Salamanca, E)
14:45 O306 Avascular necrosis after allogeneic SCT in childhood.
Description of cases enrolled in a case-control study in Italy
M. Faraci, R. Haupt, P. Padovani, E. Lanino, C. Favre, M. Nardi, M. Monconi,
C. Messina, S. Varotto, A. Iori, R. Cerretti, P. Di Bartolomeo, M. Nuara, R. Rondelli,
G. Dini, C. Uderzo on behalf of the AIEOP-SCT Group
15:00 O307 EORTC questionnaire module for assessment of quality of life during and after
high-dose treatment: update of the module development
G. Velikova, J. Weis, M. Watson, P. Morris, M. Kopp, M. Hjermstad, O. Sezer
on behalf of EORTC Quality of Life Group
15:15 O308 Factors influencing long-term quality of life in patients after allogeneic stem
cell transplantation. Results of a prospective study with 2-year follow-up
D. Biener, P. Kalhs, A. Schulenburg, H. Scheuringer, H. Greinix (Vienna, A)

Scientific Programme Tuesday, March 30, 2004
Joint session EBMT/WMDA
16:00 – 17:30 Evaluation and care of the stem cell donor
Chairs: J. Apperley (London, UK), G. Gahrton (Huddinge, S)
16:00 309 The informed consent process
T. Egeland (Oslo, N)
16:20 310 Medical clearance for donation
E. Merry (Paris, F)
16:40 311 Adverse consequences of PBSC and BW donations
P. Anderlini (Houston, USA)
17:00 312 Quality of life issues in stem cell donations
G. Switzer (Pittsburgh, USA)
18:00 – 19:00 Physicians poster presentation (P669 – P927)
(please refer to pages 90–109 for details)
20:00 Gala dinner at Reials Drassanes de Barcelona
(please refer to page 155 for details)
Auditorium
Level -1
55

Tuesday, March 30, 2004 Scientific Programme
56
Working party
16:00 – 17:30 Immunobiology
Chairs: A. Madrigal (London, UK), H. Einsele (Tuebingen, D)
16:00 313 AlloStem Report
A. Madrigal (London, UK)
16:10 314 Eurobank
A. Dickinson (Newcastle, UK)
16:20 315 Eurocord
E. Gluckman (Paris, F)
16:30 316 LMP-2a but not LMP-1 specific CD8+ T-cells can lyse efficiently
NHL-lymphoma cells. Implication for the design of adoptive immunotherapy
of relapsed EBV+ lymphomas after allogeneic SCT
M.S. Topp, O. Beck, G. Rauser, G. Kuntz, H. Hummel, C. Neff, H. Einsele (Tuebingen, D)
16:40 317 Effective recovery of functional CD4+ CMV-specific helper T-cells in the
presence of CMV-specific CD8+ T-cells is pivotal for prevention of recurrent
CMV reactivation following allogeneic stem cell transplantation
J.W. Gratama, R.A. Brooimans, G.M. Niesters, P.C. Southwick, L.A. Sullivan,
G.J.J. van Doornen, B. Löwenberg, J.J. Cornelissen (Rotterdam, NL; San Diego, USA)
16:50 318 Decreased transplant related mortality and better survival in HLA matched
(12/12 A, B, C, DRB1, DQB1, DPB1) unrelated bone marrow transplants
A. Filion, P. Loiseau, V. Rocha, R. Tamouza, S. Chevret, M. Busson, H. Esperou,
R. Traineau, E. Gluckman, D. Charron (Paris, F)
17:00 319 NK cell conditioning to T-cell-replete mismatched bone marrow
transplantation protects thymic structure and function
E. Burchielli, L. Ruggeri, K. Hafen, K. Perruccio, G. Hollander, A. Velardi
(Perugia, I; Basel, CH)
17:10 320 Dual transplants of unrelated cord blood and highly purified CD34+ from
a related voluntary donor in adults: updated results (Eurocord-III study)
M.N. Fernández, C. Regidor, R. Cabrera, J.A. García-Marco, R. Forés, J. Gayoso,
E. Ruiz, S. Gil, I. Sanjuán, A. Madrigal (Madrid, E; London, UK)
17:20 General discussion
18:00 – 19:00 Physicians poster presentation (P669 – P927)
(please refer to pages 90–109 for details)
20:00 Gala dinner at Reials Drassanes de Barcelona
(please refer to page 155 for details)
Abstract
Room J
Level -1

Scientific Programme Tuesday, March 30, 2004
Working party
16:00 – 18:00 Inborn errors
Chairs: M. Cavazzana-Calvo (Paris, F), W. Friedrich (Ulm, D)
16:00 321 Allogeneic transplantation in x-linked, childhood onset, cerebral
adrenoleukodystrophy
W. Ebell, J. Kühl, U. Sydow, G. Strauss, W. Köhler, M. Baumann, A. Weddige-
Diedrichs, J. Frahm, H. Hunneman, E. Willichowski, J. Gärtner, G. Gaedicke
(Berlin, Wermsdorf, Goettingen, D)
16:15 322 Stable T-cell engraftment in Omenn-syndrome after HLA-identical stem cell
transplantation without the use of conditioning
M. Hoenig, A. Schulz, K. Schwarz, K.M. Debatin, W. Friedrich (Ulm, D)
16:30 323 Allogeneic haemopoietic stem cell transplantation for Wiskott-Aldrich
syndrome. The GETMON experience
A. Munoz, T. Olive, M.S. Maldonado, A. Martinez, A. Sastre, J.J. Ortega
on behalf of GETMON
16:45 324 Variable mixed chimerism after stem cell transplantation for childhood onset
cerebral adrenoleukodystrophy does not affect disease control
K. Winship, R. Garland, S. Groves, P. Jardine, R. McCarter, N. Stoodley, J. Cornish,
N. Goulden, A. Oakhill, D. Pamphilon, C. Steward (Bristol, UK)
17:00 325 Successful bone marrow transplantation after low toxicity conditioning of
high-risk adults with chronic granulomatous disease
T. Güngör, R. Seger, A. Klink, J. Halter, U. Schanz (Zurich, CH)
17:15 326 Pre-implantation genetic diagnosis including HLA-typing of embryos to
enable HLA-identical cord blood transplantation in congenital anaemias and
immunodefiency diseases
H. Van de Velde, M. De Rijcke, R. Schots, K. De Hauwere, K. Sermon, W. Lissens,
P. Devroey, A. Van Steirteghem, I. Liebaers (Brussels, B)
17:30 327 Successful bone marrow transplantation for immunodeficiency, centromere
instability and facial anomalies syndrome
A.R. Gennery, A. Bhattacharya, M.A. Slatter, T.J. Flood, M. Abinun, G.J. Breese,
A.J Cant (Newcastle upon Tyne, UK)
17:45 328 Outcome of boost haemopoietic stem cell transplant for decrease in donor
chimerism or graft dysfunction in primary immunodeficiency
M.A. Slatter, A. Bhattacharya, M. Abinun, T.J. Flood, A.J. Cant, A.R. Gennery
(Newcastle upon Tyne, UK)
18:00 – 19:00 Physicians poster presentation (P669 – P927)
(please refer to pages 90–109 for details)
20:00 Gala dinner at Reials Drassanes de Barcelona
(please refer to page 155 for details)
Abstract
Mare Nostrum
(Hotel Rey Juan Carlos)
Level -1
57

Wednesday, March 31, 2004 Scientific Programme
08:00 – 08:45 General Assembly
58
Chairs: J. Apperley (London, UK), A. Urbano-Ispizua (Barcelona, E),
H. Schouten (Maastricht, NL), F. Mc Donald (Barcelona, E)
329 Agenda:
1. President's Report
J. Apperley (London, UK)
2. Secretariat's Report
A. Urbano-Ispizua, F. Mc Donald (Barcelona, E)
3. Treasurer's Report
H. Schouten (Maastricht, NL)
4. Registry Report
P. Ljungman (Huddinge, S)
5. EBMT Annual Meeting 2005
V. Koza (Prague, CZ)
Plenary session
09:00 – 10:30 Biological aspects of GvHD
Chairs: E. Carreras (Barcelona, E), E. Holler (Regensburg, D)
09:00 330 Chemokines and GvHD
K.R. Cooke (Ann Arbor, USA)
09:30 331 Impact of genetic polymorphisms
A. Dickinson (Newcaste upon Tyne, UK)
10:00 332 Vascular endothelium as a target in chronic GvHD
B. Biedermann (Basel, CH)
Joint session EBMT / IBMTR
09:00 – 10:30 Umbilical cord blood transplantation: current issues
Chairs: J. Apperley (London, UK), O. Ringden (Stockholm, S)
09:00 333 Umbilical cord blood transplants: IBMTR / New York Blood Centre
M.J. Laughlin (Cleveland, USA)
09:20 334 Umbilical cord blood transplants in adults: EBMT / Eurocord
G. Sanz (Valencia, E)
09:40 335 Cord blood banking: potentials and regulatory aspects
E.J. Shpall (Houston, USA)
10:00 336 Unrelated transplants: is there a need for cord blood?
A. Bacigalupo (Genoa, I)
Auditorium
Auditorium
Room J

Scientific Programme Wednesday, March 31, 2004
Educational session 7
11:00 – 11:45 Transplant algorithms in AML
Chair: J. Sierra (Barcelona, E)
337 The MRC perspective
A. Goldstone (London, UK)
338 The EORTC / Gimema proposal
S. Amadori (Rome, I)
339 A German approach
T. Büchner (Muenster, D)
Educational session 8
11:00 – 11:45 Aplastic anaemia
Chair: H. Schrezenmeier (Ulm, D)
340 Treatment of refractory or relapsed aplastic anaemia
J. Passweg (Basel, CH)
341 Role of stem cell transplantation for PNH
H. Schrezenmeier (Ulm, D)
Educational session 9
11:00 – 11:45 Late complications in children
Chair: G. Socié (Paris, F)
342 Non-malignant
G. Dini (Genoa, I)
343 Malignant
G. Socié (Paris, F)
Auditorium
Room J
Room F
59

Wednesday, March 31, 2004 Scientific Programme
60
Workshop 7
11:00 – 11:45 Gene therapy
Chair: M. Cavazzana-Calvo (Paris, F)
344 Haematopoietic cell disorders
J. Bueren (Madrid, E)
345 Immunodeficiencies
M. Cavazzana-Calvo (Paris, F)
Workshop 8
11:00 – 11:45 Transplantation in solid tumours
Chair: T. Demirer (Ankara, TR)
346 Current indications for autologous transplants
T. Demirer (Ankara, TR)
347 Use of reduced intensity regimens in allotransplants
D. Niederwieser (Leipzig, D)
Workshop 9
11:00 – 11:45 Upfront transplantation for CML in the STI era
Chair: A. Gratwohl (Basel, CH)
348 Pros
A. Gratwohl (Basel, CH)
349 Cons
S. O'Brien (Newcastle, UK)
Room D1
Room A
Room B

Scientific Programme Wednesday, March 31, 2004
Oral session 17
12:00 – 14:00 Chronic leukaemias
Chairs: M. Michallet (Lyon, F), A. Grañena (Barcelona, E)
12:00 O350 Reduced risk of molecular and haematological relapse in patients with CML
after KIR-mismatched haematopoietic stem cell transplantation
A.H. Elmaagacli, H. Ottinger, M. Koldehoff, R. Peceny, R. Trenschel, D.W. Beelen
(Essen, D)
12:15 O351 Imatinib restores plasmacytoid dendritic cell function in chronic myeloid
leukaemia patients
M. Mohty, E. Jourdan, N. Ben Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon,
D. Olive, B. Gaugler (Marseille, Nimes, F)
12:30 O352 Pre-treatment with glivec increases transplant-related mortality after
allogeneic transplant
A. Zander, T. Zabelina, H. Renges, H. Schieder, A. Kratochwille, N. Fehse,
C. Wolschke, H. Kabisch, N. Stute, F. Ayuk, N. Kroeger (Hamburg, D)
Auditorium
12:45 O353 Allogeneic haematopoietic stem cell transplantation – EBMT risk score
evaluation for 1084 CML patients transplanted in Brazil
C.A. De Souza, M.A. Ruiz, A.C. Vigorito, F.J.P. Aranha, R. Zulli, E.C.M. Miranda,
F.L. Dulley, D. Tabak, A.M. Azevedo, R. Byington, W.M. Azevedo, L. Silla, A. Maiolino,
M. Nucci, J.C. Voltarelli, V. Colturato, M.P. De Souza, R. Pasquini (Campinas, São José
do Rio Preto, São Paulo, Rio de Janeiro, Minas Gerais, Ribeirão Preto, Jaú, BR)
13:00 O354 A risk factor approach for selecting patients with chronic myeloid leukaemia
for allogeneic SCT: a model based on the EBMT score applied to the Spanish
Registry
J.F. Tomas, V. Gomez, E. Carreras, A. Iriondo, A. Torres, G. Sanz, A. Sureda,
R. Cabrera, R. Parody, C. Cañizo, J.M. Moraleda, J. de la Serna, J. Diez-Martin,
C. Boque (Madrid, E)
13:15 O355 In vitro purging for autologous stem cell transplantation in chronic
lymphocytic leukaemia. Preliminary results
L. Fouillard, A. Van-Biezen, M. Michallet, D. Milligan, P. Corradini, D. Niederwieser
on behalf of the chronic leukaemia working party of the EBMT
13:30 O356 Relapse of chronic myeloid leukaemia after allogeneic stem cell
transplantation: outcome and prognostic factors
C. Martínez, V. Gómez-García de Soria, J.F. Tomás, R. Parody, A. Sureda, G. Sanz,
C. Cañizo, J.L. Díez, C. Boqué on behalf of the CML Subcommittee of the Spanish
Group for Hematopoietic Transplantation (GETH)
13:45 O357 The influence of ATG source on the outcome after unrelated transplants for
chronic phase CML – a single-centre experience
M. Schleuning, J. Kaltenhäuser, M. Heshmat, H. Baurmann, R. Schwerdtfeger
(Wiesbaden, D)
61

Wednesday, March 31, 2004 Scientific Programme
62
Oral session 18
12:00 – 14:00 Paediatric diseases 2
Chairs: J. Cornish (Bristol, UK), I. Badell (Barcelona, E)
12:00 O358 Two allele HLA mismatches neither increase the incidence of severe GvHD nor
graft failure in the unrelated HCT setting in children
K. Kalwak, J. Toporski, E. Gorczyñska, D. Turkiewicz, M. Slociak, D. Wojcik,
M. Ussowicz, A. Chybicka (Wroclaw, PL)
12:15 O359 10 years of a paediatric stem cell transplant registry: the UK experience
J. Cornish, H. Hawkins, R. Thorne, P. Veys on behalf of the United Kingdom Children's
Cancer Study Group Paediatric BMT Group
12:30 O360 Clinical relevance of serial quantitative analysis of haematopoietic chimerism
after allogeneic stem cell transplantation in children for severe aplastic
anaemia
P. Bader, W. Hoelle, H. Kreyenberg, P. Lang, B. Gruhn, M. Führer, D. Niethammer,
T. Klingebiel, J.F. Beck (Tuebingen, Jena, Munich, Frankfurt, Greifswald, D)
12:45 O361 Haematopoietic stem cell transplantation in patients with haemophagocytic
lymphohistiocytosis – a retrospective analysis by the AIEOP-BMT Group
S. Cesaro, R. Rondelli, F. Locatelli, M. Pillon, F. Porta, W. Arcese, C. Messina, G. Dini,
M. Caniglia, M. Rabusin, V. Poggi, A. Pession, M. Aricò, C. Uderzo (Padua, Bologna,
Pavia, Brescia, Rome, Genoa, Trieste, Naples, Palermo, Monza, I)
13:00 O362 Allogeneic stem cell transplantation for B-thalassaemia major
(single-centre experience in 10 years)
M. Ramzi, H. Noorani, M. Zakernia (Shiraz, IR)
Room J
13:15 O363 Unrelated bone marrow transplantation for thalassaemia:
a single-centre experience
M.C. Addari, M.G. Orofino, M.A. Sanna, A. Piroddi, G.F. Rizzo, M. Badiali, F. Argiolu
(Cagliari, I)
13:30 O364 Use of amifostine as a chemoprotectant during high-dose chemotherapy plus
autologous blood stem transplantation for children and adolescents with solid
tumours
E. Kabickova, D. Sumerauer, M. Chanova, J. Prausova, P. Kobylka, V. Smelhaus,
J. Koutecky (Prague, CZ)
13:45 O365 Results of Nb 97 SFOP Protocol in children > 1 year with a stage 4
neuroblastoma
D. Valteau-Couanet, J. Michon, Y. Perel, C. Bergeron, H. Rubie, C. Coze, C. Rodary,
O. Hartmann on behalf of the SFOP Neuroblastoma Group

Scientific Programme Wednesday, March 31, 2004
Oral session 19
12:00 – 14:00 Stem cell source and biology
Room F
Chairs: T. Ruutu (Helsinki, FIN), M.N. Fernández (Madrid, E)
12:00 O366 Prognostic factors of outcome after standardised, unrelated donor umbilical
cord blood transplantation in adults with haematologic malignancies
G. Sanz, C. Jimenez, I. Lorenzo, F. Moscardo, L. Senent, D. Planelles, L. Larrea,
P. Montesinos, S. Cantero, M. Remigia, J. Sanz, N. Puig, J. Martinez, G. Martin,
I. Jarque, J. de la Rubia, M. Soler, M. Marty, M. Sanz (Valencia, E)
12:15 O367 Results of unrelated cord blood transplants in Fanconi's Anaemia
E. Gluckman, R. Pasquini, V. Rocha, R. Harris, F. Garnier, I. Ionescu, F. Locatelli
on behalf of Eurocord
12:30 O368 Factors influencing peripheral blood stem cell mobilisation in patients with
lymphoid malignancies
L. Sutton, R. Porcher, N. Azar, A. Drihème, H. Gaudin, A. Al Jijakli, N. Dhédin,
J. Gabarre, H. Gonzalez, V. Leblond, V. Morel, F. Norol, P. Weber, J.P. Vernant (Paris, F)
12:45 O369 Quantitative lymphocyte subset reconstitution after allogeneic haematopoietic
stem cell transplantation: comparison of T-cell depletion with CD34 selection,
campath in the bag and campath iv
R.F. Schlenk, M. Ringhoffer, M. Mössner, C. Schöpflin, M. Wiesneth, T. Mertens,
T. Zenz, S. von Harsdorf, S. Stilgenbauer, D. Bunjes (Ulm, D)
13:00 O370 Identical, single-centre policy for unrelated cord blood transplant in young
patients with high-risk acute lymphoblastic leukaemia: a long-term follow-up
A.P. Iori, R. Cerretti, L. De Felice, M. Screnci, A. Mengarelli, A. Roveda, A. Romano,
M. Caniglia, G. Gentile, M.L. Moleti, C. Alfieri, W. Barberi, F. Giona, M.G. Mascolo,
I. Pasqua, M.R. Pinto, A.M. Testi, F. Mandelli, W. Arcese (Rome, I)
13:15 O371 Stem cell mobilisation and collection in patients affected with primary
systemic amyloidosis
C. Perotti, C. Del Fante, G.L. Viarengo, S. Carbone, P. Bergamaschi, L. Salvaneschi
(Pavia, I)
13:30 O372 Predictors of the B lymphopoiesis after allogeneic stem cell transplantation
J. Winkler, A. Biller, W. Rösler, K. Schäfer-Eckhart, H. Wandt, C.N. Kluender,
R. Schwerdtfeger, J. Hahn, E. Holler, T.H. Winkler, M. Gramatzki
(Erlangen, Nuremberg, Wiesbaden, Regensburg, D)
13:45 O373 Good and poor CD34+ cells mobilisation in acute leukaemia:
analysis of factors affecting the yield of progenitor cells
D. Pastore, G. Specchia, A. Mestice, A. Liso, A. Pannunzio, P. Carluccio,
C. Buquicchio, G. Greco, L. Ciuffreda, G. Pietrantuono, G. Guaragna, S. Sibilla,
V. Liso (Bari, I)
63

Wednesday, March 31, 2004 Scientific Programme
64
Oral session 20
12:00 – 14:00 Donor issues
Room A
Chairs: J. de la Rubia (Valencia, E), J.L. Diez (Madrid, E)
12:00 O374 Severe donor events after stem cell donation
A. Gratwohl, Y. Kodera, H. Baldomero, G. Favre, A. Urbano Ispizua, N. Schmitz
on behalf of the JACIE accreditation office and the Japanese Society for
Hematopoetic cell Transplantation JSHCT
12:12 O375 Impact of NK cell alloreactivity on mismatched haematopoietic transplantation:
an update on donor selection criteria and on transplantation outcomes
L. Ruggeri, M. Capanni, E. Urbani, A. Tosti, A. Mancusi, A. Santucci, F. Aversa,
M.F. Martelli, A. Velardi (Perugia, I)
12:24 O376 Change of paradigm in donor selection for hematopoietic stem cell transplantation:
for patients above 40 years with early stage leukaemia HLA-identical
siblings are no longer first choice
H.D. Ottinger, D. W. Beelen, R. Peceny, A. H. Elmaagacli, H. Grosse-Wilde (Essen, D)
12:36 O377 Morphologic and karyotypic analysis of bone marrow in 166 potential donors
of hamatopoietic stem cells
E. Guggiari, A. Pescarollo, L. Seghezzi, S. Gattillo, P. Servida, M. Bernardi, C. Corti,
F. Ciceri, M. Bregni (Milan, I)
12:48 O378 Allogeneic stem-cell transplantation with matched unrelated donors in the
elderly (age 55-67 years). Age is no longer a contraindication when using
reduced-intensity conditioning
A. Shimoni, N. Kroger, A. Zander, M. Yeshurun, I. Hardan, A. Nagler
(Tel-Hashomer, IL; Hamburg, D)
13:00 O379 An automated and closed procedure for cord blood processing, freezing and
thawing: The Barcelona Cord Blood Bank Experience
S. Querol, C. Azqueta, C. Torrico, B. Amill, M. Torrabadella, L. Massuet, J. Garcia
(L'Hospitalet de Llobregat, E)
13:12 O380 Baseline CD34+ cell count does not predict response to filgrastim in healthy
donors undergoing peripheral blood progenitor cell collection
J. de la Rubia, I. Lorenzo, M. Torrabadella, R. Rivas, M. Insunza, P. Marín, C. Arbona,
C. Zamora, C. Martínez, J. Sancho, A. López, A. Alegre, A. Galmés, C. del Cañizo,
M. Díaz, M. Pascual, L. Benlloch, M. Sanz on behalf of the Spanish allo_PBT group
13:24 O381 Anti-thymocyte globulin in unrelated haematopoietic stem cell transplantation
for acute myeloid leukaemia: multicentre German Cooperative Study Group
N. Basara, A. Yaman, K. Kolbe, L. Kraut, H. Baurmann, C. Huber, A.A. Fauser,
R. Schwerdtfeger (Idar-Oberstein, Wiesbaden, Mainz, D)
13:36 O382 The influence of postgrafting G-CSF on the outcome of unrelated transplants
for AML after in vivo T-cell depletion with ATG
R. Thödtmann, I. Burlakova, A. Yaman, D. Judith, H. Baurmann, R. Schwerdtfeger,
M. Schleuning (Wiesbaden, D)

Scientific Programme Wednesday, March 31, 2004
Oral session 21a
12:00 – 13:00 Supportive care
Chairs: T. Masszi (Budapest, HUN), H. Schouten (Maastricht, NL)
12:00 O383 Naso-gastric nutrition in allogeneic stem cell transplantation reduces
infection-related early post-transplant mortality: a single-centre experience
on 45 consecutive patients
I. Yakoub-Agha, D. Seguy, J.-B. Micol, J.-H. Dalle, C. Berthon, S. Depil, F. Bauters,
P. Devos, J.P. Jouet (Lille, F)
12:12 O384 Early detection of respiratory failure after allogeneic transplantation by
maesurement of oxi-index-potential correlations with polymorphisms of the
surfactant protein B (SP-B) gene
T. Illmer, C. Theuser, S. Schiemanck, C. Thiede, J. Schetelig, A. Kiani, S. Trautmann,
M. Weise, G. Höffken, G. Ehninger (Dresden, D)
12:24 O385 The role of unfractionated heparin prophylaxis to prevent catheter-related
thrombosis in patients with haemato-oncological diseases:
a prospective randomised study
A. Abdelkefi, L. Kammoun, T. Ben Othman, F. Ladeb, L. Torjman, S. Ladeb,
N. Ben Romdhane, A. Lakhal, O. Ben Achour, M. Hsaïri, A. Ben Abdeladhim
(Tunis, TN)
12:36 O386 Obesity or underweight: Which is safer in stem cell transplantation?
T. Katz, N. Haddad, T. Zuckerman, R. Fineman, I. Avivi, A. Oliven, J.M. Rowe
(Haifa, IL)
Room B
12:48 O387 Patient's socioeconomic status influencing overall survival and transplantrelated
mortality after allogeneic stem cell transplantation
G. Fischer, H. Bittencourt, M. Grossini, A. Jochins, L. Fogliatto, S. Pilati, R. Bittencourt,
C. Astigarraga, F. Fernandes, C. Bittar, T. Onsten, L. Silla (Porto Alegre, BR)
65

Wednesday, March 31, 2004 Scientific Programme
66
Oral session 21b
13:00 – 14:00 Regulatory issues
Room B
Chairs: A. Urbano-Ispizua (Barcelona, E), A. Gratwohl (Basel, CH)
13:00 O388 Obtaining informed consent for haematopoietic cell transplantation.
How much information is enough?
A. Hotidou, C. Kartsios, I. Sakellari, P. Kalogiannidis, A. Fassas, A. Anagnostopoulos
(Rennes, F; Thessalonica, GR)
13:12 O389 Do mini-transplants have mini-costs? Cost estimation of non-myeloablative
transplants in acute myeloid leukaemia patients and comparison with
standard regimens
C. Cordonnier, H. Esperou, S. Maury, J. Beaune, M. Rodet, S. Chevret, C. Pautas,
J. Lagrange, F. Beaujean, J. Beaumont, E. Gluckman, M. Kuentz, I. Durand-Zaleski
(Creteil, Paris, F)
13:24 O390 Implementation of a total quality management programme in peripheral blood
and bone marrow transplantation – beyond accreditation
K. Aldous, G. Smith, R. Patmore, P. Hillmen, S. Kinsey, G. Cook
on behalf of The Yorkshire Blood & Marrow Transplant Programme
13:36 O391 JACIE quality management refers to an integrated programme of quality
assessment, assurance, control and improvement. How can it be set up
transplant units?
Y. Dahmen, V. Bourcy, H. Jacques, C. Guéri, N. Azar, J.L. Beaumont, F. Norol,
F. Beaujean, J.P. Vernant, M. Kuentz, M. Benbunan, E. Gluckman, H. Espérou,
C. Cordonnier, C. Boccaccio on behalf JACIE program-PHRC Ile de France
13:48 O392 Implementing the detection and evaluation of adverse events following
JACIE standards
Y. Dahmen, D. Thominet, V. Demarez, V. Bourcy, M. Kuentz, H. Boutemy,
O. Roucoules, J. Beaumont, F. Beaujean, C. Boccaccio, C. Gueri, C. Cordonnier
on behalf of JACIE program-PHRC Ile de France

Scientific Programme Wednesday, March 31, 2004
Oral session 22
12:00 – 14:00 Graft versus host disease 2 / Tolerance and rejection
Chairs: A. Zander (Hamburg, D), F. Dazzi (London, UK)
12:00 O393 Antibody-mediated depletion of human dendritic cells to prevent graftversus-host
disease in chimeric mice
J. Wilson, A. Rice, D. Hart, D. Munster (South Brisbane, AUS)
12:15 O394 IFN-gamma 3/3 genotype associated with decreased IFN-gamma production
as a risk factor of chronic GvHD in recipients of allogeneic haematopoietic
stem cell transplants
A. Mlynarczewska, B. Wysoczanska, K. Bogunia-Kubik, L. Karabon, A. Lange
(Wroclaw, PL)
12:30 O395 Transplantation tolerance in allogeneic stem cell transplantation with
reduced-intensity conditioning
R. Laylor, P. Dyson, H. Dewchand, E. Simpson, F. Dazzi (London, UK)
Room D1
12:45 O396 Kinetic of regulatory CD25+ and activated OX40+ T lymphocytes during
acute and chronic graft-versus-host disease after allogeneic bone marrow
transplantation
J. Casano, J. Sanchez, M. Alvarez, C. Martin, C. Fernandez, M. Capote, M. Jimenez,
A. Espigares, J. Garcia-Castellano, C. Herrera, P. Gomez, F. Martinez, A. Torres
(Cordoba, E)
13:00 O397 Indoleamine 2,3-dioxygenase expression mediates T-cell inhibitory,
antibacterial and antiparasitic effector functions in human bone marrow
stromal cells
R. Meisel, A. Zibert, U. Göbel, W. Däubener, D. Dilloo (Duesseldorf, D)
13:15 O398 New strategies to control T-cell mediated alloreactivity: analysis of TCR
repertoire by CDR3 size spectra-typing after depletion of MLC-activated
CD69+ cells combined with in vitro CTLA4-Ig treatment
A. Moretta, F. Locatelli, A. Cometa, E. Assirelli, R. Tonelli, P. Comoli, D. Montagna,
S. Pagani, G. Giorgiani, F. Bonetti, M. Labirio, S. Telli, R. Gentile, A. Pession,
R. Maccario (Pavia, Bologna, I)
13:30 O399 CD4+CD25+ regulatory T-cells favours leukaemia relapse after allogeneic
stem cell transplantation
E. Nadal, M. Macchiarulo, L. Lim, R. Lechler, F. Dazzi (London, UK)
13:45 O400 Impact of small bowel exploration using video-capsule endoscopy in the
management of acute gastro-intestinal graft-versus-host disease
I. Yakoub-Agha, V. Maunoury, S. Depil, S. Couignoux, F. Bauters, J.F. Colombel,
J.P. Jouet (Lille, F)
67

Wednesday, March 31, 2004 Scientific Programme
68
Oral session 23
12:00 – 13:30 Minimal residual disease / Graft versus malignancy 2
Room D4
Chairs: J. Nomdedeu (Barcelona, E), E. Kansu (Ankara, TR)
12:00 O401 Hyperactive alleles of the non-cytokine genes may affect clinical outcomes
in allo-HSCT patients
A.B. Chukhlovin, T.S. Zabelina, L. Zoubarovskaya, N. Kroeger, B.V. Afanasiev,
A.R. Zander, B. Fehse (St. Petersburg, RUS; Hamburg, D)
12:15 O402 Molecular relapse of acute lymphoblastic leukaemia after allogeneic
haematopoietic stem cell transplantation can be successfully treated with
donor lymphocyte infusions
A. Dominietto, A.M. Raiola, R. Grasso, A. Garuti, S. Bregante, C. Di Grazia,
V. Galbusera, F. Gualandi, A. Ibatici, T. Lamparelli, M.T. van Lint, F. Frassoni,
A. Bacigalupo (Genoa, I)
12:30 O403 Clinical relevance of minimal residual disease after haematopoietic stem cell
transplantation
B. Gruhn, N. Pfaffendorf, S. Wittig, I. Wolff, I. Schiller, R. Häfer, A. Voigt, D. Fuchs,
F. Zintl (Jena, D)
12:45 O404 Allografted patients with chronic myeloid leukaemia in molecular remission
harbour similar levels of Bcr-Abl transcripts compared to healthy individuals
T. Lange, W. Poenisch, H. Al-Ali, U. Hegenbart, S. Musiol, D. Niederwieser,
M. Deininger (Leipzig, D; Portland, USA)
13:00 O405 Does graft versus Thalassaemia exist? Effect of GvHD prophylaxis on relapse
after BMT in patients with Thalassaemia major
P. Polchi, C. Giardini, S. Cicconi, D. Gaziev, P. Sodani, B. Erer, G. Lucarelli
(Pesaro, Rome, I)
13:15 O406 Quantitative minimal residual disease assessment demonstrates disease
control by graft-versus-leukaemia effect in chronic lymphocytic leukaemia
after non-myeloablative allogeneic in contrast to autologous stem cell
transplantation
M. Ritgen, A. Humpe, S. Stilgenbauer, A. Kröber, D. Bunjes, H. Döhner, M. Kneba,
P. Dreger on behalf of the German CLL Study Group (DCLLSG)
14:15 – 14:45 Awards and Closing Room J

Poster Physicians Monday, March 29, 2004
18:00 –
19:00
18:00 –
19:00
Cytokines
P407 Neutralisation of IL-1 receptor antagonist is associated with increased IL-1 mediated
damage in a human in vitro model of GvHD
H. Cullup, X.N. Wang, L. Sviland, A.M. Dickinson (Newcastle-upon-Tyne, UK; Bergen, N)
P408 Pegfilgrastim is able to mobilise autologous CD34+ peripheral blood progenitor cells in
patients with lymphoid malignancies and solid tumours
F. Kroschinsky, K. Hölig, U. Platzbecker, A. Haack, M. Schaich, M. Bornhäuser, G. Ehninger
(Dresden, D)
P409 Extracorporeal photopheresis differentially regulates the expression of phosphorylated
STAT-1 and STAT-5 in treated monocytes and T-cells respectively
J. Bladon, P.C Taylor (Rotherham, UK)
P410 Adjuvant IL-2 in the treatment of relapse after allogeneic transplant refractory to donor
lymphocyte infusions: clinical and biological effects
E. Nadal, A. Fowler, S. Avery, E. Kanfer, J. Apperley, J. Goldman, F. Dazzi (London, UK)
P411 Early-acting cytokines induce the generation of dendritic cell precursors from
CD34+ cells
A. Encabo, P. Solves, P. Sepúlveda, F. Carbonell-Uberos, M.-D. Miñana (Valencia, E)
P412 Immunoregulatory effect of G-CSF on PBPC cells from healthy individuals and patients
I.L. Barbosa, P.A. Benevides, F. Gomes, C. Sousa, S. Roncon, A. Ávila, A. Campos, C.P. Vaz,
F. Campilho, P. Pimentel, A. Carvalhais (Porto, P)
P413 Maintenance therapy with rituximab (CD20 antibody) following autologous stem cell
transplantation for multiple myeloma
B. Georgievski, L. Cevreska, M. Ivanovski, N. Siljanovski, A. Stojanovik, O. Karanfilski,
Z. Stojanoski, I. Panovska, A. Pivkova (Skopje, MK)
P414 Anti-thymocyte globulin induces imbalanced release of pro- and anti-inflammatory
cytokines during pre-transplant conditioning in allogeneic stem cell transplantation
J.F. Andersen, C. Heilmann, N. Jacobsen, K. Bendtzen, K. Müller (Copenhagen, DK)
P415 G-CSF effect on NK cell phenotype of PBPC grafts from healthy individuals and patients
P.A. Benevides, C. Sousa, F. Gomes, S. Roncon, A. Ávila, A. Campos, C.P. Vaz, F. Campilho,
P. Pimentel, I.L. Barbosa, C. Carvalhais (Porto, P)
Stem cell research
P416 Co-transplantation of ex-vivo culture-expanded human mesenchymal stem cells and
allogeneic haematopoietic stem cell transplantation – report of 12 cases
S. Kang, Y. Jung, J. Park, J. Choi, H. Lim, H.C. Kim (Seongnam, Suwon, KOR)
P417 NOD/SCID mouse human haematopoietic reconstitution is not impaired by long-term
exposure of human normal CD34+ cells to STI 571
W. Piacibello, L. Gammaitoni, M. Gunetti, L. Caione, M. Aglietta (Candiolo, I)
P418 Mesenchymal stem cells cultured from human umbilical cord blood express the
intermediate filament protein Nestin and Von Willebrand factor and differentiate into
adipocyte and neural cell lineages
J. Beo, Z. Varghese, X. Ruan, P. Rajananthanan, I. Zwart, R. Navarrete, C. Navarrete (London, UK)
P419 Comparison of total bone marrow CD34+ cells and their subpopulations in the late posttransplant
period between patients undergoing sibling allo-SCT and their respective
donors
F.M. Sanchez-Guijo, L.I. Sanchez-Abarca, M.D. Caballero, P. Menendez, E.M. Villaron,
M. Alberca, N. Lopez-Holgado, A. Orfao, J.F. San Miguel, M.C. del Cañizo (Salamanca, E)
P420 Murine mesenchymal stem cells: direct selection, phenotypic characterisation,
in vitro and in vivo potential
F. Gindraux, L. Obert, Z. Selmani, D. Chalmers, P. Hervé, F. Deschaseaux (Besançon, F)
69

Monday, March 29, 2004 Poster Physicians
18:00 –
19:00
70
Stem cell research (continued)
P421 Engraftment kinetics of human CD34+ cells from cord blood and mobilised peripheral
blood co-transplanted into NOD/SCID mice (Eurocord-III study)
M. Ramírez, C. Regidor, I. Marugán, J. García-Conde, J. Bueren, M.N. Fernández
(Madrid, Valencia, E)
P422 The potential of autologous bone marrow stem cells for stroke patient management
I. Lisukov, A. Kulagin, A. Krivoshapkin, P. Pilipenko, E. Netesov, E. Chernykh, A. Ostanin,
O. Leplina, E. Melidy, A. Petrovskaya, P. Semin, V. Kanygin, V. Kozlov (Novosibirsk, RUS)
P423 Human mesenchymal stem cells may promote the engraftment of human
haematopoietic stem cells in NOD/SCID mice
D.S. Hong, S.K. Park, J.H. Won, C.K. Kim, N.S. Lee, H.S. Park (Bucheon-si, Gyeonggi-do, KOR)
P424 Mesenchymal stem cells remain of host origin long after allogeneic peripheral blood
stem cell- or bone marrow transplantation
K. Rieger, O. Marinets, T. Fietz, S. Koerper, D. Sommer, C. Muecke, B. Reufi, W. Blau, E. Thiel,
W. Knauf (Berlin, D)
P425 Migration and NOD/SCID mouse engraftment of mesenchymal progenitor cells (MPC):
comparison with haematopoietic progenitor cells
B. Rüster, B. Grace, R. Bistrian, O. Seitz, R. Henschler (Frankfurt, D)
P426 G-CSF increases the expression of VCAM-1 on stromal cells promoting the adhesion of
CD34+haematopoietic cells: studies under flow conditions
B. Fuste, M. Diaz-Ricart, G. Escolar, P. Marin, R. Mazzara, A. Ordinas (Barcelona, E)
P427 Mesenchymal stem cells inhibit the expression of IL-2 receptor (CD25) and CD38 on
phytohemagglutinin-activated lymphocytes
K. Le Blanc, I. Rasmusson, C. Götherström, C. Seidel, B. Sundberg, K. Rosendahl, C. Tammik,
O. Ringdén (Huddinge, S)
P428 Changes in megakaryocytic-specific transcription factors during in vitro expansion and
differentiation of cord blood cells
A. Vannucchi, S. Bruno, L. Bianchi, M. Gunetti, F. Paoletti, A. Pancrazzi, M. Aglietta, A. Bosi,
W. Piacibello (Florence, Candiolo, I)
P429 RT-PCR (TaqMan) and flow cytometry to characterise human bone marrow mesenchymal
stem cells cultures and proliferation
S. Urbani, R. Caporale, L. Giabbani, L. Lombardini, P. Romagnani, R. Saccardi, A. Bosi (Florence, I)
P430 Evidences for human CD34+ cells with very large telomeres
V. Martinez-Muñoz, M. Garcia-Escarp, I. Sales, J. Barquinero, J.C. Domingo, P. Marin, J. Petriz
(Barcelona, E)
P431 Human mesenchymal stem cells increase interleukin-2 and soluble IL-2 receptor in
mixed lymphocyte cultures
I. Rasmusson, O. Ringdén, B. Sundberg, L. Lönnies, K. Le Blanc (Stockholm, S)
P432 Kinetics of human platelet reconstitution in NOD/SCID-mice following transplantation
with ex vivo expanded CD34-positive cord blood cells
Y. van Hensbergen, L.F. Schipper, A. Brand, M.C. Slot, W.A. Noort, W.E. Fibbe
(Leiden, Amsterdam, NL)
P433 Origin of bone marrow mesenchymal stem cells derived from isolated CD105+ cells in
patients undergoing allogeneic stem cell transplantation
A. Spiropoulou, M. Theodosaki, E. Goussetis, K. Stefanaki, I. Peristeri, V. Kitra, D. Petropoulos,
I. Ferdinadou, S. Grafakos (Athens, GR)
P434 Expression of microsomal carnitine palmitoyl transferase and potential for mobilisation
of peripheral blood stem cells
M. Fillitz, H. Karlic, H. Tüchler, A. Lohninger, E. Pittermann, M. Pfeilstöcker (Vienna, A)
P435 Temporal changes in gene expression profile of healthy donors after G-CSF mobilisation
C. Castilla, N. C. Gutierrez, I. Isidro, E. Ocio, M. Delgado, P. Maiso, M. C. Cañizo,
J. M. Hernandez, J. F. San Miguel (Salamanca, E)

Poster Physicians Monday, March 29, 2004
18:00 –
19:00
18:00 –
19:00
Stem cell research (continued)
P436 Immunological properties of human foetal mesenchymal stem cells
C. Götherström, O. Ringdén, C. Tammik, E. Zetterberg, M. Westgren, K. Le Blanc (Stockholm, S)
P437 Factors affecting short-term engraftment after high-dose therapy and autologous stem
cell support in acute leukaemia and lymphoma patients
P. Mensah, B. Piatkowska-Jakubas, D. Hawrylecka, J. Krawczyk, M. Szostek, E. Zdzilowska,
Z. Walter, A.B. Skotnicki (Cracow, PL)
P438 7-color, 10 parameter flow cytometry: identification of side population cells by
phenotype and function
V. Martinez-Muñoz, I. Sales, M. Garcia-Escarp, J. Barquinero, J.C. Domingo, P. Marin, J. Petriz
(Barcelona, E)
P439 Refrozen cord blood haematopoietic progenitors induce multilineage engraftment in
NOD/SCID mouse
F. Timeus, N. Crescenzio, F. Sanavio, A. Doria, L. Foglia, P. Saracco, W. Piacibello, M. Berger,
F. Fagioli (Turin, I)
P440 Ex vivo expansion and differentiation of human bone marrow, cord blood and peripheral
blood mesenchymal stem cells
M. Mohyeddin, M. Bashtar, K. Alimogaddam, B Ansari, A. Ghavamzadeh (Teheran, IR)
P441 The effect of cryopreservation on mesenchymal stem cells
M. Mohyeddin, M. Bashtarr, K. Alimogaddam, B. Ansari, M. Khalili, M. Solamani,
A. Ghavamzadeh (Tehran, IR)
P442 Functional and phenotypic characterisation of directly sorted mesenchymal stem cells
Z. Selmani, F. Gindraux, L. Obert, D. Chalmers, P. Hervé, F. Deschaseaux (Besançon, F)
P443 Role of high-energy shock waves on the expansion, proliferation and transfection
of human cord blood stem cells
M. Berger, R. Frairia, F. Sanavio, E. Madon, C. Venturi, F. Fagioli (Turin, I)
Graft engineering
P444 Predictive factors for full donor chimerism after reduced-intensity conditioning for
HLA-identical allogeneic stem cell transplantation
M. Mohty, J. Eliaou, C. Faucher, K. Bilger, O. Avinens, V. Bardou, N. Vey, J. Gastaut,
D. Maraninchi, D. Blaise (Marseille, Montpellier, F)
P445 Engraftment of allogeneic CD133+ selected blood stem cells from matched sibling
donors
M. Bornhäuser, C. Thiede, U. Oelschlaegel, T. Illmer, J. Schetelig, A. Kiani, B. Mohr, G. Ehninger
(Dresden, D)
P446 In vitro expansion of haematopoietic progenitor cells induced expression of Fas antigen
and upregulation of Bax
J.H. Won, H.J. Cheong, S.J. Kim, G.H. Jang, C.K. Kim, J.T. Cheong, N.S. Lee, K.T. Lee, S.K. Park,
D.S. Hong, H.S. Park (Seoul, KOR)
P447 Partial in vitro T-cell depletion with CAMPATH-1H in combination with DLI for CML
molecular relapses decreases GVHD with 70% 5- years DFS in HLA-identical sibling
PBSC for haematological malignancies
Y. Chalandon, E. Roosnek, L. Waelchli, C. Helg, B. Chapuis (Geneva, CH)
P448 Unexpected differences in the thaw clonogenic recovery of pre-stressed peripheral
blood stem cells according to the cryoprotectant used
C. Balsa, M.J. Watts, S.J. Ings, D.C. Linch (London, UK)
P449 T-cell depletion of stem cell grafts with campath-1H “in the bag” followed by
cyclosporin immunosuppression remains a cost effective strategy in transplantation
N. Novitzky, V. Thomas, G. Hale, H. Waldmann (Cape Town, ZA; Oxford, UK)
71

Monday, March 29, 2004 Poster Physicians
72
Graft engineering (continued)
18:00 –
19:00
P450 Bone marrow transplantation after processing by gradients and negative immunomagnetic
T- and B-cell selection to prevent GvHD without loss of engraftment potential
F. Preijers, A. Schattenberg, W. Ruijs, C. Trilsbeek (Nijmegen, NL)
P451 Influence of CD34, mononuclear, CFU-GM counts and cell viability on short- and
long-term haematopoietic recovery after autologous stem cell transplantation
J.M. Sancho, A. Oriol, J.M. Ribera, M. Torrabadella, G. Martin-Henao, L. Rodríguez, M. Batlle,
B. Xicoy, C. Ferrá, A. Flores, J. Juncà, F. Millá, E. Feliu (Badalona, Barcelona, E)
P452 Long-term culture impairs engraftment of normal and 5-fluorouracil treated bone
marrow in sub-myeloablated hosts
L. D'Hondt, C. Grimaldi, J.F. Lambert, P.J. Quesenberry (Charleroi, B; Providence, USA)
P453 Use of CD3+/CD19+ depleted grafts from mismatched related donors in children
P. Lang, J. Greil, M. Schumm, M. Pfeiffer, W. Bethge, R. Handgretinger, D. Niethammer, P. Bader
(Tuebingen, D)
P454 Feasibility of a novel clinical-scale CD3/CD19 depletion procedure, and how it compares
to conventional CD34+ selection
G. Fritsch, S. Matthes, C. Peters, V. Witt, J. Pichler, D. Scharner, C. Eichstill, E. Zipperer,
H. Gadner (Vienna, A)
P456 Washing thawed autologous aphereses with the Cytomate biomedical device results
in diminished toxicity following reinfusion in cancer patients undergoing high-dose
chemotherapy
C. Lemarié, B. Calmels, C. Malenfant, V. Arnéodo, D. Blaise, F. Viret, R. Bouabdallah, P. Ladaique,
P. Viens, C. Chabannon (Marseille, F)
P457 A different but cost-effective schedule for mobilisation of CDd34+ cells for transplantation
N. Novitzky, V. Thomas, G. Davison, J. Thomson, L. Abrahams (Cape Town, ZA)
P458 Prospective characterisation of short-term repopulating cells in haematopoietic stem
cell allografts
K Raaschou-Jensen, N. Buza-Vidas, K. Theilgaard-Mönch, E. Dickmeiss, S.E. Jacobsen
(Copenhagen, DK; Lund, S)
18:00 –
19:00
Graft versus malignancy
P459 Childhood pre-B-ALL blasts are killed by alloreactive NK-cell clones, independent of a
HLA-Cw mismatch
T. Feuchtinger, A. Pfäffle, H.-M. Telschik, M. Pfeiffer, C. Weinstock, D. Niethammer, P. Lang
(Tuebingen, D)
P460 Haploidentical transplant in adult advanced leukaemia: a 3-step phase I study of growth
factors and DLI post-transplant
P. Lewalle, A. Delforge, V. De Wilde, I. Ahmad, B. Nowak, K. Theunissen, D. Bron, P. Martiat
(Brussels, B)
P461 Possible graft versus neuroblastoma effect after partially matched related
haematopoietic transplantation
L. Lacitignola, V. Tintori, F. Bambi, M. Mariani, C. Marchi, B. Porfirio, M. Gelli, A. Tamburini,
F. Tucci, A. Lippi, G. Bernini, L. Faulkner (Florence, I)
P462 Reduced-intensity conditioning prior to allogeneic transplantation of haematopoetic
stem cells: the need for T-cells early after transplantation to induce a graft-versuslymphoma
effect
B. Glass, M. Nickelsen, P. Dreger, J. Hasenkamp, G. Wulf, L. Trümper, N. Schmitz (Goettingen,
Kiel, Hamburg, D)

Poster Physicians Monday, March 29, 2004
Graft versus malignancy (continued)
18:00 –
19:00
P463 Graft-versus-leukaemia effect of donor leukocyte infusions in acute leukaemia patients
relapsing after allogenic stem cells transplantation
E. Calistri, F. Patriarca, C. Filì, A. Sperotto, A. Geromin, F. Zaja, A. Candoni, S. Prosdocimo,
M. Tiribelli, D. Damiani, R. Fanin (Udine, I)
P464 Evidence of ''graft-versus-tumour'' effect following haploidentical transplantation in a
patient with metastatic relapse of Ewing's sarcoma
I. Dolgopolov, R. Protsenko, L. Andreeva, V. Boyarshinov, R. Ravshanova, G. Mentkevich
(Moscow, RUS)
P465 Second stem cell transplantation from KIR ligant incompatible donors with reducedintensity
conditioning following AML relapse after HLA-identical BMT
S. Matthes-Martin, A. Velardi, G. Fritsch, T. Lion, O.A. Haas, C. Peters, H. Gadner
(Vienna, A; Perugia, I)
P466 Efficacy of donor lymphocyte infusion following cytoreductive chemotherapy for
relapsed acute leukaemia after allogeneic stem cell transplantation
D.-Y. Kim, K.-W. Lee, T. Yun, S.-I. Kim, S.R. Park, J.Y. Paik, I.S. Choi, D.-Y Oh, S.-S. Yoon,
J.-S. Lee, S. Park, B.K. Kim (Seoul, KOR)
P467 Non-myeloablative cell therapy with partially HLA matched lymphocytes activated
with rIL-2 in patients with resistant malignancies
A. Ackerstein, S. Morecki, Y. Gelfand, L. Dray, R. Or, S. Samuel, C. Nabet, S. Slavin (Jerusalem, IL)
18:00 –
19:00
Minimal residual disease
P468 Applicability of multiparameter immunophenotipic analysis for the investigation of MRD
in B lymphoproliferative disorders
G. Pricolo, L. Stani, A. Prudenzano, G. Pisapia, G. Palazzo, B. Amurri, A. Maggi, P. Mazza (Taranto, I)
P469 Disease eradication in patients with poor prognosis non-Hodgkin lymphoma by
non-myeloablative verus conventional haematopoietic stem cell transplantation
M. Mitterbauer, P. Kalhs, U. Jaeger, C. Mannhalter, F. Keil, N. Worel, W. Rabitsch, G. Fischer,
K. Dieckmann, I. Simonitsch-Klupp, P. Hoecker, A. Rosenmayr, W. Hinterberger, K. Lechner,
G. Mitterbauer, H. Greinix (Vienna, A)
P470 Molecular monitoring of minimal residual disease after reduced-intensity conditioning
and allogeneic stem cell transplantation in relapsed chronic lymphocytic leukaemia
L. Farina, D. Soligo, E. Rizzo, A. Dodero, A. Locasciulli, R. Scimè, A. Santoro, A.M. Gianni,
C. Tarella, M. Lucesole, A. Olivieri, P. Corradini (Milan, Rome, Palermo, Turin, Ancona, I)
P471 Minimal residual disease in chronic lymphocytic leukaemia after stem cell
transplantation. Comparison of ASO-PCR and flow cytometry
C. Moreno, N. Villamor, D. Colomer, J. Esteve, F. Bosch, E. Campo, E. Montserrat (Barcelona, E)
P472 CD34+ cell dose, reduced-intensity conditioning and prior chemotherapy:
factors with significant impact on the Kinetics of donor chimerism after allogeneic
haematopoietic cell transplantation
B. Mohr, R. Koch, C. Thiede, F. Kroschinsky, G. Ehninger, M. Bornhäuser (Dresden, D)
P473 Sensitive and quantitative chimerism analysis in ALL patients with real-time PCR
M. Uzunel, U. Sundin, J. Mattsson, M. Schaffer, D. Hauzenberger, O. Ringden (Stockholm, S)
P474 Cell lineage specific chimerism in post-haematopoietic stem cell transplant patients
S. Adams, P. Veys, J. Hollifield, B. Gaspar (London, UK)
P475 ChimerTrack: quantification of STR-based chimeric status using an interactive software
tool
D. Kristt, J. Stein, I. Yaniv, R. Narinsky, T. Klein (Petach-Tikva, IL)
73

Monday, March 29, 2004 Poster Physicians
74
Minimal residual disease (continued)
18:00 –
19:00
P476 Chimerism analysis using quantitative real-time PCR. A new method for clinical use?
M. Schaffer, M. Uzunel, D. Hauzenberger, U. Sundin (Stockholm, S)
P477 In vivo purging by campath 1H: molecular quantitative evaluation of minimal residual
disease in CLL patients resistant to fludarabine
S. Galimberti, N. Cecconi, G. Cervetti, S. Pacini, F. Guerrini, C. Manetti, R. Riccioni, A. Azzara,
G. Carulli, M. Petrini (Pisa, I)
P478 Real-time PCR SNP method for the monitoring of chimerism after allogeneic stem cell
transplantation
R. Eshel, O. Vainas, E. Naparstek (Tel Aviv, IL)
P479 Long-term follow-up of PCR status after autologous transplantation during first
remission in patients with Bcl-2/IgH positive follicular lymphoma and bone marrow
infiltration at diagnosis
T. Papajík, S. Vlachová, R. Kubaláková, L. Raida, J. Vondráková, S. Skranc, M. Jarosová,
I. Skoumalová, K. Indrák (Olomouc, CZ)
18:00 –
19:00
Reduced intensity transplants
P480 Allogeneic haematopoietic stem cell transplantation after treosulfan/fludarabine
conditioning in high-risk patients with haematologic malignancies
J. Casper, W. Knauf, W. Blau, L. Volin, T. Ruutu, H. Wandt, K. Schaefer-Eckart, J. Holowiecki,
S. Giebel, J. Aschan, A. Zander, N. Kroeger, M. Freund (Rostock, Berlin, Nuremberg, Hamburg, D;
Helsinki, FIN;, Katowice, PL; Huddinge, S)
P481 Chemo-based (reduced intensity or busulphan-based myeloablative) conditioning
preserves the in vitro growth capacity of bone marrow stroma, which remains of host
origin, compared to TBI based conditioning
A. Spyridonidis, T. Küttler, E. Sammek, M. Waterhouse, K. Potthoff, M. Egger, H. Bertz, J. Finke
(Freiburg, D)
P482 Reduced-intensity allogeneic transplants: an update report from the Australasian Bone
Marrow Transplant Recipient Registry
I. Nivison-Smith, D.D Ma, K. Bradstock, J. Szer, A. Dodds (Sydney, Melbourne, AUS)
P483 Reduced-dose conditioning followed by allogeneic stem cell transplantation induces
stable long-term remission in high-risk patients suffering from acute myeloid leukaemia
L.O. Mügge, K. Weiß, K. Wirth, K. Schilling, S. Scholl, M. Charbel-Issa, K. Höffken, H.G. Sayer
(Jena, D)
P484 Reduced-intensity conditioning and CD6-negative, G-CSF-mobilised blood cells for
HLA-haploidentical marrow transplantation in high-risk haematopoietic neoplasia
H.J. Kolb, B. Simoes, I. Bigalke, C. Schmid, M. Schleuning, J. Tischer, G. Ledderose (Munich, D)
P485 A reduced-intensity conditioning regimen for elder patients with myelodysplastic
syndrome or acute leukaemia employing radioimmunotherapy with an Yttrium-90 or
Rhenium-188 labelled monoclonal CD 66-antibody
M. Ringhoffer, M. Wiesneth, S. von Harsdorf, T. Zenz, R. Schlenk, S.N. Reske, H. Doehner,
D. Bunjes (Ulm, D)
P486 High dose of in-vitro T-cell depleted CD34+ donor peripheral stem cells after nonmyeloablative
conditioning accelerates platelet recovery but does not establish
complete donor chimerism
R.M.Y. Barge, W.A.F. Marijt, S. Osanto, C.W.J. Starrenburg, M.R. Schaafsma, W.M. Smit,
W.E. Fibbe, J.H.F. Falkenburg, R. Willemze (Leiden, Enschede, NL)
P487 Thrombotic microangiopathy after non-myeloablative stem cell transplantation
N. Worel, H.T. Greinix, C. Buchta, M. Mitterbauer, F. Keil, P. Hoecker, P. Kalhs (Vienna, A)

Poster Physicians Monday, March 29, 2004
Reduced intensity transplants (continued)
18:00 –
19:00
P488 Mixed chimerism can be associated with circulating auto-antibodies and may favour
chronic graft-versus-host disease occurrence
S. Perruche, F. Kleinclauss, R. Angonin, D. Paris, P. Tiberghien, P. Saas (Besançon, F)
P489 Non-myeloablative stem cell transplantation in beta thalassaemia major patients
A. Ghavamzadeh, A. Mousavi, M. Iravani, B. Bahar, S. Gholibeikian, M. Moradiseresht, P. Heydari
(Tehran, IR)
P490 Impact of graft composition on the outcome after non-myeloablative haematopoietic
stem cell transplantation
F. Baron, P. Frere, N. Schaaf-Lafontaine, G. Vanstraelen, E. Baudoux, C. Herens, V. Bours,
G. Fillet, Y. Beguin (Liege, B)
P491 Increased post-transplant morbidity associated with a greater cumulative in-patient stay
in recipients of reduced intensity conditioning regimens (RIC-ALLO) compared to
myeloablative conditioning regimens (CC-ALLO) in allo-stem cell transplantation
E. Stephens, S. Feyler, K. Aldous, G. Smith, S. Kinsey, G. Cook
on behalf of The Yorkshire Blood & Marrow Transplantation Programme, Leeds UK
P492 Low-dose melphalan-TBI plus fludarabine and campath-1H as conditioning regimen for
unrelated transplant in high-risk patients for age and disease: a GITMO prospective
study
A. Bosi, D. Soligo, L. Lombardini, P. Patriarca, D. Damiani, M. Cerno, A. Rambaldi, G. La Nasa,
P. Di Bartolomeo, A. Busca, T. Lamparelli, A.M. Vannucchi, S. Pollicchieni, G. Lambertenghi
for GITMO
P493 Haematopoietic stem cell transplantation with non-myeloablative conditioning in the
out-patient setting. Results, complications and admission requirements in a single
centre
S. L. Petersen, H. O. Madsen, L. P. Ryder, A. Svejgaard, H. Sengelov, C. Heilmann, E. Dickmeiss,
L. L. Vindelov (Copenhagen, DK)
P494 Case-controlled comparative analysis of ablative and reduced-intensity allogeneic
haematopoietic stem cell transplantation in standard risk CML
G. Gürman, M. Arat, P. Topcuoglu, E.A. Soydan, M. Beksac, M. Ozcan, N. Konuk, A. Uysal,
H. Koc, Ö. Arslan, H. Akan, O. Ilhan (Ankara, TR)
P495 Reduced-intensity cord blood transplantation for adult T-cell leukaemia / lymphoma
D. Kato, E. Kusumi, S. Takagi, S. Koyama, K. Yuji, J. Ueyama, S. Miyakoshi, S. Morinaga,
S. Taniguchi (Tokyo, J)
P496 The comparison of two different conditioning regimens, myeloablative versus reduced
intensive, in ABO mismatched allogeneic haematopoietic stem cell transplantation
P. Topcuoglu, M. Arat, T. Bulakbasi, E. Soydan, Y. Ozer, O. Arslan (Ankara, TR)
P497 Reduced-intensity conditioning allogeneic transplant in patients with aggressive
non-Hodgkin lymphoma: results of a prospective multicentre trial
R. Martino, M. Mateos, A. Urbano, A. León, J. Odriozola, J. Ribera, D. Valcarcel, J. Sarrá,
L. Vázquez, A. Sureda, J. Sierra, J. San Miguel (Barcelona, Salamanca, Jerez de la Frontera,
Madrid, Badalona, E)
P498 Reduced Intensity conditioning in patients with B-chronic lymphocytic leukaemia
(B- CLL): results of a prospective multicentre trial
D. Caballero, R. Martino, M. Mateos, A. León, A. Urbano, G. Sanz, J. Sarrá, J. Perez Simón,
D. Valcarcel, A. Sureda, J. Sierra, J. San Miguel (Salamanca, Barcelona, Jerez de la Frontera,
Valencia, E)
P499 Plasma pharmacokinetics of low-dose oral busulfan in Fanconi 's anaemia patients
undergoing haematopoietic stem cell transplantation
J. Kühl, A. Jenke, E. Schleier, J. Freiberg-Richter, U. Schuler, H. Neitzel, W. Ebell (Berlin, Dresden, D)
75

Monday, March 29, 2004 Poster Physicians
76
Reduced intensity transplants (continued)
18:00 –
19:00
P500 Optimisation of recombinant human erythropoietin therapy after non-myeloablative
allogeneic haematopoietic stem cell transplantation
F. Baron, G. Vanstraelen, P. Frere, G. Fillet, Y. Beguin (Liege, B)
P501 Follow-up of patients with non-acute lymphoid malignancies after reduced-intensity
conditioning regimen with allogeneic haematopoietic stem cell transplantation:
results from a single centre
T. Guillaume, B. Gueglio, P. Moreau, N. Morineau, B. Mahé, P. Chevallier, V. Dubruille, M.J. Rapp,
J.L. Harousseau, N. Milpied (Nantes, F)
P502 Reduced-intensity conditioning followed by allogeneic transplantation: poor outcome in
secondary versus de novo acute myeloid leukaemias
P. Corradini, R. Milani, A. Dodero, C. Tarella, G. Bandini, A. Locasciulli, M. Bernardi, M. Lucesole,
A. Busca, D. Soligo, A.M. Gianni, M. Bregni, A. Olivieri (Milan, Turin, Bologna, Rome, Ancona, I)
P503 Molecular monitoring of chimerism and minimal residual disease in multiple myeloma
patients after non-myeloablative stem cell transplantation
S. Galimberti, E. Benedetti, R. Fazzi, F. Papineschi, F. Caracciolo, E. Orciuolo, F. Andreazzoli,
F. Morabito, M. Cuzzola, M. Martino, P. Iacopino, M. Petrini (Pisa, Reggio Calabria, I)
P504 Cytomegalovirus infection and disease in allogeneic non-myeloablative transplant
patients: a single-centre study
M. Uzunov, O. Adam, E. Chachaty, F. Griscelli, P. Arnaud, C. Boccaccio, J. Bourhis (Villejuif, F)
P505 Reconstitution of T-cell receptor CDR3 repertoire after myeloablative and reducedintensity
conditioning allogeneic heamatopoietic stem cell transplantation
P. Hentschke, B. Omazic, J. Mattsson, I. Näsman-Björk, D. Gigliotti, L. Barkholt, O. Ringdén,
M. Remberger (Stockholm, S)
P506 Reduced-intensity conditioning followed by allografting in patients with advanced
haematological malignancies older than 60 years
A. Olivieri, M. Lucesole, S. Cecchi, A. Dodero, F. Ciceri, M. Bregni, C. Tarella, M. Falda,
A. Locasciulli, R. Scimè, F. Patriarca, M. Casini, A. Bacigalupo, P. Corradini
(Torrette di Ancona, Milan, Turin, Rome, Palermo, Udine, Bolzano, Genoa, I)
P507 The outcome of allogenic stem cell transplantation for myeloid leukaemias following
reduced-intensity conditioning regimens is highly dependent on the pre-transplant
status of disease and the occurrence of a graft-versus-host disease
M. Varvenne, T. Winkler, H. Diedrich, E. Dammann, H. Kamal, M. Eder, A. Ganser, B. Hertenstein
(Hannover, D)
P508 Reduced-intensity conditioning allogeneic transplant in patients with indolent
non-Hodgkin lymphoma: result of a prospective multicentre trial
D. Caballero, R. Martino, M. Mateos, A. Urbano, V. Rubio, J. Odriozola, J. Ribera, J. Sarrá,
D. Valcarcel, M. Cañizo, J.M. Moraleda, A. Sureda, J. Sierra, J. San Miguel
(Salamanca, Barcelona, Jerez de la Frontera, Madrid, Badalona, Murcia, E)
P509 Allogeneic haematopoietic stem cell transplantation after reduced-intensity regimen
containing fludarabine, busulfan, and antihuman T-lymphocyte globulin (ATG)
M. Doubek, J. Mayer, Z. Koristek, M. Krejci, Y. Brychtova, M. Navratil, I. Vasova, M. Tomiska,
I. Buchtova (Brno, CZ)
P510 Haematopoietic chimerism monitoring is useful in evaluation of clinical outcome in
patients with haematological malignancies treated with non-myeloablative allogeneic
transplantation
J. Gozdzik, M. Iwola, K. Lewandowski, J. Hansz, M. Komarnicki (Poznan, PL)
P511 Successful engraftment after second allogeneic haemtopoietic cell transplantation
following conditioning with 3 Gy total body irradiation in patients who rejected after
conditioning with 2 Gy TBI
U. Hegenbart, J. Shizuru, M. Stuart, L. Uharek, T. Lange, W. Pönisch, M. Raida, S. Leiblein,
H. Al-Ali, L. Grommisch, E. Edel, U. Schönfelder, S. Heyn, M. Schwittay, F. Kamprad, R.F. Storb,
K. Blume, D. Niederwieser (Leipzig, D; Stanford, Seattle, USA)

Poster Physicians Monday, March 29, 2004
Reduced intensity transplants (continued)
18:00 –
19:00
P512 Economic analysis on reduced-intensity cord blood transplantation
D. Kato, K. Yuji, S. Takagi, E. Kusumi, S. Miyakoshi, J. Ueyama, S. Morinaga, S. Taniguchi
(Minato-ku Tokyo, J)
P513 Importance of disease stage and C-GvHD for curative potential of allo-PBSCT after a
reduced-intensitiy regimen using fludarabine (125mg/m2) and melphalan( 80mg/m2)
J.F. Tomas, J. de la Serna, A. Alegre, I. Buño, F. Hernandez-Navarro, A. Roman, J. Lahuerta,
J.L. Lopez-Lorenzo, J.L. Diez-Martin (Madrid, E)
P514 Allogenic peripheral blood stem cell transplantation following a non-myeloablative
(NMST) conditioning with fludarabine and low dose TBI in patients with haematological
malignancies and metastatic melanoma: a single-center experience
E. Benedetti, F. Papineschi, F. Caracciolo, S. Galimberti, A. Azzarà, G. Carulli, M. Petrini (Pisa, I)
P515 Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation
in patients older than 60 years
M. Falda, A. Busca, S. Santarone, F. Narni, A. Rambaldi, N. Mordini, B. Bruno, F. Locatelli,
A. Bacigalupo on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
P516 Fludarabine-melphalan reduced-intensity conditioning matched sibling bone marrow
stem cell transplantation is an effective treatment for myeloid disorders
R. Malladi, A. Peniket, G. Collins, T. Littlewood (Oxford, UK)
P517 Red blood cell and reticulocyte chimerism studies in non-myeloablative allogeneic
peripheral blood haematopoietic stem cell transplantation
L. Harritshoj, A. Berkowicz, S.L. Petersen, H.O. Madsen, L.P. Ryder, L. Vindelov, P. Andersen,
E. Dickmeiss (Copenhagen, DK)
18:00 –
19:00
Regulatory issues / Supportive care
P518 Fresh frozen plasma plus heparin has a possible beneficial effect in veno-occlusive
disease prophylaxis: a retrospective multivariate analysis
E. Yannaki, I. Batsis, P. Kaloyannidis, C. Smias, I. Sakellari, A. Fassas, A. Anagnostopoulos
(Thessalonica, GR)
P519 G-CSF after CD34+ immunoselected peripheral blood stem cell transplantation:
a novel administration schedule
N. Piccirillo, S. De Matteis, P. Chiusolo, L. Laurenti, F. Sorà, R. Putzulu, G. Reddiconto,
G. Leone, S. Sica (Rome, I)
P520 Circulating endothelial cells as a marker of endothelial damage in allogeneic
haematopoetic stem cell transplantation
S. Buchholz, A. Woywodt, J. Scheer, L. Hambach, H. Kamal, A. Ganser, H. Haller, M. Haubitz,
B. Hertenstein (Hannover, D)
P521 Effectiveness of fixed 50% nitrous oxide oxygen mixture and EMLA cream for insertion
of central venous catheters in children
S. Ladeb, A. Abdelkefi, Y. Benabdennabi, F. Mellouli, T. Benothman, L. Torjman, L. Kammoun,
S. Aouf, M. Bejaoui, A. Benabdeladhim (Tunis, TN)
P522 Protein-C serum levels as a prognostic indicator of sepsis and related diseases in
allogeneic bone marrow transplantation
F. Gualandi, D. Occhini, C. Di Grazia, A. Dominietto, A.M. Raiola, A. Bacigalupo (Genoa, I)
P523 Home care in a department of paediatric haematology and oncology.
Results of 3 years of activity
M. Miano, A. Garaventa, L. Manfredini, S. Fieramosca, C. Savio, R. Tanasini, G. Dini (Genoa, I)
P524 Octreotide shortens duration of toxic diarrh0ea after high-dose therapy and autologous
stem cell transplantation
M. Kauppila, M. Itälä, M. Putkonen, K. Remes (Turku, FIN)
77

Monday, March 29, 2004 Poster Physicians
78
Regulatory issues / Supportive care (continued)
18:00 –
19:00
P525 Analysis of thrombotic tendency and endothelial dysfunction of the peri-transplant
period in patients undergoing autologous stem cell transplantation
M. David, O. Toth, A. Szomor, B. Meng, H. Losonczy (Pécs, HUN)
P526 Successful treatment of cyclophasphomide-induced intractable haemorrhagic cystitis
with novoseven (recombinant activated Factor VII ) after allogeneic bone marrow
transplantation
M. Zakerinia, H. Nourani Khojaste, M. Ramzi, M. Haghshenash, M. Karimi, E. Ahmad (Shiraz, IR)
P527 Incidence and outcome of renal dysfunction early in the course of haematopoietic cell
transplantation
Y. Caliskan, S. Kalayoglu Besisik, D. Sargin, T. Ecder (Istanbul, TR)
P528 Administration of G-CSF after autologous peripheral stem cell transplantation is clinical
and cost-effective
C. Fruchart, V. Journet, S. Damourette, A. Rivière, O. German, D. Musafiri, A.-M. Peny (Caen, F)
P529 Intensive care for haematopoietic stem cell transplant recipients:
admission and outcome. Advantage of a “pre-emptive” policy
P. Marenco, R. Cairoli, G. Grillo, A. Tedeschi, P. Brasca, A. De Gasperi, E. Morra (Milan, I)
P530 Energy balance during stem cell transplantation
H.M. Dekker-van Roessel, J.A.E. Langius, P.C. Huijgens (Amsterdam, NL)
P531 Transfusion requirements after allogeneic haematopoietic stem cell transplantation
M. Bini-Antunes, L. Santos, F. Campilho, M. Rosales, F. Amado, A. Campos, C. Pinho Vaz,
P. Pimentel, A. Carvalhais (Porto, P)
P532 Method to comply with the JACIE standards on qualification of staff involved in stem cell
transplantation
Y. Dahmen, H. Boutémy, V. Démarez, O. Roucoules, V. Bourcy, J.L. Beaumont, M. Kuentz,
F. Beaujean, C. Boccaccio, J.P. Vernant, C. Cordonnier, H. Espérou
on behalf JACIE program-PHRC Ile de France
P533 A “single” dose of G-CSF after autologous stem cell transplantation in patients with
malignant lymphoma - second interim analysis of multicentre randomised trial
comparing standard schedule with delayed application and placebo
E. Faber, R. Pytlik, M. Trneny, J. Slaby, T. Kozak, L. Raida, T. Papajik, E. Zikesova, J. Zapletalova,
I. Maresova, M. Trnkova, K. Indrak (Olomouc, Prague, CZ)
P534 Cost-benefit analysis of a programme to identify patients receiving TPN after allogeneic
stem cell transplantation
E.-M. Ocio, J.-A. Pérez Simón, B. Alonso, M.-V. Calvo, M. Díez Campelo, C. Castilla, C. Cañizo,
M.-D. Caballero, L. Vázquez, F. Domínguez Gil-Urlé, J.-F. San Miguel (Salamanca, E)
P535 Effect of human growth hormone in haemato-oncology patients receiving intensive
chemotherapy. A double-blind randomised, placebo-controlled study
R. Powles, B. Sirohi, S. Kulkarni, M. Das, J. Treleaven, C. Dearden, G. Morgan, A. Boast,
R. McCormack, C. Marriott, C. Horton, J. Wass (Sutton, Oxford, UK)
18:00 –
19:00
Stem cell source
P536 Transplantation of peripheral blood stem cells mobilised by single-dose application of
pegylated G-CSF in patients with multiple myeloma
U. Steidl, R. Fenk, I. Bruns, M. Kondakci, L. Henze, B. Hoyer, T. Graef, F. Neumann, S. Knipp,
S. Bork, R. Kronenwett, R. Haas, G. Kobbe (Duesseldorf, D)
P537 Single-centre experience of umbilical cord stem cell transplantation for primary
immunodeficiency
A. Bhattacharya, M.A Slatter, C.E Chapman, D. Barge, T.J Flood, M. Abinun, A.J Cant,
A.R Gennery (Newcastle upon Tyne, UK)

Poster Physicians Monday, March 29, 2004
Stem cell source (continued)
18:00 –
19:00
P538 The use of dimethyl sulfoxide in stem cell transplantation: a survey of EBMT centres
P. Windrum, M.B. Drake, T. Ruutu, T.C.M. Morris on behalf of the Chronic Leukemia Working
Party Complications Committee
P539 Successful transplantation of haploidentically mismatched peripheral blood stem cell
using AC133+ purified stem cells
M. Bitan, M.Y. Shapira, I.B. Resnick, I. Zilberman, S. Miron, S. Samuel, A. Ackerstein, S. Elad,
S. Israel, A. Amar, E. Fibach, R. Or, S. Slavin (Jerusalem, IL)
P540 Hydroxyethil-starch can enhance efficacy in the harvest of peripheral mononuclear
blood cells
J. Fernández, J. Dupont, R. Campestri, S. Fridman, J. Solimano, L. Riera, D. Riveros, G. Garay,
R. Cacchione (Buenos Aires, AR)
P541 Mobilisation of haematopoietic progenitor cells for autologous blood stem cell
transplantation: analysis of experience at Inha University Hospital
C. S. Kim, M. H. Lee, C. H. Nahm, I. Kim, S. K. Kim, S. H. Pai (Incheon, KOR)
P542 Circulating absolute number of CD34+ cells remain the best predictor of successful
mobilisation in cytogenetic responders to imatinib
E. Nadal, J. Davis, S. Loaiza, D. Marin, S. Avery, E. Dannie, J. Apperley (London, UK)
P543 CD133 assessment in the peripheral blood before apheresis and in the autologous PBSC
transplant is a valuable tool for prediction of the haematopoietic content of the graft
F. Nicolini, G. Clapisson, T. Prebet, Q.H. Lé, A.S. Michallet, I. Philip, M. Michallet (Lyon, F)
P544 Comparison of antigen expression on the haematopoietic stem cells derived from cord
blood and mobilised healthy donors peripheral blood
M.A. Krol, M.E. Feliksbrot, E. Urbanowska, E. Graczyk-Pol, J. Dwilewicz-Trojaczek (Warsaw, PL)
P545 Autologous transplantation in patients with poor peripheral blood stem cell mobilisation:
results according to whether or not additional stem cells are pursued
C. Arbona, R. Goterris, J.C. Hernández-Boluda, A. Teruel, C. Gómez, J. García-Conde (Valencia, E)
P546 Efficacy of unrelated donor cord blood transplantation for poor risk paediatric
haematological malignancies
R.E. Hough, R.D. Faulkner, J.C. Welch, A.J. Vora (Sheffield, UK)
P547 Autologous bone marrow transplantation in lymphomas: pre-transplant cumulative
doses of chemotherapeutic drugs have a negative impact on long-term engraftment,
but little influence on short-term haematological recovery
A. Martín, J.A. Pérez-Simón, M.D. Caballero, N. López-Holgado, M.C. Cañizo, L. Vázquez,
J.F. San Miguel (Salamanca, E)
P548 Is there any impact of stem cell source on long-term survival after allogeneic
haematopoietic stem cell transplantation? Single-centre experience
J. Pretnar, I. Preloznik Zupan, S. Zver (Ljubljana, SI)
P549 Apoptosis in the haematopoietic stem cell products obtained by continuous flow
apheresis method in allogeneic peripheral stem cell transplantation
S. Bakanay, M. Arat, K. Dalva, O. Arslan, M. Beksac, E. Ayyildiz, O. Ilhan (Ankara, TR)
P550 Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful
engraftment by sparing primitive and committed haematopoietic progenitors
C. Almici, P. Ferremi, A. Lanfranchi, G. Rossi (Brescia, I)
P551 Intensive chemotherapy with autologous peripheral progenitor stem cell support:
a single-centre experience
A. Carneiro, F. Principe, C. Granato, F. Trigo, T. Costa, A. E.Santo, P. Guimaraes, M.J. Parreira,
J.E. Guimaraes (Porto, P)
79

Monday, March 29, 2004 Poster Physicians
80
Stem cell source (continued)
18:00 –
19:00
P552 Anti-CD20 effect of haematopoietic stem cell mobilisation in patients with follicular non-
Hodgkin lymphoma, after combined treatment with fludarabine and cyclophosphamide
S. Garcia, R. Arrieta, M. Canales, M. Sanjurjo, F. Hernandez-Navarro (Madrid, E)
P553 Safety and prompt availability of UCB units can be improved by NAT
P. Bergamaschi, C. Perotti, C. Del Fante, G.L. Viarengo, L. Bellotti, A. Marchesi, L. Salvaneschi
(Pavia, I)
P554 Diagnosis of acute foetal distress does not preclude umbilical cord blood banking
A. Picardi, G. Ballatore, A. Tamburini, G. Suppo, L. Cupelli, T. Caravita, M. Mirabile, C. Malerba,
M.I. Irno Consalvo, A.R. Camilli, A. Calugi, S. Amadori (Rome, I)
P555 Volume reduction of cord blood units using top and bottom bags
P. Solves, L. Larrea, V. Mirabet, G. Palomo, F. Carbonell-Uberos, M.A Soler, R. Roig (Valencia, E)
P556 Influence of graft source on the outcome following HLA-identical sibling haematopoietic
stem cell transplantation
D. Stamatovic, L. Tukic, B. Balint, O. Tarabar, M. Elez, V. Glavicic, L. Simic, B. Todoric-Zivanovic,
M. Malesevic (Belgrade, CS)
P557 Comparison between progenitor cells from bone marrow and mobilised peripheral blood
in healthy donors
E.M. Villarón, J. Almeida, N. López, L.I. Sanchez-Abarca, F.M. Sanchez-Guijo, M. Alberca,
B. Durán, C. Pata, A. Orfao, M.C. Del Cañizo, J.F. San Miguel (Salamanca, E)
P558 Predictive value of peripheral blood haematopoietic progenitor cell count before
mobilisation with high doses of G-CSF
P. Marín, J. Petriz, N. Monfort, M.L. López, M. Pérez, V. Martínez, L. Jover, A. Ordinas
(Barcelona, E)
P559 Unrelated donor umbilical cord blood transplantation following a standardised regimen
in 37 patients with haematologic malignancies
G. Sanz, M. Gonzalez-Vicent, R. Martino, J. Ortega, C. Jimenez, M. Diaz, T. Olive, I. Lorenzo,
A. Verdeguer, A. Torres, J. Bueno, L. Madero, J. Sierra, M. Sanz
on behalf of the GETH (Spanish cooperative group for Hematopoietic Stem Cell Transplantation)
18:00 –
19:00
Stem cell donor
P560 Differences in expression of adhesion molecules in correlation to mobilisation efficacy
in healthy stem cell donors investigated by flow cytometry
U. Oelschlaegel, G. Ehninger, F. Kroschinsky (Dresden, D)
P561 Which donor should be chosen for haematopoietic stem cell transplantation among
unrelated HLA-A, -B and -DRB1 genomically identical volunteers?
O. Ringdén, M. Schaffer, K. Le Blanc, U. Persson, D. Hauzenberger, M. Abedi, O. Olerup,
P. Ljungman, M. Remberger (Stockholm, S)
P562 The probability of molecular HLA-C matching between patients and unrelated donors for
promiscuous HLA-B allele B*5101
P. Jindra, V. Koza, J. Navratilová, K. Cerná, H. Pittrová (Pilsen, CZ)
P563 Does donor-recipient ABO incompatibility have impact on the outcome following
HLA-identical sibling haematopoietic stem cell transplantation?
D. Stamatovic, L. Tukic, B. Balint, O. Tarabar, M. Elez, L. Simic, L. Ristic, M. Malesevic (Belgrade, CS)
P564 Outcomes of core and extended family donor searches – a single-centre analysis
S. Vokurka, V. Koza, P. Jindra, K. Cerna, T. Karvunidis, D. Lysak, E. Bystricka, A. Volfova, L. Novak
(Pilsen, CZ)
P565 Utility of autologous blood collection for bone marrow donation
T. Parkkali, L. Volin, E. Juvonen, E. Elonen, T. Ruutu (Helsinki, FIN)

Poster Physicians Monday, March 29, 2004
Stem cell donor (continued)
18:00 –
19:00
P566 Arterial access for peripheral blood stem cell collection
J. Stein, J. Katz, O. Gelber, A. Grunspan, Y. Sverdlov, I. Yaniv (Petach-Tikva, IL)
P567 Phenotypic analysis of CD34+ and CD133+ subsets in successive collections of
mobilised peripheral blood progenitors
L. Gopcsa, A. Barta, A. Banyai, A. Poros, K. Paloczi (Budapest, HUN)
P568 Large volume leucapheresis for peripheral blood progenitor cell collection in healthy
donors for allogeneic transplantation: a simplified single-apheresis approach
A. Alegre, J. Cannata, B. Aguado, A. Granda, R. Córdoba, S. Nistal, S. Osorio, C. Cámara, C. Aláez,
C. Blázquez, E. Martí, M.J. Fernández-Villalta, A. Figuera, J.M. Fernández-Rañada (Madrid, E)
P569 Improving probabilities of identifying a matched family donor: the use of 'vertical'
HLA typing
D. McCloskey, T. Rintala, S. Agrawal, C. Murrell, A. Gupta, S. Hemmatapour, P. Sinnott,
J. Cavenagh (London, UK)
P570 Novel HLA phenotypes added to the British Bone Marrow Registry
P.P.J. Dunn, J.R. Turton, C.J. Brown, V. Carter, A. Green, G. Cavanagh, S. Davey,
J. Harvey, P. Heard, D. Pamphilon, C.V. Navarrete (Bristol, London, Newcastle, UK)
P571 The outcome of patients with an identified HLA identical sibling donor:
impact of transplantation rate on early transplant outcome
E.A. Soydan, M. Arat, T. Bulakbasi, P. Topcuoglu, O. Arslan, M. Özcan, G. Gürman,
M. Beksac, H. Akan, O. Ilhan (Ankara, TR)
P572 Second donation of G-CSF mobilised peripheral blood stem cells: risk factors associated
with a low yield of CD34+ cells
U. Platzbecker, M. Bornhäuser, K. Zimmer, C. Rutt, G. Ehninger, K. Hölig (Dresden, Tuebingen, D)
P573 Conventional unrelated bone marrow transplantation for patients with haematological
disease: probability of finding a donor and outcome of 131 consecutive cases in a
single-centre
A. Sperotto, F. Patriarca, M. Cerno, F. Silvestri, F. Zaja, C. Filì, A. Geromin, E. Calistri, R. Stocchi,
D. Damiani, R. Fanin (Udine, I)
P574 Haploidentical transplantations following reduced-intensity conditioning regimens in
paediatric patients
I. Dolgopolov, R. Protsenko, L. Andreeva, V. Boyarshinov, R. Ravshanova, G. Mentkevich
(Moscow, RUS)
P575 Mobilisation of peripheral blood stem cells with lenograstim using a short mobilisation
regimen
C. Kreissig, A. Younis, J. Kadar (Ratingen, Cologne, D)
P576 Induced acute graft-versus-host reaction after syngeneic transplantation by shortcourse
cyclosporine A administration possibly provides acute graft-versus-malignancy
effect resulting in long lasting complete remissions
H. Bertz, B. Hackanson, O. Schmah, A. Spyridonidis, M. Egger, K. Mikesch, F. Dörfel, J. Finke
(Freiburg, D)
18:00 –
19:00
Tolerance and rejection
P577 Is mixed chimerism after conventional and reduced-intensity conditioning allogeneic
haematopoietic stem cell transplantation a good marker of early relapse detection?
S. Fürst, A.S. Michallet, V. Dubois, Q.H. Lé, F. Nicolini, X. Thomas, Y. Chelghoum, J. Troncy,
H. Rafii, A. Praire, L. Gebuhrer, M. Michallet (Lyon, F)
P578 FISH vs fluorescent STR-PCR for post-SCT chimaerism quantification
P. Nava, A. Simón, J.L. Jiménez, M. González-Rivera, P. Balsalobre, R. Carrión, D. Serrano,
A. Gómez-Pineda, J.L. Díez-Martín, I. Buño (Madrid, E)
81

Monday, March 29, 2004 Poster Physicians
82
Tolerance and rejection (continued)
18:00 –
19:00
P579 A non-myeloablative treosulfan-containing conditioning regimen is capable of allowing
long-term engraftment of allogeneic bone marrow for immunological tolerance and
adoptive immunotherapy via depletion of recipient haematopoietic stem cells in mice
R.E. Ploemacher, K.W. Johnson, E.W.C. Rombouts, J. Baumgart, M. White-Scharf, J.D. Down
(Rotterdam, NL; Charlestown, USA; Wedel, D)
P580 Influence of antecedent Glivec® therapy (imatinib mesylate) on allogeneic stem cell
transplantation outcome in CML Ph+ and ALL Ph+ patients – single-centre experience
J. Holowiecki, T. Kruzel, J. Wojnar, M. Krawczyk-Kulis, I. Wylezol (Katowice, PL)
18:00 –
19:00
Non-haematopoietic tissue repair
P581 Intramyocardial injection of mononuclear bone marrow cells to improve tissue
regeneration after myocardial infarction
C. Scheid, J. Müller-Ehmsen, P. Tossios, U. Holtick, D. Moka, U. Mehlhorn, R. Schwinger
(Cologne, D)
P582 Enhancing bone defects repair using autologous bone marrow buffy-coat:
report of 70 cases
R. Saccardi, R. Capanna, P. Bufano, R. Caporale, P. De Biase, M. Innocenti, L. Lombardini,
F. Pagliai, S. Urbani, A. Bosi (Florence, I)
P583 Correlation between the number of homed bone marrow mononuclear cells and the
extension of the infarcted area in a rat model
R. Pacchiana, R. Giordano, M. Ciulla, S. Ferrero, L. Lazzari, U. Gianelli, G. Busca, S. Bosari,
F. Magrini, P. Rebulla (Milan, I)
P584 Myocardial regenerative therapy from autologous bone marrow stem cells
M.J. Penarrubia, M.E. Fernández, A. Cantalapiedra, O. Gutierrez, A. Sanchez, A. San Román,
F. Fernandez-Avilés, J. García Frade (Valladolid, E)
P585 G-CSF-primed haematopoietic stem cells accelerate recovery from acute and chronic
carbon tetrachloride (CCl4)-induced liver injury
E. Yannaki, E. Athanasiou, A. Xagorari, V. Constantinou, I. Batsis, E. Papadakis,
A. Anagnostopoulos, A. Fassas (Thessalonica, GR)
P586 Transplantation of mobilised peripheral blood stem cells in unconditioned hosts results
in formation of donor-derived hepatocytes in an experimental liver injury model
E. Yannaki, E. Athanasiou, A. Xagorari, V. Constantinou, I. Batsis, C. Kartsios, A. Fassas,
A. Anagnostopoulos (Thessalonica, GR)
P587 Intracoronary infusion of bone marrow-derived progenitor cells in patients with
myocardial infarction
J. Toporski, K. Reczuch, D. Turkiewicz, D. Kratochwil, M. Dzidowski, R. Ryczan, B. Rybka,
W. Banasiak, A. Chybicka, P. Ponikowski (Wroclaw, PL)
P588 Quest for donor type cells in non-haematopoietic tissue in patients after HSCT.
Analysis of tissue with high need for repair: hair and sperm
A. Rovo, C. De Geyter, S. Meyer-Monard, D. Heim, J. Passweg, W. Holzgreve, A. Gratwohl,
A. Tichelli (Basel, CH)
P589 Autologous bone marrow AC133+ cell transplantation in acute myocardial infarction
C. Plesa, B. Mut, A. Plesa, E. Suciu, V. Ordodi, I. Sisca, M. Serban, S.-I. Dragulescu, V. Paunescu
(Timisoara, RO)

Poster Physicians Monday, March 29, 2004
18:00 –
19:00
18:00 –
19:00
Aplastic Anaemia
P590 Subtyping of Fanconi's anaemia patients in Spain
J.A. Casado, E. Callén, A.A. Jacome, J.C. Segovia, E. Lobitz, H. Hanemberg, J.A. Bueren
(Madrid, Barcelona, E; Duesseldorf, D)
P591 Non-myeloablative stem cell transplantation (NST) for the treatment of patients with
Fanconi's anaemia
S. Slavin, M. Bitan, M. Aker, I. Resnick, M. Shapira, R. Or (Jerusalem, IL)
P592 Severe aplastic anaemia: long-term chimerism analysis after bone marrow
transplantation
E. Cortesão, A. Guimarães, A. Machado, L. Vieira, G. Boavida, M. Jorge, H. Alaiz, M. Abecasis
(Lisbon, P)
P593 Cyclosporin-A response/dependence in paediatric patients with aplastic anaemia
P. Saracco, C. Dufour, D. Longoni, S. Varotto, G. DelVecchio, A. Iori, M. Zecca, M. Cellini,
P. Paolucci, D. Sperli, G. Zanazzo, G. Menna, P. Quarello, R. Cerchio, U. Ramenghi, A. Locasciulli
(Turin, Genoa, Monza, Padua, Bari, Rome, Pavia, Modena, Cosenza, Trieste, Naples, I)
P594 A single-centre experience in the stem cell transplantation of Fanconi's anaemia
patients
D. Balashov, P. Trakhtman, E. Pashanov, Y. Skvortsova, I. Shipitsina, Z. Dyshlevaya,
E. Skorobogatova, A. Maschan (Moscow, RUS)
P595 Donor-derived acute myelomonocytic leukaemia in a patient receiving allogenic bone
marrow transplant for severe aplastic anaemia
J. Müller, I. Haltrich, J. Szabó, G. Kovács, R. Koós, M. Garami, G. Kriván, M. Dobos, G. Fekete
(Budapest, HUN)
P596 Persisting mesenchymal stem cells is the basis of successful bone marrow
transplantation
V. Rugal, K. Abdulkadyrov, M. Bercos (St. Petersburg, RUS)
Autoimmune disease
P597 Long-term immune reconstitution in patients treated with autologous stem cell
transplantation for refractory autoimmune diseases
R. Arnold, T. Alexander, G. Massenkeil, R. Burmester, A. Radbruch, F. Hiepe, A. Thiel (Berlin, D)
P598 Autologous stem cell transplantation with in vitro purged or unpurged graft in the
treatment of 25 patients with poor-risk multiple sclerosis
T. Kozak, E. Havrdova, J. Pitha, K. Mayerova, E. Gregora, J. Slaby, P. Kobylka, S. Vodvarkova,
P. Salaj, M. Kolar, J. Pachl, M. Trneny, J. Fiedler, P. Skopek, K. Koza (Prague, Pilsen, CZ)
P599 High-dose cyclophosphamide and autologous peripheral blood stem cell transplantation
for refractory chronic inflammatory bowel diseases – a two step approach
K. Potthoff, W. Kreisel, H. Bertz, A. Schmitt-Gräff, J. Finke (Freiburg, D)
P600 Three cases of haemophagocytosis (MAS) during SCT for systemic juvenile idiopathic
arthritis, possibly caused by fludarabin
N. Wulffraat, A. van Royen-Kerkhof, M. Abinun, C. Modesto, J. Ortega, P. Veys, L. Wedderburn
(Utrecht, NL; Newcastle, London, UK; Barcelona, E)
83

Monday, March 29, 2004 Poster Physicians
84
Autoimmune disease (continued)
18:00 –
19:00
P601 Outcome of autologous HSCT for severe and refractory autoimmune diseases in Brazil
J. Voltarelli, A.-B. Stracieri, M.-C. Rodrigues, D. Godoi, D. Moraes, M. Coutinho, N. Hamerschlak,
E. Ferreira, A. Ribeiro, C. Massumoto, N. Castro, J.-C. Barros, K. Matias, M. Ostronoff,
C.-L. Santanna, W. Azevedo on behalf of the Brazilian Cooperative Trial of autologous HSCT for
autoimmune diseases
P602 Treatment of severe systemic lupus erythematosus (SLE) with autologous stem cell
transplantation: clinical outcome in 6 cases
T. Alexander, G. Massenkeil, E. Gromnica-Ihle, R. Burmester, A. Radbruch, A. Thiel, F. Hiepe,
R. Arnold (Berlin, D)
P603 Complete long term remission of relapsing pure white cell aplasia following RIC
ALLO-BMT and DLI
A.M. Marmont, F. Gualandi, A.M. Raiola, A. Dominietto, S. Bregante, M.T. van Lint, A. Bacigalupo
(Genoa, I)
P604 Alternation of T-helper 1 and T-helper 2 subsets in peripheral blood cells of patients with
multiple sclerosis following autologous haematopoietic stem cells transplantation
J. Ouyang (Nanjing, CHN)
P605 Allogenic HLA identical bone marrow transplantation in patient with juvenile idiopathic /
chronic/arthritis /JIA
K. Nagy, G. Vertesi, G. Marton, B. Lombay, S. Sipka on behalf of the Autoimmune Diseases
Working Party
P606 Expression analysis of natural killer cell immunoglobulin-like and cytotoxicity receptors
in patients with psoriatic arthritis
C. Seidl, T. Tonn, C. Wild, F. Behrens, W. Boehnke, B. Möller, E. Seifried, E. Märker-Herrmann,
P. Kaltwasser on behalf of the Psoriatic arthritis study group, Rhein Main Centre of Rheumatology
P607 The study of apoptosis and Fas ligand in peripheral blood mononuclear cells in multiple
sclerosis
A. Rezaei (Isfahan, IR)
P608 Autologous stem cell transplant in 4 patients with refractory autoimmune diseases
T.L. Lee, S.Y. Ha, G.C.F. Chan, H.K. Ho, Y.L. Lau (Hong Kong, HK)
18:00 –
19:00
Chronic leukaemias
P609 Autologous haematopoietic stem cell transplantation as a first-line intensification in B
and C chronic lymphocytic leukaemia
L. Sutton, A. Drihème, M. Diviné, H. Gonzalez, P. Travade, M. Michallet, B. Lioure, S. Lepretre,
M. Leporrier on behalf of the SFGM and French CLL Study Group
P610 PBSC collection following G-CSF mobilisation in CML patients treated with imatinib mesylate
P. Perseghin, C. Gambacorti-Passerini, L. Tornaghi, P. Pioltelli, M. Dassi, E. Elli, M. Fumagalli,
E. Pogliani (Monza, Milan, I)
P611 Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic
lymphocytic leukaemia. A study from the EBMT and IBMT Registries
M. Michallet, A.S. Michallet, Q. Le, G. Bandini, P.A. Rowlings, H.J. Deeg, G. Gahrton,
E. Montserrat, F. Nicolini, C. Rozman, A. Gratwohl, D. Niederweiser, C. Bredeson, M. Horowitz
(Lyon, F; Bologna, I; Milwaukee, Seattle, USA; Huddinge, A; Barcelona, E; Basel, CH; Leipzig, D;
Ottawa, CAN)
P612 Conventional versus reduced intensity-conditioned allogeneic stem cell transplantation
for CLL – single-centre comparison of early outcome
P. Jindra, V. Koza, M. Karas, K. Cerná, D. Lysák, V. Vozobulová, M. Schutzová, P. Skopek,
S. Vokurka, M. Svojgrová (Pilsen, CZ)

Poster Physicians Monday, March 29, 2004
Chronic leukaemias (continued)
18:00 –
19:00
P613 Unrelated donor stem cell transplantation for chronic myeloid leukaemia in first chronic
phase: the Spanish experience
M. Jiménez, V. Gómez-García, C. Martín, A. Iriondo, G. Sanz, C. Cañizo, J. Sierra, R. Cabrera,
C. Vallejo, J. López, C. Martínez, A. Torres, R. de la Cámara, E. Carreras
on behalf of the CML subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH)
P614 Low-dose (75mg) campath in reduced-intensity conditioning and allogeneic stem cell
transplantation in patients with advanced CLL
J. Schetelig, M. Bornhäuser, C. Thiede, B. Mohr, U. Oelschlägel, M. Hänel, G. Geissler, T. Illmer,
A. Kiani, G. Ehninger, W. Siegert on behalf of the Cooperative Transplant Study group
P615 Imatinib in the pre- and post-transplantation setting in philadelphia chromosome
positive CML: a retrospective analysis
M. Wabersich, R. Krahl, T. Lange, U. Hegenbart, C. Mueller, S. Musiol, S. Kim, D. Niederwieser,
H. Al-Ali (Leipzig, D)
P616 Imatinib for chronic myeloid leukaemia relapsing after allogeneic bone marrow
transplantation
M. Lucesole, A. Garuti, M. Sessarego, C. Di Grazia, M.T. van Lint, A. Dominietto, A.M. Raiola,
T. Lamparelli, F. Gualandi, D. Occhini, S. Bregante, V. Galbusera, A. Bacigalupo (Genoa, I)
P617 The ability to mobilise progenitor cells is impaired in patients with chronic lymphocytic
leukaemia compared to other haematological malignancies and this is independent of
marrow infiltration
R.A. Lovell, K. Holder, M. Karanth, C.D. Fegan, G.E.D. Pratt, D.W. Milligan (Birmingham, UK)
P618 The results of MUD-BMT in CML-CP are as good as the results of HLA identical sibling
transplants. A single-centre experience
A. Vítek, J. Sajdová, P. Cetkovsky´, D. Sponerová, M. Marková, D. Pohlreich (Prague, CZ)
P619 A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular
remission in chronic lymphocytic leukaemia
V. Pitini, C. Arrigo, C. Amata, G. La Gattuta, L. Siracusano, D. Teti (Messina, I)
P620 Imatinib mesylate therapy in patients with chronic myeloid leukaemia previously treated
with autologous stem cell transplantation
M. Cortés, A. Sureda, R. Martino, A. Aventín, J. Nomdedeu, J. Briones, D. Valcárcel, S. Brunet,
J. Sierra (Barcelona, E)
P621 Factors influencing the outcome of HLA-identical sibling transplants for chronic myeloid
leukaemia: collaborative analysis from three centres in Poland and Turkey
P. Topcuoglu, J.M. Zaucha, M. Arat, H. Akan, J. Gozdzik, D. Szatkowski, A. Hellmann, M. Beksac
(Ankara, TR; Gdansk, Poznan, PL)
P622 Effectiveness of rituximab for in vivo purging before harvest of peripheral stem cells
in chronic lymphocytic leukaemia
L. Shvidel, M. Shtalrid, L. Bassous, N. Harpaz, A. Berrebi (Rehovot, IL)
P623 Autologous transplantation after in vivo purging with alemtuzumab in chronic
lymphocytic leukaemia
I. Majolino, M. Ladetto, G. Anghel, C. Papetti, F. Benedetti, A. Gallamini, T. Chisesi, A. De Blasio,
C. Tarella on behalf of GITIL (Gruppo Italiano per le Terapie Innovative nei Linfomi)
85

Monday, March 29, 2004 Poster Physicians
18:00 –
19:00
18:00 –
19:00
18:00 –
19:00
86
Haemoglobinopathy
P624 New approaches to the second transplant for thalassaemia
J. Gaziev, C. Giardini, P. Polchi, P. Sodani, G. Lucarelli (Pesaro, I)
P625 Chronic GvHD outcome in thalassaemia major patients (12-year experience in Iran)
A. Ghavamzadeh, M. Jahani, A. Mousavi, B. Bahar, M. Iravani, K. Alimoghaddam, S. Gholibeikian,
F. Safavifar, P. Heydari (Tehran, IR)
P626 Pure red cell aplasia mimicking graft failure in a child following fludarabine-based
conditioning and allogeneic stem cell transplantation for homozygous beta-thalassaemia
L.M. Ball, A.M. Hemling, R.G.M. Bredius, A.C. Lankester, M.Y. Bilgin, P.C. Giordano,
C.L Harteveld, W.A.F. Marijt, M.J.D. van Tol, R.M. Egeler (Leiden, NL)
P627 Bone marrow transplantation for thalassemia using different conditioning regimens
including “short” anti-thymocyte globulin therapy
M. Zakerinia, H. Nourani Khojaste, M. Ramzi, M. Haghshenash (Shiraz, IR)
P628 Intensified immunosuppression for treatment of impending graft rejection in
thalassaemic patients
U. Duffner, B. Strahm, U. Kontny, C. Niemeyer (Freiburg, D)
Inborn errors
P629 Safe and efficacious allogeneic bone marrow transplantation with partial donor T-cell
depletion and no post-transplant GvHD prophylaxis
R. Elhasid, M. Ben Arush, T. Katz, I. Sami, O. Gidoni, N. Haddad, S. Postovsky, A. Ben Barak,
J.M. Rowe (Haifa, IL)
P630 Allogeneic stem cell transplantation in X-linked adrenoleukodystrophy
G. Kriván, Á. Bátai, B. Kapás, S. Lueff, M. Molnár, P. Reményi, M. Réti, A. Tremmel, T. Masszi
(Budapest, HUN)
P631 Cartilage hair hypoplasia: successful unrelated haematopoietic stem cell transplantation
V. Bordon, E. Vandecruys, C. Dhooge, G. Laureys, Y. Benoit (Ghent, B)
Multiple myeloma
P632 Comparison of immunofixation electrophoresis with serum free light chain measurement
S.D. Reid, G.P. Mead, M.T. Drayson, A.R. Bradwell (Birmingham, UK)
P633 Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell
transplantation
I. Yakoub-Agha, M. Mohty, M. Attal, G. Marit, C. Bulabois, J.J. Sotto, N. Gratecos, B. Rio, J.P. Vernant,
T. Facon, J.P. Jouet on behalf of the Intergroupe Francophne du Myélome and SFGM-TC
P634 Allogeneic transplantation after non-myeloablative conditioning consolidation therapy
following high-dose melphalan and autologous stem cell transplantation improve
outcome in high-risk multiple myeloma
M. Martino, G. Beltrami, M.T. Corsetti, G. Penna, G. Messina, F. Morabito, P. Iacopino, A. Carella
(Reggio Calabria, San Giovanni Rotond, San Giovanni Rotondo, I)
P635 Salvage of multiple myeloma patients relapse after an autologous stem cell
transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell
transplantation
I. Hardan, A. Kneller, A. Shimoni, M. Berkowicz, A. Avigdor, M. Yeshurun, P. Raanani,
Y. Davidowich, N. Shemtov, I. Ben Bassat, A. Nagler (Tel-Hashomer, IL)

Poster Physicians Monday, March 29, 2004
Multiple myeloma (continued)
18:00 –
19:00
P636 Update of autologous retransplantation in multiple myeloma patients:
intra-individual analysis of event free survival (T2 model)
R. Hajek, A. Krivanova, M. Krejci, V. Scudla, J. Bacovsky´, M. Schutzova, L. Pour, J. Mayer,
T. Buchler, V. Koza, J. Vorlicek, Z. Adam (Brno, CZ)
P637 Impact of deletion 13 detected by fluorescence in situ hybridisation on outcome after
dose-reduced allogeneic stem transplantation in patients with multiple myeloma
N. Kröger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. Perez-Simon,
J. San Miguel, M. Kiehl, A. Fauser, R. Schwerdtfeger, H. Wandt, H. Sayer, H. Myint,
H. Klingemann, T. Zabelina, F. Ayuk, J. Dierlamm, A. Hinke, A. Zander
(Hamburg, Tuebingen, Ulm, Idar-Oberstein, Wiesbaden, Nuremberg, Jena, Monheim, D;
Tel Hashomer, IL; Salamanca, E; Chicago, USA)
P638 Specific lysis of multiple myeloma cells by T-cells engineered to express a chimeric
immune receptor targeting HM 1.24
M.S. Topp, H. Hummel, G. Kuntz, C. Neff, H. Einsele (Tuebingen, D)
P639 Graft-versus-myeloma effect following reduced-intensity conditioning allogeneic stem
cell transplantation
M. Mohty, J. Boiron, G. Damaj, A. Michallet, J. Bay, C. Faucher, V. Perreau, K. Bilger, A. Stoppa,
R. Tabrizi, J. Gastaut, M. Michallet, D. Maraninchi, D. Blaise
(Marseille, Bordeaux, Lyon, Clermont Ferrand, F)
P640 Double versus single autotransplantation in multiple myeloma; single-centre experience
with 101 patients
M. Putkonen, K. Remes, A. Rauhala, M. Itälä, M. Kauppila, T.-T. Pelliniemi, A. Rajamäki
(Turku, Vaasa, FIN)
P641 Long-term follow-up of a randomised phase III multicentre study comparing a standard
versus an intensified conditioning regimen for high-dose chemotherapy in patients with
multiple myeloma
R. Fenk, P. Schneider, M. Kropff, A.-N. Huenerlituerkoglu, C. Aul, W. E. Berdel, A. Heyll, R. Haas,
G. Kobbe on behalf of the Westgerman Myeloma Study Group
P642 A multi state statistical analysis indicates a better outcome in autologous tandem
transplantation in myeloma, if the second transplant can be performed within six
months of the first
C. Morris, S. Iacobelli, R. Brand, B. Bjorkstrand, M. Drake, D. Niederwieser, G. Gahrton
on behalf of the Chronic Leukaemia Working Party Myeloma Subcommittee of the European
Blood and Marrow Transplant (EBMT) Group
P643 High-dose melphalan and autologous stem cell transplantation after VAD chemotherapy
for systemic light chain (AL) amyloidosis
J.B. Perz, S. Schoenland, M. Hundemer, R.P. Linke, A.D. Ho, H. Goldschmidt
(Heidelberg, Martinsried-Munich, D)
P644 Reduced-intensity conditioning allogeneic stem cell transplantation for multiple
myeloma. Report from the Japan Myeloma Study Group (JMSG)
C. Shimazaki, H. Fujii, T. Yoshida, T. Chou, C. Nakaseko, A. Ishii, T. Takagi, K. Takatsuki
(Kyoto, Toyama, Niigata, Chiba, J)
P645 Phase I/II study with bendamustine hydrochloride in patients with multiple myeloma
relapsing after high-dose therapy and autologous stem cell transplantation
S. Knop, C. Straka, H. Hebart, M. Haen, L. Kanz, H. Einsele (Tuebingen, Munich, D)
P646 Longitudinal monitoring of the plasma cells propidium iodide and annexin-V /CD138
indices during various phases of multiple myeloma
M. Ordeltova, J. Bacovsky, M. Vytrasova, J. Zahalkova, P. Horak (Olomouc, CZ)
87

Monday, March 29, 2004 Poster Physicians
88
Multiple myeloma (continued)
18:00 –
19:00
P647 Employment of autologous transplantation of progenitor cells following effective
treatment with thalidomide of patients with multiple myeloma resistant to conventional
chemotherapy
H. Ciepluch, W. Knopinska-Posluszny, J. Czyz, A. Hellmann (Gdansk, PL)
P648 Thalidomide stimulates peptide specific CD8+ T-cells against viral epitopes
A. Trojan, R. Giger, N. Rist, D. Jäger, C. Taverna (Zurich, CH)
P649 Serum free light chain ratio is predictive of early relapse in patients who are in complete
remission by immunofixation
B. Sirohi, R. Powles, S. Kulkarni, H.D. Carr-Smith, G. Patel, M. Das, J. Iqbal, A.R. Bradwell,
C. Dearden, J. Mehta (Sutton, Birmingham, UK)
P650 Dendritic cells vaccination post-peripheral blood stem cell transplantation in multiple
myeloma
J. Gayoso, C. Regidor, R. Yañez, F.J. Peñalver, R. Forés, G. Bautista, E. Ruiz, J.A. García-Marco,
S. Gil, I. Sanjuan, F. Díaz-Espada, M.N. Fernández, J.R. Cabrera (Madrid, E)
P651 Intravenous neridronate for treatment of skeletal involvement in patients undergoing
autologous stem cell transplantation for multiple myeloma
G. Pittari, D. Costi, L. Mangoni, S. Frigelli, M.C. Baroni, V. Rizzoli (Parma, I)
P652 Treatment of patients with multiple myeloma in first relapse after high-dose
chemotherapy with single agent thalidomide – duration of first remission is the major
prognostic factor for EFS and OS
B. Hoyer, R. Fenk, U. Steidl, U. Germing, R. Haas, G. Kobbe (Duesseldorf, D)
P653 A case control study of high-dose chemotherapy and autologous stem cell
transplantation versus conventional chemotherapy in advanced stage myeloma
E. Terruzzi, F. Rossini, M. Parma, R. Montesano, L. Verga, S. Cammarota, M. Romeo, J. Navarro,
P. Pioltelli, E. Pogliani (Monza, I)
P654 Only a minority of myeloma patients aged under 65 years receive high-dose therapy
with autologous transplantation
T.C.M. Moris, E. Ranaghan, C. Ogilve, G.H. Jackson, M.R. Velangi
(Belfast, Newcastle-upon-Tyne, UK)
P655 High-dose therapy is given to multiple myeloma patients with similar clinical
characteristics to those in conventional chemotherapy and improves survival in
multiple myeloma: a retrospective analysis from a single centre
M. Beksac, E. Soydan, M. Arat, P. Topcuoglu, M.K. Yuksel, S.K. Toprak, M. Kizil, O. Arslan,
M. Ozcan, G. Gurman, O. Ilhan, H. Akan (Ankara, TR)
P656 153 samarium-EDTMP in myeloablative dosage followed by autologous stem cell
transplantation in patients with refractory multiple myeloma
S. Knop, B. Dohmen, L. Kanz, R. Bares, H. Einsele (Tuebingen, D)
P657 Autologous stem cell transplantation for primary amyloidosis: the Finnish experience
E. Jantunen, T. Siitonen, E. Koivunen, M. Putkonen, E. Juvonen, T. Nousiainen, P. Koistinen
(Kuopio, Oulu, Tampere, Turku, Helsinki, FIN)
P658 Aiming at increasing allogeneic possibilities in multiple myeloma patients
M. Paola, R. Cairoli, G. Grillo, A. Tedeschi, P. Brasca, E. Morra (Milan, I)
P659 Combination thalidomide, doxil and dexamethasone as salvage therapy for patients
relapsed after tandem autotransplant
M. Offidani, M. Marconi, L. Corvatta, L. Malerba, A. Olivieri, A. Mele, P. Galieni, R. Centurioni,
F. Alesiani, M. Candela, P. Leoni (Ancona, Pesaro, Ascoli Piceno, Civitanova Marche, S. Severino, I)
P660 High-dose melphalan followed by autologous stem cell transplantation in patients with
primary systemic (AL) amyloidosis
S. Knop, C. Lengerke, H. Hebart, L. Kanz, H. Einsele (Tuebingen, D)

Poster Physicians Monday, March 29, 2004
18:00 –
19:00
Solid tumours
P661 Low frequency of PBPC harvest contamination with tumour cells in Ewing´s sarcoma
patients treated with VIDE induction regimen
D. Sumerauer, A. Vicha, E. Kabickova, S. Matejckova, A. Hruba, T. Eckschlager (Prague, CZ)
P662 A graft-versus-lung effect after non-myeloablative stem cell transplantation in a patient
with an advanced chemorefractory squamous tracheo-bronchial carcinoma
G.L. Banna, S.M.L. Aversa, G. Crivellari, V. Chiarion-Sileni, A. Favaretto, H. Koussis, S. Monfardini
(Padua, I)
P663 Submyeloablative chemotherapy with peripheral blood stem cell rescue in solid tumours
in childhood. A single-centre experience
M. Chanova, E. Kabickova, J. Malis, J. Koutecky (Prague, CZ)
P664 Adoptive transfer Of IL-2 activated T-cells following autologous haematopoietic cell
transplantation in patients with breast cancer
P. Pedrazzoli, J. Peccatori, R. Schiavo, S. Deola, E. Setola, F. Ciceri, M. Bernardi, S. Secondino,
C. Tullio, F. Lunghi, E. Guggiari, S. Siena, M. Bregni (Milan, I)
P665 Inflammatory cytokines dominate with tumour regression after haematopoietic stem cell
transplantation for solid cancer
R. Conrad, M. Remberger, P. Hentschke, J. Mattsson, B. Sundberg, O. Ringdén, L. Barkholt
(Stockholm, S)
P666 Megachemotherapy with autologus PBSCT in Ewing's sarcoma in children
K. Drabko, B. Wojcik, M. Choma, A. Zaucha-Prazmo, J. Zawitkowska-Klaczynska,
J.R. Kowalczyk, E. Gorczynska, J. Toporski, K. Kalwak, D. Turkiewicz (Lublin, Wroclaw, PL)
P667 Long-term survival and toxicity of tandem high-dose therapy with high-dose melphalan
and ice regimen (ifosfamide, carboplatin and etoposide) followed by autologous stem
cell support in patients with advanced breast cancer
L. De Rosa, G. Anghel, L. Pescador, F. Blandino, M. Lalle, A. Pandolfi, I. Majolino (Rome, I)
P668 Enhanced graft-versus-tumour effect with trastuzumab after non-myeloablative
allogeneic stem cell transplantation in a patient with HER2 positive metastatic
breast cancer progressed after chemotherapy and trastuzumab
G.L. Banna, S.M.L. Aversa, C. Ghiotto, G. Crivellari, G. Casarrubea, S. Monfardini (Padua, I)
89

Tuesday, March 30, 2004 Poster Physicians
18:00 –
19:00
90
Cellular therapies
P669 Purified human CD4+ T-cells can eradicate overt human acute lymphoblastic leukaemia
as demonstrated in an animal model of human acute leukaemia
B.A. Nijmeijer, M.L.J. van Schie, R. Willemze, J.H.F. Falkenburg (Leiden, NL)
P670 Normalisation of the immune system and long term remission in severe autoimmune
diseases after autologous stem cell transplantation
R. Arnold, G. Massenkeil, O. Rosen, H. Radtke, E. Gromnica-Ihle, G.R. Burmester, A. Thiel,
A. Radbruch, F. Hiepe (Berlin, D)
P671 Role of HLA class I expression and KIR-mismatch for variable NK cell lysis of tumour
cells in children with acute lymphatic leukaemia
M. Pfeiffer, R. Handgretinger, T. Feuchtinger, M. Schumm, D. Niethammer, P. Lang
(Tuebingen, D; Memphis, USA)
P672 Cyclin D1 as a target molecule for T-cell-based immunotherapy of cyclin D1-expressing
haematological malignancies
M. Zeis, S. Siegel, A. Wagner, N. Schmitz (Hamburg, D)
P673 Co-administration of apoptotic cells with a bone marrow graft to enhance marrow
engraftment induces a TGF-beta-dependent expansion of CD4+CD25+ regulatory T-cells
P. Saas, S. Perruche, H. Bittard, J.M. Chalopin, P. Tiberghien, F. Kleinclauss (Besançon, F)
P674 Expansion of bone marrow-derived mesenchymal stem cells for clinical application
H. Roelofs, R.M. Egeler, W.E. Fibbe (Leiden, NL)
P675 Slow evolution of T-cell chimerism after transplantation of allogeneic highly purified
peripheral blood CD34+ cells from HLA-identical sibling donors
R. Peceny, A.H. Elmaagacli, R. Trenschel, H. Ottinger, D.W. Beelen (Essen, D)
P676 A phenotypic marker for thymic activity: recurrence of CD31+ CD45RA+ “thymic” naive
Th-cells after stem cell transplantation indicates reactivation of thymic activity
A. Thiel, C.A. Schmidt, G. Przybylski, T. Alexander, S. Kohler, S. Kimmig, F. Hiepe, R. Arnold,
A. Radbruch (Berlin, Greifswald, D)
P677 Small interfering RNAs directed against growth factor independence 1B gene (Gfi-1B)
inhibit proliferation and induce apoptosis in leukaemic cell lines
M. Koldehoff, N. Steckel, R. Peceny, R. Trenschel, D. Beelen, B. Opalka, A. Elmaagacli (Essen, D)
P678 NKG2D receptor-mediated NK activity induced by allogeneic CD34+ blood cells
M. Arpinati, B. Urbini, G. Perrone, G. Chirumbolo, M. Baccarani, D. Rondelli
(Bologna, I; Chicago, USA)
P679 Human lineage-negative cells for regenerative stem cell therapy
E. Rohde, D. Thaler, G. Lanzer, W. Linkesch, D. Strunk (Graz, A)
P680 Detection of frequencies of allo-reactive natural killer cells with granzyme B
ELISPOT assay
J. Hasenkamp, S. Dingeldein, B. Glass (Goettingen, D)
P681 Donor leukocyte infusion after stem cell transplantation in patients with juvenile
myelomonocytic leukaemia
A. Yoshimi, S. Matthes-Martin, U. Duffner, J. Star_, P. Bader, D. Dilloo, T. Klingebiel, F. Locatelli,
C. Niemeyer on behalf of the European Working Group of MDS in Childhood (EWOG-MDS)
P682 Immunisation of donor T-cells against minor histocompatibility antigens for conversion
of mixed chimerism in DLA-identical chimeras
M. Weber, W. Guenther, A. Kohn, H.-J. Kolb (Munich, D)
P683 Lymphocyte subset reconstitution after allogeneic haematopoietic stem cell
transplantation from unrelated donors
V. Vavilov, T. Zabelina, N. Kroeger, B. Fehse, N. Fehse, A. Pugachov, A. Zander, B. Afanasyev
(St. Petersburg, RUS; Hamburg, D)

Poster Physicians Tuesday, March 30, 2004
Cellular therapies (continued)
18:00 –
19:00
P684 Clinical experience of dendritic cells in various malignancies
J. Park, Y. Jung, J. Choi, H. Lim, Y.J. Kim, H.C. Kim (Suwon, KOR)
P685 Pharmacokinetics of treosulfan in a myeloablative conditioning combination with
cyclophosphamide prior to allogeneic haematopoietic stem cell transplantation
R.A. Hilger, M.E. Scheulen, R. Trenschel, S. Seeber, D.W. Beelen (Essen, D)
P686 Immunotherapy using rIL-2 activated mismatched donor lymphocytes positively selected
for CD56+ for the treatment of resistant haematologic malignancies after stem cell
transplantation
S. Slavin, S. Morecki, M. Shapira, S. Samuel, A. Ackerstein, Y. Gelfand, I. Resnick, M. Bitan, R. Or
(Jerusalem, IL)
18:00 –
19:00
Graft versus host disease
P687 Elimination of human alloreactive T-lymphocytes by anti-CD95 mediated activationinduced
cell death for preventing graft-versus-host disease in allogeneic bone marrow
transplantation
U. Hartwig, M. Nonn, S. Khan, W. Herr, C. Huber (Mainz, D)
P688 Recipient specific transfusion with IL-2 into donor induced CD4+CD25+ cells preventing
lethal GvHD
D. Jeong, N. Chung, B. Choi, S. Park, C. Han (Inchon, Seoul, KOR)
P689 Does donor/recipient parity have any impact on graft-versus-host disease?
The results of a single-centre retrospective multivariate analysis
M. Arat, E.A. Soydan, P. Topcuoglu, B. Aktas, M. Beksac (Ankara, TR)
P690 Graft-versus-host disease of the liver: 109 cases from a single-centre
R.F. Duarte, J. Delgado-Gonzalez, A.F. Quaglia, B. Shaw, D. Wrench, M. Ethell, A.P. Dhillon,
S. Mackinnon, M.N. Potter (London, UK)
P691 Patient and donor polymorphisms within the HLA class III genes associate with the
outcome of allogeneic haematopoietic stem cell transplantation
K. Bogunia-Kubik, A. Lange (Wroclaw, PL)
P692 The conditioning regimen influences migration of donor T-cells in recipient tissues
L. Cannella, R. Laylor, H. Dewchand, E. Simpson, F. Marelli-Berg, F. Dazzi (London, UK)
P693 HLA-DPB1 mismatch is associated with acute GvHD after HLA-identical sibling donor
stem cell transplantation
D. Gallardo, S. Brunet, A. Torres, M. Alonso-Nieto, C. Vallejo, A. Jiménez, M. González, G. Sanz,
D. Serrano, I. Espigado, S. Osorio, E. Carreras, C. Martín, C. Sanz-Rodríguez, J. Sierra, J. Zuazu,
M.F. González-Escribano, J. R. González, J. Román, J. Pérez de Oteyza, R. de la Cámara
On behalf oh the GvHD Subcommittee of the Spanish Group of hematopoietic stem cell
transplantation (GETH: Grupo Español de Trasplante Hemopoyético).
P694 GvHD after allogeneic peripheral blood stem cell transplantation: comparison between
conventional and reduced-intensity conditioning regimens
J.A. Perez-Simon, E. Ocio, M.D. Caballero, V. Mateos, F.M. Sanchez-Guijo, L. Vazquez,
J.F. San Miguel (Salamanca, E)
P695 A retrospective study on the efficacy and safety of campath in the prophylaxis of
graft-versus-host disease in paediatric transplantation
J. Shankari, M. Ortin, S. Patel, R. Ridwan, P. Fomasagaram, R. Sinha, S. Ball, J. Treleaven
(London, Sutton, UK)
P696 Persistence of CAMPATH-1H at detectable and functional levels 28 days after treatment
in recipients of stem cell transplants: a comparison with antithymocyte globulin
R. Garland, S. Groves, J. Hallinan, S. West, K. Winship, S. Robinson, A. Oakhill, J. Cornish,
D. Pamphilon, D. Marks, N. Goulden, C. Steward (Bristol, UK)
91

Tuesday, March 30, 2004 Poster Physicians
92
Graft versus host disease (continued)
18:00 –
19:00
P697 Efficacy of tumour-necrosis-factor alpha blockade with infliximab for the treatment
of severe steroid-refractory acute graft-versus-host disease
F. Patriarca, A. Sperotto, S. Prosdocimo, D. Damiani, G. Morreale, A. Olivieri, F. Bonifazi,
G. Milone, J. Peccatori, P. Corradini, R. Fanin
on behalf of Italian Group of Bone Marrow Transplantation (GITMO)
P698 Molecular mechanisms of the AICD paradoxon in human T-cells revealed by an apototic
role for CD25
G. Richter, K. Hahnewinkel, S. Burdach (Munich, Halle, D)
P699 Impact of GvHD in long-term remission after escalated donor lymphocyte infusions
E. Nadal, S. Marktel, R. Szydlo, E. Olavarria, E. Kanfer, A. Rahemtulla, J. Apperley, J. Goldman,
F. Dazzi (London, UK)
P700 Extracorporeal photochemotherapy for acute and chronic GvHD, a single-centre report
of 43 patients
E.J. Dann, E. Badian, I. Avivi, N. Haddad, T. Stravets, R. Fineman, L. Bonstein, A. Oliven,
E. Kertsman, T. Zuckerman, J.M. Rowe (Haifa, IL)
P701 Activation-associated phenotype of CD3+ T-cells in acute graft-versus-host disease
S. Vidal, M. Morante, J. Briones, R. Martino, J. Sierra, J. Rodriguez-Sanchez (Barcelona, E)
P702 Towards functional transplant donor matching by measurement of granzyme A and
granzyme B production levels
B. Kircher, E. Hack, A. Dickinson, X. Wang, M. Oudshoorn, E. Goulmy
(Innsbruck, A; Amsterdam, NL; Newcastle upon Tyne, UK; Leiden, NL)
P703 Outcome of patients treated with pentostatin as salvage therapy of steroid refractory
acute intestinal graft-versus-host disease
S.A. Klein, G. Bug, B. Waßmann, D. Hoelzer, H. Martin (Frankfurt, D)
P704 Risk factors for graft-versus-host disease of the gut in paediatric haematopoietic stem
cell transplant
A.S. Hassan, M.A. Elawad, G. Davies, K. Rao, P. Amrolia, P. Veys (London, UK)
P705 Combination therapy of daclizumab and sirolimus is effective in steroid refractory
intestinal GvHD
M. Weisser, V. Goede, X. Schiel, H.J. Kolb (Munich, D)
P706 Impact of CD8+ T-cell dose on GvhD after antithymocyte globulin (ATG)-based reducedintensity
conditioning (RIC) for allogeneic stem cell transplantation
M. Mohty, C. Faucher, S. Bagattini, V. Bardou, K. Bilger, B. Gaugler, C. Chabannon, P. Ladaique,
C. Lemarie, N. Vey, J.A. Gastaut, D. Maraninchi, D. Olive, D. Blaise (Marseille, F)
P707 Dendritic cells (DC1 and DC2) recovery after allogeneic and autologous stem cell
transplantation
R. Stocchi, D. Damiani, P. Masolini, A. Michelutti, A. Geromin, M. Cerno, A. Sperotto,
M. Baccarani, R. Fanin (Udine, Bologna, I)
P708 Incidence of acute GvHD is reduced in mice transplanted with bone marrow from
MHC mismatched donors pre-treated with G-CSF
J.M. Wang, Y.B. Cao, W.P. Zhang, J.W. Lou, H. Zhou (Shanghai, CHN)
P709 A comparison of the number of informative short tandem repeat loci between HLA
identical donor-recipient pairs and the frequency of graft-versus-host disease
K. Dalva, M. Arat, E. Serbest, M. Beksac (Ankara, TR)
P710 Mycophenolate mofetil, cyclosporine and methotrexate as graft-versus-host disease
prevention regimen in recipients of unrelated bone marrow transplantation
H. Huang, Z. Cai, M.F. Lin, W.Z. Xie, L. Li, Y. Luo, J.S. He, W.Y. Zheng, J. Zhang, X.J. Ye, B. Liang
(Hangzhou, CHN)

Poster Physicians Tuesday, March 30, 2004
Graft versus host disease (continued)
18:00 –
19:00
P711 Primary PUVA phototherapy can be effective for acute graft-versus-host disease of the
skin
T. Wetzig, H. K. Al-Ali, S. Kirstner, U. Hegenbart, M. Sticherlin, D. Niederwieser (Leipzig, D)
P712 Results of extracorporeal photopheresis performed with 2 different techniques in
18 patients with chronic graft-versus-host disease
A. Indovina, R. Mannino, A.M. Cavallaro, S. Tringali, R. DiBella, R. Scimè (Palermo, I)
P713 Treatment of chronic graft-versus-host disease by extracorporeal photochemotherapy
H. Ullrich, J. Hahn, E. Holler, G. Schmitz (Hamburg, Regensburg, D)
P714 The effect of conditioning therapy on Langerhans' cell density in human bone marrow
transplantation
M. Collin, T. Booth, A. Dickinson (Newcastle-upon-Tyne, UK)
P715 Mycophenolate mofetil in combination with cyclosporine-A (CsA) ± prednisolone –
the new standard for GvHD prophylaxis?
D. Linck, K. Schaefer-Eckardt, M. Kroeger, M. Bornhaeuser, I. Blau, H. Wandt, A. Jenke,
J. Kienast, V. Armstrong, N. Basara, H. Schroeder, A. Fauser, M.G. Kiehl
(Idar-Oberstein, Nuremberg, Muenster, Dresden, Berlin, Goettingen, D)
P716 Oral beclomethasone dipropionate for the treatment of gut acute graft-versus-host
disease
C. Castilla, J. A. Perez-Simon, F. M. Sanchez-Guijo, M. D. Caballero, M. C. Cañizo, M. Diez,
E. M. Ocio, L. Vazquez, J. F. San Miguel (Salamanca, E)
P717 Treatment of severe acute graft-versus-host disease with third party haploidentical
mesenchymal stem cells
K. Le Blanc, I. Rasmusson, B. Sundberg, C. Götherström, M. Hassan, M. Uzunel, O. Ringdén
(Stockholm, S)
P718 Unconventional treatment of steroid-refractory acute GvHD: pulse cyclophosphamide
and/or intra-arterial steroid administration
J. Mayer, M. Doubek, Y. Brychtova, M. Krejci (Brno, CZ)
P719 Changes in dendritic cells following irradiation
B. Turner, A. Burns, D. Munster, D. Hart, A. Rice (South Brisbane, AUS)
P720 The impact of human leucocyte antigens in graft-versus-host disease and survival after
haematopoietic stem cell transplantation in patients with leukaemia
K. Ozdilli, F. Savran Oguz, H. Bilgen, S. Anak, M.N. Carin, G. Gedikoglu (Istanbul, TR)
P721 Expression of cytokine genes in mononuclear blood cells from haematopoetic stem cell
transplantation patients with acute graft-versus-hostdisease
M Zaraiski, N. Mikhaylova, N. Ivanova, A. Vitrischak, A. Pugachov, V. Vavilov, L. Zubarovskaya,
B. Afanasyev (St. Petersburg, RUS)
P722 Graft-versus-host disease is associated with a lower relapse incidence after
haematopoietic stem cell transplantation in patients with acute lymphoblastic
leukaemia
A. Nordlander, J Mattsson, O. Ringden, K. Le Blanc, B. Gustavsson, P. Ljungman, P. Svenberg,
J. Svennilson, M. Remberger (Stockholm, S)
P723 Blocking ICOS: ICOSL interaction before allogeneic bone marrow transplantation may
increase acute graft-versus-host disease
G. Richter, E. Uhlmann, S. Burdach (Munich, Halle, D)
P724 Efficacy of receptor blockade, engraftment and toxicity under targeted adjuvant therapy
with anti-CD25 in paediatric allogeneic transplant recipients
A. Wawer, O. Diwan, St. Burdach (Munich, Halle, D)
93

Tuesday, March 30, 2004 Poster Physicians
94
Graft versus host disease (continued)
18:00 –
19:00
P725 Kinetics of chimerism donor cells in different non-myeloablative conditioning regimens
and GvHD
L. Savino, M. Carella, G. Beltrami, M.M Greco, M. Centra, A. M. Carella (San Giovanni Rotondo, I)
P726 Treatment of steroid refractory acute GvHD with campath-1H
H. Biersack, R. Trenschel, R. Peceny, A. Elmaagacli, D.W. Beelen (Essen, D)
P727 CD8+ cell dose impact on development of Grade>iii acute graft-versus-host disease
in allogeneic stem cell transplantation
A. Prudenzano, G. Palazzo, L. Stani, G. Pricolo, G. Pisapia, B. Amurri, P. Mazza (Taranto, I)
P728 Extracorporeal photoimmune therapy with uvadex® for the prevention of acute
graft-versus-host disease in patients undergoing standard myeloablative conditioning
and allogeneic haematopoietic stem cell transplantation
P.J. Shaughnessy, B.J. Bolwell, K. van Besien, S. Abhyankar, M. Mistrik, O. Ilhan, A. Grigg,
H.M. Prince, T. Dodds, A. Machado, J. Wang, U. Thienel, F. Foss, J. Apperley
(San Antonio, Cleveland, Chicago, Kansas City, Exton, Boston, USA; Bratislavia, SK;
Ankara, TR; Melbourne, East Melbourne, Sydney, AUS; Lisbon, P; London, UK)
P729 Late-onset non-infectious pulmonary complications after unrelated donor stem cell
transplantation are strongly associated with chronic graft-versus-host disease and
with the graft-versus-malignancy effect
F. Patriarca, C Skert, A Sperotto, D. Damiani, M. Cerno, A. Geromin, F. Zaja, S. Prosdocimo,
C. Filì, R. Stocchi, R. Fanin (Udine, I)
P730 The impact of HLA-dr antigens on chronic graft-versus-host disease associated oral
lichenoid lesions
H.E. Sanli, E. Ozdemir, M. Arat, P. Ekmekci, K. Dalva, M. Beksac (Ankara, TR)
P731 ATG-fresenius allows for successful transplantation from mismatched unrelated donors
A. Zander, T. Zabelina, F. Ayuk, H. Kabisch, R. Erttmann, N. Fehse, B. Fehse, C. Wolschke,
N. Stute, A. Kratochwille, H. Schieder, J. Panse, T. Eiermann, N. Kroeger (Hamburg, D)
P732 Clinical impact of early complete donor chimerism after allogeneic stem cell
transplantation
M. Bieniaszewska, J. Balon, M. Reichert, K. Halaburda, M. Zaucha, R. Pawlowski, A. Hellmann
(Gdansk, PL)
P733 The identification of patients at risk for GvHD by means of a more sensitive mixed
lymphocyte culture
A. Müller, R. Häfner, U. Schrey, H. Vogelsang, F. Zintl (Jena, D)
18:00 –
19:00
Infectious complications
P734 Surveillance of nosocomial sepsis and pneumonia in patients after haematopoetic stem
cell transplantation. A multicentre project
H. Bertz, M. Dettenkofer, S. Wenzler, R. Babikir, W. Ebner, H. Rüden, P. Gastmeier, F. Daschner
(Freiburg, Berlin, Hannover, D)
P735 Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell
transplantation in patients with prior systemic or invasive fungal infections
N. Stute, A. Kratochwille, T. Zabelina, N. Fehse, W. Hassenpflug, J. Panse, C. Woltschke,
F. Ayuketang, H. Schieder, H. Renges, R. von Hinüber, H. Kabisch, A.R. Zander, N. Kröger (Hamburg, D)
P736 Impact of cytomegalovirus infection on T-cell function after allogeneic haematopoietic
stem cell transplantation
S. Giebel, R. Maccario, M.A. Avanzini, M. Marconi, G. Rossi, R. Gentile, F. Locatelli
(Katowice, PL; Pavia, I)

Poster Physicians Tuesday, March 30, 2004
Infectious complications (continued)
18:00 –
19:00
P737 Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplant
based on molecular monitoring is predictive of lymphoproliferative disease
A. Dominietto, E. Tedone, M. Soracco, S. Bregante, C. di Grazia, V. Galbusera, F. Gualandi,
T. Lamparelli, A.M. Raiola, M.T. van Lint, F. Frassoni, A. Bacigalupo (Genoa, I)
P738 Delayed recovery of B-lymphocytes following high-dose sequential chemotherapy plus
rituximab (R-HDS) does not increase the incidence of infective events in non-Hodgkin
lymphoma patients
A. Assanelli, M. Di Nicola, M. Magni, L. Devizzi, P. Matteucci, A. Guidetti, M. Milanesi,
C. Carlo Stella, A.M. Gianni (Milan, I)
P739 Pre-emptive treatment with rituximab efficiently prevents EBV lymphoproliferative
disease (EBV-LPD) in paediatric allogeneic stem cell recipients
J. Kalpoe, M. van Tol, R. Bredius, D. van Baarle, N. Annels, E Claas, A Kroes, A. Lankester
(Leiden, Amsterdam, NL)
P740 Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation
using HLA-matched sibling donor: DLI and previous history of early CMV infection
S. Sohn, D. Kim, J. Kim, W. Sung, K. Lee, K. Lee (Daegu, KOR)
P741 Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative
donor: incidence, risk factors and outcome
A.M. Raiola, C. Viscoli, V. Galbusera, A. Dominietto, F. Gualandi, C. Di Grazia, S. Bregante,
D. Occhini, T. Lamparelli, F. Frassoni, M. Machetti, M.T. van Lint, A. Bacigalupo (Genoa, I)
P742 Bacteraemia after haematopoietic stem cell transplantation: incidence and predictive
value of surveillance cultures
P. Frere, J.P. Hermanne, M.H. Debouge, G. Fillet, Y. Beguin (Liege, B)
P743 What are the infections which increase mortality after allogeneic stem cell transplantation?
Results of a prospective scoring system used in 190 consecutive patients
C. Cordonnier, S. Maury, P. Ribaud, M. Kuentz, M. Legrand, F. Bassompierre, E. Gluckman,
S. Chevret (Creteil, Paris, F)
P744 Viral infections among paediatric stem cell transplant recipients post-transplant
H. Savolainen, U. Pihkala, L. Hovi, K. Vettenranta (Helsinki, FIN)
P745 Non-invasive ventilation in haematologic unit: single-centre experience in 24 patients
F. Ciceri, M. Lupo Stanghellini, J. Peccatori, P. Servida, A. Pescarollo, M. Bernardi, D. Giudici,
S. Colombo, D. Salaris, G. Torri, M. Bregni (Milan, I)
P746 Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole
prophylaxis
E. Jantunen, A. Nihtinen, L. Volin, E. Juvonen, T. Parkkali, T. Ruutu, V. Anttila (Kuopio, Helsinki, FIN)
P747 Infectious complications in multiple myeloma patients undergoing autologous stem
cell transplantation after high dose melphalan: a single centre retrospective analysis
towards outpatient strategy
G. Irrera, M. Martino, G. Messina, G. Console, F. Morabito, M. Kropp, F. Iuliano, D. Mamone,
M. Brugiatelli, C. Stelitano, V. Callea, C. Musolino, S. Molica, P. Iacopino
(Reggio Calabria, Catanzaro, Messina, I)
P748 Clinical relevance of screening sinus CT scans and results of endoscopic sinus surgery
in bone marrow transplant patients
I. Yorulmaz, E. Soydan, M. Kizil, B. Ceydilek, M. Arat (Ankara, TR)
P749 Human herpesvirus-6 antigenaemia: an association to acute GvHD?
L. Volin, I. Lautenschlager, E. Juvonen, A. Nihtinen, V.-J. Anttila, T. Ruutu (Helsinki, FIN)
P750 The use of dendritic cells transfected with in vitro transcribed mRNA for the analysis of
CMVpp65-specific T-cell reconstitution after allogeneic stem cell transplantation
R.G. Meyer, C.M. Britten, A. Gstoettner, C. Huber, T. Woelfel, W. Herr (Mainz, D)
95

Tuesday, March 30, 2004 Poster Physicians
96
Infectious complications (continued)
18:00 –
19:00
P751 T-cell depletion rather than persistent graft-failure determines the risk of viral but not
fungal deaths in children undergoing second attempt HSCT for graft dysfunction
L.M. Ball, M.S. Page, A.C. Lankester, R.G.M. Bredius, M.J.D. van Tol, R.M. Egeler (Leiden, NL)
P752 Reduced and delayed incidence of human cytomegalovirus infection following
non-myeloablative allogeneic stem cell transplantation in patients with refractory
solid tumours
A. Zambelli, D. Lilleri, P. Pedrazzoli, J. Peccatori, F. Baldanti, V. Fregoni, F. Ciceri, M. Renga,
E.-P. Alessandrino, G. Gerna, G.-A. Da Prada, S. Siena, M. Bregni (Pavia, Milan, I)
P753 Prophylactic use of rituximab to prevent EBV reactivation following HSCT in patients
with inherited metabolic storage diseases
A. Rovelli, P. Corti, A. Balduzzi, D. Longoni, M. Dassi, P. Perseghin, G. Gaipa, R. Parini, G. Uziel,
A. Biondi, C. Uderzo on behalf of the MOMIN: Monza-Milano Network for Lysosomal &
Peroxisomal Diseases, Italy
P754 Comparison of quantitative CMV-PCR in plasma and CMV antigenaemia assay in
monitoring patients after allogeneic stem cell transplantation
A. Picardi, G. Gentile, P. de Fabritiis, A. Capobianchi, L. Cudillo, T. Dentamaro, A. Tendas,
L. Cupelli, M. Ciotti, A. Volpi, S. Amadori, P. Martino (Rome, I)
P755 Lamivudine for treatment and pre-emptive therapy of Hepatitis B virus reactivation
following haematopoietic stem cell transplantation
A. Locasciulli, L. Forte, L. Pescador, M. Gabriel Arana, M.R. Capobianchi, I. Majolino (Rome, I)
P756 Comparable risk of cytomegalovirus infection after allogeneic haematopoietic stem cell
transplantation following non-myeloablative or myeloablative preparative regimen in
patients affected by haematologic malignancies
D. Caldera, D. Lilleri, P. Bernasconi, A. Colombo, F. Montanari, F. Ardizzone, M. Parea,
M. Lazzarino, G. Gerna, E. Alessandrino (Pavia, I)
P757 Granulocyte transfusions for successful treatment of critically ill neutropenic patients
with septic complications
H.G. Heuft, L. Goudeva, N. Pulver, L. Grigull, B. Hertenstein, R. Blasczyk (Hannover, D)
P758 Secondary prophylaxis with voriconazole for invasive aspergillosis in stem cell
transplantation
D. Mattei, N. Mordini, C. Lo Nigro, M. Musso, D. Rapezzi, A. Gallamini (Cuneo, I)
P759 Delayed reactivation of Epstein-Barr virus in recipients of reduced-intensity conditioned
allogeneic stem cell transplantation with campath-1H may impact on surveillance and
pre-emptive strategies
Q. Hill, T. Collyns, A. Hale, T. Fawcett, A. Hancox, G. Cook (Leeds, UK)
P760 Invasive aspergillosis in immunocompromised patients: clinical findings and therapeutic
options
C. Peters, S. Matthes-Martin, A. Lawitschka, M. Minkov, M. Dworzak, T. Lion, P. Höcker,
H. Gadner (Vienna, A)
P761 Sirolimus – itraconazole drug interaction after allogeneic stem cell transplantation
X. Schiel, J. Tischer, C. Rieger, A. Haas, M. Vogeser, U. Spoehrer, H.J. Kolb, H. Ostermann
(Munich, D)
P762 A high BK virus load in urine samples combined with graft-versus-host disease
frequently precedes and may predict a risk for haemorrhagic cystitis in haematopoietic
stem cell transplanted patients
G. Bogdanovic, P. Priftakis, G. Giraud, M. Kuzniar, P. Kokhaei, H. Mellstedt, M. Remberger,
P. Ljungman, J. Winiarski, T. Dalianis (Stockholm, Huddinge, S)
P763 Cidofovir as prophylactic therapy for CMV infection in reduced-intensity allogeneic stem
cell transplant
M. Musso, F. Porretto, A. Crescimanno, V. Polizzi, R. Scalone (Palermo, I)

Poster Physicians Tuesday, March 30, 2004
Infectious complications (continued)
18:00 –
19:00
P764 Candida colonisation of patients undergoing haematopoetic stem cell transplantation
and receiving fluconazole prophylaxis
J. Sinkó, N. Radka, P. Reményi, S. Lueff, A. Bátai, G. Kriván, M. Réti, T. Masszi (Budapest, HUN)
P765 Prolonged duration of cytomegalovirus viraemia after in vitro T-cell depleted
non-myeloablative compared to myeloablative alloSCT
J.S. Kalpoe, R.M.Y. Barge, R. Willemze, N. Vaessen, A.C.M. Kroes (Leiden, NL)
P766 Secretory IgA of the oral saliva normalises earlier than IgA in serum after
haematopoietic stem cell transplantation in children
R. Haefer, M. Steinbrenner, B. Gruhn, A. Mueller, D. Fuchs, F. Zintl (Jena, D)
P767 A retrospective study examining the United Kingdom Cancer Care Study Group’s fungal
management strategy in practice
R. Nolan, J. McDerra, S. Peters, J. Cornish (Bristol, UK)
P768 Influence of CD34+ selection in cytomegalovirus infection after allogeneic peripheral
blood stem cell transplantation
S. Cantero, G. Sanz, F. Moscardó, J. Sanz, M. Remigia, I. Lorenzo, G. Martín, I. Jarque,
C. Jiménez, J. Martínez, J. De la Rubia, M. Sanz (Valencia, E)
P769 Infections after reduced-intensity conditioning for allogeneic blood stem cell
transplantation in metastatic solid tumours
L. Barkholt, M. Blomkvist, P. Hentschke, L. Klingspor, I. Lewensohn-Fuchs, J. Mattsson,
R. Milosavljevic, P. Pisa, M. Remberger, P. Svenberg, A. Thörne, P. Wersäll, O. Ringdén
(Stockholm, S)
P770 Autologous stem cell transplantation in HIV-infected patients affected by lymphoma:
virological and immunological parameters during high-dose chemotherapy
M. Michieli, C. Simonelli, M. Rupolo, M. T. Bartolin, M. Mazzucato, S. Zanussi, M. Spina,
L. Abbruzzese, P. De Paoli, L. De Marco, V. Gattei, M. Berretta, U. Tirelli (Avione, I)
P771 Occurrence of Cytomegalovirus infection and/or viraemia shortens overall survival
P. Topcuoglu, M. Arat, E. Soydan, K. Dalva, A. Ciftcioglu, H. Akan, O. Ilhan, M. Beksac (Ankara, TR)
P772 Central nervous system toxoplasmosis in bone marrow transplant patients
A. Georgala, K. Mboumi, P. Martiat, J. Debruyne, V. Duchateau, M. Aoun (Brussels, B)
P773 Prospective surveillance of nosocomial infection among allogeneic haematological stem
cell transplant recipients stratified by grade of neutropenia at a teaching hospital
R. Fagnani, L.G.O. Cardoso, S.R.P.E. Dantas, M.L. Leichsenring, M.C.S. Carvalho, P. Trabasso
(Campinas, BR)
P774 Mucormycosis after allogeneic haematopoietic stem cell transplantation
L. Clement, A. Salmon, L. Mansuy, S. Paczesny, P. Bordigoni (Vandoeuvre les Nancy, F)
P775 Conjugated vaccines after autologous stem cell transplantation
A.M.T. van der Velden, A.M.E. Claessen, H. van Velzen-Blad, D.H. Biesma, G.T. Rijkers
(Nieuwegein, Utrecht, NL)
P776 Secondary prophylaxis with voriconazole in patients undergoing stem cell
transplantation with previous invasive aspergillosis
A.M. Raiola, C. Viscoli, V. Galbusera, A. Dominietto, F. Gualandi, C. Di Grazia, S. Bregante,
D. Occhini, T. Lamparelli, F. Frassoni, M. Machetti, M.T. van Lint, A. Bacigalupo (Genoa, I)
P777 Invasive aspergillosis and haematopoietic stem cell transplantation in paediatric
patients
N. Crassard, M.-A. Piens, C. Galambrun, T. Basset, J.-C. Berthier, C. Pondarré, N. Philippe,
G. Souillet, Y. Bertrand (Lyon, F)
97

Tuesday, March 30, 2004 Poster Physicians
98
Infectious complications (continued)
18:00 –
19:00
P778 Systemic fungal infections (SFI) in patients with haematological malignancies treated by
voriconazole or amphotericin B. Descriptive analysis and impact of demographic,
haematological and SFI factors on survival
S. Fürst, Q.H. Le, A. Michallet, F. Nicolini, X. Thomas, Y. Chelghoum, J. Troncy, A. Thiébaut,
F. Persat, S. Picot, M. Piens, M. Michallet (Lyon, F)
P779 Epstein-Barr virus after haematopoietic stem cells transplantation.
Incidence, risk factors, and treatment. Single-centre experience
S. Guidi, C. Nozzoli, M. Bonolis, A. Orsi, L. Lombardini, R. Saccardi, A. Vannucchi, A. Bosi
(Florence, I)
P780 CMV-prophylaxis after T-cell depleted allogeneic stem cell transplantation:
a comparison of 4 regimens
S. Von Harsdorf, M. Bommer, T. Zenz, M. Ringhoffer, R. Schlenk, T. Schmid, W. Hampl,
S. Stilgenbauer, H. Döhner, T. Mertens, D. Bunjes (Ulm, D)
P781 Tuberculosis post stem cell transplantation
C. Burton, E. Thomson, E. Kanfer, T. Rogers, J. Goldman, J. Apperley (London, UK)
P782 The affigene(R) OPI panel for opportunistic infections – viral load monitoring of
cytomegalovirus, Epstein-Barr virus and human herpesvirus 6
T. Eriksson, S. Palm, V. Törmänen, M. Järpenge, A. Hedrum (Bromma, S)
P783 In children undergoing HSCT, multiple and simultaneous non-albicans yeasts commonly
occur but do not signify a risk of early dissemination or anti-fungal therapy resistance
L.M. Ball, M.A. Bes, E.J. Kuijper, T. Boekhout, B. Theelan, R.M. Egeler (Leiden, Utrecht, NL)
P784 Blood transfusion requirements and febrile complications after autologous PBSCT:
cause or consequence?
C. Scheid, C. Fritzsche, U. Holtick, M. Fuchs, D. Waldschmidt, K. Hübel, V. Diehl, D. Söhngen
(Cologne, D)
P785 Anti-fungal primary and secondary prophylaxis with liposomal amphotericin B
(AmBisome) in patients undergoing family haploidentical allogeneic haematopoietic cell
transplantation for high-risk haematologic malignancies
F. Ciceri, M. Tassara, J. Peccatori, F. Lunghi, P. Servida, E. Guggiari, M. Bernardi, A. Pescarollo,
M. Bregni (Milan, I)
P786 Retrospective analysis of the use of valganciclovir in the prevention of cytomegalovirus
following stem cell transplantation
J. Subedi, J. Chappell, W. Ingram, M. Zuckerman, S. Devereux, A. Ho, G. Mufti, A. Pagliuca
(London, UK)
P787 Anti-fungal combination therapy for the treatment of invasive aspergillosis in patients
undergoing allogeneic stem cell transplantation
J. Tischer, X. Schiel, C. Rieger, G. Ledderose, H. Ostermann, H.-J. Kolb (Munich, D)
P788 Infectious complications in severe aplastic anaemia: single-centre experience
P. Saracco, P. Quarello, R. Cerchio, M. Giacchino, E. Parodi, E. Incarbone,
L. Cordero di Montezemolo (Turin, I)
P789 Hepatitis B and C infections in haemopoietic stem cell transplant patients and donors
V. Milovic, S. Brioschi, J. Altclas, G. Jaimovich, A. Requejo, V. Listello, G. Drelichman, M. Garate,
L. Feldman (Buenos Aires, AR)
P789a Imipenem/cilastatin with/without a glycopeptide as initial empirical antibiotic
therapy in recipients of autologous haematopoietic stem cell transplants:
results of a multicentre study
M. Sanz Jr., R. Martino, I. Jarque, M. Salavert, L. Vázquez, M. Rafel, A. Figuera, J. López,
M. Batlle, A. Julià, J. Lahuerta, G. Debén, C. Pérez, R. García Boyero, J. Sierra,
M. Sanz on behalf of the Antimicrobial Therapy Group of the Spanish PETHEMA Group

Poster Physicians Tuesday, March 30, 2004
18:00 –
19:00
Late effects and Quality of life
P790 Metabolic syndrome associates with partial growth hormone deficiency as a late effect
in children and adolescents after stem cell transplantation perfomed in childhood
M. Taskinen, M. Lipsanen-Nyman, L. Hovi, U. Saarinen-Pihkala (Helsinki, FIN)
P791 Malignant complications after BMT for thalassaemia
J. Gaziev, P. Polchi, C. Giardini, P. Sodani, G. Lucarelli, G. Visani, E. Angelucci, D. Baronciani,
G. Leopardi, F. D'Adamo, B. Guiducci, M. Mele (Pesaro, I)
P792 Immune reconstitution following allogeneic haematopoietic stem cell transplantation:
8 year, single-centre experience from more than 300 patients and nearly 1000 lymphocyte
subset determinations
A. Spyridonidis, D. Behringer, E. Bernhardt, C. Bachl, M. Egger, H. Bertz, J. Finke
(Freiburg, Bochum, D)
P793 Endocrine complications after paediatric haematopoietic cell transplantation
G. Carreras, I. Badell, N. Pardo, M. Torrent, C. Lopez, J. Cubells (Barcelona, E)
P794 Late toxicity after autologous stem cell transplantation for non-Hodgkin lymphoma
patients: a competing risks analysis
N. Mounier, G. Sergent, R. Ruiz-Soto, P. Brice, C. Hennequin, J. Marolleau, E. De Kerviller,
J. Briere, C. Gisselbrecht (Paris, F)
P795 Central nervous system involvement with seizures in patients undergoing haematopoietic
stem cell transplantation. Single-centre experience in more than 500 patients
S. Guidi, A. Gaudenzi, C. Nozzoli, G. Muscas, A. Vannucchi, M. Paganini, L. Lombardini,
R. Saccardi, G. Pellicanò, M. Bonolis, A. Bosi (Florence, I)
P796 Bone metabolism and risk-adjusted ibandronate drug therapy after allogeneic blood
stem cell transplantation
B. Steiner, D. Wolff, M. Freund (Rostock, D)
P797 Quality of life as an important outcome of high-dose therapy+autologous stem cell
transplantation (HDCT+ASCT) in multiple sclerosis patients
Y. Shevchenko, A. Novik, T. Ionova, I. Lesukov, A. Kulagin, O. Malysheva, V. Melnichenko,
G. Bisaga, L. Chelombit, A. Kishtovich (Moscow, Novosibirsk, St. Petersburg, RUS)
P798 Quality of life assessment in long-term survivors post allogeneic haematopoietic cell
transplantation. Are quantitative methods accurate enough?
A. Hotidou, P. Kaloyannidis, C. Kartsios, I. Sakellari, A. Anagnostopoulos, A. Fassas
(Rennes, F; Thessalonica, GR)
P799 Autoimmune thyroid dysfunction after stem cell transplantation: a revisit
W.Y. Au, A.K.W. Lie, A.W.C. Kung, R. Liang (Hong Kong, HK)
P800 Nephrotic syndrome as late complication of chronic graft-versus-host disease after
allogeneic haemopoietic stem cell transplantation
A.A. Colombo, C. Rusconi, P. Bernasconi, D. Caldera, P. Bertazzoni, C. Esposito, M. Lazzarino,
E.P. Alessandrino (Pavia, I)
P801 DHEA replacement after allogeneic bone marrow transplantation
E. Morello, R. Gaiardoni, M. Sorio, N. Pescosta, M. Casini, F. Benedetti (Bolzano, Verona, I)
P802 Osteoporosis after autologous bone marrow transplantation: a short-term compliance
R. Ria, A.M. Scarponi, F. Falzetti, S. Ballanti, M. Di Ianni, M. Cimminiello, C. Gasbarrino,
B. Pallone, F. Russo, T. Cirulli, G. Di Pietro, A. Vacca, F. Dammacco, E. Mannarino, M.F. Martelli,
A. Tabilio (Bari, Perugia, I)
P803 Neurological complications after allogeneic stem cell transplantation: a retrospective
study of prognostic factors 183 patients
F. Bonifazi, M. Guarino, C. La Morgia, S. Falcioni, B. Giannini, M. Stanzani, F. Palandri,
A. Stracciari, M. Arpinati, F. Cirignotta, M. Baccarani, G. Bandini (Bologna, I)
99

Tuesday, March 30, 2004 Poster Physicians
100
Late effects and Quality of life (continued)
18:00 –
19:00
P804 Severe hypogammaglobulinaemia in patients with lymphoid neoplasia after allogeneic
HSCTwith rituximab during preceding therapy
A. Buser, C. Bucher, D. Heim, G. Petitjean, T. Hauser, A. Rolink, A. Tichelli, J. Passweg,
A. Gratwohl (Basel, CH)
P805 Salivary gland function following stem cell transplantation: a prolonged study comparing
non-myeloablative versus myeloablative conditioning
R. Nagler, L. Barness-Hadar, S. Slavin, A. Nagler (Haifa, Jerusalem, Tel-Hashomer, IL)
P806 Renal function shortly and 1-year after allogeneic haematopoietic stem cell
transplantation
M. Ertem, T. Ileri, F. Azik, F. Yalcinkaya, M. Ekim (Ankara, TR)
P807 The role of inherited hypercoagulable abnormalities in paediatric haematopoietic stem
cell transplantation
M. Ertem, F. Azik, T. Ileri, E. Akar, A. Ulu, N. Akar (Ankara, TR)
P808 Features of the metabolic syndrome present in survivors of bone marrow
transplantation in adulthood
K. Higgins, C. Noon, V. Cartwright, M. Davies, T. Howlett, A. Hunter (Leicester, UK)
P809 Psychosocial late effects of bone marrow transplant in adolescents
G. Peykerli, S. Anak, S. Ozgenc, E. Can, H. Bilgen, E. Tugrul Saribeyoglu, G. Gedikoglu (Istanbul, TR)
18:00 –
19:00
Paediatric issues
P810 Reconstitution of lymphocyte subpopulations in a paediatric cohort following stem cell
transplantation from haploidentical family donors
D. Chandra, J. Motwani, P.J. Darbyshire, S.E. Lawson (Birmingham, UK)
P811 Haploidentical transplantation in paediatric patients with ALL:
a comparison with unmanipulated grafts
P. Lang, J. Greil, P. Bader, R. Handgretinger, T. Klingebiel, P. Schlegel, D. Niethammer (Tuebingen, D)
P812 Unrelated donor marrow transplantation in children with-high risk haematologic
malignancies in a single-centre from 1989 to 2002
C. Galambrun, G. Souillet, V. Dubois, N. Bleyzac, M.-P. Pages, C. Pondarré, Y. Bertrand (Lyon, F)
P813 Treatment of liver failure due to veno-occlusive disease in a two-year old child
after stem cell transplantation with living donor liver transplantation from the same
HLA-identical donor
K. Mellgren, A. Fasth, J. Abrahamsson, R. Saalman, M. Olausson (Gothenburg, S)
P814 Role of echodobutamine in the evaluation of cardiac dysfunction in children more than
10 years after bone marrow transplantation
C. Uderzo, E. Cavatorta, G. Trocino, A. Rovelli, D. Longoni, E. Viganò, A. Tagliabue, A. Balduzzi,
G. Masera (Monza, I)
P815 Prevalence and clinical outcome of polyoma BK virus infection in children and
adolescents after allogeneic haematopoietic cell transplantation
E. Gorczynska, D. Turkiewicz, K. Rybka, J. Toporski, K. Kalwak, A. Dyla, A. Chybicka (Wroclaw, PL)
P816 High-dose chemotherapy followed by autologous peripheral blood stem cell
transplantation in children with solid tumours: a paediatric hospital experience
G. Deb, A. Landolfo, C. Ciscato, I. Ilari, R. Cozza, L. De Sio, P. Fidani, A. Jenkner, A. Castellano,
G. M. Milano, F. Zinno, G. Isacchi, A. Donfrancesco (Rome, I)
P817 Adoptive immunotherapy with recombinant human IL-2 after autologous bone marrow
transplantation for high risk neuroblastoma
A. Prete, R. Rondelli, F. Locatelli, S. Pierinelli, F. Fagioli, C. Messina, A. Garaventa, A. Pession
(Bologna, Pavia, Turin, Padua, Genoa, I)

Poster Physicians Tuesday, March 30, 2004
Paediatric issues (continued)
18:00 –
19:00
P818 Chimerism after paediatric stem cell transplantation
H. Bilgen, F. Aydin, K. Ozdilli, F. Savran, S. Anak, S. Ozgenc, M. Carin, G. Gedikoglu (Istanbul, TR)
P819 High-dose busulfan and thiotepa followed by autologous stem cell transplantation in
previously irradiated medulloblastoma patients: high toxicity and lack of efficacy
D. Valteau-Couanet, B. Filippini, E. Benhamou, C. Kalifa, J. Grill, O. Hartmann (Villejuif, F)
P820 Combined chemo-immunotherapy in children with ALL who relapse after allogeneic
stem cell transplantation – an option to induce long term remission
P. Bader, E. Koscielniak, P.-G. Schlegel, A. Kors, A. Lankester, H. Kreyenberg, P. Lang, J. Greil,
D. Niethammer, T. Klingebiel (Tuebingen, Stuttgart, Wuerzburg, Frankfurt, D; Utrecht, Leiden, NL)
P821 Cyclosporine-A induced severe neurological events after allogeneic haematopoietic
stem cell transplantation in children
D. Wojcik, M. Slociak, J. Toporski, E. Gorczynska, D. Turkiewicz, K. Kalwak, A. Chybicka
(Wroclaw, PL)
P822 Cord blood – a valid option for allogeneic transplantation in a heterogeneous risk
population of 15 children lacking an adequately matched donor
S. Schönberger, T. Niehues, H.J. Laws, R. Meisel, G. Kögler, P. Wernet, U. Göbel, D. Dilloo
(Duesseldorf, D)
P823 Rhesus mismatch in paediatric allogeneic haemopoietic progenitors transplants:
a retrospective study on its influence on outcome
R. Ridwan, M. Ortin, S. Patel, J. Shankari, P. Fomasagaram, S. Ball, J. Marsh, J. Treleaven
(Sutton, London, UK)
P824 KIR ligand incompatibility in haploidentical inborn errors transplants
L. Dal Cortivo, I. Hirch, M. Ouachée-Chardin, S. Blanche, A. Velardi, A. Fischer,
M. Cavazzana-Calvo, S. Caillat-Zucman (Paris, F; Perugia, I)
P825 Low toxicity with a fludarabine-based conditioning regimen in haematopoetic stem cell
transplantation for children with mucopolysaccharidosis (M. Hurler)
L. Grigull, A. Beilken, A. Sander, T. Luecke, M. Schrappe, K. Welte, A. Das, H. Schmid, K. Sykora
(Hannover, D)
P826 Allogeneic haematopoietic stem cell transplantation in children with myelodysplastic
syndrome in Poland
D. Wojcik, J. Toporski, E. Gorczynska, D. Turkiewicz, K. Kalwak, M. Slociak, W. Pietras, A. Chybicka,
K. Drabko, J. Kowalczyk, M. Leda, J. Wachowiak, K. Pajdosz (Wroclaw, Lublin, Poznan, PL)
P827 A preparatory regimen of high-dose busulphan and melphalan for autologous
haematopoietic cell transplantation in childhood high-risk acute myeloblastic
leukaemia, neuroblastoma and Ewing sarcoma
E. Gorczynska, D. Turkiewicz, J. Toporski, K. Kalwak, A. Dyla, A. Chybicka (Wroclaw, PL)
P828 Transplantation activity in Spanish paediatric stem cell transplantation centres:
report from RETMON (Registro Español De Trasplante De Médula Osea En Niños)
A. Rodriguez-Villa, J.J. Ortega, M.A. Diaz, I. Badell, A. Martinez-Rubio, M. Maldonado,
A. Verdeguer, E. Bureo, P. Gomez-Garcia, J.M. Perez-Hurtado, J. Estella, E. Gonzalez-Valentin
(Cordoba, Barcelona, Madrid, Valencia, Santander, Sevilla, Malaga, E)
P829 A retrospective study on the influence of cyclosporin levels on GvL, viral infections and
overall outcome in paediatric allogeneic HPT
R. Ridwan, M. Ortin, S. Patel, J. Shankari, P. Fomasagaram, R. Sinha, S. Ball, J. Marsh,
J. Treleaven (Sutton, London, UK)
P830 Analysis of KIR-ligand incompatibility in children with haematological malignancies after
allogeneic haematopoietic cell transplantation from unrelated donors
D. Turkiewicz, E. Gorczynska, J. Toporski, K. Kalwak, A. Chybicka (Wroclaw, PL)
101

Tuesday, March 30, 2004 Poster Physicians
102
Paediatric issues (continued)
18:00 –
19:00
P831 Outcome of haematopoietic stem cell transplantation for refractory or relapsed acute
leukaemia in paediatric patients: a single-centre analysis in Japan
T. Tanabe, Y. Kawano, Y. Nagatoshi, J. Nagayama, Y. Shinkoda, O. Ijichi, J. Okamura
(Kagoshima, Fukuoka, J)
P832 Differential analysis of cell-line specific chimerism after blood stem cell transplantation
U. Koehl, O. Beck, D. Schwabe, E. Seifried, T. Klingebiel, C. Seidl (Frankfurt, D)
P833 12 Gy FTBI versus 13, 2 Gy FTBI in preparative regimen for allogeneic BMT from
matched sibling donors in children with ALL in II CR
J. Wachowiak, D. Boruczkowski, J. Malicki, G. Kosicka, M. Leda, A. Pieczonka, G. Stryczynska
(Poznan, PL)
P834 Survival of children with high-risk neuroblastoma after conventional treatment followed
by high-dose chemotherapy and autologous stem cell transplantation
G. Caldas, A.F. Lacerda, A. Neto, E. Vieira, F. Pereira, M.J. Ribeiro, M. Chagas, A. Ambrosio,
N. Miranda, F. Leal-da-Costa, J.L. Passos-Coelho, M. Abecasis (Lisbon, P)
P835 ATG as part of the preparative regimen for paediatric allogeneic peripheral blood stem
cell transplantation
A. Kupesiz, G. Tezcan, V. Hazar, M.A Yesilipek (Antalya, TR)
P836 CD34+ selected autologous peripheral blood stem cell transplantation in neuroblastoma
H.S. Ahn, H.J. Kang, H.S. Choi, H.Y. Shin (Seoul, Goyang-si, KOR)
P837 Low-dose imatinib may convert the recipient with overt haematologic relapse of
Ph+ CML after allogeneic MUD-BMT to complete donor chimera and induce haematologic
and cytogenetic remission
K. Kalwak, D. Turkiewicz, E. Gorczyñska, J. Toporski, D. Wojcik, M. Ussowicz, A. Chybicka
(Wroclaw, PL)
P838 Dealing with the double role – experiences of parents donating haploidentical peripheral
blood stem cells. A phenomenological study
A. van Walraven, L. Ball, H. Koopman, R. Bredius, C. Ropes-de Jong, A. de Jong, M. Egeler
(Leiden, Utrecht, NL)
P839 B-cell recovery in a SCID patient after a second BMT following minimal myelosuppressive
conditioning
P. Hoogerbrugge, P. Brons, M. van der Burg, J. van Dongen, C. Weemaes
(Nijmegen, Rotterdam, NL)
P840 Treosulfan-based reduced toxicity conditioning for allogeneic BMT in children with
refractory Langerhans cell histiocytosis – report of two cases
A. Pieczonka, J. Wachowiak, D. Boruczkowski, M. Leda, J. Jólkowska, M. Witt (Poznan, PL)
P841 Non-myeloablative stem cell transplant in paediatric neuroblastoma
C. Castellini, A. Prete, F. Melchionda, M. Franzoni, R. Rondelli, A. Pession (Bologna, I)
P842 Sequential reduced intensity and full intensity allografting using same donor in child
with chronic granulomatous disease with coexistent, significant morbidity
J.A.T. Nicholson, R. Wynn, T.F. Carr, A.M Will (Manchester, UK)
P843 Autologous peripheral blood stem cell transplantation with BCVAC conditioning in
childhood acute myeloid leukaemia
H. J. Kang, H. Y. Shin, H. S. Choi, K. S. Han, H. S. Ahn (Goyang-si, Gyeonggi-do, Seoul, KOR)
P844 Autologous and allogeneic peripheral blood stem cell transplantation as compared with
bone marrow transplantation in children with leukaemia
A. Mousavi, A. Ghavamzadeh, A. Hedayatiasl, A. Shamshiri, M. Iravani, B. Bahar, M. Jahani,
S. Gholibeikian, P. Heydari, M. Moradiseresht (Teheran, IR)
P845 Epstein-Barr virus in paediatric stem cell transplantation
F. Staehelin, D. Beutler, P. Avoledo, A. Gratwohl, T. Kühne
for the Stem Cell Transplantation Team Basel

Poster Physicians Tuesday, March 30, 2004
Paediatric issues (continued)
18:00 –
19:00
P846 CAMPATH 1H in conditioning or reconditioning for allogeneic haematopoietic cell
transplantation in children – analysis of outcome and early immune recovery
J. Toporski, D. Turkiewicz, E. Gorczynska, K. Kalwak, R. Ryczan, B. Rybka, A. Chybicka
(Wroclaw, PL)
P847 CMV reactivation in paediatric HPT: A retrospective study on risk factors and efficacy of
secondary prophylaxis
S. Patel, M. Ortin, P. Fomasagaram, J. Shankari, R. Ridwan, D. Lancaster, J. Treleaven, S. Ball
(Sutton, London, UK)
P848 Correlation of immune reconstitution and survival in children undergoing allogeneic
haematopoietic stem cell transplantation
U. Koehl, K. Bochennek, S.Y. Zimmermann, R. Esser, C. Andreas, J. Soerensen, H. Gruettner,
A. Ackermann, D. Schwabe, T. Klingebiel, T. Lehrnbecher (Frankfurt, D)
P849 Non-radiotherapy-based conditioning with stem cell transplantation from alternative
donors for children with refractory severe aplastic anaemia
C. Urban, M. Benesch, K.W. Sykora, W. Schwinger, H. Lackner, E. Kloibhofer (Graz, A; Hannover, D)
P850 Nine years of experience in use based on ATG conditioning of allogeneic human stem
cells transplantation in Fanconi's anaemia patients.
J. Lange, D. Dlubek, B. Wysoczanska, D. Dobrowolska, A. Lange (Wroclaw, PL)
P851 Haematopoietic stem cell transplantation is effective curative treatment in paediatric
refractory/aggressive Langerhans cell histiocytosis
M. Caniglia, A. Lombardi, R. Pinto, I. Rana, F. Zinno, G. Peluso, C. Rapanotti, A. Angioni,
C. Roberti, B. Pinazzi, G. Isacchi, W. Arcese, G. De rossi
on behalf of the Inborn Errors Working Party
P852 Analysis of immunoglobulin gene expression in CD27+ memory B cells after
haematopoietic stem cell transplantation in children
D. Di Martino, M.P. Terranova, F. Scuderi, L. Scarso, S. Iacovone, C. Cermelli, A. Valetto,
S. Dallorso, G. Morreale, G. Dini (Genoa, Pisa, I)
P853 Cidofovir in children after allogeneic stem cell transplantation
M. Fernández-Sanmartín, M. Izquierdo, J.M. Fernández-Navarro, A. Verdeguer, V. Castel
(Valencia, E)
18:00 –
19:00
Acute leukaemia
P854 Haematopoietic stem cell transplantation for acute leukaemia treatment.
Catalonia, 1988 – 2002
M.L. Amado, M. Clèries, E. Vela, C. Moreno, A. Bosch (Barcelona, E)
P855 Treatment of relapsed acute myeloid leukaemia after allogeneic bone marrow
transplantation with combination chemotherapy of cytarabine, idarubicin plus etoposide
and subsequent donor leukocyte infusion: a prospective study
S.J. Choi, J.H. Lee, J.H. Lee, S. Kim, M. Seol, Y.S. Lee, J.S. Lee, W.K. Kim, K.H. Lee (Seoul, KOR)
P856 Genetic instability in CD34 positive haematopoietic progenitor cells from patients with
AML in first complete remission and in the corresponding AML blasts at diagnosis
A. Reichle, M. Zaiss, B. Panzer, P.J. Wild, G. Rothe, R. Andreesen, F. Hofstaedter, W. Dietmaier
(Regensburg, D)
P857 High-dose idarubicin and busulphan as conditioning regimen to autologous stem cell
transplantation in acute myeloid leukaemia
F. Ferrara, S. Palmieri, M. De Simone, M.R. D'Amico, A. Fasanaro, A. Viola, M. Annunziata,
G. Mele (Naples, I)
103

Tuesday, March 30, 2004 Poster Physicians
104
Acute leukaemia (continued)
18:00 –
19:00
P858 Allogeneic bone marrow transplantation compared with autologous peripheral blood
stem cell transplantation in patients with acute myeloid leukaemia in first complete
remission
M. Jimenez, A. Espigares, J. Santiago, C. Fernandez, M. Capote, C. Martin, C. Herrera,
J. Casaño, A. Torres (Cordoba, E)
P859 Allogeneic haematopoietic stem cell transplantation during aplasia induced by salvage
chemotherapy for otherwise refractory haematological malignancies
M. Ditschkowski, R. Trenschel, M. Hlinka, N.K. Steckel, M. Koldehoff, A.H. Elmaagacli,
D.W. Beelen (Essen, D)
P860 Improved overall survival in poor risk AML/MDS patients using PBSC compared to BM
after allogeneic unrelated donor transplantation
H. Bertz, M. Egger, A. Spyridonidis, B. Hackanson, O. Schmah, K. Mikesch, F. Dörfel, J. Finke
(Freiburg, D)
P861 Autologous bone marrow transplantation in first complete remission AML patients:
the influence of infused TNC for engraftment and LFS differs after purged and unpurged
marrow
G. Milone, A. Tornello, S. Leotta, U. Consoli, P. Murgano, M. Poidomani, S. Mercurio, F. Indelicato,
V. Pinto, R. Giustolisi (Catania, I)
P862 GvHD and intensive chemotherapy prior to transplantation allow better leukaemic
control in high risk CR1 AML after reduced-intensity conditioning HLA-identical
allogeneic transplantation
C. Faucher, J.M. Boiron, M. Mohty, J. Bay, V. Perreau, K. Bilger, N. Vey, A.M. Stoppa, D. Coso,
P. Ladaique, D. Maraninchi, D. Blaise (Marseille, Bordeaux, Clermont-Ferrand, F)
P863 Autologous stem cell support of induction therapy prior to allogeneic transplantation to
improve treatment delivery in patients with relapsing or secondary acute leukemia and
CML blast crisis
I. Hardan, A. Shimoni, A. Avigdor, A. Kneller, M. Berkowicz, P. Raanani, S.M. Stemmer,
N. Shemtov, M. Yeshurun, I. Ben-Bassat, A. Nagler (Tel-Hashomer, IL)
P864 Factors influencing normal B-lymphopoiesis restoration and leukaemia detection after
allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukaemia
J. Sanchez, J. Serrano, P. Gomez, F. Martinez, C. Martin, A. Rodriguez, J. Garcia-Castellano,
C. Herrera, J. Casaño, A. Torres (Cordoba, E)
P865 Combined in vitro drug resistance profile to prednisolone, vincristine and L-asparaginase
predicts relapse after stem cell transplantation in childhood acute leukaemia,
regardless of its type
J. Styczynski, J. Toporski, D. Boruczkowski, B. Wojcik, M. Wysocki, A. Chybicka, J. Wachowiak,
J. Kowalczyk (Bydgoszcz, Wroclaw, Poznan, Lublin, PL)
P866 High-dose melphalan is an effective salvage therapy in AML patients relapsing after
autologous PBSCT
G. Bug, J. Atta, S. Klein, B. Hertenstein, L. Bergmann, S. Boehrer, D. Hoelzer, H. Martin
(Frankfurt, Hannover, D)
P867 Allogeneic transplantation of Bcr-Abl positive acute lymphoblastic leukaemia is
associated with a low incidence of relapse
M. Weisser, J. Tischer, G. Ledderose, H.J. Kolb (Munich, D)
P868 Increased angiogenesis in the bone marrow of patients with AML: influence on survival
and outcome after allogeneic bone marrow transplantation
W. Rabitsch, W. Sperr, K. Lechner, A. Chott, E. Prinz, P. Valent, P. Kalhs (Vienna, A)
P869 BAVC regimen and ABMT in acute promyelocytic leukaemia in II molecular CR. Updated
results
S. Capria, D. Diverio, M. Ribersani, M. Breccia, E. Baldacci, F. Simone, A.P. Iori, F. Mandelli,
G. Meloni (Rome, I)

Poster Physicians Tuesday, March 30, 2004
Acute leukaemia (continued)
18:00 –
19:00
P870 Haematopoietic chimerism status may predict relapse after in vitro T-cell depleted
allogeneic stem cell transplantation for acute leukaemia
I. Baas, W. Marijt, R. Barge, I. Starrenburg, R. Willemze, J. Falkenburg (Leiden, NL)
P871 Comparison of long-term outcome after autologous transplantation of noncryopreserved
bone marrow and allogeneic haematopoietic stem cell transplantation
for the treatment of high-risk adult acute lymphoblastic leukaemia
J. Holowiecki, S. Giebel, J. Wojnar, M. Krawczyk-Kulis, M. Wojciechowska, L. Kachel, T. Czerw
(Katowice, PL)
P872 Development of Bcr-Abl positive acute lymphoblastic leukaemia in donor cells after
allogeneic haematopoietic cell transplantation for Philadelphia positive ALL
A. Athanasiadou, K. Stamatopoulos, I. Sakellari, I. Zorbas, M. Gaitatzi, A. Fassas,
A. Anagnostopoulos (Thessaloniki, GR)
P873 In vivo/ex vivo T-cell depletion with anti-CD52 monoclonal antibodies:
long-term results in patients with acute leukaemia in CR1
D. Bunjes, M. Wiesneth, B. Hertenstein, M. Stefanic, C. Duncker, J. Novotny, W. Heit, R. Arnold,
G. Hale, H. Waldmann, H. Heimpel (Ulm, Hannover, Essen, Berlin, D; Oxford, UK)
P874 Haemopoietic progenitor transplantation in the treatment of Philadelphia positive acute
lymphoblastic leukaemia: a single-centre study on prognostic factors
R. Sinha, M. Ortin, S. Patel, R. Ridwan, P. Somasegarem, J. Shankari, S. Mellor, J. Swansbury,
J. Treleaven (Sutton, UK)
P875 Role of stem cell transplantation in patients with advanced acute myeloid leukaemia
M. Camós, J. Esteve, M. Rovira, A. Urbano-Ispizua, C. Martínez, J. Bladé, F. Bosch, F. Cervantes,
A. López-Guillermo, F. Fernández-Avilés, P. Marín, B. Nomdedeu, E. Carreras, E. Montserrat
(Barcelona, E)
P876 High percentage of CD 34 positive cells in peripheral blood after chemotherapy correlate
with high relapse rate in AML patients. Single-centre experience
K. Steinerova, V. Koza, D. Lysak, P. Jindra, M. Karas, P. Skopek, S. Vokurka (Pilsen, CZ)
P877 Granulocytic sarcoma in childhood acute myelogenous leukaemia: clinical characteristics
and management
H. Kook, C. Oh, S.Y. Kim, S.J. Kim, H. Noh, H. Nam, T. Hwang (Gwangju, KOR)
P878 Haematopoietic stem cell transplantation in treatment of adult patients with acute
myeloid leukaemia in single-centre experience: results and risk factor analysis
L. Gil, A. Czyz, A. Lojko, K. Sawinski, M. Kozlowska-Skrzypczak, M. Komarnicki (Poznan, PL)
P879 Liposomal daunorubicin plus aracytin for relapsed acute lymphoblastic leukaemia
can be a good reinduction chemotherapy before matched unrelated bone marrow
transplantation
A. Candoni, M. Cerno, A. Sperotto, R. Mestroni, A. Geromin, C. Skert, D. Damiani, R. Fanin
(Udine, I)
P880 ATG versus campath in BuCy transplant conditioning for adult patient with leukaemia
in unrelated donor setting
M. Sedzimirska, K. Suchnicki, J. Lange, B. Wysoczanska, D. Dlubek, A. Lange (Wroclaw, PL)
P881 Unsustained platelet recovery after PBSCT in 39 AML patients autografted in first
complete remission
S.M. Trisolini, S. Capria, E. Baldacci, M.S. De Propris, M.L. Dessanti, M. Gozzer, M. Ribersani,
C. Timarco, N. Villiva', G. Meloni (Rome, I)
P882 The impact of the source of stem cells on the outcome of autologous haematopoietic
progenitor transplantation (HPT) in patients with AML
J. Berlanga, D. Gallardo, D. Benéitez, M. Hermosilla, M. Encuentra (Barcelona, E)
P883 Stem cell transplantation in acute leukaemia: a single-centre experience
S.I. Moiseev, R. Golovchenko, M. Nujja, K. Abdulkadirov (St. Petersburg, RUS)
105

Tuesday, March 30, 2004 Poster Physicians
106
Acute leukaemia (continued)
18:00 –
19:00
P884 Fludarabine-based regimens as salvage chemotherapy before bone marrow
transplantation for relapsed and refractory acute lymphoblastic leukaemia
M. Cioch, D. Jawniak, J. Manko, A. Dmoszynska (Lublin, PL)
P885 Arabinosylguanine (araG) - an effective and selective therapy in T-ALL relapse after
allogeneic stem cell transplantation
H. Horst, A. Humpe, R. Schoch, R. Siebert, S. Gesk, M. Kneba, D. Hoelzer, N. Goekbuget
(Kiel, Frankfurt, D)
18:00 –
19:00
Lymphoma
P886 Predictive value of gallium-67 scintigraphy in high-grade non-Hodgkin lymphoma
patients undergoing haematopoietic stem cell transplantation
I. García Escobar, J. Pérez Simón, P. Tamayo, J. Mateos, E. Pérez, D. Caballero,
J. García Talavera, J. San Miguel (Salamanca, E)
P887 Relapse or progression after autologous stem cell transplantation in patients
with non-Hodgkin's lymphoma: a nation-wide survey
T. Kuittinen, T. Wiklund, E. Elonen, K. Remes, T. Lehtinen, O. Kuittinen, S. Leppä, R. Räty,
M. Putkonen, T. Nousiainen, T. Turpeenniemi-Hujanen, E. Jantunen
(Kuopio, Helsinki, Turku, Tampere, Oulu, FIN)
P888 Improved overall survival of mantle cell lymphoma patients after high-dose chemotherapy
and autotransplantation compared to non-transplant patients.
A single centre report of 114 consecutive patients
J. Romejko-Jarosinska, K. Domanska-Czyz, G. Rymkiewicz, O. Mioduszewska, R. Maryniak,
J. Walewski (Warsaw, PL)
P889 The number of DexaBEAMs given prior to autologous stem cell transplantation seems
to have no effect on outcome in relapsed and refractory non-Hodgkin lymphoma
S. Kim, H. K. Al-Ali, R. Krahl, W. Zschille, U. Hegenbart, A. Aldaoud, F.-A. Hoffmann, H.-J. Hurtz,
R. Rohrberg, M. Wabersich, D. Niederwieser (Leipzig, Zwickau, Halle, D)
P890 Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive
non-Hodgkin lymphoma – results of A multicentre Phase II study
A. Josting, M. Sieniawski, J.O. Staak, J.P. Glossmann, V. Diehl, A. Engert (Cologne, D)
P891 Tandem transplant for follicular lymphoma
C. Recher, A. Huynh, F. Huguet, A. Cazeneuve, S. Galloin, T. Al Saati, G. Delsol, M. Attal (Toulouse, F)
P892 Outcome of lymphoma patients undergoing autologous transplantation:
Effect of increasing the dose of etoposide in the BEAM regimen
A. Martín, M.D. Caballero, J.A. Pérez-Simón, N. López-Holgado, M.C. Cañizo, L. Vázquez,
J.F. San Miguel (Salamanca, E)
P893 Salvage treatment with pegylated liposomal doxorubicin (Caelyx), cyclophosphamide –
rituximab (DC-R) plus GM-CSF in B-diffuse large cell lymphoma (B-DLCL) after
autologous stem cell transplantation failure
A. Olivieri, M. Montanari, L. Spitaleri, D. Capelli, M. Lucesole, I. Scortechini, M. Offidani, G. Gini,
E. Troiani, P. Leoni (Ancona, I)
P894 Long-term follow-up in patients with diffuse large B-cell lymphoma treated with highdose
chemotherapy and autologous stem cell transplantation in first partial remission
F. Gaudio, V. Pavone, A. Guarini, T. Perrone, P. Curci, A. Giordano, R. De Francesco, V. Liso (Bari, I)
P895 Double induction combined with tandem autologous stem cell transplantation in
relapsed and refractory aggressive lymphoma
A. Reichle, A. Berand, E. Holler, R. Andreesen (Regensburg, D)

Poster Physicians Tuesday, March 30, 2004
18:00 – Lymphoma (continued)
19:00
P896 Ifosfamide, carboplatin and etoposide for autologous stem cell transplantation in
non-Hodgkin lymphomas
L. Nassi, L. Rigacci, S. Guidi, R. Alterini, V. Carrai, C. Nozzoli, R. Saccardi, L. Lombardini,
A.M. Vannucchi, A. Bosi (Florence, I)
P897 Efficacy and safety of tailored high-dose chemotherapy with in vivo purged autologous
stem cell transplantation in relapsed/resistant follicular lymphoma
M. Magni, M. Di Nicola, C. Carlo-Stella, L. Devizzi, A. Guidetti, P. Matteucci, A. Assanelli,
F. Ravagnani, M. Gianni (Milan, I)
P898 R-DHAP – sequential high-dose chemotherapy with autologous stem cell support in
combination with the anti-CD20 antibody Rituximab in relapsed aggressive non-Hodgkin
lymphoma
M. Sieniawski, J.0. Staak, H. Scheuß, J.P. Glossmann, V. Diehl, A. Engert, A. Josting (Cologne, D)
P899 Allogeneic stem cell transplantation as salvage therapy for patients with lymphoma
F. Zaja, C. Skert, A. Sperotto, F. Patriarca, C. Filì, M. Cerno, S. Prosdocimo, A. Geromin,
D. Damiani, R. Fanin (Udine, I)
P900 Double autologous transplant seems not to improved survival compared to single
transplant for patients with Hodgkin's disease
J. Czyz, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, M. Osowiecki, J. Walewski,
W. Jurczak, A. Skotnicki, W. Knopinska-Posluszny
(Gdansk, Katowice, Poznan, Warsaw, Cracow, PL)
P901 Impact of a treatment with rituximab before autologous stem cell transplantation on
haematological reconstitution
F. Bouchand, N. Mounier, J. Manson, D. Nabet, J. Larghero, P. Brice, I. Madelaine-Chambrin,
J. Brière, J.-P. Marolleau, C. Gisselbrecht (Paris, F)
P902 Autologous stem cell transplantation for lymphoma: comparison of CBV and beam
preparative regimens
M. Remigia, J. de la Rubia, G. Martín, G. Sanz, I. Lorenzo, I. Jarque, J. Martínez, P. Montesinos,
C. Jiménez, M. Sanz (Valencia, E)
P903 Autografting followed by dose-reduced conditioning and allogeneic haematopoietic
stem cell transplantation in poor risk malignant lymphoma
M. Haenel, F. Kroschinsky, U. Platzbecker, G. Geissler, C. Thiede, G. Ehninger, M. Bornhaeuser
(Chemnitz, Dresden, D)
P904 High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood
stem cell transplantation in patients with lymphoma – a retrospective evaluation
T. Demirer, E. Soydan, T. Fen, O. Ilhan, M. Ayli, M. Arat, M. Ozcan, N. Gunel, O. Arslan, Y. Genc,
A. Uysal, R. Haznedar, S. Buyukberber, G. Gurman, N. Ustaer, B. Hazar, G. Ozet, H. Akan
(Ankara, Gaziantep, Mersin, TR)
P905 The impact of rituximab in stem cell mobilisation and engraftment in high-grade
non-Hodgkin lymphoma
P. Kaloyannidis, C. Kartsios, I. Sakellari, C. Vadikolia, M. Marantidou, A. Anagnostopoulos,
A. Fassas (Thessalonica, GR)
P906 Tandem autologous stem cell transplantation or non-myeloablative allogeneic stem cell
transplantation following autologous stem cell transplantation for transformed
low-grade lymphoma
V. Dubruille, N. Morineau, P. Moreau, T. Guillaume, B. Mahe, P. Chevalier, J. Harousseau,
N. Milpied (Nantes, F)
P907 Prognostic factors and autologous haematopoietic stem cell transplantation in
lymphoma patients
N.B. Mikhaylova, L.S. Zoubarovskaya, A.Y. Zaritsky, B.V. Afanasyev (St. Petersburg, RUS)
107

Tuesday, March 30, 2004 Poster Physicians
18:00 – Lymphoma (continued)
19:00
P908 Choice of adequate risk adapted strategy in Hodgkin disease
W.J. Jurczak, A. Zaluska, D. Krochmalczyk, B. Piatkowska - Jakubas, A.B. Skotnicki (Cracow, PL)
P909 Autologous tandem transplantation with high-dose etoposide mobilised peripheral blood
stem cells in patients with refractory Hodgkin's and aggressive non-Hodgkin lymphoma
M. Sieniawski, J.P. Glossmann, J.O. Staak, L. Nogova, J. Kisro, C. Rudolph, M. Reiser, C. Scheid,
A. Engert, V. Diehl, A. Josting (Cologne, Luebeck, Cottbus, D)
P910 Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's
disease – an 8 year experience
H. Minigo, R. Vrhovac, A. Planinc-Peraica, S. Ostojic Kolonic, R. Kusec, D. Radic-Kristo,
I. Kardum-Skelin, D. Sustercic, B. Jaksic (Zagreb, HR)
P911 Allogeneic haematopoietic stem cell transplantation in patients with non-aggressive
lymphoproliferative malignancies - single-centre experiences
I.W. Blau, W.U. Knauf, O. Marinets, K. Rieger, T. Fietz, E. Thiel (Berlin, D)
P912 In vivo purging with hyper-CVAD plus rituximab in newly diagnosed mantle cell
lymphoma
E. Benedetti, F. Papineschi, F. Caracciolo, S. Galimberti, G. Cervetti, G. Castiglioni, S. Mechelli,
P. Scatena, M. Pelosini, M. Petrini (Pisa, I)
P913 High-dose sequential followed by autologous bone marrow transplantation as salvage
treatment in advanced Hodgkin's disease
M.T. Delamain, R.C. Baldissera, K.B.B. Pagnano, G.B. Oliveira, I. Lorand-Metze, A.C. Vigorito,
F.J.P. Aranha, K.A.B. Eid, E.C.M. Miranda, C.A. De Souza (Campinas, BR)
P914 High- and low-risk high-grade NHL patients display no significant survival difference in
terms of long-term follow-up after up-front high-dose chemotherapy with autologous
stem cell support
H. Bertz, R. Zeiser, W. Lange, D. Frauenschuh, S. Fetscher, C.F. Waller, J. Finke (Freiburg, D)
P915 Non-myeloablative stem cell transplantation for mantle cell lymphoma
S. Van Steenweghen, J. Maertens, R. Schots, A. Van de Velde (Antwerp, Leuven, Brussels, B)
P916 Allogeneic HSCT for adult lymphoma patients. A retrospective study of myeloablative
compared to reduced-intensity conditioning
H. Hägglund, M. Remberger, P. Ljungman, J. Aschan, C. Löfgren, O. Ringden, E. Kimby
(Stockholm, S)
P917 Allogenic haematopoetic stem cell transplantation after reduced intensity conditioning
for patients with non-Hodkgin lymphoma
H. Schieder, N. Kröger, T. Zabelina, F. Ayuk, A. Kratochwille, B. Fehse, N. Fehse, C. Wolschke,
H. Renges, A. Zander (Hamburg, D)
P918 Autologous stem cell transplantation in patients with aggressive or follicular
non-Hodgkin lymphoma between 8/1984 and 9/2003
H. Kasparu, J. König, H. Hauser, O. Krieger, M. Girschikofsky, M. Bernhart, D. Lutz
(Linz, Vienna, A)
P919 Intensified full-dose induction therapy (HD-machop radiotherapy) followed by
consolidation with BAVC regimen and autologous stem cell transplantation as front-line
therapeutic approach for high-risk aggressive non-Hodgkin lymphoma
F. Zaja, A. Sperotto, V. Tomadini, F. Patriarca, C. Filì, F. Kikic, D. Damiani, R. Mestroni, M. Tiribelli,
R. Fanin (Udine, I)
108

Poster Physicians Tuesday, March 30, 2004
18:00 –
19:00
18:00 –
19:00
Myelodisplasia
P920 Allogeneic stem cell transplantation for patients with refractory anaemia with matched
related and unrelated donors: T-cell depletion and reduced-intensity regimens are
associated with an increased relapse risk
T. de Witte, R. Brand, A. van Biezen, P. Guardiola, J. Cornelissen, A. Gratwohl, M. Boogaerts,
V. Runde, R. Arnold, J.-L. Harrousseau, A. Fauser, G. Mufti, D. Niederwieser
on behalf for the EBMT, CLWP-MDS subcommittee
P921 Treosulfan/fludarabine as dose-reduced conditioning followed by allogeneic stem cell
transplantation from related and unrelated donors in patients with AML and MDS/sAML
N. Kröger, T. Zabelina, H. Schieder, K. Kratochwille, F. Ayuk, N. Stute, N. Fehse, J. Hassenpflug,
J. Panse, J. Casper, M. Freund, A. Zander (Hamburg, Rostock, D)
P922 Intensive treatment in patients with high-risk myelodysplastic syndromes and
secondary acute leukaemia
J. Bargay, S. Brunet, J. Esteve, J. Ribera, J. Ribera, A. Llorente, J. Marti, J. Sarrà, R. Guardia,
C. Pedro, B. Nomdedeu, J. Sierra, J. Besalduch
on behalf of the CETLAM Spanish Group
Data management Poster Data Management
P923 Trends in haematopoietic stem cell transplantation 1995 – 2002:
a comparison of the Austrian Stem Cell Transplant Registry data with the EBMT megafile
B. Lindner, D. Nachbaur, H. Greinix (Innsbruck, Vienna, A)
P924 The Czech National Stem Cell Transplantation Registry
K. Benesova, M. Trnkova , I. Karlachova, K. Doskocilova, I. Maresova, S. Hrabetova, A. Vrzalova,
Z. Koristek, J. Nepomucka (Prague, Hradec Kralove, Olomouc, Brno, CZ)
P925 The history and future of data collection and data flow. Single-centre experience
K. Steinerova, V. Koza, P. Jindra, D. Lysak, B. Varvarovska (Pilsen, CZ)
P926 Electronic management of the stem cell transplant schedule
P. Balsalobre, I. Buño, R. Carrion, D. Serrano, S. Carrasco, A. Gomez-Pineda, P. Berasategui,
J.L. Diez-Martin (Madrid, E)
P927 Data management system in a single-centre
S. Gholibeikian, P. Heydari, M. Moradiseresht, F. Safavifar (Tehran, IR)
109

Sunday, March 28, 2004 Data Management Group
110
Data management
09:00 – 15:00 ProMISe 2 training sessions
Chair: C. Ruiz de Elvira (London, UK)
928 Agenda:
09:00 Database presentation
10:00 Coffee break
10:30 Practical session
12:30 Lunch break
13:30 Practical session continued
18:30 – 20:45 Opening Session
(please refer to page 22 for details)
20:45 Welcome reception
in the foyers of the Palau de Congressos de Catalunya
ProMISe
Auditorium

Data Management Group Monday, March 29, 2004
Data management
09:00 – 15:00 ProMISe 2 training sessions
Chair: C. Ruiz de Elvira (London, UK)
929 Agenda:
09:00 Database presentation
10:00 Coffee break
10:30 Practical session
12:30 Lunch break
13:30 Practical session continued
09:00 – 10:30 Data management educational session
930 Good clinical practice in clinical trials
M. Vignetti, U. Filibeck, K. Champion (Rome, I; London, UK)
Data management
11:00 – 17:30 MED-B sessions
11:00 931 Autograft
G. Rosti, M. Vignetti (Ravenna, Rome, I)
12:30 Lunch break
14:00 932 Acute leukaemia
V. Rocha (Paris, F)
15:30 Coffee break
16:00 933 Infectious diseases
C. Cordonnier (Creteil, F)
ProMISe
Room D4
Room D4
111

Tuesday, March 30, 2004 Data Management Group
Data management
09:00 – 15:30 ProMISe 2 training sessions
Chair: C. Ruiz de Elvira (London, UK)
934 Agenda:
09:00 Database presentation
10:00 Coffee break
10:30 Practical session
12:30 Lunch break
13:30 Practical session continued
Data management
09:00 – 15:30 MED-B sessions
09:00 935 Myeloma
B. Björkstrand (Stockholm, S)
10:30 Coffee break
11:00 936 Allograft/HLA
J. Apperley (London, UK)
12:30 Lunch break
13:30 937 MDS & relapsed CML
T. de Witte, C. Guglielmi (Nijmegen, NL; Rome, I)
112
ProMISe
Room D4

Data Management Group Tuesday, March 30, 2004
Data management
16:00 – 17:30 Statistical symposium
Chair: R. Brand (Leiden, NL)
938 Analysis of chronic GvHD after allogeneic transplant by the Landmark method
F. Bonifazi, G. Bandini, S. Falcioni, M. Stanzani, F. Palandri, M. Arpinati, B. Giannini,
M. Baccarani (Bologna, I)
939 The current state of the EBMT statistical guidelines
M. Labopin, S. Iacobelli (Paris, F; Leiden, NL)
940 Methodology like competing risk, multi-state etc. to be expected to become
“normal” in the next decade
M. Labopin (Paris, F)
941 Problems (and solutions) to be expected when converting to the new Data
base structure as implemented in Promise-2 , in the framework of survival
analsyis
R. Brand (Leiden, NL)
942 Round-table
Informal meeting of all people involved in the actual analysis of BMT data,
both statisticians and clinicians and data managers
R. Brand, M. Labopin, S. Iacobelli (Leiden, NL; Paris, F)
18:00 – 19:00 Data management poster presentation (P923–P927)
(please refer to page 109 for details)
20:00 Gala dinner at Reials Drassanes de Barcelona
(please refer to page 155 for details)
Abstract
Room D4
113

Sunday, March 28, 2004 Nurses Group
18:30 – 20:45 Opening Session
114
(please refer to page 22 for details)
20:45 Welcome reception
(in the foyers of the Palau de Congressos de Catalunya)
Auditorium
Nurses Group Monday, March 29, 2004
Nurses educational session 1
08:00 – 09:00 Central venous care ◆
Chair: T. Von Boxtel (Utrecht, NL)
Nurses educational session 2
08:00 – 09:00 Complimentary therapies
Chair: A. Buxton-King (London, UK)
Nurses oral session
09:00 – 10:30 Supportive care 1 ◆
Chairs: M. Stephens (London, UK), C. Laborda (Barcelona, E)
09:00 N943 Welcome by the president of the EBMT Nurses Group
M. Stephens (London, UK)
09:10 N944 Influence of relaxation on adverse events during infusion of cryopreserved
haematopoietic progenitor cells – a pilot study
E. Gris, C. León, R. Laborda, M. Palao, N. Llàcer (Barcelona, E)
09:30 N945 Stress reduction through massage in transplant patients
J. Stringer, R. Swindell, R. Chopra (Manchester, UK)
Room H
Room E1
Room H
09:50 N946 Experience of nurse support to improve rehabilitation after allogeneic stem
cell transplantation
A. Kisch, A. Pizunski (Lund, S)
10:10 N947 Changing communication between nurses and their patients with regards to
sexuality by Business Process Redesign (BPR)
C. Eeltink, P. Ruel, J. Kruijmer, A. Scheringa (Amsterdam, NL)
◆ Simultaneous translation into Spanish

Nurses Group Monday, March 29, 2004
Nurses oral session
11:00 – 12:20 Donor issues ◆
Chairs: M. Jansen (Maastricht, NL), J. Larsen (Stockholm, S)
11:00 N948 How well organised is the care of the stem cell donor?
W. de Nooij, T. de Vries, M. Verhoeven, H. Overbeek, H. van der Woude, C. Lubbers,
P. Meijers-Sleiderink on behalf of the Working Party LOVeST
11:20 N949 A nurse-led service for healthy PBSC donors
L.A. Ritchie, R.F. Duarte, M.N. Potter, G. Poonawala (London, UK)
11:40 N950 Coping strategies of parents donating haploidentical peripheral blood
stem cells
A. van Walraven, L. Ball, F. van Iperen, W. Broekhof, M. Egeler, H. Koopman (Leiden, NL)
12:00 N951 Should we use children as bone marrow donors? The ethical and legal
implications
J. Stone (London, UK)
12:30 – 13:30 Nurses National group meetings
12:30 – 13:30 Workshops
Workshop 1: Breaking bad news
Chair: B. Quinn (London, UK)
Workshop 3: Research skills
Chair: A.M. van Walraven (Leiden, NL)
Workshop 4: Presentation skills
Chair: T. Von Boxtel (Utrecht, NL)
Workshop 5: Methods of stress reduction
Chair: A. Buxton-King (London, UK)
15:00 – 16:00 Workshop 2: Internet skills
Chairs: M. Stephens, P. Morris (London, UK),
Simultaneous translation into Spanish
This year we are delighted to be able to offer simultaneous translation into Spanish
of the Scientific Programme of the Nurses Group.
◆ Simultaneous translation into Spanish
Room H
Rooms H, D4, E5, E6
Room E1
Room E6
Room E5
Room E3
ProMISe
115

Monday, March 29, 2004 Nurses Group
Nurses oral session
16:00 – 17:40 Paediatric issues
Chairs: H. Harvey (Newcastle, UK), C. Pino Molina (Basel, CH)
16:00 N952 Support group for parents of children post-allogeneic stem cell transplantation
D. Hutt, M. Weiss (Tel-Hashomer, IL)
16:20 N953 Choices to be made: the role of the transplant team in empowering children
and families to make personal end of life decisions
F. van Iperen, L.M. Ball, J.K. Anninga, S. Harmsen, A. Nederstigt, S.A. Muntz,
K. de Wit, R.M. Egeler (Leiden, NL)
16:40 N954 Death after paediatric bone marrow transplant: does place of death make
a difference to parents?
D. Drew, B. Goodenough, S. Higgins, S. Trethewie (Randwick, AUS)
17:00 N955 Pre-existent psychological disturbances are not an absolute contra
indication to allogeneic stem cell transplantation in the paediatric setting
but necessitate a comprehensive and structured multi disciplinary
team approach
C.C.M. Hofstra, C.C.M. Klein, F. van Iperen, L.M. Ball (Leiden, NL)
17:20 N956 Working together: meeting the social and emotional needs of children and
families during BMT at Great Ormond Street Children’s Hospital
D. Melvin, N. O'Neil (London, UK)
Nurses oral session
16:00 – 17:40 Nutritional support
Chairs: E. Aerts (Zurich, CH), B. Quinn (London, UK)
16:00 N957 Nausea and vomiting in breast cancer patients who receive chemotherapy in
high doses with the support of peripheral stem cells: the educational role of
the professional nurse and the writing out of instructions
L. Orlando, G. Vasaturo, M. Clerici, C. Berti, C. Di Leverano, L. Casellato, A. Cocquio,
S. Cinieri, G. Martinelli (Milan, I)
16:20 N958 Developing an evidence-based nutritional care protocol for patients
undergoing bone marrow transplant
M. Davies, J. McLellan, J. Commins, C. Wilson (Manchester, UK)
16:40 N959 Low bacterial diet in neutropenic patients. A review
J. Iserte, S. Carrillo, A. Mantecón (Barcelona, E)
17:00 N960 Addressing the issues of poor nutrition in the BMT population –
towards a nurse led protocol
S. Sinclair, A. Hewitt, L. Nicholls (London, UK)
18:00 – 19:00 Nurses poster presentation (P991 – P1086)
116
(please refer to pages 122–127 for details)
Room A
Room B

Nurses Group Monday, March 29, 2004
Nurses oral session
16:00 – 17:40 Addressing clinical issues ◆
Chair: E. Gris (Barcelona, E), M. Ni Chonghaile (Dublin, IRL)
16:00 N961 The incidence of catheter-related infections from day 0 to day 100 in
allogeneic stem cell transplant patients
A. Berthelsen, H. Laursen, T. Lanther, J. Holder, S. Rasmussen, C. Heilmann
(Copenhagen, DK)
16:20 N962 Are groshong lines meeting the needs of our patients?
L. Taylor (Bristol, UK)
16:40 N963 Stomatitis: measurement and intervention as an integral part of routine
nursing care in bone marrow transplant wards
S. Shoen, D. Taou, A Morag (Tel-Hashomer, IL)
17:00 N964 The hidden work behind the implementation of an individualised,
patient-based, mucositis pain management protocol
A. Ciurana, M.C. Rodriguez, C. Martinez, E. Chavas, A. Ovalle, I. Ruiz, N. Vidal,
N. Borras, M. Valverde (Barcelona, E)
17:20 N965 Improving mouth-care seems possible: knowledge, convenience and
compliance regarding a mouth-care protocol for haematology patients
M. van Vliet, C. Potting, N. Blijlevens, T. van Achterberg (Nijmegen, NL)
18:00 – 19:00 Nurses poster presentation (P991 – P1086)
(please refer to pages 122–127 for details)
◆ Simultaneous translation into Spanish
Room H
117

Tuesday, March 30, 2004 Nurses Group
Educational session 3
08:00 – 09:00 Nutrition in transplant ◆
Chairs: M. Ni Chonghaile (Dublin, IRL), I. Schlosser (Rotterdam, NL)
Educational session 4
08:00 – 09:00 The pathophysiology and treatment of acute leukaemia
Chair: M. Stephens (London, UK)
Joint session Nurses / Physicians
09:00 – 10:30 Critical care in transplantation ◆
Chairs: J. Apperley (London, UK), M. Stephens (London, UK)
The different points of view from a haematologist, an intensivist, a nurse and
a family member
09:00 211 Haematologist's perspective
H. Schouten (Maastricht, NL)
09:20 212 Intensivist's perspective
E. Azoulay (Paris, F)
09:40 213 Nurse's perspective
O. Power (Dublin, IRL)
10:00 214 Family's perspective
B. Kay (Grantham, UK)
118
◆ Simultaneous translation into Spanish
Room H
Room E1
Auditorium

Nurses Group Tuesday, March 30, 2004
Nurses oral session
11:00 – 12:40 Standards of care ◆
Chairs: A.M. van Walraven (Leiden, NL), M. Brown (London, UK)
11:00 N966 Rituals and evidence based nursing in stem cell transplantation:
a contradiction?
A. Mank (Amsterdam, NL)
11:20 N967 The evidence-based practice for prevention of opportunistic infections among
haematopoietic stem cell transplant recipients: descriptive study in Milan area
C. Soliman, S. Bonalumi, M. Casati (Milan, I)
11:40 N968 Earlier discharge? Evidence-based study on planning discharge and feelings
of safety for neutropenic patients
A. Mank, H. v.d. Lelie (Amsterdam, NL)
12:00 N969 Respiratory viral infections in haematological patients.
J.M. Portos, M. Peyret, R. Martino, C. Salvador (Barcelona, E)
12:20 N970 Facilitating the timely initiation of first line antibiotics in neutropenic sepsis
P. Ryan (Sutton, UK)
13:00 – 14:00 Nurses general meeting ◆
Nurses debate
14:00 – 15:30 Protective isolation – a waste of time? ◆
Chair: C. Wardley (Manchester, UK)
N971 Proposers:
E. Aerts (Zurich, CH)
A. Mank (Amsterdam, NL)
◆ Simultaneous translation into Spanish
Room H
Room H
Room H
119

Tuesday, March 30, 2004 Nurses Group
Nurses oral session
14:00 – 15:40 Managing care
Chairs: P. Ryan (Sutton, UK), I. Skoda (Ljubljana, SI)
14:00 N972 The role of nurse-led care in complex BMT patients
A. Hewitt, M. Real (London, UK)
14:20 N973 Developing shared care for blood and marrow transplant recipients
M. Ni Chonghaile (Dublin, IRL)
14:40 N974 User involvement in the bone marrow transplant unit
H. Vos, A. Finch, C. Kirk (London, UK)
15:00 N975 Computerised data collection and database for bone marrow transplant
co-ordination and quality control
T. Faibish, H. Leibzirer, M. Markovitz, T. Zuckerman (Haifa, IL)
15:20 N976 A qualitative exploratory study examining bone marrow transplant nurse
views of palliative care within their speciality
S. Carey (London, UK)
Nurses oral session
16:00 – 17:40 Psychosocial issues ◆
Chairs: N. Borras (Barcelona, E), T. Von Boxtel (Utrecht, NL)
16:00 N977 Making sense of cancer
B. Quinn (London, UK)
16:20 N978 The cost of cancer: exploration of the socio-economic issues affecting
haematology patients undergoing stem cell transplantation
J. Richardson (London, UK)
16:40 N979 The negative impact of stem cell transplantation on psychological status;
a single-centre experience
F. T.Bilgin, N. Akgul, B. Paroz, A. Akgul, N. Yildirim, N. Cayir, H. Bilgen, S. K. Besisik
(Istanbul, TR)
17:00 N980 The patients' experiences of symptoms during stem cell transplantation
J. Larsen, G. Nordström, P. Ljungman, A. Gardulf (Huddinge, S)
17:20 N981 A longitudinal study of hope in adults undergoing bone marrow
transplantation
G. Butters (Bristol, UK)
18:00 – 19:00 Nurses poster presentation (P991 – P1086)
(please refer to pages 122–127 for details)
20:00 Gala dinner at Reials Drassanes de Barcelona
120
(please refer to page 155 for details)
◆ Simultaneous translation into Spanish
Room E1
Room H

Nurses Group Wednesday, March 31, 2004
Nurses oral session
09:00 – 10:20 Critical care issues ◆
Chairs: B. Quinn (London, UK), O. Power (Dublin, IRL)
09:00 N982 The decison and influencing factors in haemto-onocology patients being
transferred to a critical care bed – a study exploring views of qualified nurses
J.E. Green (Croydon, UK)
09:20 N983 From ward to intensive care – utilising early warning scores in the
haematology and bone marrow transplantation setting
K.A. Midgley, R. Copland (Leeds, UK)
09:40 N984 Critical care outreach improves outcome in haemato-oncology patients
requiring intensive care admission
J. McLellan, P. Haji Michael, J. Epstein, D. Tansey, I. Kapilla, R. Chopra (Manchester, UK)
10:00 N985 Retrospective analysis of characteristics concerning death in patients
undergoing stem cell transplant
R. Panadero, C. San Roman, L. Suela, V. Gonzalez, P. Balsalobre, I. Buño,
P. Berasategui, J.L. Diez-Martin, S. Carrasco (Madrid, E)
Nurses oral session
11:00 – 12:00 Supportive care 2 ◆
Chairs: M. Stephens (London, UK), E. Bystricka (Prague, CZ)
11:00 N986 A novel approach of specialising haematology nurses in their current posts to
become a specialist resource for information and support to patients with myeloma
T. King (Edinburgh, UK)
11:20 N987 Regulation of haemopoietic stem cell collection: a network approach
A. K Booth (Potts Point, AUS)
11:40 N988 Improving symptom management: an ongoing prospective audit mapping
specific symptoms experienced by patients who have undergone an
autologous BEAM peripheral blood stem cell transplant
C. Demosthenous, P. Statham (London, UK)
Nurses
12:00 – 12:30 Medical update / Awards and closing ◆
12:00 N989 Update from physicians meeting
J. Sierra (Barcelona, E)
12:15 N990 Awards
Closing remarks
M. Stephens (London, UK)
◆ Simultaneous translation into Spanish
Room H
Room H
Room H
121

Monday, March 29 and Posters Nurses
Tuesday, March 30, 2004
18:00 –
19:00
18:00 –
19:00
Management
P991 Cord blood collections: a Queensland (Australia) experience
J. Shergold, L. Lockwood, C. Hutchins (Brisbane, AUS)
P992 The management of chronic leukaemia during pregnancy
E. Dannie (London, UK)
P993 Management of CML: Glivac right from the start. NICE recommendations
E. Dannie (London, UK)
P994 The roles of the BMT out-patient nurse and the transplant nurse co-ordinator
S. Haavisto, R. Keskimäki (Helsinki, FIN)
P995 Making standing orders work on an adult bone marrow transplant unit
R. Wilkinson, E. Higgins, C. Healy (Dublin, IRL)
P996 Sibling BMT- donor and core family donor searches in patients –
coordination and data methods
E. Bystricka, A. Volfova, K. Novak, S. Vokurka, K. Cerna, T. Karvunidis, P. Jindra, V. Koza
(Pilsen, CZ)
P997 Haematology and haemato-oncology nurses in the Czech Republic –
their projects and challenges within the Czech Haematology Society and EBMT
E. Bystricka, V. Kaslova, V. Pavlicova, J. Scudlova, J. Vitkova, D. Mjartanova
(Pilsen, Hradec Kralove, Olomouc, CZ)
P998 Allogenic bone marrow transplantation in the patient of aplastic anaemia with
Wolff-Parkinson-White syndrome
B.S. Kim, I. Choi, K. Park, S. Yoon, S. Oh, J. Seo, C. Choi, S. Shin, Y.H. Kim, J.S. Kim
(Seoul, KOR)
P999 Necessity of coordination in haematopoietic stem cell transplantation
V. Bons, V. Rocha, E. Gluckman (Paris, F)
Out patient developments
P1000 A study of perceived quality in the Homecare Programme for Autologous Stem Cell
Transplantation
L. Garcia, C. Gallego, A. Hernando, S. Segura, L. Nevado, J. Güell, F. Fernández-Avilés,
E. Carreras, M. Valverde (Barcelona, E)
P1001 The continuing expansion of BMT out-patient services: delivering bone marrow top ups
in a day care setting
E. Walls, H. Harvey (Newcastle upon Tyne, UK)
P1002 Homecare Programme for Autologous Stem Cell Transplantation: the role of hospital day
care support
D. Rambla, M. Monné, A. Hernando, C. Gallego, A. Ciurana, P. Pinedo, F. Fernández-Avilés,
M. Valverde (Barcelona, E)
122

Posters Nurses Monday, March 29 and
Tuesday, March 30, 2004
18:00 –
19:00
Education and support of nurses
P1003 Nurses are “invaluable players” in pharmacokinetic studies
A.C.M. Smiet, B. Ruiterkamp, L.P.A. Kant (Nijmegen, NL)
P1004 Education facilitation in oncology/BMT/ -taking the role forward
A. Fraser, S. Peters (Bristol, UK)
P1005 The importance of conceptional training for nursing newcomers in BMT units
B. Kindel, J. Oertel (Hannover, D)
P1007 Information and training needs of paediatric patients undergoing BMT
G. Deiana, G. Bisaccia, E. Cervetto, M. Contarini, M. Cotrozzi, F. Esibiti, M. Francesia Berta,
M. Matarese, C. Picasso, A. Raiola, M. Canepa (Genoa, I)
P1008 Recognising the critically ill patient
G. Parkin (Bristol, UK)
P1009 Spiritualy: exploring its potential as a framework for staff support
L.C Reid (Birmingham, UK)
18:00 –
19:00
18:00 –
19:00
Palliative care
P1010 Palliative care in the bone marrow transplant setting: Is it properly utilised?
S. Mc Guckin (Dublin, IRL)
Quality of life
P1012 Tandem approach medical and nursing, does improve quality of life in patients
transplanted with a non-myeloablative regimen who develop acute-graft-versus host
disease
A. Albiani, L. Martinelli (Pisa, I)
P1013 Long-term follow-up of bone marrow transplant, is there a need for a specialist nurse?
F. M. Allen (Dublin, IRL)
P1014 Audit of bone marrow transplant late effects nurse-led clinic
A. Griffiths, A. Bridgman, P. Saul (Birmingham, UK)
P1015 Quality of life of patients going through allogeneic transplantation with reducedintensity
conditioning. Frequent evaluations on 38 patients during the first
three months
U. Frödin, G. Juliusson (Linkoping, S)
123

Monday, March 29 and Posters Nurses
Tuesday, March 30, 2004
18:00 –
19:00
Psychosocial Issues
P1016 Unrelated stem cell transplantation – anxiety related to the unknown donor
C. Pimpão, I. Maestre, T. Moreno, J. Lacerda (Lisbon, P)
P1017 Stem cell collection process as an empowering experience for patients through the
transplantation pathway
O. Daniel, E. Rom (Tel Aviv, IL)
P1018 Is there a need for a support group 5 years post chemotherapy and/or bone marrow
transplant?
M. Murphy, Y. Ibbotson, G. McGlade (Manchester, UK)
P1019 Impact of anxiety and depression on pain experienced during bone marrow biopsy and
aspirate
T. Bin, A. Zubani, P. Capodivento, L. Calabrese, C. Bressan, D. Laszlo, A. Cocquio, F. Peccatori,
G. Martinelli (Milan, I)
P1020 Research into the emotional and psychological aspects of bone marrow transplantation
M. Rowe, A. Bunning (Newcastle upon Tyne, UK)
P1021 Positive intervention to relieve the psychological effects on parents whose children are
experiencing bone marrow transplantation for immune deficiencis
M. Allan (Newcastle upon Tyne, UK)
P1022 Caring for the child and family prior to bone marrow transplant
H. Harvey, E. Walls (Newcastle upon Tyne, UK)
P1023 Is there a difference in health-related quality of life between autologous and allogeneic
stem cell transplanted patients?
I. Andersson, C. Kristiansson, M. Brune, D. Stockelberg (Gothenburg, S)
P1024 Quality of life in patients with aplastic anaemia and hypocellular myelodysplastic
syndrome following treatment with anti-lymphocyte globulin
M. Murphy, D. Macey, J. Nicholson (London, UK)
P1025 How patients remember the experience of autologous transplant
T. Santos, C. Gonzalez, R. Marco, E. Avellan, M.J. Majado, A. Navarrete (Murcia, E)
P1026 Cancer: the impact of diagnosis
C. Pimpão, A. Gomes, A. Ferreira (Lisbon, P)
P1027 Why let the patients tell their story over and over?
J.W.J. Repping, M. Verhoeven, N. Vermeulen, S. Damen (Nijmegen, NL)
P1028 Psycho-social issues when having a transplant
C. Smith, S. Levak (Surrey, UK)
P1029 Trust and honesty, a prerequisite for a good medical outcome
E. Mermans, L. Thys, G. Van Ackerbroeck (Antwerp Edegem, B)
P1030 Peer group for allogeneic stem cell transplantation patients and their families:
a single-centre analysis in Helsinki 2003
H. Ikäheimo, P. Peltonen, T. Seppänen-Savela, M. Ekholm (Hus, FIN)
P1031 Turning point in couple relationship following the ordeal of allo-BMT is an unexpected
frontier for patients during the general coping process
E. Rom, H. Schimmel (Tel Aviv, IL)
124

Posters Nurses Monday, March 29 and
Tuesday, March 30, 2004
18:00 –
19:00
Standards of care
P1032 A mouth care protocol for patients undergoing bone marrow transplantation.
Our experience on implementation
M. Pallejà, C. Serrano, M. Florit, R. Azor, A. Lobo, S. Llorens (Barcelona, E)
P1033 Central venous catheter care starts with insertion - the benefits of a nurse-led line
insertion team
A. Green (Cambridge, UK)
P1034 Nursing care for paediatric patients treated with IL-2 post-BMT
M. Suero, G. Tamborero, G. Martinez, A. Clemente, I. Badell, N. Pardo, J. Cubells (Barcelona, E)
P1035 Combination therapy for post haematopoietic peripheral blood stem cell transplant
cerebral and pulmonary aspergillosis using voriconazole and terbinafine: a case report
J. Shergold, M. Whyte, M. Nissen, D. Siebert, T. Hassall, K.A Robertson, L. Lockwood
(Brisbane, AUS)
P1036 Percutaneous endoscopic gastrostomy in children undergoing SCT
G. Hansson, A. Fasth, G. Göthberg, C. Fondin, A-L. Gustafsson (Gothenburg, S)
P1037 Epstein-Barr virus – a case study
J. Douglas (Manchester, UK)
P1038 The need for an evidence based approach in preventing chemical dermatitis in infants
undergoing BMT
G. Pritchard (Manchester, UK)
P1039 Review of enteral support in children undergoing stem cell transplantation for
non-malignant disease
C. Elwig, M. Conboy-Twomey, M. McCloy (London, UK)
P1040 PBSC collection using existing Hickman line – a single paediatric centre experience
N. Comey, A. O`Meara, A. O`Marcaigh, F. Clinton (Dublin, IRL)
P1041 Re-establishing CVC patency with rtpa in paediatric patients
E. Mourão, Z. Felix (Lisbon, P)
P1042 Bone marrow transplant of unrelated donor in T-acute lymphoblastic leukaemia:
a paediatric case
A. Ferreira, C. Pimpão, C. Gomes (Lisbon, P)
P1043 VP-16 is an efficient peripheral blood stem cell mobilisation regimen
M. Azizan, K. Fazillah, S.Q. Chui, S. Tan, T.C. Ong, S. Jameela, A. Yong, K.M. Chang,
V. Purushotaman (Kuala Lumpur, MY)
P1044 Large-volume leukapheresis for stem cell collection in donors for allogeneic
transplantation using a femoral catheter is a highly efficient and safe procedure
B. Odijk, M. Ek, E. Bertelsmann, M. Koopman, J. van der Lelie (Amsterdam, NL)
P1045 Two cases of autologous peripheral blood haematopoietic stem cell transplantation
patients with severe and refractory multiple sclerosis in Bulgaria
G. Mihaylov, B. Avramova, L. Gartcheva, M. Jordanova, D. Bobev, L. Popov, P. Chotekov (Sofia, BG)
P1046 Autologous stem cell transplantation with alemtuzumab as part of the conditioning for
B-cell prolymphocytic leukaemia
M. Eibl, H. Auner, W. Zinke-Cerwenka, H. Sill, W. Linkesch (Graz, A)
P1047 Nursing care protocol: patients' needs registered by nurses in the autologous transplant
M. Prieto, A. Lobo, F. Vizcaino (Barcelona, E)
P1048 Nutritional status of patients undergoing allogeneic stem cell transplantation, from
pre-transplant to one year post-transplant
F. Gossmann, H. Petersen, H. Borup, H. Laursen (Copenhagen, DK)
P1049 Efficacy of vitamin E during acute mucositis in bone marrow transplantation
P. Agüeros, M. Bárcena, M. Del Campo, P. Lucero, A. Bermúdez, L. Yañez (Santander, E)
125

Monday, March 29 and Posters Nurses
Tuesday, March 30, 2004
Standards of care (continued)
18:00 –
19:00
P1050 Pain: is it a subjective sign for the quality of peripheral blood stem cell collection in
unrelated donors?
A. Peles Bortz, J. Limor, A. Grunspan, Y. Sverdlov, Y. Kodman, J. Stein, I. Yaniv (Petah-Tikva, IL)
P1051 Prevention and treatment of conventional respiratory virus (CRV) infections in adult
recipients of haematopoietic stem cell Transplantation
I. Magallanes, P. Net, T. Romero, M. Sanosa, R. Martino (Barcelona, E)
P1052 The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) –
a challenge for nursing staff
A. Schwarzl, B. Birkenau (Vienna, A)
P1053 Cryotherapy during chemotherapy. Could it delay or alleviate the development of mucositis?
Ac Svanberg, K Öhrn (Uppsala, S)
P1054 Hypoxaemic acute respiratory failure in haematological patients: feasibility and efficacy
of non-invasive ventilation
P. Monni (Milan, I)
P1055 Meeting the challenges of communication: the pivotal role of the specialised paediatric
nursing team for families of different ethnic backgrounds whose child is undergoing
stem cell transplantation
C.C. Hofstra, C.C. Klein, F. van Iperen, A.G.M. Neuman, W. Broekhof, R.M. Egeler, L.M. Ball
(Leiden, NL)
P1056 Prevention of haemorrhage in patients undergoing stem cell transplantation:
information protocol
M.A. Turró-Castillejo, A. Marín-Martínez, J. Martínez-Sisquella, C. Omedes-Fumadó,
M.A. Corredor-Lobato, J.L. López-Mayor (Barcelona, E)
P1057 Patients' knowledge about nutrition during illness
S.S. Laursen, M. Schmidt, P. Trust, L. Vittinghus (Copenhagen, DK)
P1058 Educating a patient in self-application of subcutaneous injections
I.K. Skoda (Ljubljana, SI)
P1059 Beating the bug!
L. Sturgess-Durden (Bristol, UK)
P1060 Importance of the position of the patient during catheter removal
D. Quiroga, N. Vieites, F. Vidal, V. Docampo (La Coruña, E)
P1061 Nurse care, responsibility and reporting of PBPC collections
B. Szymczak (Wroclaw, PL)
P1062 The best of all mouthwashes: water
C. Potting, W. Scholte op Reimer, T. van Achterberg (Nijmegen, Rotterdam, NL)
P1063 Review of the use of Filgrastim post autologous stem cell transplant
C. Burnett, G. Gagne, B. Morin, L. O´Hagan, Y. Rousseau (Montreal, CAN)
P1064 Caring for Afro-Caribbean and Asian patients undergoing bone marrow transplantation
M. Brown (London, UK)
P1065 Risks and benefit of double-prolonged interval of central venous catheter dressing changes
in patients treated by intensive chemotherapy – proposal of a new randomised nurses' trial
E. Bystricka, I. Chvojkova, J. Suvova, N. Mullerova, S. Vokurka, V. Koza, J. Scudlova, D. Mjartanova,
J. Vitkova (Pilsen, Olomouc, CZ)
P1066 Nursing clinical pathways in autologous bone marrow transplant
M. Pallejà, C. Sánchez, A. Durán, M. Galiano, M. Mansilla, M. Baños, T. Peralta
(Hospitalet- Barcelona, E)
P1067 Guide for intravenous applications at in a haemato-oncological ward –
development of new guidelines
D. Zappová, J. Maaloufová, D. Pohlreich, P. Cetkovsk_ (Prague, CZ)
126

Posters Nurses Monday, March 29 and
Tuesday, March 30, 2004
Standards of care (continued)
18:00 –
19:00
P1068 How do you ensure clear and standardised information to the autologous bone marrow
transplant patient and their family?
I. Bonne (Aarhus, DK)
P1069 Irradiated blood products – communication is the weakest link
J. Nicholls (Bristol, UK)
P1070 Skin care for paediatric patients undergoing busulfan-conditioning:
comparsion of two different topical treatments
S. Eichner, B. Birkenau, W. Kail, S. Matthes, C. Peters (Vienna, A)
P1071 How the findings of a retrospective audit on the UKCCSG anti-fungal strategy will affect
current practice for BMT staff and patients
S. Peters, R. Nolan, J. McDerra, J. Cornish (Bristol, UK)
P1072 Accompaniment of the adolescent, a challenge?
M. Verbeek, Y. Blokland, D. Klootwijk (Rotterdam, NL)
P1073 Nutritional monitoring of patients after allogeneic bone marrow transplantation
M. Patorkova, A. Molcanova, K. Formankova, P. Benes, P. Cetkovsky (Prague, CZ)
P1074 Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral
mucositis in patients with haematologic malignancies receiving high-dose chemotherapy
and stem cell support
N. Bae, S. Sohn, D. Kim, J. Kim (Daegu, KOR)
P1075 Why does the patient undergoing stem cell transplantation need nutrition support?
S. Westin, S. Edlund (Stockholm, S)
P1076 Mucositis and pain management in at-home autologous stem cell transplantation
S. Segura, C. Gallego, A. Hernando, L. García, L. Nevado, J. Güell, M. Valverde,
F. Fernández-Avilés, E. Carreras, E. Montserrat (Barcelona, E)
P1077 BK polyomavirus and haemorrhagic cystitis after allogeneic bone marrow transplant;
increasing pressures on transplant nurses
C. Guest, P Hetherington, E. Ion, A Pettitt, R. Clark (Liverpool, UK)
P1078 Respiratory syncytial virus – The Liverpool experience
E. Ion, P. Hetherington, C. Guest, R. Clark, A. Pettitt (Liverpool, UK)
P1079 The use of pain relief prior to a bone marrow aspirate
D. Johanson, M. Plucinski (London, UK)
P1080 Nurses' care of patients with skin-graft-versus-host disease
M. Hebras, M. Bordy, Y. Idir, K. Tabani, S. Simonelli, H. Esperou, G. Socie, C. Ferry, E. Gluckman
(Paris, F)
P1081 Investigation of platelet requirement during haemopoietic stem cell transplantation
H.S. Cho, B.E. Song, Y.H. Ki, S.H. Kim, Y.H. Na, H.J. Kang, S.S. Han, J.Y. Ban, J.H. Yun, E.Y. Hong
(Seoul, KOR)
P1082 Pilot study on self-administration of medicines scheme and its effects on patients and
nursing staff
A. Tan (Bristol, UK)
P1083 Bone marrow transplantation and intensive care: patient centred
V. Lewis (Cambridge, UK)
P1084 An audit to evaluate the effectiveness of chemotherapy advice sheets
T. Arthur (Bristol, UK)
P1085 Implementing a new standard of care
L.D. Cornelissen, M.A. Kok (Amsterdam, NL)
P1086 Bone marrow transplant nursing: does networking work?
A. Booth (Potts Point, AUS)
127

Fast Intermediate and High Resolution
Tissue Typing Services
Tailored services to fit your needs
Histogenetics provides a suite of tissue-typing services
with the highest level of quality assurance and
accelerated turnaround time for results.
Fast Typing Services
HLA-A, -B, -C intermediate and allele level typing
for exons 2 and 3.
HLA-DRB1, -DRB3, -DRB4, -DRB5 and DBQ1
intermediate and allele level typing for exon 2.
Typing Services for Other Loci
Allele level DQA1 typing for exon 2.
Allele level DPA1 and DPB1 typing for exon 2.
Registry Typing
High volume, intermediate level HLA-A, -B, -C,
-DRB1, -DRB3, -DRB4, -DRB5, -DQB1 typing.
Consulting Services
Donor selection services, etc…
High quality and fast turnaround
Through a proprietary process developed by Soo Young Yang,
Ph.D. and Nezih Cereb, M.D., Histogenetics provides high and low
throughput molecular tissue typing services at competitive costs.
We are currently serving both regional and national transplant
centers and national and international donor registries and centers,
most notably The National Marrow Donor Program and DKMS.
CONTACT US:
Histogenetics, Inc.
Tel. 914-762-0300
info@histogenetics.com
www.histogenetics.com

Instructions for Authors
Speakers Centre / Audiovisual Equipment
The Speakers' Service Centre is located in the Palau de Congressos de Catalunya on level -1 and will
be available for speakers making an oral presentation.
All lecture rooms will be equipped with a computer and a data projector (beamer) for PowerPoint
presentations. PowerPoint presentations must be handed in via floppy disc, CD-ROM, USB compatible
memory stick, or via the own laptop at the Speakers' Service Centre at least one hour before the
beginning of the session. Speakers will have the opportunity to check their presentations on PCs
available in the Speakers Service Centre.
Poster Sessions Physicians
Date Poster No Poster Sessions Poster Mounting Poster Removal
Monday, March 29, 2004 P407–P668 18.00 h–19.00 h 08.00 h–09.00 h 19.00 h–19.30 h
Tuesday, March 30, 2004 P669–P927 18.00 h–19.00 h 08.00 h–09.00 h 19.00 h–19.30 h
Authors are kindly asked to be present from 18.00–19.00 h
during the respective Poster Sessions.
It is extremely important that authors mount and remove their posters at the above mentioned
times to enable the poster boards to be used for the following session.
Poster Measurements for Physicians are horizontal (landscape)!
Size of posters: Width: 180 cm (70.86"), Height: 90 cm (35.43")
Poster Sessions Nurses Group
The posters of the Nurses Group (P991 – P1086) will be on display during the whole EBMT 2004
congress, Monday – Wednesday. (Contrary to the posters of the physicians there will be no change of
posters for the Nurses Group).
Authors of the Nurses Group will have the opportunity to discuss their poster with the participants
during the following poster session times:
Date Poster No Poster Sessions Poster Mounting Poster Removal
Monday, March 29, 2004 P991–P1086 18.00 h–19.00 h Monday, Wednesday,
March 29, 2004 March 31, 2004
Tuesday, March 30, 2004 P991–P1086 18.00 h–19.00 h 08.00 h–09.00 h 11.00 h–13.00 h
Authors are kindly asked to be present from 18.00 – 19.00 h
during the respective Poster Sessions.
Poster Measurements for Nurses are vertical (high format)!
Size of posters: Width: 90 cm (35.43"), Height: 130 cm (51.18")
Publication of Abstracts
All accepted abstracts will be published in the Supplement of the Bone Marrow Transplantation Journal
as well as on a CD-ROM. Both items will be available during the congress and are included in the
registration fee.
As of March 28, 2004, accepted abstracts can also be viewed on the congress homepage:
http://www.akm.ch/ebmt2004.
129

List of Chairs
Name Page Name Page Name Page
Aerts, E. 116
Alegre, A. 31
Apperley, J. 22, 25, 29, 42,
43, 55, 58, 118
Bacigalupo, A. 23
Badell, I. 62
Björkstrand, B. 31
Borras, N. 120
Bow, E.J. 17
Brand, R. 113
Brown, M. 119
Brunet, S. 47
Bueren, J. 35
Buxton-King, A. 114, 115
Bystricka, E. 121
Caballero, D. 49
Carreras, E. 29, 58
Cavazzana-Calvo, M. 35, 57,
60
Conde, E. 49
Cordonnier, C. 17, 44
Cornelissen, J.J. 47
Cornish, J. 62
Corradini, P. 38
Dazzi, F. 67
de la Rubia, J. 64
de Witte, T. 46
Demirer, T. 28, 60
Diez, J.L. 64
Dini, G. 39, 52
Ehninger, G. 18
Einsele, H. 23, 36, 56
Espigado, I. 37
Fassas, A. 27
Fernández, M.N. 46, 63
Fibbe, W. 29, 33
Figuera, A. 34
Frassoni, F. 26
Friedrich, W. 57
Gahrton, G. 55
García-Conde, J. 48
130
Gisselbrecht, C. 23, 45, 48
Gluckmann, E. 21
Gorin, C. 29, 43
Grañena, A. 61
Gratwohl, A. 20, 60, 66
Gris, E. 117
Harvey, H. 116
Holler, E. 58
Iriondo, A. 53
Jansen, M. 115
Kansu, E. 68
Labopin, M. 26
Laborda, C. 114
Larsen, J. 115
Lion, T. 24
Ljungman, P. 42
Lotz, J.P. 28
Madrigal, A. 41, 56
Marin, P. 37
Marsh, J. 37
Martelli, M. 46
Martino, R. 15, 50
Maschmeyer, G. 15
Masszi, T. 65
Mc Donald, F. 58
Michallet, M. 61
Montserrat, E. 41
Moraleda, J.M. 42
Morris, P. 115
Ni Chonghaile, M. 117, 118
Niederwieser, D. 38
Niethammer, D. 29, 39
Nomdedeu, J. 68
Odriozola, J. 54
Olavarria, E. 53
Ortega, J.J. 52
Passweg, J. 40
Perez Calvo, J. 49
Perez Simon, J.A. 51
Pino Molina, C. 116
Power, O. 121
Pròsper, F. 33, 41
Quinn, B. 115, 116, 121
Reusser, P. 18, 44
Ribera, J.M. 24
Ringden, O. 58
Rosti, G. 46, 49
Rovira, M. 36
Ruiz de Elvira, C. 110, 111,
112
Ruutu, T. 63
Ryan, P. 120
Saccardi, R. 37
Sanz, M.A. 29, 50
Schlosser, I. 118
Schmitz, N. 19, 30, 45
Schouten, H. 58, 65
Schrezenmeier, H. 40, 59
Sierra, J. 18, 22, 25, 59
Skoda, I. 120
Slavin, S. 32, 46
Socié, G. 46, 59
Stephens, M. 43, 114, 115,
118, 121
Sureda, A. 30
Tomas Martinez, J.F. 21, 32
Tichelli, A. 46, 54
Torres, A. 34
Tyndall, A. 24, 27
Urbano-Ispizua, A. 15, 43, 58,
66
van Walraven, A.M. 115, 119
Von Boxtel, T. 114, 115, 120
Wardley, C. 119
Willemze, R. 51
Zander, A. 67

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Abbruzzese, L. P770
Abdelkefi, A. O385, P521
Abdulkadirov, K. P883
Abdulkadyrov, K. P596
Abecasis, M. P592, P834
Abedi, M. P561
Abhyankar, S. P728
Abinun, M. O161, 327, 328,
P537, P600
Abrahams, L. P457
Abrahamsson, J. P813
Ackermann, A. P848
Ackerstein, A. P467, P539, P686
Adam, O. P504
Adam, Z. P636
Adams, S. P474
Addari, M.C. O363
Aerts, E. N971
Afanasiev, B.V. O401
Afanasyev, B.V. P683, P721, P907
Aglietta, M. 94, 95, O115,
P417, P428
Agrawal, S. P569
Aguado, B. P568
Agüeros, P. P1049
Ahmad, E. P526
Ahmad, I. P460
Ahn, H.S. P836, P843
Aitoro, G. O115
Aivado, M. 69
Akan, H. P494, P571, P621,
P655, P771, P904
Akar, E. P807
Akar, N. P807
Aker, M. P591
Akgul, A. N979
Akgul, N. N979
Akhtar, S. O259
Aktas, B. P689
Al Jijakli, A. O368
Al Saati, T. P891
Aláez, C. P568
Alaiz, H. P592
Al-Ali, H. O404, P511, P615,
P711, P889
Albani, S. O151
Alberca, M. P419, P557
Albiani, A. P1012
Albrecht, C. O141
Alcoceba, M. O131
Aldaoud, A. P889
Aldous, K. O390, P491
Alegre, A. O117, O298, O380,
P513, P568
Alesiani, F. P659
Alessandrino, E. O251, P752,
P756, P800
Alexander, T. O160, P597, P602,
P676
Alfieri, C. O370
Alimogaddam, K. P440, P441
Alimoghaddam, K. P625
Allan, M. P1021
Allen, F.M. P1013
Allione, B. O108, O115
Almarza, E. 66
Almeida, J. O131, P557
Almici, C. P550
Alonso, B. P534
Alonso-Nieto, M. P693
Altclas, J. P789
Alter, B. O164
Alterini, R. P896
Alvarez, I. O125, O283
Alvarez, M. O396
Alvarez-Barrientos, A. O128
Amado, F. P531
Amado, M.L. P854
Amadori, S. 69, 338, P554, P754
Amar, A. P539
Amata, C. P619
Ambrosio, A. P834
Amill, B. O379
Amrolia, P. O150, O290, O291,
P704
Amurri, B. O109, P468, P727
Anagnostopoulos, A. P O388, P518,
P585, P586, P798, 872, P905
Anak, S. P720, P809, P818
Anasetti, C. 196
Anderlini, P. 311
Andersen, J.F. P414
Andersen, P. P517
Andersson, I. P1023
Andreas, C. P848
Andreazzoli, F. P503
Andreesen, R. 52, P856, P895
Andreeva, L. P464, P574
André-Schmutz, I. O142
Angelopoulou, M.K. O257
Angelucci, E. S48, 183, P791
Anghel, G. P623, P667
Angioni, A. P851
Angonin, R. P488
Annels, N. P739
Anninga, J.K. N953
Annunziata, M. P857
Ansari, B P440, P441
Anttila, V. P746, P749
Aouf, S. P521
Aoun, M. P772
Apperley, J. S98, O112, O113,
O114, 176, 209, O302, P410,
P542, P699, P728, P781, 936
Appert, M. 67
Aramendia, J.M. O267
Aranha, F.J.P. O353, P913
Arat, M. 241, P494, P496, P549,
P571, P621, P655, P689,
P709, P730, P748, P771, P904
Arbona, C. O380, P545
Arcese, W. O361, O370, P851
Ardizzone, F. P756
Argiolu, F. O363
Aricò, M. O361
Armstrong, V. P715
Arnaud, P. P504
Arnéodo, V. P456
Arnold, R. 96, O160, P597, P602,
P670, P676, P873, P920
Arpinati, M. P678, P803, 938
Arranz, R. O107, O125
Arrieta, R. P552
Arrigo, C. P619
Arseniev, L. 68
Arslan, O. P494, P496, P549,
P571, P655, P904
Arthur, T. P1084
Arvidson, J. 219
Asahara, T. 204
Aschan, J.O155, O276, P480,P916
Assanelli, A. P738, P897
Assirelli, E. O398
Astigarraga, C. O387
Athanasiadou, A. P872
Athanasiou, E. P585, P586
Atsuta, Y. O277
Atta, J. P866
Attal, M. O110, O121, O296,
P633, P891
Au, W.Y. P799
Aul, C. 69, P641
Auner, H. P1046
Avanzini, M.A. P736
Avellan, E. P1025
Aventín, A. P620
Aversa, F. S42, O375
Aversa, S.M.L. P662, P668
Avery, S. O114, O302, P410, P542
Avigdor, A. O122, P635, P863
Ávila, A. P412, P415
Avinens, O. P444
Avivi, I. O386, P700
Avoledo, P. P845
Avramova, B. P1045
Aydin, F. P818
Ayli, M. P904
Aymerich, M. O298
Ayuk, F. O117, O118, O352,
P637, P731, P917, P921
Ayuketang, F. P735
Ayyildiz, E. P549
Azar, N. O368, O391
Azevedo, A.M. O353
Azevedo, W. O353, P601
Azik, F. P806, P807
Azizan, M. P1043
Azor, R. P1032
Azoulay, E. 212
Azqueta, C. O379
Azzara, A. P477, P514
Baas, I. P870
Babikir, R. P734
Baccarani, M. P678, P707, P803,
938
Bachl, C. P792
Bacigalupo, A. S18, 58, O119,
O162, 189, 190, O251, O260,
O281, 336, O402, P506, P515,
P522, P603, P616, P737,
P741, P776
Bacovsky, J. P636, P646
Badell, I.O165, P793, P828, P1034
Bader, P. 184, O274, O360, P453,
P681, P811, P820
Badiali, M. O363
Badian, E. P700
Bae, N. P1074
Bagattini, S. P706
Bahar, B. P489, P625, P844
131

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Baidildina, D.D. O163
Bakanay, S. P549
Balas, A. O148
Balashov, D. P594
Baldacci, E. P869, P881
Baldanti, F. P752
Baldissera, R.C. P913
Baldomero, H. O374
Balduzzi, A. P753, P814
Balint, B. P556, P563
Ball, L.M. P626, P751, P783,
P838, N950, N953,
N955, P1055
Ball, S. P695, P823, P829, P847
Ballanti, S. P802
Ballatore, G. P554
Balon, J. P732
Balsa, C. P448
Balsalobre, P. O253, P578, P926,
N985
Bambi, F. P461
Ban, J.Y. P1081
Banasiak, W. P587
Bandini, G. O119, P502, P611,
P803, 938
Banna, G.L. P662, P668
Baños, M. P1066
Banyai, A. P567
Bar, I. O132
Barber, S. O291
Barberi, W. O370
Barbosa, I.L. P412, P415
Bárcena, M. P1049
Bardou, V. P444, P706
Bares, R. P656
Bargay, J. 71, P922
Barge, D. P537
Barge, R. O246, P870, P486, P765
Barkholt, L. 97, O155, O261,
P505, P665, P769
Barness-Hadar, L. P805
Baron, F. P490, P500
Baronciani, D. P791
Baroni, M.C. P651
Barquinero, J. P430, P438
Barros, J.-C. P601
Barta, A. P567
Bartolin, M. T. P770
Basara, N. 73, O381, P715
Bashtar, M. P440
Bashtarr, M. P441
Basset, T. P777
Bassompierre, F. P743
Bassous, L. P622
Bátai, A. P630, P764
Batlle, M. O298, P451, P789a
Batsis, I. P518, P585, P586
Battelli, F. O297
Baudoux, E. P490
Baumann, M. 321
Baumgart, J. P579
Baurmann, H. O299, O357, O381,
O382
Bauters, F. O383, O400
Bautista, G. P650
Bavaro, P. O115
Bay, J. P639, P862
132
Beaujean, F. O389, O391, O392,
P532
Beaumont, J. O389, O391, O392,
P532
Beaune, J. O389
Beck, J.F. O360
Beck, O. 316, P832
Beck, R. O274
Beeldens, F. 69
Beelen, D.W. O134, O144, O250,
O303, O350, O376, P675,
P677, P685, P726, P859
Beguin, Y. P490, P500, P742
Behrens, F. P606
Behringer, D. P792
Beilken, A. P825
Bejaoui, M. P521
Békássy, A. 219, 220
Beksac, M. P494, P549, P571,
P621, P655, P689, P709,
P730, P771
Belhabri, A. 69
Bellotti, L. P553
Beltrami, G. P634, P725
Ben Abdeladhim, A. O385
Ben Achour, O. O385
Ben Arush, M. P629
Ben Barak, A. P629
Ben Bassat, I. P635
Ben Mami, N. O351
Ben Othman, T. O385
Ben Romdhane, N. O385
Benabdeladhim, A. P521
Benabdennabi, Y. P521
Benavente, C. O165
Ben-Bassat, I. P863
Benboubker, L. O110
Benbunan, M. O391
Bendtzen, K. P414
Benedetti, E. P503, P514, P912
Benedetti, F. P623, P801
Benéitez, D. P882
Benes, P. P1073
Benesch, M. P849
Benesova, K. P924
Benevides, P.A. P412, P415
Benhamou, E. P819
Benlloch, L. O380
Bennet-Rees, N. O150
Benoit, Y. P631
Benothman, T. P521
Beo, J. P418
Berand, A. P895
Berasategui, P. P926, N985
Bercos, M. P596
Berdel, W. O103, P641
Berenguer, J. O253
Bergamaschi, P. O371, P553
Berger, M. P439, P443
Bergeron, C. O365
Bergmann, L. O245, P866
Berkowicz, A. P517
Berkowicz, M. P635, P863
Berlanga, J. 71, P882
Bermúdez, A. P1049
Bernal, M. O107
Bernal, T. O125
Bernardi, M. O264, O377, P502,
P664, P745, P785
Bernasconi, P. P756, P800
Bernhardt, E. P792
Bernhart, M. P918
Bernini, G. P461
Berrebi, A. P622
Berretta, M. P770
Bertazzoni, P. P800
Bertelsmann, E. P1044
Berthelsen, A. N961
Berthier, J.-C. P777
Berthon, C. O383
Berthou, C. O110
Berti, C. N957
Bertrand, Y. P777, P812
Bertz, H. O133, P481, P576, P599,
P734, P792, P860, P914
Bes, M.A. P783
Besalduch, J. O120, P922
Besson, C. O153
Bethge, W. O262, P453
Beutler, D. P845
Beyer, J. O117, O118
Bhattacharya, A. 327, 328, P537
Bianchi, L. P428
Biedermann, B. 332
Biener, D. O308
Bieniaszewska, M. P732
Bierings, M. O151
Biersack, H. O250, P726
Biesma, D.H. P775
Bigalke, I. P484
Bilgen, H. P720, P809, P818, N979
Bilger, K. O121, O273, P444, P639,
P706, P862
Bilgin, M.Y. P626
Biller, A. O372
Bin, T. P1019
Bini-Antunes, M. P531
Biondi, A. P753
Birkenau, B. P1052, P1070
Biron, P. 93
Bisaccia, G. P1007
Bisaga, G. P797
Bistrian, R. O127, P425
Bitan, M. P539, P591, P686
Bittar, C. O387
Bittard, H. P673
Bittencourt, H. O279, O387
Bittencourt, R. O387
Björklund, A. O276
Bjorkstrand, B. 171, O112, O113,
201, P642, 935
Bladé, J. P875
Bladon, J. P409
Blaise, D. S16, S35, 90, O121,
O273, O351, P444, P456,
P639, P706, P862
Blanche, S. P824
Blandino, F. P667
Blasczyk, R. P757
Blau, I. P715, P911
Blau, W. P424, P480
Blázquez, C. P568
Bleyzac, N. P812
Blijlevens, N. S101, O270, N965

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Blokland, Y. P1072
Blomkvist, M. P769
Blume, K. P511
Boast, A. P535
Boavida, G. P592
Bobev, D. P1045
Boccaccio, C. O391, O392, P504,
P532
Boccadoro, M. O115, O252
Bochennek, K. P848
Bock, T. O274, O286
Boeckh, M. S11, 219
Boehme, V. O105
Boehnke, W. P606
Boehrer, S. P866
Boekhout, T. P783
Bogatcheva, N.Y. O163
Bogdanovic, G. P762
Bogunia-Kubik, K. O394, P691
Boiron, J. O121, O124, P639, P862
Bolwell, B.J. P728
Bommer, M. P780
Bonalumi, S. N967
Bonetti, F. O398
Bonfim, C.S. 184
Bonhomme, D. O142
Bonifazi, F. P697, P803, 938
Bonne, I. P1068
Bonolis, M. P779, P795
Bons, V. P999
Bonstein, L. P700
Boogaerts, M. O123, P920
Booth, A. N987, P1086
Booth, T. P714
Boqué, C. 176, O354, O356
Bordigoni, P. O121, P774
Bordon, V. P631
Bordy, M. P1080
Bork, S. P536
Bornhäuser, M. O135, O248, O272,
P408, P445, P472, P572,
P614, P715, P903
Borras, N. N964
Boruczkowski, D.P833, P840, P865
Borup, H. P1048
Bos, G. O282
Bosari, S. P583
Bosch, A. P854
Bosch, F. P471, P875
Bosi, A. 222, P428, P429, P492,
P582, P779, P795, P896
Bouabdallah, R. P456
Bouchand, F. P901
Bouliong, E. O293
Bourcy, V. O391, O392, P532
Bourhis, J. O111, P504
Bourin, P. O296
Bours, V. P490
Boutemy, H. O392, P532
Bow, E.J. S20, S22
Boyarshinov, V. P464, P574
Braakman, E. O275
Bradstock, K. P482
Bradwell, A.R. O116, P632, P649
Brand, A. P432
Brand, R. O117, 175, 181, O246,
P642, P920, 941, 942
Brandt, B. O136
Brasca, P. P529, P658
Breccia, M. P869
Bredeson, C. S15, P611
Bredius, R. O161, P626, P739,
P751, P838
Breese, G.J. 327
Bregante, S. O402, P603, P616,
P737, P741, P776
Bregni, M. 97, O119, O251, O252,
O264, O377, P502, P506,
P664, P745, P752, P785
Breidenbach, C. 68
Brenmoehl, J. 52
Bressan, C. P1019
Bretagne, S. 218
Brice, P. O254, P794, P901
Bridenbaugh, S. O293
Bridgman, A. P1014
Brière, J. P794, P901
Brinch, L. 220
Brinkman, D. O161
Briones, J. O283, P620, P701
Brioschi, S. P789
Britten, C.M. P750
Broekhof, W. N950, P1055
Broers, A.E.C. O275
Broliden, P.-A. O276
Bron, D. O123, P460
Brons, P. P839
Brooimans, R.A. 317
Brown, C.J. P570
Brown, M. P1064
Brugiatelli, M. O106, P747
Brune, M. P1023
Brunes, M. 97
Brunet, S. 71, O249, O283, P620,
P693, P922
Bruno, B. O115, P515
Bruno, S. P428
Bruns, I. P536
Brusamolino, E. O106
Brychtova, Y. P509, P718
Bucher, C. P804
Buchholz, S. P520
Buchler, T. P636
Buchmann, I. O245, O304
Büchner, T. O247, 339
Buchta, C. P487
Buchtova, I. P509
Buck, A. O245
Buckstein, R. S29
Bueno, J. 71, O249, P559
Bueren, J. 66, O128, O129, O146,
O148, O165, 344, P421, P590
Bufano, P. P582
Bug, G. P703, P866
Bulabois, C. P633
Bulakbasi, T. P496, P571
Bunjes, D. 79, O244, O245, O304,
O369, O406, P485, P780, P873
Bunning, A. P1020
Buño, I. O253, P513, P578, P926,
N985
Buquicchio, C. O373
Burchielli, E. 70, 319
Burdach, S. P698, P723, P724
Bureo, E. P828
Burlakova, I. O382
Burmester, G.R. O160, P670
Burmester, R. P597, P602
Burnett, C. P1063
Burns, A. P719
Burt, R.K. S5
Burton, C. P781
Busca, A. O115, P492, P502, P515
Busca, G. P583
Buser, A. P804
Busson, M. 67, 318
Butters, G. N981
Buyukberber, S. P904
Buza-Vidas, N. P458
Byington, R. O353
Byrne, J. O263
Bystricka, E. P564, P996, P997,
P1065
Caballero, D. O125, O255, P498,
P508, P886
Caballero, M.D.O107, O120, O131,
O305, P419, P534, P547,
P694, P716, P892
Cabrera, J.R. P650
Cabrera, R. 320, O354, P613
Cacchione, R. P540
Cahn, J.Y. O121
Cai, Z. P710
Caillat-Zucman, S. P824
Caione, L. P417
Cairoli, R. P529, P658
Calabrese, L. P1019
Caldas, G. P834
Caldera, D. P756, P800
Cale, C. O150
Caliskan, Y. P527
Calistri, E. P463, P573
Callea, V. P747
Callen, E. O165, P590
Calmels, B. P456
Calore, E. O152
Calugi, A. P554
Calvillo, M. O162
Calvo, M.-V. P534
Cámara, C. P568
Camilli, A.R. P554
Cammarota, S. P653
Camós, M. P875
Campestri, R. P540
Campilho, F. P412, P415, P531
Campo, E. P471
Campos, A. P412, P415, P531
Can, E. P809
Canales, M. O125, P552
Candela, M. P659
Candoni, A. P463, P879
Canepa, M. P1007
Caniglia, M. O361, O370, P851
Cañizo, C. O354, O356, P534,
P613
Cañizo, M. O305, P435, P508,
P547, P716, P892
Cannata, J. P568
Cannella, L. P692
Cant, A.J. 327, 328, P537
133

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Cantalapiedra, A. P584
Cantalejo, A. O165
Cantero, S. O295, O366, P768
Cao, Y.B. P708
Capanna, R. P582
Capanni, M. O375
Capasso, M. O162
Capelli, D. P893
Capobianchi, A. P754
Capobianchi, M.R. P755
Capodivento, P. P1019
Caporale, R. P429, P582
Capote, M. O396, P858
Capria, S. P869, P881
Caracciolo, D. O252
Caracciolo, F. P503, P514, P912
Caravita, T. P554
Carbone, S. O371
Carbonell-Uberos, F. P411, P555
Cardoso, L.G.O. P773
Carella, A. 176, P634, P725
Carella, M. P725
Carey, S. N976
Carin, M. P720, P818
Carlo-Stella, C. P738, P897
Carluccio, P. O373
Carmagnat, M. 67
Carminati, O. 97
Carneiro, A. P551
Carnevale-Schianca, F. O115
Carosi, G. O108
Carr, T. O291, P842
Carrai, V. P896
Carrasco, S. P926, N985
Carreras, E. S39, O249, O298,
O354, P613, P693, P875,
P1000, P1076
Carreras, G. P793
Carrillo, S. N959
Carrion, R. O253, P 578, P926
Carr-Smith, H.D. P649
Carter, V. P570
Cartwright, V. P808
Carulli, G. P477, P514
Carvalhais, A. P412, P531
Carvalhais, C. P415
Carvalho, M.C.S. P773
Casado, J.A. O129, O165, P590
Casaño, J. O396, P858, P864
Casanovas, O. O254
Casari, S. O108
Casarrubea, G. P668
Casassus, P. O110
Casati, M. N967
Casellato, L. N957
Casini, M.O115, O252, P506, P801
Casper, J. P480, P921
Castel, V. P853
Castellano, A. P816
Castellini, C. P841
Castiglioni, G. P912
Castilla, C. P435, P534, P716
Castro, N. P601
Cattaneo, C. O108
Cavallaro, A.M. P712
Cavanagh, G. P570
Cavatorta, E. P814
134
Cavazzana-Calvo, M. O142, O145,
345, P824
Cavenagh, J. P569
Cayir, N. N979
Cazeneuve, A. P891
Cecchi, S. P506
Cecconi, N. P477
Cela, E. O165
Cellini, M. P593
Centra, M. P725
Centurioni, R. P659
Cerchio, R. P593, P788
Cermelli, C. P852
Cerna, K. P562, P564, P612, P996
Cerno, M. P492, P573, P707,
P729, P879, P899
Cerretti, R. O306, O370
Cerutti, P. O300
Cervantes, F. P875
Cervera, J. O165, O295
Cervetti, G. P477, P912
Cervetto, E. P1007
Cesaro, S. O152, 222, 225, O361
Cetkovsk_, P. P618, P1067, P1073
Cevreska, L. P413
Ceydilek, B. P748
Chabannon, C. P456, P706
Chachaty, E. P504
Chagas, M. P834
Chakraverty, R. O118
Chalandon, Y. O272, P447
Challine, D. O153
Chalmers, D. P420, P442
Chalopin, J.M. P673
Champion, K. 176, 930
Chan, G.C.F. P608
Chandra, D. O288, P810
Chang, K.M. P1043
Chanova, M. O364, P663
Chapman, C.E P537
Chappell, J. P786
Chapuis, B. P447
Charbel-Issa, M. P483
Charron, D. 67, 318
Chatziandreou, I. O149
Chavas, E. N964
Chelghoum, Y. P577, P778
Chelombit, L. P797
Cheong, H.J. P446
Cheong, J.T. P446
Chernykh, E. P422
Chesnel, V. 223
Chevalier, P. P906
Chevallier, P. P501
Chevret, S. 318, O389, P743
Chiarion-Sileni, V. P662
Chir, Z. O121
Chirumbolo, G. P678
Chisesi, T. P623
Chiusolo, P. P519
Chklovskaia, E. O293
Cho, H.S. P1081
Choi, B. P688
Choi, C. P998
Choi, H.S. P836, P843
Choi, I. P466, P998
Choi, J. P416, P684
Choi, S.J. P855
Choma, M. P666
Chopra, R. O118, N945, N984
Chotekov, P. P1045
Chott, A. P868
Chou, T. P644
Chui, S.Q. P1043
Chukhlovin, A.B. O401
Chung, N. P688
Chvojkova, I. P1065
Chybicka, A. O358, P587, P815,
P821, P826, P827, P830,
P837, P846, P865
Cicconi, S. O405
Ciceri, F. 97, O119, O264, O377,
P506, P664, P745, P752, P785
Ciepluch, H. P647
Ciftcioglu, A. P771
Cimminiello, M. P802
Cinieri, S. N957
Cioch, M. P884
Ciotti, M. P754
Cirignotta, F. P803
Cirulli, T. P802
Ciscato, C. P816
Ciuffreda, L. O373
Ciulla, M. P583
Ciurana, A. N964, P1002
Claas, E P739
Claessen, A.M.E. P775
Clapisson, G. P543
Clark, R. P1077, P1078
Clave, E. 67
Claviez, A. 230
Clement, L. P774
Clemente, A. P1034
Clerici, M. N957
Clèries, M. P854
Clinton, F. P1040
Cocquio, A. N957, P1019
Coiffier, B. O102
Collin, M. P714
Collins, G. P516
Collyns, T. P759
Colombat, P. O254
Colombel, J.F. O400
Colombo, A. P756, P800
Colombo, S. P745
Colomer, D. P471
Colturato, V. O353
Cometa, A. O398
Comey, N. P1040
Commins, J. N958
Comoli, P. O300, O398
Conboy-Twomey, M. P1039
Conde, E. O107, O253
Conrad, R. P665
Console, G. O258, P747
Consoli, U. P861
Constans, M. O107
Constantinou, V. P585, P586
Contarini, M. P1007
Cook, G. O390, P491, P759
Cooke, K.R. 330
Cooper, N. O290
Copland, R. N983
Córdoba, R. O107, P568

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Cordonnier, C. S25, S43, 54, O153,
218, 219, 221, 222, 223, 226,
O389, O391, O392, P532,
P743, 933
Corey, L. O271
Cornelissen, J.J. 217, O246, O271,
O275, 317
Cornelissen, L.D. P1085
Cornelly, O. 228
Cornely, O. O271
Cornish, J. 182, 186, O291, 324,
O359, P696, P767, P1071
Corradini, P. 97, O115, O119,
O252, O260, O355, P470,
P502, P506, P697
Corredor-Lobato, M.A. P1056
Corsetti, M.T. P634
Cortellazzo, S. O106
Cortés, M. P620
Cortesão, E. P592
Corti, C. O377
Corti, P. P753
Corvatta, L. P659
Coser, P. O115
Coso, D. P862
Costa, T. P551
Costi, D. P651
Cotrozzi, M. P1007
Couignoux, S. O400
Coutinho, M. P601
Coze, C. O365
Cozza, R. P816
Craddock, C. O118
Crassard, N. P777
Crescenzio, N. P439
Crescimanno, A. P763
Creutzig, U. O301
Crivellari, G. P662, P668
Cubells, J. P793, P1034
Cubitt, D. O150
Cudillo, L. O281, P754
Cullup, H. P407
Cupelli, L. P554, P754
Curci, P. P894
Cuzzola, M. P503
Czerw, T. P871
Czyz, A. P878
Czyz, J. P647, P900
Da Prada, G.-A. P752
D'Adamo, F. P791
Dagis, A. O257
Dahmen, Y. O391, O392, P532
Dal Cortivo, L. P824
Dalianis, T. P762
Dalle, J.-H. O383
Dallorso, S. O281, O285, P852
Dalva, K. P549, P709, P730, P771
Damaj, G. O351, P639
Damen, S. P1027
Damiani, D. P463, P492, P573,
P697, P707, P729, P879,
P899, P919
D'Amico, M.R. P857
Dammacco, F. P802
Dammann, E. P507
Damourette, S. P528
Daniel, O. P1017
Dann, E.J. P700
Dannie, E. P542, P992, P993
Danos, O. O145
Dantas, S.R.P.E. P773
Darbyshire, P.J O288, P810
Das, A. P825
Das, M. P535, P649
Daschner, F. P734
Das-Gupta, E. O263
Dasí, A. O165
Dassi, M. P610, P753
Däubener, W. O397
Daudt, L. O300
Davey, S. P570
David, M. P525
Davidowich, Y. P635
Davies, G. O150, O290, P704
Davies, M. P808, N958
Davis, J. P542
Davison, G. P457
Dazzi, F. O130, O395, O399, P410,
P692, P699
De Biase, P. P582
De Blasio, A. P623
de Carvalho Bittencourt, M. O294
De Fabritiis, P. O115, O251, O260,
P754
De Felice, L. O370
De Francesco, R. O258, P894
De Gasperi, A. P529
De Geyter, C. P588
De Giorgi, U. O265, O268
De Hauwere, K. 326
De Ioanni, M. O297
de Jager, W. O151
de Jong, A. P838
De Kerviller, E. P794
de Kleer, I. O161
de la Camara, R. 219, 223, P613,
P693
de la Rubia, J. O366, O380, P768,
P902
de la Serna, J. O125, O354, P513
de Lima, M. O244
De Marco, L. P770
De Matteis, S. P519
De Meuter, A. O123
de Nooij, W. N948
De Paoli, P. P770
De Propris, M.S. P881
De Rijcke, M. 326
de Rijke, B. O137
De Rosa, L. P667
De rossi, G. P851
De Simone, M. P857
De Sio, L. P816
De Souza, C.A. O353, P913
De Souza, M.P. O353
de Villartay, J.P. O145
de Vries, T. N948
De Wilde, V. P460
de Wit, K. N953
de Witte, T. 69, O137, 172, 175,
P920, 937
Dearden, C. P535, P649
Deb, G. P816
Debatin, K.M. 322
Debén, G. P789a
Debouge, M.H. P742
Debruyne, J. P772
Deeg, H.J. P611
Deiana, G. P1007
Deininger, M. O404
Dekker, A. 219
Dekker-van Roessel, M. P530
Del Campo, M. P1049
del Cañizo, C. O380
Del Cañizo, M.C.O131, P419, P557
Del Fante, C. O371, P553
Del Papa, B. O297
del Valle, F. 79
Delamain, M.T. P913
Delforge, A. P460
Delforge, M. 69
Delgado, M. P435
Delgado-Gonzalez, J. P690
Delsol, G. P891
DelVecchio, G. P593
Demarez, V. O392, P532
Demirer, T.87, 92, 97, O265, O268,
346, P904
Demosthenous, C. N988
Demuynck, H. O123
Denning, D. 53
Dentamaro, T. P754
Deola, S. O264, P664
Depala, M. O150
Depil, S. O383, O400
Deschaseaux, F. P420, P442
Dessanti, M.L. P881
Dettenkofer, M. P734
Devereux, S. O120, P786
Devergie, A. O279
Devizzi, L. O106, P738, P897
Devos, P. O383
Devroey, P. 326
Dewchand, H. O395, P692
Dhédin, N. O368
Dhillon, A.P. P690
D'Hondt, L. P452
Dhooge, C. P631
Di Bartolomeo, P. O159, O251,
O260, O306, P492
Di Grazia, C. O402, P522, P616,
P737, P741, P776
Di Ianni, M. O297, P802
Di Leverano, C. N957
Di Martino, D. P852
Di Michele, P. O162
Di Nicola, M. P738, P897
Di Pietro, G. P802
Diaz, M. O380, P559, P828
Díaz-Espada, F. P650
Diaz-Ricart, M. P426
DiBella, R. P712
Dickinson, A.M. 52, 314, 331,
P407, P702, P714
Dickmeiss, E. P458, P493, P517
Dieckmann, K. P469
Diedrich, H. P507
Diehl, V. P784, P890, P898, P909
Dierlamm, J. P637
Dietmaier, W. P856
135

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Diez, M. P716
Díez, J.L. O125, O356
Díez Campelo, M. P534
Diez-Martin, J.L. O253, O354,
P513, P578, P926, N985
Dilloo, D. 184, O397, P681, P822
Dingeldein, S. P680
Dini, G. 186, 189, O268, O285,
O287, O306, 342, O361, P523,
P852
Ditschkowski, M. O250, P859
Diverio, D. P869
Divine, M. O254, P609
Diwan, O. P724
Dlubek, D. P850, P880
Dmoszynska, A. P884
Dobos, M. P595
Dobrowolska, D. P850
Docampo, V. P1060
Dodds, A. P482
Dodds, T. P728
Dodell, B. O271
Dodero, A. O119, O252, P470,
P502, P506
Doehner, H. P485
Dohmen, B. P656
Döhner, H. 79, O245, O247, O304,
O406, P780
Döhner, K. 79
Dohr, D. O245, O304
Dolgopolov, I. P464, P574
Dolstra, H. O137
Domanska-Czyz, K. P888
Domingo, J.C. P430, P438
Domínguez Gil-Urlé, F. P534
Dominietto, A. O281, O402, P522,
P603, P616, P737, P741, P776
Donelli, A. O159
Donfrancesco, A. P816
Donnelly, J.P. S21, O270
Doorduijn, J. O104
Dörfel, F. P576, P860
Doria, A. P439
Dörken, B. 96
Dörrschuck, A. O141
Doskocilova, K. P924
Douay, C. 67
Doubek, M. P509, P718
Douglas, J. P1037
Down, J.D. P579
Doyen, C. O110, O123
Doz, F. O285
Drabko, K. P666, P826
Dragulescu, S.-I. P589
Drake, M. O112, O113, 169, P538,
P642
Dray, L. P467
Drayson, M.T. P632
Dreger, P. O105, 181,181a,
O406, P462
Drelichman, G. P789
Drew, D. N954
Drexler, H. 68
Dreyling, M. 233
Drihème, A. O368, P609
Driscoll, T. O271
Duarte, R.F. P690, N949
136
Dubois, V. P577, P812
Dubruille, V. P501, P906
Duchateau, V. P772
Duffner, U. 184, P628, P681
Dufour, C. O162, P593
Dulley, F.L. O353
Duncker, C. O245, P873
Dunn, P.P.J. P570
Dupont, J. P540
Durán, A. P1066
Durán, B. P557
Durand-Zaleski, I. O389
Durbecq, J. O256
Dwilewicz-Trojaczek, J. P544
Dworzak, M. P760
Dyla, A. P815, P827
Dyshlevaya, Z. P594
Dyson, P. O395
Dzidowski, M. P587
Ebell, W. O289, 321, P499
Ebner, W. P734
Ecder, T. P527
Eckschlager, T. P661
Edel, E. P511
Eder, M. P507
Edlund, S. P1075
Eeltink, C. N947
Egeland, T. 309
Egeler, M. P838, N950
Egeler, R.M. O246, P626, P674,
P751, P783, N953, P1055
Egger, M. P481, P576, P792, P860
Ehninger, G. O135, O244, O247,
O248, O384, P408, P445,
P472, P560, P572, P614, P903
Eibl, M. P1046
Eichner, S. P1070
Eichstill, C. P454
Eid, K.A.B. P913
Eiermann, T. P731
Einsele, H. S10, O156, 206, 218,
219, 222, 223, O272, O286,
316, P637, P638, P645, P656,
P660
Eissner, G. 52
Ek, M. P1044
Ekholm, M. P1030
Ekim, M. P806
Ekmekci, P. P730
El Weshi, A. O259
Elad, S. P539
Elawad, M.A. P704
Elez, M. P556, P563
Elhasid, R. P629
Eliaou, J. P444
Elli, E. P610
Elmaagacli, A. O134, O144, O250,
O350, O376, P675, P677,
P726, P859
Elonen, E. P565, P887
Elwig, C. P1039
Emi, N. O277
Emile, J-F. O102
Encabo, A. P411
Encuentra, M. P882
Engelhard, D. 221, 222, 223
Engert, A. O103, P890, P898, P909
Epstein, J. N984
Erer, B. O405
Eriksson, T. P782
Ertem, M. P806, P807
Erttmann, R. P731
E.Santo, A. P551
Escolar, G. P426
Eshel, R. P478
Esibiti, F. P1007
Esperou, H. O279, 318, O389,
O391, P532, P1080
Espigado, I. P693
Espigares, A. O396, P858
Esposito, C. P800
Esser, R. P848
Estella, J. O165, P828
Esteve, J. 71, 181, O249, P471,
P875, P922
Ethell, M. P690
Faber, E. 222, P533
Faber, P. O133
Fabregat, I. O128
Facon, T. O110, P633
Fagioli, F. O281, P439, P443, P817
Fagnani, R. P773
Faibish, T. N975
Falcioni, S. P803, 938
Falda, M. O115, P506, P515
Falk, P. O257
Falkenburg, J.H.F. O147, P486,
P669, P870
Falzetti, F. P802
Fanin, R. O115, P463, P573, P697,
P707, P729, P879, P899, P919
Faraci, A.M. 185
Faraci, M. 222, O306
Farge, D. 82, O158
Farina, L. P470
Fasanaro, A. P857
Fassas, A. 220, O388, P518, P585,
P586, P798, P872, P905
Fasth, A. P813, P1036
Faucher, C. O273, P444, P639,
P706, P862
Faulkner, L. P461
Faulkner, R.D. P546
Fauser, A. O117, O118,
O244,O381, P637, P715, P920
Favaretto, A. P662
Favre, C. O306
Favre, G. O374
Fawcett, T. P759
Fazillah, K. P1043
Fazzi, R. P503
Federico, M. O106
Fegan, C.D. P617
Fehervizyova, Z. O127
Fehse, B. O401, P683, P731, P917
Fehse, N.O352, P683, P731, P735,
P917, P921
Feinberg, M. O132
Fekete, G. P595
Feldman, L. P789
Feliksbrot, M.E. P544
Feliu, E. O249, P451

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Felix, Z. P1041
Fen, T. P904
Fenk, R. O284, P536, P641, P652
Ferdinadou, I. P433
Ferencik, S. O134
Ferme, C. O102, O254
Fernandes, F. O387
Fernandez, C. O396, P858
Fernández, J. P540
Fernández, M.E. P584
Fernández, M.N. 320, P421, P650
Fernández-Abellan, P. O107
Fernández-Avilés, F. O298, P584,
P875, P1000, P1002, P1076
Fernandez-Hidalgo, O. O267
Fernández-Navarro, .M. P853
Fernández-Rañada, J.M. P568
Fernández-Sanmartín, . P853
Fernández-Villalta, M.J. P568
Ferrá, C. P451
Ferrant, A. 69, O123, 220, O256
Ferrara, F. P857
Ferreira, A. P1026, P1042
Ferreira, E. P601
Ferremi, P. O108, P550
Ferrero, S. P583
Ferro, T. O165
Ferry, C. P1080
Ferster, A. O161
Fetscher, S. P914
Feuchtinger, T. O274, O286, P459,
P671
Feugier, P. O102, O254
Feyler, S. P491
Fibach, E. P539
Fibbe, W.E. 78, O126, P432, P486,
P674
Fidani, P. P816
Fiedler, J. P598
Fieramosca, S. P523
Fietz, T. P424, P911
Figuera, A. P568, P789a
Filì, C. P463, P573, P729, P899,
P919
Filibeck, U. 930
Filion, A. O279, 318
Filippi, M. O159
Filippini, B. P819
Fillet, G. P490, P500, P742
Fillion, A. 67
Fillitz, M. P434
Finch, A. N974
Fineman, R. O386, P700
Finke, J. O133, 181, O244, P481,
P576, P599, P792, P860, P914
Fischer, A. O142, O145, 184, P824
Fischer, G. 52, O292, O387, P469
Fischer, J.T. 79
Fleischhauer, K. O264
Flood, T.J. 327, 328, P537
Flores, A. P451
Florit, M. P1032
Foglia, L. P439
Fogliatto, L. O387
Follo, M. O133
Fomasagaram, P. P695, P823,
P829, P847
Fondin, C. P1036
Font, L. 71, O249
Foo, M. O150
Forés, R. 320, P650
Forman, S.J. O257
Formankova, K. P1073
Forte, L. P755
Foss, F. P728
Fouillard, L. 80, O124, 180, O355
Fowler, A. P410
Frahm, J. 321
Frairia, R. P443
Francesia Berta, M. P1007
Frank, K.H. O135
Franklin, I. 220
Franzoni, M. P841
Fraser, A. P1004
Frassoni, F. 72, 78, 80, O124,
208, O244, O402, P737,
P741, P776
Frauenschuh, D. P914
Fregoni, V. P752
Freiberg-Richter, J. P499
Freitas, A. O143
Frere, P. P490, P500, P742
Freund, M. P480, P796, P921
Fridman, S. P540
Friedrich, W. 322
Frigelli, S. P651
Fritsch, G. O292, P454, P465
Fritzsche, C. P784
Frödin, U. P1015
Fruchart, C. P528
Fruehauf, S. O146
Fuchs, D. O403, P766
Fuchs, M. P784
Führer, M. O360
Fujii, H. P644
Fumagalli, M. P610
Fung, H. O257
Fürst, S. O121, P577, P778
Fuste, B. P426
Fuzibet, J.G. O110
Gabarre, J. O102, O368
Gabriel Arana, M. O260, P755
Gadner, H. O157, O292, P454,
P465, P760
Gaedicke, G. 321
Gagne, G. P1063
Gahrton, G. O112, O113, P611,
P642
Gaiardoni, R. P801
Gaipa, G. P753
Gaitatzi, M. P872
Galambrun, C. P777, P812
Galanski, M. 68
Galbusera, V. O402, P616, P737,
P741, P776
Galiano, M. P1066
Galieni, P. P659
Galimberti, S. P477, P503, P514,
P912
Gallamini, A. O106, O115, P623,
P758
Gallardo, D. P693, P882
Gallego, C. P1000, P1002, P1076
Gallo, E. O258
Galloin, S. P891
Galmés, A. O380
Galski, H. O132
Gambacorti-Passerini, C. P610
Gammaitoni, L. P417
Ganepola, S. O154
Ganser, A. 68, O247, O280, P507,
P520
Garami, M. P595
Garate, M. P789
Garaventa, A. P523, P817
Garay, G. P540
Garban, F. O110
Garcia, J. O379
Garcia, L. P1000, P1076
Garcia, P. O283
Garcia, S. P552
García Boyero, R. P789a
García Escobar, I. O255, P886
García Frade, J. P584
García Talavera, J. P886
Garcia-Castellano, J. O396, P864
Garcia-Cecilia, J.M. O305
García-Conde, J. O107, P421,
P545
Garcia-Escarp, M. P430, P438
García-Laraña, J. O107
García-Marco, J.A. 320, P650
García-Talavera, J. O255
Garderet, L. 170
Gardulf, A. N980
Garland, R. 324, P696
Garnier, F. 67, O367
Garrido, G. O165
Gartcheva, L. P1045
Gärtner, J. 321
Garuti, A. O402, P616
Gasbarrino, C. P802
Gaspar, B. P474
Gaspar, H. O149, O150
Gastaut, J. O273, P444, P639,
P706
Gastmeier, P. P734
Gattei, V. P770
Gattillo, S. O377
Gaudenzi, A. P795
Gaudin, H. O368
Gaudio, F. O258, P894
Gaugler, B. O273, O351, P706
Gavalda, J. S44
Gayoso, J. 320, P650
Gaziev, D. O405
Gaziev, J. P624, P791
Gebuhrer, L. P577
Gedikoglu, G. P720, P809, P818
Geissler, G. P614, P903
Gelber, O. P566
Gelfand, Y. P467, P686
Gelli, M. P461
Genc, Y. P904
Gennery, A.R. 327, 328, P537
Gentile, G. 219, O370, P754
Gentile, R. O398, P736
Georgala, A. P772
Georgievski, B. P413
German, O. P528
137

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Germing, U. 79, O284, P652
Gerna, G. P752, P756
Geromin, A. P463, P573, P707,
P729, P879, P899
Gesk, S. P885
G.Gomez, S. 66
Ghavamzadeh, A. P440, P441,
P489, P625, P844
Ghiotto, C. P668
Gholibeikian, S. P489, P625, P844,
P927
Giabbani, L. P429
Giacchino, M. P788
Giaccone, L. O115
Gianelli, U. P583
Gianni, A.M. O119, O252, P470,
P502, P738
Gianni, M. P897
Giannini, B. P803, 938
Giardini, C. O405, P624, P791
Gidoni, O. P629
Giebel, S. P480, P736, P871
Giger, R. P648
Gigliotti, D. P505
Gil, L. P878
Gil, S. 320, P650
Gilmour, K. O150
Gilyead, M. O263
Gindraux, F. P420, P442
Gini, G. P893
Giona, F. O370
Giordani, L. O162
Giordano, A. O258, P894
Giordano, P.C. P626
Giordano, R. P583
Giorgiani, G. O398
Giraud, G. P762
Girschikofsky, M. P918
Gisselbrecht, C. 55, O102, P794,
P901
Giudici, D. P745
Giustolisi, R. P861
Glasmacher, A. S2, 79
Glass, B. O103, O140, P462, P680
Glatting, G. O245
Glavicic, V. P556
Glennie, S. O130
Glossmann, J.P. P890, P898, P909
Gluckman, E. S47, 67, 80, O164,
186, 216, O279, 315, 318,
O367, O389, O391, P743,
P999, P1080
Glückmann, M. O141
Göbel, U. O397, P822
Godoi, D. P601
Goede, V. P705
Goekbuget, N. P885
Goldman, J. 51, 176, O114, O302,
P410, P699, P781
Goldschmidt, H. P643
Goldstone, A. 337
Golovchenko, R. P883
Gomes, A. P1026
Gomes, C. P545, P1042
Gomes, F. P412, P415
Gomez, P. O396, P864
Gomez, V. O354
138
Gomez-Garcia, P. P828
Gómez-García, V. P613
Gomez-Garcia de Soria, V. 220,
O356
Gomez-Pineda, A. O253, P578,
P926
Gonzalez, C. P1025
Gonzalez, H. O368, P609
Gonzalez, V. N985
González, J.R. P693
González, M. P693
González-Escribano, F. P693
Gonzalez-Murillo, A. O146
Gonzalez-Porras, J.R. O305
González-Rivera, M. P578
Gonzalez-Valentin, E. P828
Gonzalez-Vicent, M. P559
Goodenough, B. N954
Gopcsa, L. P567
Gorczynska, E. O358, P666, P815,
P821, P826, P827, P830,
P837, P846
Gorin, N. O124, O244
Goronkova, O.V. O163
Gossmann, F. P1048
Goterris, R. P545
Göthberg, G. P1036
Götherström, C. P427, P436, P717
Götze, K. 79
Goudeva, L. P757
Goulden, N. O291, 324, P696
Goulmy, E. 198, P702
Gourlain, K. O153
Goussetis, E. P433
Gozdzik, J. P510, P621, P900
Gozzer, M. P881
Grace, B. P425
Graczyk-Pol, E. P544
Graef, T. O284, P536
Grafakos, S. P433
Gramatzki, M. O372
Granato, C. P551
Granda, A. P568
Grasso, R. O402
Gratama, J.W. O275, 317
Gratecos, N. P633
Gratwohl, A. S34, S40, 69, 80, 86,
O293, 348, O374, P588, P611,
P804, P845, P920
Greco, G. O373
Greco, M.M P725
Green, A. P570, P1033
Green, J.E. N982
Gregora, E. P598
Greil, J. S8, O274, O286, P453,
P811, P820
Greinix, H. 52, 220, O308, P469,
P487, P923
Griesinger, F. 79
Griffiths, A. P1014
Grigg, A. P728
Grigull, L. P757, P825
Grill, J. P819
Grillo, G. P529, P658
Grimaldi, C. P452
Grimminger, W. 79, O245
Gris, E. N944
Griscelli, F. P504
Grommisch, L. P511
Gromnica-Ihle, E. P602, P670
Grosse-Wilde, H. O134, O376
Grossini, M. O387
Groves, S. 324, P696
Gruber, A. 220
Gruettner, H. P848
Gruhn, B. O360, O403, P766
Grüllich, K. O133
Grunspan, A. P566, P1050
Grynspan, F. O132
Gstoettner, A. P750
Gualandi, F. O159, O402, P522,
P603, P616, P737, P741, P776
Guaragna, G. O373
Guardia, R. 71, O249, P922
Guardiola, P. 173, P920
Guarini, A. O258, P894
Guarino, M. P803
Gueglio, B. P501
Güell, J. P1000, P1076
Guenechea, G. 66, O146
Guenther, W. P682
Gueri, C. O391, O392
Guerrini, F. P477
Guest, C. P1077, P1078
Guetta, E. O132
Guggiari, E. O264, O377, P664,
P785
Guglielmi, C. 168, 937
Guidetti, A. P738, P897
Guidi, S. O281, P779, P795, P896
Guiducci, B. P791
Guillaume, T. P501, P906
Guimaraes, A. P592
Guimaraes, J.E. P551
Guimaraes, P. P551
Gunel, N. P904
Gunetti, M. P417, P428
Güngör, T. 325
Gupta, A. P569
Gurman, G. P655, P904
Gürman, G. P494, P571
Gustafsson, A.-L. P1036
Gustavsson, B. P722
Gutierrez, N. C. P435
Gutierrez, O. P584
Ha, S.Y. P608
Haack, A. P408
Haas, A. P761
Haas, O.A. P465
Haas, R. O284, P536, P641, P652
Haavisto, S. P994
Hack, E. P702
Hackanson, B. P576, P860
Haddad, N. O386, P629, P700
Haen, M. P645
Hafen, K. 319
Häfer, R. O403
Häfner, R. P733, P766
Hagberg, H. O104
Hagedoorn, R. O147
Hagemeijer, A. 69
Hägglund, H. P916
Haghshenash, M. P526, P627

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Hagman, A. O112, O113
Hahn, J. 52, O372, P713
Hahnewinkel, K. P698
Haioun, C. S31, O102
Hajek, R. P636
Haji Michael, P. N984
Halaburda, K. P732
Hale, A. P759
Hale, G. P449, P873
Haller, H. P520
Hallinan, J. P696
Halter, J. 239, 325
Haltrich, I. P595
Hamajima, N. O277
Hambach, L. P520
Hamerschlak, N. P601
Hamlin, D. O262
Hampl, W. P780
Hamprecht, K. O286
Han, C. P688
Han, K. S. P843
Han, S.S. P1081
Hancox, A. P759
Handgretinger, R. P453, P671,
P811
Hänel, M. P614, P903
Hanemberg, H. P590
Hansson, G. P1036
Hansz, J. 181, P510, P900
Hardan, I. O122, O378, P635, P863
Harmsen, S. N953
Harousseau, J.L. O110, O268,
P501, P906, P920
Harpaz, N. P622
Harris, R. O367
Harritshoj, L. P517
Hart, D. O393, P719
Harteveld, C.L P626
Hartmann, F. 79
Hartmann, O. O285, O365, P819
Hartung, G. O140, O154
Hartwig, U. O136, P687
Harvey, H. P1001, P1022
Harvey, J. P570
Hasenkamp, J. O140, P462, P680
Hasford, J. 176
Hassall, T. P1035
Hassan, A. O150
Hassan, A.S. P704
Hassan, M. P717
Hassenpflug, J. P921
Hassenpflug, W. P735
Haubitz, M. P520
Haupt, R. O162, O306
Hauser, H. P918
Hauser, T. P804
Hauzenberger, D. P473, P476,
P561
Haveman, L.M. O151
Havrdova, E. P598
Hawkey, C. 85
Hawkins, H. O359
Hawrylecka, D. P437
Haynes, A. O263
Hazar, B. P904
Hazar, V. P835
Haze, S. O275
Haznedar, R. P904
He, J.S. P710
Healy, C. P995
Heard, P. P570
Hebart, H. O156, P645, P660
Hebras, M. P1080
Hedayatiasl, A. P844
Hedrum, A. P782
Heemskerk, M.H.M. O147
Hegenbart, U. O404, P511, P615,
P711, P889
Hehlmann, R. 176
Heilmann, C. P414, P493, N961
Heim, D. P588, P804
Heimpel, H. P873
Heit, W. P873
Helg, C. P447
Hellmann, A. P621, P647, P732,
P900
Helström-Lindberg, E. 69
Hemling, A.M. P626
Hemmatapour, S. P569
Hennequin, C. P794
Henschler, R. O127, P425
Hensel, M. 79
Hentschke, P. P505, P665, P769
Henze, L. P536
Herbrecht, R. O102
Herens, C. P490
Herfarth, H. 52
Hermanne, J.P. P742
Hermosilla, M. P882
Hernandez, J. M. P435
Hernández-Boluda, J.C. O107,
O125, P545
Hernandez-Navarro, F. P513, P552
Hernando, A.P1000, P1002, P1076
Herr, W. O136, O141, P687, P750
Herrera, C. O298, O396, P858,
P864
Hertenstein, B. 68, O272, O280,
P507, P520, P757, P866, P873
Hervé, P. P420, P442
Heshmat, M. O357
Hess, U. 69
Hetherington, P. P1077, P1078
Heuft, H.G. P757
Hewitt, A. N960, N972
Hewitt, N. O150
Heydari, P. P489, P625, P844,
P927
Heyll, A. P641
Heyn, S. P511
Hiepe, F. O160, P597, P602, P670,
P676
Higgins, E. P995
Higgins, K. P808
Higgins, S. N954
Hilbers, U. O140, O154
Hilger, R.A. P685
Hill, Q. P759
Hillmen, P. O390
Hinke, A. P637
Hinterberger, W. P469
Hirch, I. P824
Hjermstad, M. O307
Hlinka, M. O250, P859
Ho, A. O120, P643, P786
Ho, H.K. P608
Höcker, P. O292, P469, P487, P760
Hoelle, W. O360
Hoelzer, D. S65, P703, P866, P885
Hoenig, M. 322
Höffken, G. O384
Höffken, K. P483
Hoffmann, F.-A. P889
Hofmann, J. O154
Hofstaedter, F. P856
Hofstra, C.C.M. N955, P1055
Holbova, R. O132
Holder, J. N961
Holder, K. P617
Hölig, K. P408, P572
Hollander, G. 319
Holler, E. 52, O280, O372, P713,
P895
Hollifield, J. P474
Holowiecki, J. P480, P580, P871,
P900
Holtick, U. P581, P784
Holzgreve, W. P588
Hong, D.S. P423, P446
Hong, E.Y. P1081
Hoogeboom, M. O147
Hoogerbrugge, P. P839
Horak, P. P646
Horneff, G. O161
Hornig, B. 68
Horowitz, M. P611
Horst, H. P885
Horton, C. P535
Hossam,K. S49
Hotidou, A. O388, P798
Hough, R.E. P546
Hovi, L. P744, P790
Howlett, T. P808
Hows, J. 240
Hoyer, B. O160, P536, P652
Hrabetova, S. P924
Hruba, A. P661
Hsaïri, M. O385
Huang, H. P710
Hübel, K. P784
Huber, C. O136, O141, O381,
P687, P750
Hue, C. O145
Huenerlituerkoglu, A.-N. P641
Huguet, F. P891
Huijgens, P.C. P530
Hulin, C. O110
Humaidan, H. O259
Hummel, H. 316, P638
Humpe, A. O406, P885
Hundemer, M. P643
Hunneman, H. 321
Hunold, A. O301
Hunter, A. P808
Hurtz, H.-J. P889
Hussan, A. O290
Hutchins, C. P991
Hutt, D. N952
Huyn, A. O121
Huynh, A. O296, P891
Hwang, T. P877
139

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Iacobelli, S. 175, P642, 939, 942
Iacopino, P. O258, P503, P634,
P747
Iacovone, S. P852
Ibatici, A. O402
Ibbotson, Y. P1018
Idir, Y. P1080
Ijichi, O. P831
Ikäheimo, H. P1030
Ilari, I. P816
Ileri, T. P806, P807
Ilhan, O. P494, P549, P571, P655,
P728, P771, P904
Illmer, T. O248, O384, P445, P614
Incarbone, E. P788
Indelicato, F. P861
Indovina, A. P712
Indrak, K. P533
Ingram, W. P786
Ings, S.J. P448
Innocenti, M. P582
Insunza, M. O380
Iolascon, A. O162
Ion, E. P1077, P1078
Ionescu, I. O367
Ionova, T. P797
Iori, A. O162, O306, O370, P593,
P869
Iqbal, J. P649
Iravani, M. P489, P625, P844
Iriondo, A. O354, P613
Irno Consalvo, M.I. P554
Irrera, G. P747
Isacchi, G. P816, P851
Iserte, J. N959
Ishii, A. P644
Isidro, I. P435
Isnardon, D. O351
Israel, S. P539
Itälä, M. P524, P640
Iuliano, F. P747
Ivanova, N. P721
Ivanovski, M. P413
Iwola, M. P510
Izquierdo, M. P853
Izzi, I. O108
Jackson, G. S45, 52, P654
Jacobsen, N. P414
Jacobsen, S.E. P458
Jacome, A. O129, O165, P590
Jacques, H. O391
Jaeger, U. P469
Jäger, D. P648
Järpenge, M. P782
Jahani, M. P625, P844
Jahn, G. O156
Jaimovich, G. P789
Jaksic, B. P910
Jameela, S. P1043
Jang, G.H. P446
Jansen, J. 69
Jantunen, E. P657, P746, P887
Jardine, P. 324
Jarosová, M. P479
Jarque, I. O366, P768, P789a,
P902
140
Jawniak, D. P884
Jayne, D. 61
Jenke, A. P499, P715
Jenkner, A. P816
Jeong, D. P688
Jimenez, A. P693
Jimenez, C. O295, O366, P559,
P768, P902
Jimenez, J.L. P578
Jimenez, M. O396, P858, P613
Jindra, P. P562, P564, P612, P876,
P925, P996
Jochins, A. O387
Johanson, D. P1079
Johnsen, H. O104
Johnson, K.W. P579
Jólkowska, J. P840
Jones, A. O150
Jonsson, J. O155
Jordanova, M. P1045
Jorge, M. P592
Josting, A. 56, 231, P890, P898,
P909
Jouet, J.P. O121, O383, O400,
P633
Jourdan, E. O351
Journet, V. P528
Jover, L. P558
Judith, D. O299, O382
Juergens, H. O285
Julia, A. O249, P789a
Juliusson, G. 219, P1015
Juncà, J. P451
Jung, Y. P416, P684
Jurczak, W. P900, P908
Juvonen, E. P565, P657, P746,
P749
K. Besisik, S. N979
Kabickova, E. O364, P661, P663
Kabisch, H. O352, P731, P735
Kabish, H. 184
Kachel, L. P871, P900
Kadar, J. P575
Kahls, P. O272
Kail, W. P1070
Kaiser, T. O280
Kalayoglu Besisik, S. P527
Kalberer, C.P. O293
Kalhs, P. O308, P469, P487, P868
Kalifa, C. P819
Kalogiannidis, P. O388
Kaloyannidis, P. P518, P798, P905
Kalpoe, J. P739, v
Kaltenhäuser, J. O357
Kaltwasser, P. P606
Kalwak, K. O358, P666, P815,
P821, P826, P827, P830,
P837, P846
Kamal, H. O280, P507, P520
Kammoun, L. O385, P521
Kampmann, B. O150
Kamprad, F. P511
Kanfer, E. O114, O302, P410,
P699, P781
Kang, H.J. P836, P843, P1081
Kang, S. P416
Kansu, E. 242
Kant, L.P.A. P1003
Kanygin, V. P422
Kanz, L. O244, P645, P656, P660
Kapás, B. P630
Kapilla, I. N984
Karabon, L. O394
Karadimitris, A. 223
Karanfilski, O. P413
Karanth, M. P617
Karas, M. O141, P612, P876
Kardum-Skelin, I. P910
Karimi, M. P526
Karlachova, I. P924
Karlhuber, S. O157
Karlic, H. P434
Kartsios, C. O388, P586, P798,
P905
Karvunidis, T. P564, P996
Kaslova, V. P997
Kasparu, H. P918
Kato, D. P495, P512
Kato, S. O277
Katz, J. P566
Katz, T. O386, P629
Kauppila, M. P524, P640
Kawano, Y. P831
Kay, B. 214
Keck, B. O157
Keil, F. P469, P487
Kenyon, M. O120
Kertsman, E. P700
Keskimäki, R. P994
Khalili, M. P441
Khan, S. P687
Ki, Y.H. P1081
Kiani, A. O384, P445, P614
Kiehl, M. O117, O118, P637, P715
Kienast, J. P715
Kikic, F. P919
Kim, B.K. P466
Kim, B.S. P998
Kim, C. S. P541
Kim, C.K. P423, P446
Kim, D. P740, P1074
Kim, D.-Y. P466
Kim, H.C. P416, P684
Kim, I. P541
Kim, J. P740, P998, P1074
Kim, S. P615, P855, P889
Kim, S.K. P541
Kim, S.H. P1081
Kim, S.-I. P466
Kim, S.J. P446, P877
Kim, S.Y. P877
Kim, W.K. P855
Kim, Y.H. P998
Kim, Y.J. P684
Kimby, E. 181, P916
Kimmig, S. P676
Kindel, B. P1005
King, T. N986
Kinsey, S. O390, P491
Kirchen, H. 79
Kircher, B. P702
Kirk, C. N974
Kirk, S. O288

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Kirstner, S. P711
Kisch, A. N946
Kishtovich, A. P797
Kisro, J. P909
Kitra, V. P433
Kizil, M. P655, P748
Klein, C.C. N955, P1055
Klein, M.R. O151
Klein, S. P703, P866
Klein, T. P475
Kleinclauss, F. O294, P488, P673
Klingebiel, T. O156, 182, 186,
O360, P681, P811, P820,
P832, P848
Klingemann, H. O117, P637
Klingspor, L. P769
Klink, A. 325
Kloess, M. O103
Kloibhofer, E. P849
Klootwijk, D. P1072
Kluender, C.N. O372
Knauf, W. P424, P480, P911
Kneba, M. O105, O406, P885
Kneller, A. P635, P863
Knipp, S. P536
Knoester, M. 193
Knop, S. P645, P656, P660
Knopinska-Posluszny, W. P647,
P900
Kobbe, G. O284, P536, P641, P652
Kobylka, P. O364, P598
Koc, H. P494
Koch, R. P472
Kodera, Y. O374
Kodman, Y. P1050
Koehl, U. P832, P848
Koerper, S. P424
Kögler, G. P822
Kogut, N. O257
Kohler, S. P676
Köhler, W. 321
Kohn, A. P682
Koistinen, P. P657
Koivunen, E. P657
Kok, M.A. P1085
Kokhaei, P. P762
Kolar, M. P598
Kolb, H.-J. O280, P484, P682,
P705, P761, P787, P867
Kolbe, K. O381
Koldehoff, M. O144, O250, O350,
P677, P859
Koller, E. 79
Komarnicki, M. P510, P878
Kondakci, M. P536
König, J. P918
Kontny, U. P628
Konuk, N. P494
Kook, H. P877
Koopman, H. P838, N950
Koopman, M. P1044
Koós, R. P595
Kopp, M. O307
Koristek, Z. P509, P924
Kors, A. P820
Korte, T. 68
Korthhof, L. 184, 184
Korthof, E. 192, 193
Koscielniak, E. O285, P820
Kosicka, G. P833
Kotzerke, J. O245
Koussis, H. P662
Koutecky, J. O364, P663
Kovács, G. P595
Kovacsovics, T. 69
Kowalczyk, J. P666, P826, P865
Koyama, S. P495
Koza, K. P598
Koza, V. P562, P564, P612, P636,
P876, P925, P996, P1065
Kozak, T. P533, P598
Kozlov, V. P422
Kozlowska-Skrzypczak, M. P878
Krahl, R. O247, P615, P889
Kratochwil, D. P587
Kratochwille, A. O352, P731, P735,
P917
Kratochwille, K. P921
Kraut, L. O381
Krauter, J. O247
Kravchenko, E.G. O163
Krawczyk, J. P437
Krawczyk-Kulis, M. P580, P871
Kreisel, W. P599
Kreissig, C. P575
Krejci, M. P509, P636, P718
Kremers, S. 79
Kreyenberg, H. O360, P820
Krieger, O. P918
Krishnan, A. O257
Kristiansson, C. P1023
Kristt, D. P475
Kriván, G. P595, P630, P764
Krivanova, A. P636
Krivoshapkin, A. P422
Kröber, A. O406
Krochmalczyk, D. P908
Kroes, A P739, P765
Kröger, N. O117, O118, 174, O272,
O352, O378, O401, P480,
P637, P683, P715, P731,
P735, P917, P921
Krol, M.A. P544
Kronenwett, R. P536
Kropff, M. P641, P747
Kroschinsky, F. P408, P472, P560,
P903
Kruijmer, J. N947
Kruisselbrink, A.B. O126
Kruzel, T. P580
Kubaláková, R. P479
Kuentz, M. O121, O153, O389,
O391, O392, P532, P743
Kühl, J. O289, 321, P499
Kühne, T. P845
Kuijper, E.J. P783
Kuis, W. O161
Kuittinen, O. P887
Kuittinen, T. P887
Kulagin, A. P422, P797
Kulkarni, S. P535, P649
Kung, A.W.C. P799
Kuntz, G. 316, P638
Kupesiz, A. P835
Kusec, R. P910
Kusumi, E. P495, P512
Küttler, T. P481
Kuzniar, M. P762
Kvalheim, G. O104
Kvaloy, S. O104
La Gattuta, G. P619
La Morgia, C. P803
La Nasa, G. O159, O251, P492
Labar, B. S64, 77
Labirio, M. O398
Labopin, M. 72, 80, O124, 176,
186, 223, O244, 939, 940, 942
Laborda, R. N944
Lacerda, A.F. P834
Lacerda, J. P1016
Lacitignola, L. P461
Lackner, H. P849
Ladaique, P. P456, P706, P862
Ladeb, F. O385
Ladeb, S. O385, P521
Ladenstein, R. O268, O285
Ladetto, M. P623
Lagrange, J. O389
Lagresle, C. O145
Lahuerta, J. O107, P513, P789a
Lakhal, A. O385
Lalle, M. P667
Lam, E. O130
Lamana, M. O148
Lambert, J.F. P452
Lambertenghi, G. P492
Lambertenghi Deliliers, G. 181,
O251
Lamparelli, T. O402, P492, P616,
P737, P741, P776
Lancaster, D. P847
Lanciotti, M. O162
Landolfo, A. P816
Lanfranchi, A. O108, P550
Lang, P. O274, O286, O360,
P453, P459, P671, P811, P820
Lange, A. O394, P691, P850, P880
Lange, J. P850, P880
Lange, T. O140, O154, O404,
P511, P615
Lange, W. P914
Langius, J.A.E. P530
Lanino, E. 184, O306
Lankester, A. P626, P739, P751,
P820
Lanther, T. N961
Lanzer, G. P679
Larghero, J. P901
Larrea, L. O366, P555
Larsen, J. N980
Larsson, K. O155, 219
Laszlo, D. P1019
Latinne, D. O256
Lau, Y.L. P608
Laufs, S. O146
Laughlin, M.J. 333
Laurenti, L. P519
Laureys, G. P631
Laursen, H. N961, P1048
Laursen, S.S. P1057
141

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Lautenschlager, I. P749
Lawitschka, A. O157, O292, P760
Lawitshka, A. 185
Laws, H.J. P822
Lawson, S.E O288, P810
Laylor, R. O395, P692
Lazarus, H. 176
Lazzari, L. P583
Lazzarino, M. P756, P800
Le, Q. O121, P611, P543, P577,
P778
Le Blanc, K.78, O261, P427, P431,
P436, P561, P717, P722
Leal-da-Costa, F. P834
Leblond, V. O368
Lechler, R. O399
Lechner, K. P469, P868
Leda, M. P826, P833, P840
Ledderose, G. P484, P787, P867
Ledermann, J. 91
Lee, J.H. P855, P855
Lee, J.S. P466, P855
Lee, K. P740, P740
Lee, K.H. P855
Lee, K.T. P446
Lee, K.-W. P466
Lee, M. H. P541
Lee, N.S. P423, P446
Lee, T.L. P608
Lee, Y.S. P855
Legger, E. O151
Legrand, M. P743
Lehmann, S. O289
Lehrnbecher, T. P848
Lehtinen, T. P887
Leiblein, S. P511
Leibzirer, H. N975
Leichsenring, M.L. P773
Lemarie, C. P456, P706
Lengerke, C. P660
Lenhoff, S. 97
Lennerz, V. O141
Leon, A. O117, P497, P498
León, C. N944
Leone, G. P519
Leoni, P. P659, P893
Leopardi, G. P791
Leor, J. O132
Leotta, S. P861
Leplina, O. P422
Leporrier, M. P609
Leppä, S. P887
Leppert, M. O137
Lepretre, S. P609
Lesukov, I. P797
Levak, S. P1028
Levis, A. O115
Lewalle, P. P460
Lewandowski, K. P510
Lewensohn-Fuchs, I. O155, O156,
P769
Lewis, V. P1083
Leyvraz, S. 88, O265
Li, J. O138
Li, L. P710
Liang, B. P710
Liang, R. P799
142
Lie, A.K.W. P799
Liebaers, I. 326
Liebert, U.G. O154
Liebisch, P. P637
Lilleri, D. P752, P756
Lim, H. P416, P684
Lim, L. O399
Limor, J. P1050
Lin, M.F. P710
Linch, D.C. P448
Linck, D. P715
Lindmark, A. 219
Lindner, B. P923
Linke, R.P. P643
Linkesch, W. P679, P1046
Lion, T. 63, O157, O292,
P465, P760
Lioure, B. P609
Lippi, A. P461
Lippolt, P. 68
Lipsanen-Nyman, M. P790
Lisini, D. O300
Liso, A. O373
Liso, V. O258, O373, P894
Lissens, W. 326
Listello, V. P789
Lisukov, I. P422
Littlewood, T. P516
Litzow, M. O156
Ljungman, P. S13, O155, O156,
205, 219, 220, 222, 223, 224,
O269, O276, P561, P722,
P762, P916, N980
Llàcer, N. N944
Llorens, S. P1032
Llorente, A. 71, O249, P922
Llort, A. O301
Lo Nigro, C. P758
Loaiza, S. P542
Lobitz, E. P590
Lobo, A. P1032, P1047
Locasciulli, A. O162, 189, 220,
222,223, O251, O260, O281,
P470, P502, P506, P593, P755
Locatelli, F. 184, 186, 189, O300,
O361, O367, O398, P515,
P681, P736, P817
Lockwood, L. P991, P1035
Loeffler, J. O156
Loening, S. 96
Löffler, M. O103
Löfgren, C. O276, P916
Lohninger, A. P434
Loiseau, P. 318
Lojko, A. P878
Lombardi, A. P851
Lombardini, L. P429, P492, P582,
P779, P795, P896
Lombay, B. P605
Longoni, D. O162, P593, P753,
P814
Lonial, S. O138
Lönnies, L. P431
Lopez, A. O380
Lopez, C. P793
Lopez, J. P613, P789a
Lopez, M.L. P558
López, N. O131, P557
López-Guillermo, A. P875
López-Holgado, N. P419, P547,
P892
Lopez-Lorenzo, J.L. P513
López-Mayor, J.L. P1056
Lopez-Picazo, J.M. O267
Lopponen, T. O112, O113
Lorand-Metze, I. P913
Lorenzo, I. O295, O366, O380,
P559, P768, P902
Loseto, G. O258
Losonczy, H. P525
Lotz, J. 68
Lou, J.W. P708
Lovell, R. O116, P617
Löwenberg, B. O275, 317
Lozano, M. L. O146
Lubbers, C. N948
Lucarelli, G. O405, P624, P791
Lucero, P. P1049
Lucesole, M. O119, P470, P502,
P506, P616, P893
Luecke, J. O286
Luecke, T. P825
Lueff, S. P630, P764
Lunenberg, L. O156
Lunghi, F. O264, P664, P785
Luo, Y. P710
Lupo Stanghellini, M. P745
Lutsar, I. O271
Lutz, D. P918
Lysak, D. P564, P612, P876,
P925
Ma, D.D P482
Maaloufová, J. P1067
Maas, F. O137
Maccario, R. O300, O398, P736
Macchiarulo, M. O399
Macey, D. P1024
Machado, A. P592, P728
Machetti, M. P741, P776
Mackinnon, S. O118, P690
Madelaine-Chambrin, I. P901
Madero, L. O165, P559
Madon, E. P443
Madrigal, A. 197, 313, 320
Madsen, H.O. P493, P517
Maertens, J. O123, 218, 219, 222,
P915
Maestre, I. P1016
Magallanes, I. P1051
Maggi, A. O109, P468
Maghfoor, I. O259
Magni, M. P738, P897
Magrini, F. P583
Mahe, B. P501, P906
Maiolino, A. O353
Maiso, P. P435
Majado, M.J. P1025
Majolino, I. O119, O260, P623,
P667, P755
Malassis, M. O142
Malassis-Séris, M. O145
Malcovati, L. O251
Maldonado, M. 323, P828

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Malenfant, C. P456
Malerba, C. P554
Malerba, L. P659
Malesevic, M. P556, P563
Malicki, J. P833
Malis, J. P663
Malladi, R. P516
Maloney, D. O115
Malysheva, O. P797
Mamone, D. P747
Mancardi, G.L. O159
Mancusi, A. O375
Mandel, J. O132
Mandelli, F. O370, P869
Manetti, C. P477
Manfredini, L. P523
Mangoni, L. P651
Mank, A. N966, N968, N971
Manko, J. P884
Mannarino, E. P802
Mannhalter, C. P469
Mannino, R. P712
Mansilla, M. P1066
Manson, J. P901
Mansuy, L. P774
Mantecón, A. N959
Manz, R. A. O160
Mapara, M. 96
Maraninchi, D. P444, P639, P706,
P862
Marantidou, M. P905
Marchesi, A. P553
Marchi, C. P461
Marco, R. P1025
Marconi, M. P659, P736
Marelli-Berg, F. P692
Marenco, P. P529
Maresova, I. P533, P924
Mariani, M. P461
Marie, J.P. 69
Marijt, W. P486, P626, P870
Marin, D. P542
Marin, P. O298, O380, P426, P430,
P438, P558, P875
Marinets, O. P424, P911
Marín-Martínez, A. P1056
Mariotti, J. O119
Marit, G. O110, P633
Märker-Herrmann, E. P606
Marková, M. P618
Markovitz, M. N975
Marks, D. P696
Marktel, S. P699
Marmont, A. O159, P603
Marolleau, J. P794, P901
Marriott, C. P535
Marrone, A. O162
Marsh, J. 188, 190, P823, P829
Martelli, M. 70, O106, O297, O375,
P802
Marti, J. 71, P922
Martí, E. P568
Martiat, P. O123, P460, P772
Martín, A. P547, P892
Martin, C. O295, O396, P613,
P693, P858, P864
Martin, G. O366, P768, P902
Martin, H. O135, P703, P866
Martin, P. O137
Martin-Algarra, S. O267
Martinelli, G. N957, P1019
Martinelli, L. P1012
Martinez, A. 323
Martinez, C. O356, O380, P613,
P875, N964
Martinez, F. O396, P864
Martinez, G. P1034
Martinez, J. O366, P768, P902
Martínez, V. P558
Martinez-Badas, M.P. O165
Martinez-Muñoz, V. P430, P438
Martinez-Rubio, A. P828
Martínez-Sisquella, J. P1056
Martin-Henao, G. P451
Martín-Mateos, M. O107
Martino, M. P503, P634, P747
Martino, P. P754
Martino, R. S3, 97, O117, O120,
175, 181, 200, 218, 222, 223,
227, O283, O298, P497, P498,
P508, P559, P620, P701,
P789a , N969, P1051
Marton, G. P605
Marty, M. O295, O366
Marugán, I. P421
Maryniak, R. P888
Maschan, A. O163, P594
Maschan, M.A. O163
Maschmeyer, G. S4
Mascolo, M.G. O370
Masera, G. P814
Masolini, P. P707
Massaia, M. O115
Massenkeil, G. 96, O160, P597,
P602, P670
Massuet, L. O379
Massumoto, C. P601
Masszi, T. P630, P764
Matarese, M. P1007
Matejckova, S. P661
Mateos, J. O255, P886
Mateos, M. O107, P497, P498,
P508
Mateos, V. P694
Matias, K. P601
Mattei, D. O106, P758
Matteucci, P. P738, P897
Matthes, S. P454, P1070
Matthes-Martin, S. O157, O292,
P465, P681, P760
Mattsson, J. O261, O269, O278,
P473, P505, P665, P722, P769
Maunoury, V. O400
Maury, S. O153, O389, P743
Mayer, J. P509, P636, P718
Mayerova, K. P598
Mazza, P. O109, O251, P468,
P727
Mazzara, R. P426
Mazzi, B. O264
Mazzucato, M. P770
Mazzuccato, M. O108
Mboumi, K. P772
Mc Guckin, S. P1010
McCann, S. 194
McCarter, R. 324
McCloskey, D. P569
McCloy, M. P1039
McCormack, R. P535
McDerra, J. P767, P1071
McGlade, G. P1018
McLellan, J. N958, N984
Mead, G. O116, P632
Mechelli, S. P912
Mehlhorn, U. P581
Mehta, J. P649
Meijers-Sleiderink, P. N948
Meisel, R. O397, P822
Melchionda, F. P841
Mele, A. P659
Mele, G. P857
Mele, M. P791
Melidy, E. P422
Mellgren, K. P813
Mellor, S. P874
Mellouli, F. P521
Mellstedt, H. P762
Melnichenko, V. P797
Meloni, G. P869, P881
Melvin, D. N956
Menendez, P. P419
Meng, B. P525
Mengarelli, A. O370
Mengoli, C. O152
Menichetti, F. S24
Menna, G. O162, P593
Mensah, P. P437
Mentkevich, G. P464, P574
Mercurio, S. P861
Mergenthaler, H.G. 79
Mermans, E. P1029
Merry, E. 310
Mertens, T. O369, P780
Messina, C. O152, O306, O361,
P817
Messina, G. P634, P747
Mestice, A. O373
Mestroni, R. P879, P919
Metzner, B. O103
Meyer, G.P. 68
Meyer, R.G. O136, P750
Meyer-Monard, S. P588
Miano, M. P523
Michallet, A. O121, P543, P577,
P611, P639, P778
Michallet, M. O110, O121, 178,
181, O355, P543, P577, P609,
P611, P639, P778
Michaux, L. O256
Michelutti, A. P707
Michieli, M. O108, P770
Michon, J. O365
Micol, J.-B. O383
Midgley, K.A. N983
Mihaylov, G. P1045
Mikesch, K. P576, P860
Mikhaylova, N. P721, P907
Milanesi, M. P738
Milani, R. P502
Milano, G. M. P816
Millá, F. P451
143

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Milligan, D.O118, 181, O355, P617
Milone, G. O281, P697, P861
Milosavljevic, R. P769
Milovic, V. P789
Milpied, N. S1, O121, P501, P906
Miñana, M.-D. P411
Minigo, H. P910
Minkov, M. P760
Mioduszewska, O. P888
Mirabet, V. P555
Mirabile, M. P554
Miralles, P. O253
Miranda, E.C.M. O353, P913
Miranda, N. P834
Miron, S. P539
Mischak, H. O280
Mischak-Weissinger, .M. S12
Mistrik, M. P728
Mitterbauer, G. P469
Mitterbauer, M. P469, P487
Miyakoshi, S. P495, P512
Mjartanova, D. P997, P1065
Mlynarczewska, A. O394
Modesto, C. P600
Mohr, B. P445, P472, P614
Mohty, A.M O273
Mohty, M. O273, O351, P444,
P633, P639, P706, P862
Mohyeddin, M. P440, P441
Moiseev, S.I. P883
Moka, D. P581
Molcanova, A. P1073
Moleti, M.L. O370
Molica, S. P747
Molina, A. O257
Möller, B. P606
Molnár, M. P630
Monari, M. O264
Monconduit, M. O110
Monconi, M. O306
Monfardini, S. P662, P668
Monfort, N. P558
Monné, M. P1002
Monni, P. P1054
Montagna, D. O300, O398
Montagnoli, C. O139
Montanari, F. P756
Montanari, M. P893
Montesano, R. P653
Montesinos, P. O366, P902
Montini, E. O300
Montserrat, E. S30, 71, 199, O249,
O298, P471, P611, P875, P1076
Morabito, F. P503, P634, P747
Moradiseresht, M. P489, P844,
P927
Moraes, D. P601
Morag, A N963
Moraleda, J. O107, O120, O125,
O354, P508
Morante, M. P701
Mordini, N. O115, O251, P515,
P758
Moreau, P. O110, O121, P501,
P906
Morecki, S. P467, P686
Morel, V. O368
144
Morello, E. P801
Moreno, C. P471, P854
Moreno, M.E. O283
Moreno, T. P1016
Moretta, A. O300, O398
Moretti, L. O297
Morgan, G. P535
Morillon, E. O145
Morin, B. P1063
Morinaga, S. P495
Morinaga, S. P512
Morineau, N. P501, P906
Moris, T.C.M. P654
Morra, E. P529, P658
Morreale, G. P697, P852
Morris, C. O112, O113, 167, P642
Morris, P. O307
Morris, T.C.M. P538
Morschhauser, F. O102, O254
Moscardo, F. O366
Moscardó, F. O295, P768
Mössner, M. O369
Motwani, J. O288, P810
Mounier, N. O102, P794, P901
Mourão, E. P1041
Mousavi, A. P489, P625, P844
Muecke, C. P424
Mueller, C. P615
Mufti, G. O120, P786, P920
Mügge, L.O. P483
Müller, A. P733, P766
Müller, J. P595
Müller, K. P414
Müller-Ehmsen, J. P581
Mullerova, N. P1065
Mundhenk, P. 222
Munoz, A. O165, 323
Munster, D. O393, P719
Muntz, S.A. N953
Murgano, P. P861
Murialdo, A. O159
Murphy, M. P1018, P1024
Murrell, C. P569
Murrone, A. O152
Musafiri, D. P528
Muscas, G. P795
Musiol, S. O404, P615
Musolino, C. P747
Musso, M. P758, P763
Mut, B. P589
Muus, P. 69
Myint, H. O117, P637
Na, Y.H. P1081
Nabet, C. P467
Nabet, D. P901
Nachbaur, D. P923
Nadal, E.O114, O302, O399, P410,
P542, P699
Nademanee, A. O257
Nagatoshi, Y. P831
Nagayama, J. P831
Nagler, A. O117, O118, O122,
O132, O378, P635, P637,
P805, P863
Nagler, R. P805
Nagy, K. O146, P605
Nagy, M. 96
Nahm, C. H. P541
Naik, P. O150
Najman, A. O110
Nakaseko, C. P644
Nam, H. P877
Naoe, T. O277
Naparstek, E. P478
Nardi, M. O306
Narinsky, R. P475
Narni, F. O252, O260, P515
Näsman-Björk, I. P505
Nassi, L. P896
Nauta, A.J. O126
Nava, P. P578
Navarrete, A. P1025
Navarrete, C. P418, P570
Navarrete, R. P418
Navarro, J. P653
Navarro, S. O129, O165
Navratil, M. P509
Navratilová, J. P562
Nederstigt, A. N953
Neff, C. 316, P638
Neitzel, H. O289, P499
Nepomucka, J. P924
Net, P. P1051
Netesov, E. P422
Neto, A. P834
Neubauer, A. O248
Neuhäuser, F. O286
Neuman, A.G.M. P1055
Neumann, F. O284, P536
Nevado, L. P1000, P1076
Ni Chonghaile, M. N973
Nicholls, J. P1069
Nicholls, L. N960
Nicholson, J. P84, P1024
Nickelsen, M. P462
Nicolini, F. P543, P577, P611, P778
Niederwieser, D. 89, 97, O140,
O154, 166, 175, 176, 181,
O247, 347, O355, O404, P511,
P611, P615, P642, P711,
P889, P920
Niehues, T. P822
Niemeyer, C. 184, P628, P681
Niesters, G.M. 317
Niethammer, D.O274, O286, O360,
P453, P459, P671, P811, P820
Nihtinen, A. P746, P749
Nijmeijer, B.A. P669
Nissen, M. P1035
Nistal, S. P568
Nivison-Smith, I. P482
Noellke, P. 184
Noens, L. O123
Nogova, L. P909
Noh, H. P877
Nolan, R. P767, P1071
Nomdedeu, B. P875, P922
Nomdedeu, J. 71, P620
Nonn, M. O136, P687
Noon, C. P808
Noorani, H. O362
Noort, W.A. O126, P432
Nordlander, A. O269, P722

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Nordström, G. N980
Norol, F. O368, O391
Nosari, A. O108
Nourani Khojaste, H. P526, P627
Nousiainen, T. P657, P887
Novak, K. P996
Novak, L. P564
Novichkova, G. O163
Novik, A. P797
Novitzky, N. P449, P457
Novo, A. O249
Novotny, J. P873
Nowak, B. P460
Nozzoli, C. P779, P795, P896
Nuara, M. O306
Nucci, M. O353
Nujja, M. P883
Oakhill, A. 324, P696
Obert, L. P420, P442
O'Brien, S. 176, 349
Occhini, D. P522, P616, P741,
P776
Ocio, E. P435, P534, P694, P716
Odijk, B. P1044
O'Donnell, M.R. O257
Odriozola, J. P497, P508
Oelschlägel, U. P445, P560, P614
Oertel, J. P1005
Offidani, M. P659, P893
Ogilve, C. P654
Oh, C. P877
Oh, D.-Y. P466
Oh, S. P998
O´Hagan, L. P1063
Öhrn, K P1053
Okamura, J. P831
Olausson, M. P813
Olavarria, E. O114, 176, O302,
P699
Olerup, O. P561
Olive, D. O273, O351, P706
Olive, T. 323, P559
Oliveira, G.B. P913
Oliven, A. O386, P700
Olivieri, A. O119, O251, O260,
P470, P502, P506, P659,
P697, P893
Oltra, S. O295
O`Marcaigh, A. P1040
Omazic, B. P505
O`Meara, A. P1040
Omedes-Fumadó, C. P1056
O'Neil, N. N956
Ong, T.C. P1043
Onsten, T. O387
Opalka, B. O144, P677
Or, R. P467, P539, P591,
P686
Orciuolo, E. P503
Ordeltova, M. P646
Ordinas, A. P426, P558
Ordodi, V. P589
Orfao, A. O143, P419, P557
Oriol, A. O249, P451
O'Riordan, J. 220
Orlando, L. N957
Orofino, M.G. O363
Orsi, A. P779
Ortega, J.J. 182, 186, O165, O301,
323, P559, P600, P828
Ortin, M. P695, P823, P829, P847,
P874
Osanto, S. P486
Osorio, S. P568, P693
Osowiecki, M. P900
Ossenkoppele, G. 69, O246
Ostanin, A. P422
Ostermann, H. P761, P787
Ostojic Kolonic, S. P910
Ostronoff, M. P601
Otterud, B. O137
Ottinger, H. O134, O144, O250,
O350, O376, P675
Ottmann, O. 76
Ouachée-Chardin, M. P824
Oudshoorn, M. P702
Ouyang, J. P604
Ovalle, A. N964
Overbeek, H. N948
Oving, E. O282
Ozcan, M. P494, P571, P655,
P904
Ozdemir, E. P730
Ozdilli, K. P720, P818
Ozer, Y. P496
Ozet, G. P904
Ozgenc, S. P809, P818
Pacchiana, R. P583
Pachl, J. P598
Pacini, S. P477
Paczesny, S. P774
Padovani, P. O306
Pagani, S. O398
Paganini, M. P795
Page, M.S. P751
Pages, M.-P. P812
Pagliai, F. O159, P582
Pagliuca, A. O120, P786
Pagnano, K.B.B. P913
Pai, S. H. P541
Paik, J.Y. P466
Paiva, A. O143
Pajdosz, K. P826
Palandri, F. P803, 938
Palao, M. N944
Palazzo, G. O109, P468, P727
Pallejà, M. P1032, P1066
Pallone, B. P802
Palm, S. P782
Palmieri, S. P857
Paloczi, K. P567
Palomo, G. P555
Palshof, T. O266
Palù, G. O152
Palumbo, A. O115
Pamphilon, D. 324, P570, P696
Panadero, R. N985
Pancrazzi, A. P428
Pandolfi, A. P667
Pannunzio, A. O373
Panovska, I. P413
Panse, J. P731, P735, P921
Panzer, B. P856
Paola, M. P658
Paoletti, F. P428
Paolucci, P. P593
Papadakis, E. P585
Papajik, T. P479, P533
Papatryphonos, A. O122
Papetti, C. P623
Papiani, G. O265
Papineschi, F. O159, P503, P514,
P912
Pardo, N. P793, P1034
Parea, M. P756
Parini, R. P753
Paris, D. O294, P488
Park, H.S. P423, P446
Park, J. P416, P684
Park, K. P998
Park, S. P466, P688
Park, S.K. P423, P446
Park, S.R. P466
Parker, A. O118
Parker, P.M. O257
Parkin, G. P1008
Parkkali, T. P565, P746
Parma, M. P653
Parodi, E. P788
Parody, R. 218, O354, O356
Paroz, B. N979
Parreira, M.J. P551
Pascual, M. O380
Pashanov, E. P594
Pasqua, I. O370
Pasquini, R. O353, O367
Passos-Coelho, J.L. P834
Passweg, J. S7, 84, 192, 193,
340, P588, P804
Pastore, D. O373
Pata, C. P557
Patel, G. P649
Patel, R. O156
Patel, S. P695, P823, P829, P847,
P874
Patmore, R. O390
Patorkova, M. P1073
Patriarca, F. O115, O119, O252,
P463, P506, P573, P697,
P729, P899, P919
Patriarca, P. P492
Pauksen, K. 223
Paunescu, V. P589
Pautas, C. O153, O389
Pavlicova, V. P997
Pavone, V. O258, P894
Pawlotsky, J.M. O153
Pawlowski, R. P732
Paya, C. O156
Peccatori, F. P1019
Peccatori, J. 97, O264, P664,
P697, P745, P752, P785
Peceny, R. O134, O144, O250,
O350, O376, P675, P677, P726
Pedrazzoli, P. 97, P664, P752
Pedro, C. 71, O249, P922
Peggs, K. O118
Peled, T. O132
Peles Bortz, A. P1050
145

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Pellegrin, B. O153
Pellicanò, G. P795
Pelliniemi, T.-T. P640
Pelosini, M. P912
Peltonen, P. P1030
Peluso, G. P851
Peñalver, F.J. P650
Penarrubia, M.J. P584
Peniket, A. P516
Penna, G. P634
Peny, A.-M. P528
Peralta, T. P1066
Perea, G. 71
Pereira, F. P834
Perel, Y. O365
Pérez, C. P789a
Pérez, E. O255, P886
Pérez, M. P558
Pérez de Oteyza, J. P693
Perez Simón, J. O117, O120, O131,
O255, O298, P498, P534,
P547, P637, P694, P716,
P886, P892
Perez-Bercoff, L. 220
Perez-Calvo, J. O267
Perez-Hurtado, J.M. P828
Peristeri, I. P433
Perotti, C. O371, P553
Perreau, V. P639, P862
Perreau 176
Perrone, G. P678
Perrone, T. O258, P894
Perruccio, K. 70, O139, 319
Perruche, S. O294, P488, P673
Persat, F. P778
Perseghin, P. P610, P753
Persson, U. P561
Perz, J.B. P643
Pescador, L. P667, P755
Pescarollo, A. O264, O377, P745,
P785
Pescosta, N. P801
Pession, A. 182, 184, 189, O361,
O398, P817, P841
Peters, C. O157, 184, O292, P454,
P465, P760, P1070
Peters, S. P767, P1004, P1071
Petersen, H. P1048
Petersen, S.L. P493, P517
Petitjean, G. P804
Petrini, M. P477, P503, P514,
P912
Petriz, J. O298, P430, P438, P558
Petropoulos, D. P433
Petrovskaya, A. P422
Pettengell, R. S28, 235
Pettitt, A P1077, P1078
Peykerli, G. P809
Peyret, M. N969
Pfaffendorf, N. O403
Pfäffle, A. P459
Pfeiffer, M. P453, P459, P671
Pfeilstöcker, M. P434
Pfreundschuh, M. O103
Philip, I. P543
Philip, T. O285
Philippe, N. P777
146
Piacibello, W. P417, P428, P439
Piatkowska-Jakubas, B. P437,
P908
Picardi, A. P554, P754
Picasso, C. P1007
Piccirillo, N. P519
Pichler, J. P454
Picot, S. P778
Pieczonka, A. P833, P840
Piens, M. P777, P778
Pierinelli, S. P817
Pietrantuono, G. O373
Pietras, W. P826
Pihkala, U. P744
Pilati, S. O387
Pilipenko, P. P422
Pillon, M. O152, O162, O361
Pimentel, P. P412, P415, P531
Pimpão, C. P1016, P1026, P1042
Piñana, J.L. O283
Pinazzi, B. P851
Pinedo, P. P1002
Pinho Vaz, C. P531
Pinto, M.R. O370
Pinto, R. P851
Pinto, V. P861
Pioltelli, P. P610, P653
Piroddi, A. O363
Pisa, P. P769
Pisapia, G. P468, P727
Pitha, J. P598
Pitini, V. P619
Pittari, G. P651
Pittermann, E. P434
Pittrová, H. P562
Pivkova, A. P413
Pizunski, A. N946
Planelles, D. O295, O366
Planinc-Peraica, A. P910
Platzbecker, U. O248, P408, P572,
P903
Plesa, A. P589
Plesa, C. P589
Ploemacher, R.E. P579
Plucinski, M. P1079
Poetschger, U. O285
Poggi, V. O361
Pogliani, E. O115, P610, P653
Pohlreich, D. P618, P1067
Poidomani, M. P861
Polchi, P. O405, P624, P791
Polge, E. 80, O124
Politou, M. O114
Polizzi, V. P763
Pollicchieni, S. P492
Pondarré, C. P777, P812
Pongiglione, C. O162
Ponikowski, P. P587
Pönisch, W. O404, P511
Poonawala, G. N949
Popov, L. P1045
Popplewell, L. O257
Porcellinin, A. O104
Porcher, R. O279, O368
Porfirio, B. P461
Porkka, K. 177
Poros, A. P567
Porretto, F. P763
Porta, F. O361
Portos, J.M. N969
Postovsky, S. P629
Potter, M. 220, P690, N949
Potthoff, K. P481, P599
Potting, C. N965, P1062
Pour, L. P636
Power, O. 213
Powles, R. P535, P649
Praire, A. P577
Prakken, B.J. O151
Pralle, H. 79
Pratt, G. O116, P617
Prausova, J. O364
Prebet, T. P543
Preijers, F. P450
Preiss, J. 79
Preloznik Zupan, I. P548
Prete, A. 189, P817, P841
Pretnar, J. P548
Pricolo, G. O109, P468, P727
Prieto, M. P1047
Prieur, A. O161
Priftakis, P. P762
Prince, H.M. P728
Principe, F. P551
Prinz, E. P868
Pritchard, G. P1038
Prosdocimo, S. P463, P697, P729,
P899
Prosper, F. 202, O267
Protsenko, R. P464, P574
Prudenzano, A. O109, P468,
P727
Przybylski, G. P676
Pugachov, A. P683, P721
Puig, N. O366
Pulver, N. P757
Puozzo, C. S37
Purushotaman, V. P1043
Putkonen, M. P524, P640, P657,
P887
Putzulu, R. P519
Pytlik, R. P533
Qasim, W. O149
Qian, W. O104
Quaglia, A.F. P690
Quarello, P. P593, P788
Queipo de Llano, M.P. 71
Querol, S. O379
Quesenberry, P.J. P452
Quinn, B. N977
Quintana-Bustamante, O. O128
Quiroga, D. P1060
Quittet, P. O254
Raanani, P. P635, P863
Raaschou-Jensen, K P458
Rabian, C. 67
Rabitsch, W. P469, P868
Rabusin, M. O361
Radbruch, A. O160, P597, P602,
P670, P676
Radic-Kristo, D. P910
Radka, N. P764

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Radtke, H. P670
Rafel, M. P789a
Rafii, H. P577
Raghuram, C.P. O291
Rahal, M. O259
Rahemtulla, A. O114, O302,
P699
Raida, L. P479, P533
Raida, M. P511
Raiola, A. O281, O402, P522,
P603, P616, P737, P741,
P776,
P1007
Rajamäki, A. P640
Rajananthanan, P. P418
Rambaldi, A. O115, O119, O252,
P492, P515
Rambla, D. P1002
Ramenghi, U. O162, P593
Ramirez, A. 66
Ramírez, M. P421
Ramzi, M. O362, P526, P627
Rana, I. P851
Ranaghan, E. P654
Rank, A. O280
Rao, K. O150, O290, O291,
P704
Rapanotti, C. P851
Rapezzi, D. P758
Rapp, M.J. P501
Rasmussen, S. N961
Rasmusson, I. P427, P431, P717
Räty, R. P887
Rauhala, A. P640
Rauser, G. 316
Ravagnani, F. P897
Ravshanova, R. P464, P574
Razonable, R. O156
Re, A. O108
Re, F. O264
Real, M. O150, N972
Rebollo, J. O267
Rebulla, P. P583
Recher, C. O102, P891
Reczuch, K. P587
Reddiconto, G. P519
Regateiro, F. O143
Regidor, C. 320, P421, P650
Reichert, M. P732
Reichle, A. P856, P895
Reid, L.C P1009
Reid, S.D. P632
Reiffers, J. 176
Reig, M. O295
Reinhardt, D. O301
Reiser, M. P909
Remberger, M. 97, O261, O278,
P505, P561, P665, P722,
P762, P769, P916
Reményi, P. P630, P764
Remes, K. P524, P640, P887
Remigia, M. O295, O366, P768,
P902
Renga, M. P752
Renges, H. O352, P735, P917
Repping, J.W.J. P1027
Requejo, A. P789
Resino, S. O253
Reske, S. O245, O304, P485
Resnick, I. P539, P591, P686
Réti, M. P630, P764
Reufi, B. P424
Reusser, P. 223, O272
Revesz, T. 184
Rezaei, A. P607
Ria, R. P802
Ribaud, P. S23, 223, O271, O279,
P743
Ribeiro, A. P601
Ribeiro, M.J. P834
Ribera, J. O107, O125, O249,
P497, P508, P922, P922
Ribera, J.M. 71, O253, P451
Ribersani, M. P869, P881
Riccardi, M. O260
Riccioni, R. P477
Rice, A. O393, P719
Richards, S. 176
Richardson, J. N978
Richter, G. P698, P723
Ridwan, R. P695, P823, P829,
P847, P874
Rieger, C. P761, P787
Rieger, K. P424, P911
Riera, L. P540
Rieux-Laucat, F. O145
Rifon, J. O107, O267
Rigacci, L. O106, P896
Rijkers, G.T. P775
Ringdén, O. 78, 97, O155, O261,
O269, O276, O278, P427,
P431, P436, P473, P505,
P561, P665, P717, P722,
P769, P916
Ringes-Lichtenberg, S. 68
Ringhoffer, M. O245, O304, O369,
P485, P780
Rintala, T. P569
Rio, B. P633
Rio, P. O129
Rist, N. P648
Ristic, L. P563
Ritchie, L.A. N949
Ritgen, M. O406
Rivas, R. O380
Riveros, D. P540
Rivière, A. P528
Rizzo, E. P470
Rizzo, G.F. O363
Rizzoli, V. P651
Roberti, C. P851
Robertson, K.A P1035
Robinson, S. P696
Rocha, E. O267
Rocha, V. 67, 74, 75, 80, O124,
207, O244, O279, 318, O367,
932, P999
Rodary, C. O365
Rodet, M. O389
Rodrigues, M.-C. P601
Rodrigues Fernandez, J. 220
Rodriguez, A. P864
Rodriguez, M.C. N964
Rodriguez, R. O257
Rodríguez, L. P451
Rodriguez-Sanchez, J. P701
Rodriguez-Villa, A. O165, P828
Roelofs, H. P674
Rogers, T. P781
Rogler, G. 52
Rohde, E. P679
Rohde, F. O272
Rohrberg, R. P889
Roig, R. P555
Roigas, J. 96
Rolink, A. P804
Rom, E. P1017, P1031
Romagnani, P. P429
Roman, A. P513
Roman, J. 62, P693
Romani, L. O139
Romano, A. O370
Rombouts, E.W.C. P579
Romejko-Jarosinska, J. P888
Romeo, M. P653
Romero, T. P1051
Roncon, S. P412, P415
Rondelli, D. P678
Rondelli, R. O306, O361, P817,
P841
Roosnek, E. P447
Ropes-de Jong, C. P838
Rosales, M. P531
Rosen, O. P670
Rosenberg, P. O164
Rosendahl, K. P427
Rosenmayr, A. O292, P469
Rösler, W. O372
Rossi, G. O108, P550, P736
Rossini, F. P653
Rosti, G. 97, O265, O268, 931
Rothe, G. P856
Rotta, M. O115
Roucoules, O. O392, P532
Rousseau, Y. P1063
Roveda, A. O370
Rovelli, A. P753, P814
Rovira, M. 220, 222, 223, P875
Rovo, A. P588
Rowe, J.M. 176, O386, P629, P700
Rowe, M. P1020
Rowlings, P.A. P611
Rozman, C. P611
Ruan, X. P418
Rubie, H. O365
Rubio, V. P508
Rubio-Félix, D. O125
Rüden, H. P734
Rudolph, C. P909
Ruel, P. N947
Rugal, V. P596
Ruggeri, L. O139, 319, O375
Ruhnke, M. O271
Ruijs, W. P450
Ruiterkamp, B. P1003
Ruiz, C. 182
Ruiz, E. 320, P650
Ruiz, I. N964
Ruiz, M.A. O353
Ruiz de Elvira, C. O287, 928, 929,
934
147

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Ruiz-Soto, R. P794
Runde, V. 69, P920
Rupolo, M. O108, P770
Rusconi, C. P800
Russel, J. S17, S38
Russell, N. S100, O263
Russo, F. P802
Rüster, B. O127, P425
Rutt, C. P572
Ruutu, T. 223, O244, P480, P538,
P565, P746, P749
Ryan, P. N970
Rybka, B. P587, P846
Rybka, K. P815
Ryczan, R. P587, P846
Ryder, L.P. P493, P517
Rymkiewicz, G. P888
Saalman, R. P813
Saarinen-Pihkala, U. P790
Saas, P. O294, P488, P673
Saccardi, R.83, O159, P429, P582,
P779, P795, P896
Sadoun, A. O121
Safavifar, F. P625, P927
Saglio, G. O159
Sahebi, F. O257
Sajdová, J. P618
Sakellari, I. O388, P518, P798,
P872, P905
Salaj, P. P598
Salaris, D. P745
Salavert, M. P789a
Sales, I. P430, P438
Salgado, E. O267
Salinero, M. O305, O305
Salmon, A. P774
Salooja, N. O302
Salvador, C. N969
Salvaneschi, L. O371, P553
Salwender, H. 79
Sami, I. P629
Sammek, E. P481
Samuel, S. P467, P539, P686
San Miguel, J. O117, O255, P497,
P498, P508, P637, P886
San Miguel, J.F.O131, O305, P419,
P435, P534, P547, P557,
P694, P716, P892
San Roman, C. N985
San Román, A. P584
Sanavio, F. P439, P443
Sanchez, A. P584
Sánchez, C. P1066
Sanchez, J. 71, O249, O396, P864
Sanchez-Abarca, L.I. O131, P419,
P557
Sánchez-Abarca, I. O298
Sánchez-Calero, J. O165
Sanchez-Guijo, F.M. O131, P419,
P557, P694, P716
Sancho, J. O380, P451
Sander, A. P825
Sandmaier, B. O115, O262
Sanjuan, I. 320, P650
Sanjurjo, M. P552
Sanli, H.E. P730
148
Sanna, M.A. O363
Sanosa, M. P1051
Santanna, C.-L. P601
Santarone, S. P515
Santiago, J. P858
Santoro, A. P470
Santos, E.B. O262
Santos, L. P531
Santos, T. P1025
Santucci, A. O375
Sanz, G.
Sanz, G. O120, O295, 334, O354,
O356, O366, P498, P559,
P613, P693, P768, P902
Sanz, J. O366, P768
Sanz, M. 222, O295, O366, O380,
P559, P768, P789a , P902
Sanz Jr., M. P789a
Sanz-Rodríguez, C. P693
Saracco, P. P439, P593, P788
Sargin, D. P527
Sarrá, J. P497, P498, P508, P922
Sastre, A. 323
Sauerland, C. O247
Saul, P. P1014
Savina, J. O289
Savino, L. P725
Savio, C. P523
Savolainen, H. P744
Savran, F. P818
Savran Oguz, F. P720
Sawinski, K. P878
Sayer, H. O117, O118, P483, P637
Scalone, R. P763
Scarponi, A.M. P802
Scarso, L. P852
Scatena, P. P912
Schaaf-Lafontaine, N. P490
Schaafsma, M.R. P486
Schaefer-Eckart, K. 222, O372,
P480, P715
Schaffer, M. P473, P476, P561
Schaich, M. O247, O248, P408
Schäkel, U. O248
Schanz, U. 325
Scharner, D. P454
Schattenberg, A.O246, O270, P450
Scheer, J. P520
Scheid, C. P581, P784, P909
Scheringa, A. N947
Schetelig, J. O384, P445, P614
Scheulen, M.E. P685
Scheuringer, H. O308
Scheuß, H. P898
Schiantarelli, C. O108
Schiavo, R. P664
Schieder, H. O352, P731, P735,
P917, P921
Schiel, X. P705, P761, P787
Schiemanck, S. O384
Schiller, I. O403
Schilling, G. P637
Schilling, K. P483
Schimmel, H. P1031
Schindler, D. O289
Schipper, L.F. P432
Schlegel, P.-G. P811, P820
Schleier, E. P499
Schlenk, R. 79, O245, O247,
O369, P485, P780
Schleuning, M. O299, O357,
O382, P484
Schmah, O. P576, P860
Schmid, C. P484
Schmid, H. P825
Schmid, T. P780
Schmidt, A. O141
Schmidt, C.A. P676
Schmidt, M. P1057
Schmitt-Gräff, A. P599
Schmitz, G. P713
Schmitz, N. S27, S32, O103, O105,
215, 229, O374, P462, P672
Schneider, M.M. O163
Schneider, P. P641
Schnürer, E. O136, O141
Schoch, R. P885
Schoenland, S. P643
Scholl, S. P483
Schölmerich, J. 52
Scholte op Reimer, W. P1062
Schönberger, S. P822
Schönfelder, U. P511
Schöpflin, C. O369
Schots, R. O123, 326, P915
Schouten, H. 69, O104, 211, 234,
O246, O282
Schrappe, M. P825
Schrey, U. P733
Schrezenmeier, H. 187, 188, 189,
192, 193, 195, 341
Schroeder, H. P715
Schroyens, W. O123
Schulenburg, A. O308
Schuler, U. O248, O271, P499
Schulte, C. O303
Schulz, A. 322
Schumm, M. O286, P453, P671
Schutzova, M. P612, P636
Schwabe, D. P832, P848
Schwartz, S. O271
Schwarz, K. 322
Schwarzl, A. P1052
Schwerdtfeger, R. O117, O118,
O135, O299, O357, O372,
O381, O382, P637
Schwinger, R. P581
Schwinger, W. P849
Schwittay, M. P511
Scimè, R. O119, O251, O260,
O281, P470, P506, P712
Scortechini, I. P893
Screnci, M. O370
Scuderi, F. P852
Scudla, V. P636
Scudlova, J. P997, P1065
Sebban, C. O254
Secondino, S. P664
Sedzimirska, M. P880
Seeber, S. P685
Seger, R. 325
Seghezzi, L. O377
Segovia, J. 66, O128, O129, O165,
O165, P590

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Segura, S. P1000, P1076
Seguy, D. O383
Seidel, C. P427
Seidl, C. P606, P832
Seifried, E. P606, P832
Seitz, O. P425
Seitz, U. O245
Selleri, C. O281
Selleslag, D. 69, O123
Selmani, Z. P420, P442
Seltz, F. O142
Semin, P. P422
Senent, L. O295, O366
Sengelov, H. P493
Seo, J. P998
Seol, M. P855
Seppänen-Savela, T. P1030
Sepúlveda, P. P411
Serban, M. P589
Serbest, E. P709
Sergent, G. P794
Sermon, K. 326
Serrano, C. P1032
Serrano, D. O253, P578, P693,
P926
Serrano, J. P864
Servida, P. O377, P745,
P785
Sessarego, M. P616
Setola, E. P664
Sette, A. O151
Sevilla, J. O165
Seyfarth, B. O105
Sezer, O. O307
Shamshiri, A. P844
Shankari, J. P695, P823, P829,
P847, P874
Shapira, M. P539, P591, P686
Shaughnessy, P.J. P728
Shaw, B. P690
Shaw, P. 220, 222
Shemtov, N. P635, P863
Shergold, J. P991, P1035
Shevchenko, Y. P797
Shimazaki, C. P644
Shimoni, A. O117, O118,
O122, O378, P635,
P637, P863
Shin, H.Y. P836, P843
Shin, S. P998
Shinkoda, Y. P831
Shipitsina, I. P594
Shizuru, J. P511
Shoen, S. N963
Shpall, E.J. 335
Shtalrid, M. P622
Shvidel, L. P622
Sibilla, S. O373
Sica, S. O281, P519
Siebert, D. P1035
Siebert, R. P885
Siegel, S. P672
Siegert, W. P614
Siena, J. 97
Siena, S. P664, P752
Sieniawski, M. P890, P898,
P909
Sierra, J. S14, S19, 71, 97, S99,
O107, O120, O125, O249,
O283, O298, P497, P498,
P508, P559, P613, P620,
P693, P701P789a, P922, N989
Siitonen, T. P657
Siljanovski, N. P413
Sill, H. P1046
Silla, L. O353, O387
Silva, R. O143
Silva-Jr, W. O279
Silvestri, F. P573
Simic, L. P556, P563
Simoes, B. P484
Simón, A. P578
Simone, F. P869
Simonelli, C. P770
Simonelli, S. P1080
Simonitsch-Klupp, I. P469
Simpson, E. O395, P692
Sinclair, S. N960
Sinha, R. P695, P829, P874
Sinkó, J. P764
Sinnott, P. P569
Sipka, S. P605
Siracusano, L. P619
Sirohi, B. P535, P649
Sisca, I. P589
Skert, C. P729, P879, P899
Skoda, I.K. P1058
Skopek, P. P598, P612, P876
Skorobogatova, E. P594
Skotnicki, A.B. P437, P900, P908
Skoumalová, I. P479
Skranc, S. P479
Skvortsova, Y. P594
Slaby, J. P533, P598
Slatter, M.A. 327, 328, P537
Slavin, S. O268, P467, P539,
P591, P686, P805
Slociak, M. O358, P821, P826
Slot, M.C. P432
Smelhaus, V. O364
Smias, C. P518
Smiet, A.C.M. P1003
Smit, W.M. P486
Smith, C. P1028
Smith, D. O257
Smith, E.P. O257
Smith, G. O390, P491
Snyder, D. O257
Socié, G. O121, O164, 188, 189,
191, 195, 219, 236, 243,
O279, 343, P1080
Sodani, P. O405, P624, P791
Soeiro, I. O130
Soerensen, J. P848
Sohn, S. P740, P1074
Söhngen, D. P784
Solamani, M. P441
Solano, C. O120
Solari, A. O159
Soler, M. O366, P555
Soligo, D. O115, P470, P492,
P502
Soliman, C. N967
Solimano, J. P540
Solves, P. P411, P555
Somasegarem, P. P874
Sommer, D. P424
Song, B.E. P1081
Sonnen, R. O105
Sorà, F. P519
Soracco, M. P737
Sorio, M. P801
Sotto, J.J. O110, P633
Souillet, G. P777, P812
Sousa, C. P412, P415
Southwick, P.C. 317
Soydan, E. P494, P496, P571,
P655, P689, P748, P771, P904
Sparrelid, E. O155
Specchia, G. O373
Specchia, M. O109
Sperli, D. P593
Sperotto, A. P463, P573, P697,
P707, P729, P879, P899, P919
Sperr, W. P868
Spielberger, R. O257
Spina, M. O108, P770
Spiropoulou, A. P433
Spitaleri, L. P893
Spoehrer, U. P761
Sponerová, D. P618
Sportoletti, P. O297
Spyidonidis, A. O133
Spyridonidis, A. P481, P576, P792,
P860
Staak, J.O. P890, P898, P909
Staehelin, F. P845
Stamatopoulos, K. P872
Stamatovic, D. P556, P563
Stamm, C. 203
Stani, L. O109, P468, P727
Stanzani, M. P803, 938
Starrenburg, C.W.J. P486
Starrenburg, I. P870
Stary, J. 184, P681
Statham, P. N988
Steckel, N. O250, P677, P859
Stefanaki, K. P433
Stefanic, M. O245, P873
Steidl, U. O284, P536, P652
Stein, A. O257
Stein, J. P475, P566, P1050
Steinbrenner, M. P766
Steiner, B. P796
Steinerova, K. P876, P925
Stelitano, C. O106, P747
Stemmer, S.M. P863
Stephens, E. P491
Stephens, M. N943, N990
Steward, C. O291, 324, P696
Sticherlin, M. P711
Stilgenbauer, S. O369, O406, P780
Stocchi, R. P573, P707, P729
Stockelberg, D. P1023
Stockholm, D. O145
Stojanoski, Z. P413
Stojanovik, A. P413
Stone, J. N951
Stoodley, N. 324
Stoppa, A. P639, P862
Storb, R. O115, O262, P511
149

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Stracciari, A. P803
Stracieri, A.-B. P601
Strahm, B. 184, P628
Straka, C. P645
Strauss, G. 321
Stravets, T. P700
Stringer, J. N945
Stroszczynski, C. 96
Strunk, D. P679
Stryczynska, G. P833
Stuart, M. P511
Stuhlmann, R. O105
Sturgess-Durden, L. P1059
Stute, N. O352, P731, P735, P921
Styczynski, J. P865
Subedi, J. P786
Suchnicki, K. P880
Suciu, E. P589
Suciu, S. 69
Suela, L. N985
Suero, M. P1034
Sullivan, L.A. 317
Sumerauer, D. O364, P661
Sundberg, B. P427, P431, P665,
P717
Sundin, U. P473, P476
Sung, W. P740
Suntzova, E.V. O163
Suppo, G. P554
Sureda, A. 57, O107, O125, 232,
O283, O354, O356, P497,
P498, P508, P620
Surrallés, J. O165
Sustercic, D. P910
Sutton, L. O368, P609
Suvova, J. P1065
Svahn, B.-M. O278
Svahn, J. O162
Svanberg, Ac P1053
Svejgaard, A. P493
Svenberg, P. P722, P769
Svennilson, J. P722
Sverdlov, Y. P566, P1050
Sviland, L. P407
Svojgrová, M. P612
Swansbury, J. P874
Swindell, R. N945
Switzer, G. 312
Sydes, M. O104
Sydow, U. 321
Sykora, K. P825, P849
Szabó, J. P595
Szatkowski, D. P621
Szer, J. P482
Szomor, A. P525
Szostek, M. P437
Szydlo, R. O114, O302, P699
Szymczak, B. P1061
Tabak, D. O353
Tabani, K. P1080
Tabilio, A. O297, P802
Tabrizi, R. P639
Tagliabue, A. P814
Takagi, S. P495, P512
Takagi, T. P644
Takatsuki, K. P644
150
Talarn, C. O298
Talavera, M. O165
Talvensaari, K. 67
Tamayo, P. O255, P886
Tamborero, G. P1034
Tamburini, A. P461, P554
Tammik, C. P427, P436
Tamouza, R. 318
Tan, A. P1082
Tan, S. P1043
Tanabe, T. P831
Tanasini, R. P523
Taniguchi, S. P495, P512
Tanimoto, M. O277
Tansey, D. N984
Taou, D. N963
Tapias, M. O165
Tapprich, C. O284
Tarabar, O. P556, P563
Tarella, C. O119, O252, P470,
P502, P506, P623
Taskinen, M. P790
Tassara, M. P785
Taverna, C. P648
Taylor, L. N962
Taylor, P.C P409
Tbakhi, A. O259
T.Bilgin, F. N979
Tedeschi, A. P529, P658
Tedone, E. P737
Telli, S. O398
Telschik, H.-M. P459
Ten Cate, R. O161
Tendas, A. P754
Teodósio, C. O143
Terpos, E. O114
Terranova, M.P. P852
Terruzzi, E. P653
Teruel, A. P545
Testi, A.M. O370
Teti, D. P619
Tezcan, G. P835
Thaler, D. P679
Theelan, B. P783
Theilgaard-Mönch, K. P458
Theobald, M. 210
Theodosaki, M. P433
Theunissen, K. O123, P460
Theuser, C. O135, O384
Thiébaut, A. P778
Thiede, C. O248, O384, P445,
P472, P614, P903
Thiel, A. O160, P597, P602, P670,
P676
Thiel, E. O271, P424, P911
Thienel, U. P728
Thödtmann, R. O382
Thomas, V. P449, P457
Thomas, X. O121, P577, P778
Thominet, D. O392
Thomson, E. P781
Thomson, J. P457
Thomson, K. O118
Thorne, R. O359
Thörne, A. P769
Thrasher, A. O149
Thys, L. P1029
Tiberghien, P. O294, P488, P673
Tichelli, A. 188, 191, 195, 238,
P588, P804
Tilly, H. O102
Timarco, C. P881
Timeus, F. P439
Tintori, V. P461
Tirelli, U. O108, P770
Tiribelli, M. P463, P919
Tischer, J.P484, P761, P787, P867
Tobler, A. O268
Todeschini, G. O106
Todoric-Zivanovic, B. P556
Tomadini, V. P919
Tomas, J.F. O117, O354, O356,
P513
Tomas Martinez, J.F. S41, S46
Tomiska, M. P509
Tonelli, R. O398
Tonn, T. P606
Tönnies, H. O289
Top, B. O156
Topcuoglu, P. P494, P496, P571,
P621, P655, P689, P771
Topini, F. 70
Toporski, J. O358, P587, P666,
P815, P821, P826, P827,
P830, P837, P846, P865
Topp, M.S. S6, 316, P638
Toprak, S.K. P655
Torjman, L. O385, P521
Törmänen, V. P782
Tormo, M. 71, O249
Tornaghi, L. P610
Tornello, A. P861
Torrabadella, M. O379, O380, P451
Torrent, M. P793
Torres, A. O298, O354, O396,
P559, P613, P693, P858, P864
Torres, P. 71
Torri, G. P745
Torrico, C. O379
Tossios, P. P581
Tosti, A. 70, O375
Toth, O. P525
Toubert, A. 67
Trabasso, P. P773
Traineau, R. 318
Trakhtman, P. P594
Trautmann, S. O384
Travade, P. P609
Treleaven, J. P535, P695, P823,
P829, P847, P874
Tremmel, A. P630
Trenschel, R. O250, O350, P675,
P677, P685, P726, P859
Trethewie, S. N954
Tridello, G. O152
Trigo, F. P551
Trilsbeek, C. P450
Tringali, S. P712
Trisolini, S.M. P881
Trneny, M. P533, P598
Trnkova, M. P533, P924
Trocino, G. P814
Troiani, E. P893
Trojan, A. P648

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Troke, P. O271
Troncy, J. P577, P778
Trümper, L. O103, P462
Trust, P. P1057
Tsolakis, F. O122
Tucci, F. P461
Tüchler, H. P434
Tugrul Saribeyoglu, E. P809
Tukic, L. P556, P563
Tullio, C. P664
Turin, I. O300
Turkiewicz, D. O358, P587, P666,
P815, P821, P826, P827,
P830, P837, P846
Turner, B. P719
Turpeenniemi-Hujanen, T. P887
Turró-Castillejo, M.A. P1056
Turton, J.R. P570
Tyndall, A. 60, 81, O158
Uderzo, C. 184, 237, O281, O306,
O361, P753, P814
Ueno, N. 95
Ueyama, J. P495, P512
Uharek, L. O140, O154, P511
Uhlmann, E. P723
Uhrberg, M. O140
Ullmann, A.J. 218, 222, 223
Ullrich, H. P713
Ulu, A. P807
Urban, C. P849
Urbani, E. O375
Urbani, S. P429, P582
Urbano Ispizua, A. O120, O125,
O298, O374, P497, P498,
P508, P875
Urbanowska, E. P544
Urbini, B. P678
Ussowicz, M. O358, P837
Ustaer, N. P904
Uysal, A. P494, P904
Uziel, G. P753
Uzunel, M. O261, P473, P476,
P717
Uzunov, M. P504
Vacca, A. P802
Vadikolia, C. P905
Vaessen, N. P765
Vainas, O. P478
Valcarcel, D. P497, P498, P508
Valcárcel, D. O283, P620
Valencia, A. O295
Valent, P. P868
Valetto, A. P852
Vallejo, C. P613, P693
Valteau-Couanet, D. O365, P819
Valverde, M. N964, P1000, P1002,
P1076
van Achterberg, T. N965, P1062
Van Ackerbroeck, G. P1029
van Baarle, D. P739
van Besien, K. P728
van Biezen, A. 175, 181, O246,
O355, P920
Van de Velde, A. P915
Van de Velde, H. 326
van de Wiel-van emenade, E. O137
Van Den Neste, E. O256
van der Burg, M. P839
Vanderheyden, M. S9
van der Holt, B. O275
van der Lelie, H. N968
van der Lelie, J. P1044
van der Straaten, H.M. O246
van der Velden, A.M.T. P775
van der Woude, H. N948
van Dongen, J. P839
van Doornen, G.J.J. 317
van Hensbergen, Y. P432
van Iperen, F. N950, N953, N955,
P1055
van Laar, J. O158
van Lint, M.T. O281, O402, P603,
P616, P737, P741, P776
van Royen-Kerkhof, A. P600
van Schie, M.L.J. P669
Van Steenweghen, S. P915
Van Steirteghem, A. 326
van Tol, M. P626, P739,
P751
van Velzen-Blad, H. P775
van Vliet, M. N965
van Walraven, A. P838, N950
VanClee, A. O282
Vandecruys, E. P631
Vannucchi, A. P428, P492, P779,
P795, P896
Vanstraelen, G. P490, P500
van'tLand, B. O270
Varghese, Z. P418
Varotto, S. O152, O306, P593
Varvarovska, B. P925
Varvenne, M. P507
Vasaturo, G. N957
Vasova, I. P509
Vassal, G. S36
Vaupel, M. O284
Vavilov, V. P683, P721
Vaz, C.P. P412, P415
Vázquez, L. P497, P534, P547,
P694, P789a, P716, P892
Vela, E. P854
Velangi, M.R. P654
Velardi, A. 70, O139, 319, O375,
P465, P824
Velikova, G. O307
Venturi, C. P443
Verbeek, M. P1072
Verdeguer, A. P559, P828, P853
Verdonck, L.F. O246
Verga, L. P653
Verhoeven, M. N948, P1027
Vermeulen, N. P1027
Vernant, J.P. O368, O391, P532,
P633
Vertesi, G. P605
Vettenranta, K. P744
Vey, N. O351, P444, P706, P862
Veys, P. O150, O161, O290, O291,
O359, P474, P600, P704
Viarengo, G.L. O371, P553
Vicario, J. O148
Vicha, A. P661
Vidal, F. P1060
Vidal, M. O107
Vidal, N. N964
Vidal, S. P701
Vieira, E. P834
Vieira, L. P592
Vieites, N. P1060
Viens, P. P456
Viganò, E. P814
Viganò, M. O108
Vignetti, M. 930, 931
Vigorito, A.C. O353, P913
Vilà, R. O249
Vilela, G. O279
Villamor, N. P471
Villarón, E.M. O131, P419, P557
Villegas, A. O165
Villiva', N. P881
Vindelov, L. P493, P517
Viola, A. P857
Viret, F. P456
Visani, G. P791
Viscoli, C. P741, P776
Vítek, A. P618
Vitkova, J. P997, P1065
Vitolo, U. O258
Vitrischak, A. P721
Vittinghus, L. P1057
Vivancos, P. 71
Vizcaino, F. P1047
Vlachová, S. P479
Vodvarkova, S. P598
Vogelsang, H. P733
Vogeser, M. P761
Voigt, A. O403
Voillat, L. O110
Vokurka, S. P564, P612, P876,
P996, P1065
Volfova, A. P564, P996
Volin, L. P480, P565, P746, P749
Volpi, A. P754
Volpi, I. 70
Voltarelli, J. O353, P601
von Harsdorf, S. O245, , O304,
O369, P485, P780
von Hinüber, R. P735
Vondráková, J. P479
Vora, A.J. P546
Vorlicek, J. P636
Vormoor, J. O289
Vos, H. N974
Vozobulová, V. P612
Vrhovac, R. P910
Vrzalova, A. P924
Vytrasova, M. P646
Wabersich, M. P615, P889
Wachowiak, J. P826, P833, P840,
P865
Waelchli, L. P447
Wagner, A. P672
Wahlin, A. 222
Waldmann, H. P449, P873
Waldschmidt, D. P784
Walewski, J. P888, P900
Waller, C.F. P914
Waller, E. O138
151

List of Speakers and Authors
Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.
Walls, E. P1001, P1022
Walter, Z. P437
Wandt, H. O265, O372, P480,
P637, P715
Wang, J. P708, P728
Wang, X. P407, P702
Waßmann, B. P703
Wass, J. P535
Waterhouse, C. 79
Waterhouse, M. O133, P481
Watson, M. O307
Watts, M.J. P448
Wawer, A. P724
Webb, D. O290, O291
Weber, M. P682
Weber, P. O368
Wedderburn, L. O161, P600
Weddige-Diedrichs, A. 321
Weemaes, C. P839
Wehler, T.C. O136
Weinstock, C. P459
Weis, J. 239, O307
Weiß, K. P483
Weise, M. O384
Weiss, M. N952
Weisser, M. P705, P867
Weissinger, E. O280
Welch, J.C. P546
Welte, K. P825
Wenzler, S. P734
Wernet, P. P822
Wersäll, P. P769
West, S. P696
Westgren, M. P436
Westin, S. P1075
Wetzig, T. P711
White-Scharf, M. P579
Whyte, M. P1035
Wiesneth, M. O245, O369,
P485, P873
Wijermans, P. 69
Wiklund, T. P887
Wiktor-Jedrzejczak, W. 179
Wilbur, D.S. O262
Wild, C. P606
Wild, P.J. P856
Wilkinson, R. P995
Will, A. O291, P842
Wille, A. 96
Willemze, R. 69, O126, O147,
P486, P669, P765, P870
Willichowski, E. 321
Wilson, C. N958
Wilson, J. O393
Windrum, P. P538
Winiarski, J. O155, O276, P762
Winkler, J. O372
Winkler, T. O372, P507
Winship, K. 324, P696
Wirth, K. P483
Witt, M. P840
Witt, V. P454
Wittig, S. O403
Wodnar-Filipowicz, A. O293
Woelfel, T. P750
Wojciechowska, M. P871
Wojcik, B. P666, P865
152
Wojcik, D. 238, O358, P821,
P826, P837
Wojnar, J. P580, P871
Wölfel, C. O136, O141
Wölfel, T. O141
Wolff, D. P796
Wolff, I. O403
Wollert, K.C. 68
Wolschke, C. O352, P731, P735,
P917
Won, J.H. P423, P446
Worel, N. P469, P487
Woywodt, A. P520
Wrench, D. P690
Wulf, G. P462
Wulffraat, N. O161, P600
Wylezol, I. P580
Wynn, R. O291, P842
Wysocki, M. P865
Wysoczanska, B. O394, P850,
P880
Xagorari, A. P585, P586
Xicoy, B. P451
Xie, W.Z. P710
Yakoub-Agha, I. O383, O400,
P633
Yakouben, K. 223
Yalcinkaya, F. P806
Yaman, A. O381, O382
Yanada, M. O277
Yañez, L. P1049
Yañez, R. P650
Yaniv, I. O268, P475, P566,
P1050
Yannaki, E. P518, P585, P586
Yates, F. O142, O145
Ye, X.J. P710
Yeshurun, M. O122, O378,
P635, P863
Yesilipek, M.A P835
Yildirim, N. N979
Yong, A. P1043
Yoon, S. P466, P998
Yorulmaz, I. P748
Yoshida, T. P644
Yoshimi, A. P681
Younis, A. P575
Yuji, K. P495, P512
Yuksel, M.K. P655
Yun, J.H. P1081
Yun, T. P466
Yun, Z. O155
Zabelina, T. O117, O118, O352,
O401, P637, P683, P731,
P735, P917, P921
Zachee, P. O123
Zago, M.A. O279
Zahalkova, J. P646
Zain, J. O257
Zaiss, M. P856
Zaja, F. O106, P463, P573, P729,
P899, P919
Zakerinia, M. P526, P627
Zakernia, M. O362
Zallio, F. O119, O252
Zaluska, A. P908
Zambelli, A. P752
Zamora, C. O380
Zanazzo, G. P593
Zander, A. 59, O117, O118, 219,
O352, O378, O401, P480,
P637, P683, P731, P735,
P917, P921
Zanette, D. O279
Zanussi, S. P770
Zapletalova, J. P533
Zappová, D. P1067
Zaraiski, M P721
Zaritsky, A.Y. P907
Zaucha, J.M. P621
Zaucha, M. P732
Zaucha-Prazmo, A. P666
Zdzilowska, E. P437
Zecca, M. 184, O300, P593
Zei, T. O297
Zeis, M. P672
Zeiser, R. O133, P914
Zenz, T. O245, O304, O369, P485,
P780
Zetterberg, E. P436
Zey, C. O299
Zhang, J. P710
Zhang, W.P. P708
Zharikova, L.I. O163
Zheng, W.Y. P710
Zhou, H. P708
Zibert, A. O397
Zikesova, E. P533
Zilberman, I. P539
Zimmer, K. P572
Zimmermann, S.Y. P848
Zinke-Cerwenka, W. P1046
Zinno, F. P816, P851
Zintl, F. O161, O403, P733, P766
Zipperer, E. P454
Zoetbrood, A. O137
Zorbas, I. P872
Zoubarovskaya, L. O401, P907
Zschille, W. P889
Zuazu, J. P693
Zubani, A. P1019
Zubarovskaya, L. P721
Zuckerman, M. P786
Zuckerman, T. O386, P700, N975
Zulli, R. O353
Zver, S. P548
Zwart, I. P418

General Information
Venue and Address during the Meeting
Palau de Congressos de Catalunya and
Hotel Rey Juan Carlos I
Av.Diagonal, 661-671
08028 Barcelona / Spain
www.pcongresos.com / www.hrjuancarlos.com
Tel. +34 93 364 44 57
Fax +34 93 364 44 58
Dates
Sunday, March 28, 2004 through
Wednesday, March 31, 2004
Language
English
Address before and after the EBMT 2004
ISAM-EBMT
Organising Secretariat
c/o AKM Congress Service
PO Box, 4005 Basel / Switzerland
Tel. +41 61 686 77 11
Fax +41 61 686 77 88
E-mail: ebmt@akm.ch
www.akm.ch/ebmt2004
Opening hours:
Monday–Friday during CET business hours.
Congress Registration
All documents including registration packets (congress
wallet, personal name badge, abstract book,
vouchers) will be handed over to the registered
participants during the following opening hours:
Saturday March 27, 2004: 18.00 – 19.00 h
Sunday March 28, 2004: 09.00 – 19.30 h
Monday March 29, 2004: 07.30 – 18.30 h
Tuesday March 30, 2004: 07.30 – 18.30 h
Wednesday March 31, 2004: 07.30 – 15.00 h
Registration Fee
Payment
All fees for the congress registration and social
events should be paid in EURO (EUR) – clearly
stating the participant‘s name and address –
–by bank transfer (free of charge) to
UBS AG, Kloten/Switzerland,
Account No. 278-821.000.64N (EBMT 2004)
– IBAN Code: CH15 0027 8278 8210 0064 N
Clearing Number: 278 /
Swift Code: UBSWCHZH80A
–by credit card (Visa, Eurocard/Mastercard
or by bank cheque).
– beneficiary: EBMT 2004
c/o AKM Congress Service
Responsibility
The participant acknowledges that he/she has no
right to lodge damage claims against the organisers
should the holding of the congress be
hindered or prevented by unexpected political or
economic events or generally by force majeure,
or should the non-appearance of speakers or
other reasons necessitate programme changes.
With registration, the participant accepts this
proviso.
Confirmation
Upon receipt of the correct registration fee,
each participant will receive a confirmation of
registration. Please bring this confirmation to
the registration desk at the conference center
as proof of your registration.
until as from January 16 As from
January 15, 2004 to March 4, 2004 March 5, 2004
Physicians EBMT-Member € 300.– € 375.– € 425.–
Non-Member € 375.– € 450.– € 500.–
Nurses EBMT-Member € 220.– € 280.– € 330.–
Non-Member € 280.– € 350.– € 400.–
Data Management EBMT-Member € 220.– € 280.– € 330.–
Group Non-Member € 280.– € 350.– € 400.–
Accompanying Person € 25.– € 25.– € 25.–
The fee for active participants includes unlimited access to all Sessions, the Welcome Reception, access to the Exhibition, one copy of
the Final Programme and one copy of the Abstract Book. The fee for accompanying persons includes the Welcome Reception and
access to the Exhibition.
153

General Information
Cancellation / Refund Policy
Refund of registration fees, less 25% administrative
charges, can be applied for in writing
until January 31, 2004 to the Organising
Secretariat in Basel / Switzerland. After this
date no refund will be possible. For any change
of names, a fee of EUR 30.– will be charged.
Badges
Access to all scientific events will only be
possible with your personal badge which you
will receive at the registration desk in Barcelona.
Please always wear your badge!
Lost badges will only be replaced with proof of
your original registration.
Final Programme
The final programme is also available on the
internet www.akm.ch/ebmt2004
Exhibition
An exhibition of the latest technical equipment
and pharmaceutical products will take place in
the exhibition hall on Level 0 of the congress
venue.
Exhibition Dates and Hours
Sunday March 28, 2004 13.00 h–21.30 h
(20.00–21.30 h Welcome Reception in the exhibition hall)
Monday March 29, 2004 08.30 h–18.00 h
Tuesday March 30, 2004 08.30 h–18.00 h
Wednesday March 31, 2004 08.30 h–12.30 h
EBMT Society Booth
Throughout the congress, EBMT staff will be
available at the EBMT booth to answer any
questions you may have or to deal with any
matters concerning the EBMT Society.
Important elections are being held this
year and you are encouraged to vote.
The EBMT booth is located in the exhibition hall
(Booth Nr. 171).
Lunches
On Monday – Wednesday, lunch bags will be
served in the Palau de Congressos de Catalunya.
154
Internet Corner
Internet terminals will be availbable for all
congress participants in the exhibition hall.
Hotel Accommodation
Before the Meeting
AKM Travel AG
Messeplatz 10
CH-4016 Basel / Switzerland
Tel. +41 61 690 94 11
Fax +41 61 690 94 14
e-mail: ebmt@akmtravel.ch
During the Meeting
AKM Travel will be present at a special desk in
the registration area during the meeting. Please
contact the counter “Hotel” during the congress.
Tel. +34 93 364 44 55
Fax +34 93 364 44 56
‘EBMT Annual Meeting’ “online”
In connection with an on-line registration and
abstract submission programme, the following
homepage has been set up for the EBMT 2004
Meeting in Barcelona
www.akm.ch/ebmt2004
Before, during and after the congress this
homepage will provide you with the following
services/information:
• Programme of the EBMT2004
(regularly updated)
• Online abstract submission
•Online congress registration
(payment by credit card required)
• Online hotel reservation
• Scientific programme including chairpersons
and speakers
• Possibility to set up your personal congress
programme: You can search for topics and
authors
• Access to the accepted abstracts starting
March 28, 2004
• Information on the congress venue and the
city of Barcelona, social events, tours, hotel
accommodation.

Social Events
Sunday, March 28, 2004, 20.00 h
Welcome Reception
After the opening lecture 80 musicians from
the Catalonia Philharmonic Orchestra and
Puig-Reig Poliphonic chorus will take to the
stage to perform a selection of classical
compositions. The Catalonia Philharmonic
Orchestra is renowned for its innovative style
and vanguard streak, whilst Puig-Reig
Poliphonic started-out in the Catalonian
folk circuit and now performs widely in the
international arena.
Participants, accompanying persons and
exhibitors are cordially invited to this concert
in the Auditorium and the following welcome
reception to be held in the foyers of the Palau
de Congressos de Catalunya.
Free Admission
Tuesday, March 30, 2004, 20.00 h
Gala Dinner at Reials Drassanes
de Barcelona
(including a visit to the Royal Shipyard and
Maritime Museum)
Prior to Gala Dinner, the participants will have
the opportunity to visit the Maritime Museum.
This museum harks back to Barcelona’s
seafaring past, with a staggering number of
nautical exhibits, including a map by Amerigo
Vespucci.
The museum is housed in the magnificent
Reials Drassanes (Royal Shipyards) where the
Gala Dinner will take place.
The Reials Drassanes dates from the
13 th century and is the world’s most important
gothic civil monument.
After dinner the famous Catalan rock fusion
band «La Tribu de Santi Arisa» will up the temp
so that guests can dance the night away.
Admission: € 90.– (Physicians)
€ 65.– (Nurses and
Data Management Group)
19.30 h
Departure of buses from various keypoints
and hotels.
Bus schedules are available at the
«Local information» counter.
La Pedrera
155

Daily Tours
Monday, March 29, 2004, 09.00 – 13.00 Old Barcelona:
Gothic quarter and Picasso Museum
€ 42.– / person
Tuesday, March 30, 2004, 09.00 – 18.00 The Costa Brava and Dalí Museum
€ 80.– / person
Tuesday, March 30, 2004, 09.00 – 13.00 Montjüic Park: Olympic Ring
National Museum of Catalan Art
and Miro Foundation
€ 48.– / person
Wednesday, March 31, 2004, 09.00 – 13.00 Gaudí and Modernism
Note for all tours
156
€ 48.– / person
Meeting point: Main entrance of the Palau de Congressos de Catalunya (congress venue),
15 minutes before departure.
Tours are based on a minimum of 25 participants. If a tour does not take place due to insufficient
numbers, the ticket fee will be reimbursed in full. Otherwise please note that tickets for excursions are
non-refundable. An English-speaking guide will conduct all excursions.
For registration and more information please conduct the «Local information» counter.
“Dona i Ocell”, Woman with Bird, Joan Miró

Sponsors supporting the EBMT congress
The organisers of the EBMT 2004 express their thanks and appreciation to all those who
are generously contributing to the success of this meeting.
Amgen (Europe) AG
Amgen S.A.
Fresenius BioTech GmbH
F. Hoffmann-La Roche Ltd.
Genzyme – SangStat
Gilead Sciences
Hoffmann-La Roche AG
Merck, Sharp und Dohme
Miltenyi Biotec GmbH
Pfizer Inc.
Pierre Fabre Médicament
Roche Farma S.A.
Schering
Therakos, Johnson & Johnson
157

Useful Information about Barcelona
City of Barcelona
Barcelona, the capital of Catalonia, is located on
the Mediterranean coast and bounded by the
Sierra of Collserola and the rivers Besòs and
Llobregat to the north and south respectively.
Since its foundation over 2000 years ago, the
city has served as been the traditional gateway
of Spain. Romans, Arabs and Christians have
all passed through, leaving their distinct mark
on the city. The visitor will gain a sense of
Barcelona’s history simply by walking through
the city, whether roaming the streets of the
Gothic Quarter, built on the original Roman site
or the Modernist Eixample district that is
illuminated by the exuberant architecture of
Antoni Gaudí.
Such diversity and harmony also flourishes in
the character of Barcelona’s citizens.
Enterprising and hard-working, they also
possess a hedonistic streak along with strong
civic pride and a love for culture. These traits
have made Barcelona into a first-class tourist
destination and the perfect setting for meetings
and congresses. This open, welcoming city
which hosted the Olympic Games in 1992 is
now focusing all its energies on another global
project: the Universal Forum of Cultures, which
will be held in 2004 and will enable the city to
complete its seafront area.
For more information on Barcelona, you should
refer to the official city council web site:
www.bcn.es.
Climate
Barcelona enjoys a mild climate and an average
annual temperature of 17 degrees Celsius.
The sun shines on most days of the year and
the Mediterranean brings cooling sea breezes to
the city and moisture to the atmosphere. Rainfall
is light, except during the few rainy months of
the year, and needless to say, it rarely snows.
Even the lowest temperatures are relatively mild.
At the end of March, one can expect temperatures
of approximately 13 to 15 degrees Celsius.
(in alphabetical order)
Currency
Since the incorporation of Spain into the
Economic and Monetary Union in January 2002,
the Euro (€) has replaced pesetas as the official
currency of Spain. The banknotes are in
denominations of € 5, 10, 20, 50, 100, 200
and 500. Coins are minted in the following
denominations: 1, 2, 5, 10, 20 and 50 cent or
€ 1 and € 2 pieces. You can change money
at the city’s banks and savings banks (‘caja’
or ‘caixa’) as well as at the exchange booths
located in the city centre and main tourist
sights.
Credit Cards
Major credit cards such as American Express,
Visa, Eurocard and Diners are accepted in
hotels, stores and restaurants.
Language
In Barcelona, as in the rest of Catalonia, there
are two official languages:
Catalan – the language of the region – and
Castellano – the official language of Spain.
Restaurants – Spanish Cuisine
The Mediterranean diet originated here by the
sea and amongst the olive groves, vines and
wheat fields of Catalonia. In Barcelona, you can
eat out in the sun on open-air seafront terraces
almost all year round. Choose from local cuisine
including seafood and cured hams, or from a
wide variety of ethnic restaurants. You can also
enjoy tapas,small portions, which allow you to
sample a selection of typical Spanish dishes.
In Barcelona, as is common in Spain, people
normally have their meals later than in other
European countries. The first meal of the day,
esmorzar, is usually eaten between 9:00 and
11:00 and tends to be lighter than in the rest
of Europe, being similar to what hotels call a
‘continental’ breakfast. People sit down for
lunch between 14:00 and 15:00 and for dinner
between 21:00 and 22:00. Nevertheless,
restaurant hours are adapted to the pace of
working life, and you can find lunch as early
as 13:00, while dinner may be serve as late
as 23:30.

Useful Information about Barcelona
Shopping
Barcelona has a wide and varied range of shops
for all tastes and budgets. Known for its
excellent personal customer service, the city has
become a magnet for shoppers and traders
alike, and whether searching for designer goods
or local craftwork it’s unlikely you’ll be disappointed.
The Ramblas, the Born, Plaça de
Catalunya, Passeig de Gràcia, Diagonal and the
numerous shopping centres scattered around
the city and its suburban areas are a delight for
shoppers.
Shops in Barcelona open their doors between
9:00 and 10:00 and generally close for lunch
at 13:30 or 14:00. They open again in the
afternoon between 16:00 and 17:00 and remain
open until 20:00 or 20:30. Nevertheless, it
should be noted that many shopping centres
and larger establishments do not close at
midday. Many shops and all department stores
and shopping centres open on Saturday
afternoons, while all shops close Sundays,
except for a few dates when they are permitted
to open.
Tax Refunds
Value Added Tax (VAT) is charged at 16% on
most goods. Cash back is the simplest and most
widely used VAT refund service that issues cash
refunds on departure from the country for a
handling fee. Ask for a cash back form when
you make your purchase.
(in alphabetical order)
Time
Barcelona is one hour ahead of Greenwich
Mean Time (GMT). As in most European
countries, the official time is subject to change
throughout the year.
In 2004 clocks will be put forward one
hour on Sunday, March 28.
Tipping
Service is almost always included in hotel and
restaurant bills. If in doubt, ask “Está incluido
el servicio” (Spanish is pronounced exactly as
it is spelt.) A further tip of a few small coins
is appropriate. Some typical percentages for
tipping are: Waiter 5% (optional);
Taxi driver 5%, Tourist guide 10%
Working hours
The workday generally begins at 8:00 or 9:00
and lasts till about 20:00 with a one- or twohour
break for lunch in the early afternoon.
159

Cuestión de
mentalidad.
Time for
change.
www.iberia.com
160
Cuando llevamos más de 75 años haciendo posibles los negocios de
millones de personas. Cuando disponemos de la mayor red de
conexiones entre Europa y Latinoamérica. Cuando ofrecemos a nuestros
pasajeros la flota más moderna y hasta 560 destinos en todo el mundo.
Entonces ¿por qué cambiamos de mentalidad? Porque a partir de ahora
nosotros nos adaptamos aún más a ti. A tu tiempo, a tu economía, a tus
gustos gastronómicos, a tus necesidades de atención, a tu trabajo, a tu
ocio… Ahora en Iberia, decides tú.
With more than 75 years experience of making your business our
business, achieving the largest route network between Europe and Latin
America, a state-of-the-art fleet and up to 560 destinations world-wide,
why change now? From now on, we will adapt even more to suit your
needs; schedules, budgets, taste in food, special requirements, work,
leisure... Now with Iberia, you decide.

Travel to and within Barcelona
Barcelona Airport
The international airport was designed by Ricardo
Bofill for the 1992 Olympics. It is currently
undergoing an extension programme in order to
double its capacity. The airport is located 12 km
from the city in El Prat de Llobregat and can be
reached by the Castelldefels highway and by
public transport.
Official Carrier TRANSPORTISTA OFICIAL / OFFICIAL CARRIER
IBERIA AIRLINES has been appointed Official
Carrier for the EBMT 2004. Please contact your
local IBERIA sales office referring to EBMT 2004
or AKM Travel Basel for a 25% discount on
full Business, Economy and Eurobudget fares.
By Road
A17 motorway from Barcelona to La Jonquera
(at the French border) links up with the French
motorway network, and then to northern Europe,
or through to eastern Europe via Nice, Monaco
and Italy. The A-7 motorway to the west and
south connects Barcelona with the rest of Spain.
Travel from the airport to the city centre
By taxi: There is a taxi rank outside the main
terminal building. A taxi to the city centre or the
congress venue should cost between € 15.–
to € 20.– depending on the time of day.
By bus: There is an Aerobus shuttle which runs
every 12 minutes between Barcelona Airport
and Plaza Catalunya. The length of the journey
is approx. 40 minutes.
(Fares: One way: € 3.45, Round trip € 5.90).
By train: In the terminal, look for signs for the
train. These may not be very clear but as soon
as you walk out of the terminal(s) you will see
a covered walkway leading from the terminal
buildings over the car park. This will bring you
to the train station where trains leave every
30 minutes.
It takes approx. 25 minutes from the airport to
the Sants Station where you can connect with
the metro network. The last train leaves the
airport at 23.40 h. (Fare: One way: € 2.20)
Travel within the city centre
Taxi: Barcelona has 11,000 yellow and black,
mid-to-high-level range taxis. A green light on
top of the taxi indicates its availability. You can
take a taxi from any of the city’s numerous
ranks and if you want to hail one in the street,
just put your hand up when you see one
approaching.
Public Transport: An extensive public transport
network covers the whole of Barcelona.
The system, made up of 5 metro lines and a
fleet of 800 buses runs over 80 routes and
covers virtually the whole city. Metro travel is
quick and easy and there are a variety of travel
passes available. A T10 pass allows you
10 combined journeys by bus and metro. Three
and five-day passes are also available for
unlimited travel over these days. More information
is available at www.tmb.net/eng.
Courtesy of Roche Farma, Spain each
participant is entitled to receive a T-10
transportation ticket (allows 10 combined
journeys in any means of transport)
The transportation ticket can be received
on-site at the local information desk
and/or the secretariat in exchange to the
corresponding voucher which is included
in the congress documentation.
Travel from the city centre to the Congress
venue
The Congress venue, Palau de Congresos de
Catalunya can be reached by metro, line L3,
which is the green line in direction Zona Universitaria.
Get off at the last stop, which is called
‘Zona Universitaria’.
Please note – Barcelona is unfortunately known for its pickpockets. Thieves target travellers, particularly in the
metro at Sants, the main railway station and on arrival by bus at Plaza Catalunya. Common sense is normally
sufficient, although it must be remembered that these are professional thieves and are consequently very skilled.
161

Barcelona City Map
1 A
13
2
3
B
12
11
4
10
C
9

7
6
8
5
14
A
B
C
1
2
3
4
5
6
7
8
9
10
11
12
13
Congress Venue
(Palau de Congressos de Catalunya)
Sants Railway Station (connections to the airport)
Gala Banquet at Reials Drassanes de Barcelona
Hotels
Rey Juan Carlos
Princesa Sofia Inter-Continental
Hilton
Melia Barcelona
Majestic
Cristal/Calderon/Avenida Palace
Le Meridien
Colon
Grand Maria
Tryp Apolo
Fira Palace
Barcelona Plaza
NH Ralle
163

Metro Map
1
2
3
4
5
6
7
8
9
10
11
12
13
14
164
Hotels Nearest Metro Stations
Rey Juan Carlos Zona Universitaria
Princess Sofia
Inter-Continental Maria Cristina
Hilton Maria Cristina
Melia Barcelona No Metro (Bus or Tram)
Majestic Passeig de Gràcia
Cristal / Calderon /
Avenida Palace Catalunya
Le Meridien Catalunya or Liceu
Colon Liceu
Gran Marina Drassanes
Tryp Apolo Paral.lel
Fira Palace Espanya
Barcelona Plaza Espanya
NH Ralle Les Corts
Arts Ciutadella Vila Olìmpica
1
2 3
13
11 12
6
7
10
9

7
8
5
Buses
The following buses will stop at the Palau de Congressos de Catalunya:
From Passeig de Gracia take bus no. 7, 67, 68
On Avenida Diagonal take bus no. 7, 68, 33
14
165

Exhibition Floor Plan Level 0
166
to Level +1
Posters Nurses
to Level +1 Posters Nurses
Level 0
Ground Floor
List of exhibitors in alphabetical order
135 Amgen (Europe) AG, Lucerne / Switzerland
155 artus - the PCR reference, Hamburg / Germany
147 Baxter Europe, Madrid / Spain
173 Biosafe S.A., Eysins / Geneva / Switzerland
151 Cell Therapeutics Inc.,
London / United Kingdom
105 CellGenix, Freiburg / Germany
193 Chart Industries Inc., Sunbury / United Kingdom
121 Chugai-Aventis, Antony / France
193 Custom Biogenic Systems,
Shelby Township / United States of America
171 European Group for Blood and Marrow
Transplantation (EBMT)
to Level -1
Lecture Rooms
Posters Physicians
@-Corner
Auditorium
113 Fresenius BioTech GmbH, Gräfelfing / Germany
127 Fujisawa GmbH, Munich / Germany
123 Gambro BCT, Brussels / Belgium
133 Gilead Sciences,
Foster City / United States of America
179 Janssen Pharmaceutica N.V., Beerse / Belgium
185 Lipomed AG, Arlesheim / Switzerland
177 MDS Nordion, Ottawa / Canada
183 medac GmbH, Wedel / Germany
125 Miltenyi Biotec, Bergisch Gladbach / Germany
143 MSD, Madrid / Spain
159 Nature Publishing Group,
London / United Kingdom

EHA / Hotel
Local Information
Secretariat
to Level +1
ProMISe Training Sessions
to Level -1
Lecture Rooms
Posters Physicians
Main Entrance
Registration
List of exhibitors in alphabetical order (continued)
101 Novartis Farma s.p.a., Origgio (VA) / Italy
107 OPi, Dardilly / France
141 Pfizer Inc., New York / United States of America
191 Pharmion, Cambridge / United Kingdom
181 Pierre Fabre Medicament, Boulonge / France
193 Planer PLC, Sunbury / United Kingdom
145 PRETTL Reinraumtechnik GmbH,
Pfullingen / Germany
131 Roche, Basel / Switzerland
129 Sangstat, Lyon / France
175 Sangtec Molecular Diagnostics AB,
Bromma / Sweden
111 Schering AG, Berlin / Germany
Palau de Congressos de Catalunya
Book Display
153 StemCell Technologies, Vancouver / Canada
184 StemSoft Software Inc., Vancouver / Canada
193 Telstar Industrial S.L., Terrassa / Spain
157 The Binding Site,
Birmingham / United Kingdom
103 Therakos - Johnson & Johnson Medical Ltd,
Ascot / United Kingdom
161 Valeant Pharmaceuticals International,
Hampshire / United Kingdom
163 Wisepress Online Bookshop Ltd,
London / United Kingdom
167

List of exhibitors
in numerical order
101 Novartis Farma s.p.a., Origgio (VA) / Italy
103 Therakos - Johnson & Johnson Medical Ltd, Ascot / United Kingdom
105 CellGenix, Freiburg / Germany
107 OPi, Dardilly / France
111 Schering AG, Berlin / Germany
113 Fresenius BioTech GmbH, Gräfelfing / Germany
121 Chugai-Aventis, Antony / France
123 Gambro BCT, Brussels / Belgium
125 Miltenyi Biotec, Bergisch Gladbach / Germany
127 Fujisawa GmbH, Munich / Germany
129 Sangstat, Lyon / France
131 Roche, Basel / Switzerland
133 Gilead Sciences, Foster City / United States of America
135 Amgen (Europe) AG, Lucerne / Switzerland
141 Pfizer Inc., New York / United States of America
143 MSD, Madrid / Spain
145 PRETTL Reinraumtechnik GmbH, Pfullingen / Germany
147 Baxter Europe, Madrid / Spain
151 Cell Therapeutics Inc., London / United Kingdom
153 StemCell Technologies, Vancouver / Canada
155 artus - the PCR reference, Hamburg / Germany
157 The Binding Site, Birmingham / United Kingdom
159 Nature Publishing Group, London / United Kingdom
161 Valeant Pharmaceuticals International, Hampshire / United Kingdom
163 Wisepress Online Bookshop Ltd, London / United Kingdom
171 European Group for Blood and Marrow Transplantation (EBMT)
173 Biosafe S.A., Eysins / Geneva / Switzerland
175 Sangtec Molecular Diagnostics AB, Bromma / Sweden
177 MDS Nordion, Ottawa / Canada
179 Janssen Pharmaceutica N.V., Beerse / Belgium
181 Pierre Fabre Medicament, Boulonge / France
183 medac GmbH, Wedel / Germany
184 StemSoft Software Inc., Vancouver / Canada
185 Lipomed AG, Arlesheim / Switzerland
191 Pharmion, Cambridge / United Kingdom
193 Telstar Industrial S.L., Terrassa / Spain
193 Planer PLC, Sunbury / United Kingdom
193 Chart Industries Inc., Sunbury / United Kingdom
193 Custom Biogenic Systems, Shelby Township / United States of America
168

Floor Plan Level -1 Palau de Congressos de Catalunya
Room H
Room A Room B
Room J
to Mare Nostrum (Hotel Rey Juan Carlos)
to Level 0
Posters Physicians
Room D1
Posters Physicians
Room D4
Room E1 Room E3 Room
E5 Room
E6
Speakers’
Centre
Room F
169

Give simple, powerful
protection.
■ Neulasta ® provides
powerful
protection
against
neutropenic
complications
and offers the
freedom of
one dose per
chemotherapy
cycle.
■ In clinical trials a single
injection of Neulasta ® led to
a lower incidence of febrile
neutropenia compared to daily
G-CSF (filgrastim) injections. 1,2
■ The simple dosing schedule of
Neulasta ® gives patients freedom
from daily G-CSF (filgrastim)
injections. 1
Neulasta ® is indicated to reduce the
duration of neutropenia and the
incidence of febrile neutropenia in
patients receiving cytotoxic
chemotherapy for malignancy (with
the exception of chronic myeloid
leukaemia and myelodysplastic
syndromes).
1. Siena S, Piccart MJ, Holmes FA, Glaspy J,
Hackett J, Renwick J. A combined analysis of two
pivotal randomized trials of a single dose of
pegfilgrastim per chemotherapy cycle and
daily Filgrastim in patients with stage II-IV
breast cancer. Oncol. Reports 2003; 10: 715-
724. 2. Misset JL, Dieras V, Gruia G, et al.
Dose-finding study of docetaxel and
doxorubicin in first-line treatment of
patients with metastatic breast cancer.
Ann Oncol. 1999;10:553-560.
LEGAL CLASSIFICATION: Medicinal product subject to medical prescription. MARKETING AUTHORISATION
HOLDER: Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, The Netherlands. FURTHER INFORMATION
may be obtained from your local Amgen office. MARKETING AUTHORISATION NUMBER: EU/1/02/227/001.
DATE OF PREPARATION: October 2002 © 2002 Amgen Inc. All rights reserved.
Please refer to the full Neulasta ® prescribing information
available from Amgen (Europe) AG, Alpenquai 30,
P.O. Box 2065,Lucerne, Switzerland CH-6002.